

01654954-24-01430010-Q Catheter Precision Inc. 2024.11132044113204450204451204451 0 0001654954-24-014300 10-Q 106 20240930 20241114 20241114 Catheter Precision, Inc.
0001716621 3841 383661826 DE 1231 10-Q 34 0001-38677 241456514 1670 HIGHWAY 160 WEST SUITE 205 FORT MILL SC 29708 973-691-2000 1670 HIGHWAY 160 WEST SUITE 205 FORT
MILL SC 29708 Ra Medical Systems, Inc. 20170908 10-Q 1 vtask 10q.htm FORM 10-Q vtask 10q.htm0001716621false-12-
31Q320243000000000.00013452652702662720315404100000000.00010.00010.0001126561265604578126561500000.0500000.000P0YP0Y000017166212024-01-012024-09-300001716621us-
gaap:SubsequentEventMemberbvtask:InducementOfferMember2024-01-012024-10-240001716621us-gaap:SubsequentEventMemberbvtask:SeriesKWarrantsWarrantsMember2024-10-012024-10-
240001716621us-gaap:SubsequentEventMemberbvtask:InducementOfferMemberbvtask:SeriesIWarrantsWarrantsMember2024-10-240001716621us-
gaap:SubsequentEventMemberbvtask:InducementOfferMemberbvtask:SeriesHWarrantsWarrantsMember2024-10-240001716621us-
gaap:SubsequentEventMemberbvtask:SeriesWarrantsWarrantsMember2024-10-240001716621us-gaap:SubsequentEventMemberbvtask:SeriesHWarrantsWarrantsMember2024-10-
240001716621us-gaap:SubsequentEventMemberbvtask:SeriesKWarrantsWarrantsMember2024-10-240001716621us-gaap:SubsequentEventMemberbvtask:BottomMember2024-10-240001716621us-
gaap:SubsequentEventMemberbvtask:TopMember2024-10-240001716621us-gaap:SubsequentEventMember2024-10-012024-10-240001716621us-
gaap:SubsequentEventMemberbvtask:PreFundedWarrantThreeMember2024-10-012024-10-290001716621us-gaap:SubsequentEventMemberbvtask:SeriesIWarrantMember2024-10-012024-10-
210001716621us-gaap:SubsequentEventMemberbvtask:SeriesHWarrantMember2024-10-012024-10-210001716621us-gaap:SubsequentEventMemberbvtask:PreFundedWarrantTwoMember2024-
10-012024-10-210001716621us-gaap:SubsequentEventMemberbvtask:PreFundedWarrantOneMember2024-10-012024-10-160001716621us-
gaap:SubsequentEventMemberbvtask:PreFundedWarrantMember2024-10-012024-10-040001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2023-01-012023-01-
090001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2023-03-012023-03-210001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2023-01-
090001716621vtask:MrJenkinsMemberbvtask:SeriesJWarrantsWarrantsMember2024-09-030001716621vtask:MrJenkinsMemberbvtask:SeriesIWarrantsWarrantsMember2024-09-
030001716621vtask:MrJenkinsMemberbvtask:SeriesHWarrantsWarrantsMember2024-09-030001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2024-09-
030001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2023-03-210001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2024-07-012024-09-
300001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2024-08-022024-08-230001716621vtask:MrJenkinsMemberbvtask:PreFundedWarrantsWarrantsMember2024-09-
012024-09-030001716621vtask:MrJenkinsMemberbvtask:SeriesJWarrantsWarrantsMember2024-09-012024-09-030001716621vtask:MrJenkinsMemberbvtask:SeriesIWarrantsWarrantsMember2024-
09-012024-09-030001716621vtask:MrJenkinsMemberbvtask:SeriesHWarrantsWarrantsMember2024-09-012024-09-012024-09-
030001716621vtask:ChiefCommercialOfficerMemberbvtask:MayFirstTwentyTwentyFourMember2024-01-012024-09-300001716621vtask:MargritThomassenMember2024-01-012024-01-
310001716621vtask:MargritThomassenMember2024-01-012024-09-300001716621vtask:JenkinsFamilyCharitableInstituteMember2024-09-
300001716621vtask:JenkinsFamilyCharitableInstituteMember2024-01-012024-09-300001716621vtask:FatBoyCapitalTwoMember2024-09-300001716621vtask:FatBoyCapitalTwoMember2024-01-
012024-09-300001716621vtask:FatBoyCapitalOneMember2024-09-300001716621vtask:FatBoyCapitalOneMember2024-01-012024-09-300001716621vtask:FatBoyCapitalMember2024-09-
300001716621vtask:FatBoyCapitalMember2024-01-012024-09-300001716621vtask:DavidJenkinsMember2024-09-300001716621vtask:DavidJenkinsMember2024-01-012024-09-300001716621us-
gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001716621us-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-
300001716621us-gaap:ShareBasedCompensationAwardTrancheTwoMemberbvtask:BottomMember2024-01-012024-09-300001716621us-
gaap:ShareBasedCompensationAwardTrancheTwoMemberbvtask:TopMember2024-01-012024-09-300001716621us-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-
300001716621vtask:TwoThousandTwentyThreeStockCompensationPlanMember2023-12-310001716621vtask:TwoThousandTwentyThreeStockCompensationPlanMember2024-09-
300001716621vtask:TwoThousandTwentyStockCompensationPlanMember2024-09-
300001716621vtask:TwoThousandTwentyStockCompensationPlanMemberbvtask:RestrictedStockAwardsMember2023-12-
310001716621vtask:TwoThousandEighteenEquityStockPurchasePlanMember2023-12-310001716621vtask:TwoThousandEighteenEquityStockPurchasePlanMember2024-09-
300001716621vtask:TwoThousandTwentyStockCompensationPlanMember2023-12-310001716621vtask:TwoThousandTwentyThreeStockCompensationPlanMember2024-01-012024-09-
300001716621vtask:TwoThousandEighteenEquityStockPurchasePlanMember2018-09-300001716621vtask:TwoThousandEighteenEquityStockPurchasePlanMember2018-09-012018-09-
300001716621vtask:TwoThousandEighteenEquityStockPurchasePlanMember2023-01-012023-12-310001716621vtask:TwoThousandEighteenEquityStockPurchasePlanMember2023-01-012024-
09-300001716621vtask:TwoThousandEighteenStockCompensationPlanMember2023-01-012023-09-300001716621vtask:TwoThousandEighteenStockCompensationPlanMember2023-07-012023-
09-300001716621vtask:TwoThousandEighteenStockCompensationPlanMember2024-07-012024-09-300001716621vtask:TwoThousandEighteenStockCompensationPlanMember2024-01-012024-
09-300001716621vtask:StockOptionsAssumedInMergerMember2023-01-012023-01-090001716621vtask:EquityIncentivePlanMember2024-07-
090001716621vtask:EquityIncentivePlanMember2024-04-240001716621vtask:EquityIncentivePlanMemberbvtask:EmployeesMember2024-02-
260001716621vtask:EquityIncentivePlanMemberbvtask:EmployeesAndConsultantsMember2024-01-080001716621vtask:EquityIncentivePlanMembersrt:DirectorMember2024-01-
080001716621vtask:EquityIncentivePlanMember2024-01-012024-01-080001716621vtask:EmployeesMemberbvtask:NonPlanOptionsIssuedMember2024-01-012024-09-
300001716621vtask:EquityIncentivePlanMember2024-01-012024-09-300001716621vtask:EmployeesMemberbvtask:NonPlanOptionsIssuedMember2024-04-012024-04-
240001716621vtask:EquityIncentivePlanMember2024-07-012024-07-090001716621vtask:EquityIncentivePlanMember2024-04-012024-04-
240001716621vtask:EquityIncentivePlanMemberbvtask:EmployeesMember2024-02-012024-02-260001716621vtask:EquityIncentivePlanMemberbvtask:EmployeesAndConsultantsMember2024-01-
012024-01-080001716621vtask:EquityIncentivePlanMembersrt:DirectorMember2024-01-012024-01-080001716621vtask:RestrictedStockUnitsMember2024-09-
300001716621vtask:RestrictedStockAwardsMember2024-09-300001716621vtask:StockOptionsMember2024-09-300001716621vtask:StockOptionsMember2024-01-012024-09-
300001716621vtask:RestrictedStockUnitsMember2024-01-012024-09-300001716621vtask:RestrictedStockAwardsMember2024-01-012024-09-
300001716621vtask:NonPlanOptionsIssuedMemberbvtask:MayOneTwoZeroTwoFourMember2024-01-012024-09-300001716621vtask:EmployeesMember2024-02-012024-02-
260001716621vtask

us-gaap:CustomerRelationshipsMember2024-09-300001716621vtak:DevelopedTechnologyLockeTMember2024-12-310001716621vtak:DevelopedTechnologyVivoMember2024-09-300001716621vtak:DevelopedTechnologyVivoMember2024-12-310001716621vtak:TrademarksTradeNamesMember2024-01-090001716621vtak:TrademarksTradeNamesVivoMember2024-01-090001716621vtak:TrademarkRelationshipsMember2024-01-090001716621vtak:DevelopedTechnologyVivoMember2024-01-090001716621vtak:LocketAnimationVideoMember2024-09-300001716621vtak:VivoDemoClinicalSystemsMember2024-09-300001716621vtak:LocketAnimationVideoMember2024-12-310001716621vtak:VivoDemoClinicalSystemsMember2024-12-310001716621vtak:ComputerHardwareAndSoftwareMember2024-09-300001716621vtak:ComputerHardwareAndSoftwareMember2024-12-310001716621us-gaap:MachineryAndEquipmentMember2024-09-300001716621us-gaap:MachineryAndEquipmentMember2024-09-300001716621vtak:MergerAgreementOneMember2023-01-090001716621vtak:MergerAgreementOneMember2023-01-090001716621vtak:MergerAgreementMember2023-07-012023-09-300001716621vtak:MergerAgreementMember2023-01-012023-09-300001716621vtak:ProFormaFinancialInformationMember2023-07-012023-09-300001716621vtak:TrademarkLockettMember2024-01-012024-09-300001716621vtak:TrademarkVivoMember2024-01-012024-09-300001716621us-gaap:CustomerRelationshipsMember2024-01-012024-09-300001716621vtak:DevelopedTechnologyLockeTMember2024-01-012024-09-300001716621vtak:DevelopedTechnologyVivoMember2024-01-012024-09-300001716621vtak:TrademarkLockettMember2023-01-090001716621vtak:TrademarkVivoMember2023-01-090001716621us-gaap:CustomerRelationshipsMember2023-01-090001716621vtak:DevelopedTechnologyLockeTMember2023-01-090001716621vtak:DevelopedTechnologyVivoMember2023-01-090001716621vtak:AssetsAcquiredMember2023-01-090001716621vtak:LiabilitiesAssumedMember2023-01-090001716621vtak:CathetersMember2023-01-090001716621vtak:ConvertiblePreferredStockSeriesXSharesMember2023-01-0900017166212023-01-090001716621vtak:RevenueMembersvakt:ThreeAndFourCustomersMember2023-01-012023-09-300001716621vtak:RevenueMembersvakt:ThreeAndFiveCustomersMember2024-01-012024-09-300001716621vtak:RevenueMembersvakt:ThreeAndFourCustomersMember2023-07-012023-09-300001716621srt:EuropeMember2023-01-012023-09-300001716621vtak:USMember2023-01-012023-09-300001716621srt:EuropeMember2023-07-012023-09-300001716621vtak:USMember2024-01-012024-09-300001716621srt:EuropeMember2024-01-012024-09-300001716621srt:EuropeMember2024-07-012024-09-300001716621vtak:USMember2024-07-012024-09-300001716621vtak:LocketAnimationVideoMember2024-01-012024-09-300001716621vtak:VivoDemoClinicalSystemsMembersvkt:TopMember2024-01-012024-09-300001716621vtak:VivoDemoClinicalSystemsMembersvkt:BottomMember2024-01-012024-09-300001716621us-gaap:ComputerEquipmentMembersvkt:TopMember2024-01-012024-09-300001716621us-gaap:ComputerEquipmentMembersvkt:BottomMember2024-01-012024-09-300001716621us-gaap:MachineryAndEquipmentMembersvkt:TopMember2024-01-012024-09-300001716621us-gaap:MachineryAndEquipmentMembersvkt:BottomMember2024-01-012024-09-3000017166212023-01-012023-12-310001716621us-gaap:FairValueInputsLevel3Member2024-09-300001716621us-gaap:FairValueInputsLevel2Member2024-09-300001716621us-gaap:FairValueInputsLevel1Member2024-09-300001716621us-gaap:FairValueInputsLevel1Member2023-12-310001716621vtak:TwoThousandTwentyFourInducementOfferMember2024-01-012024-09-300001716621vtak:SeptemberTwoThousandTwentyFourPublicOfferingMember2024-01-012024-09-300001716621vtak:SeptemberTwoThousandTwentyFourPublicOfferingMember2024-09-300001716621vtak:RelatedPartyNotesMember2024-01-012024-09-300001716621vtak:ReverseStockSplitMember2024-07-012024-07-150001716621vtak:ReverseStockSplitMember2024-07-150001716621us-gaap:RetainedEarningsMember2024-09-300001716621us-gaap:AdditionalPaidInCapitalMember2024-09-300001716621us-gaap:CommonStockMember2024-09-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2024-09-300001716621us-gaap:RetainedEarningsMember2024-07-012024-09-300001716621us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001716621us-gaap:CommonStockMember2024-07-012024-09-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2024-07-012024-09-300001716621vtak:SeriesXConvertiblePreferredStockMember2024-07-012024-09-3000017166212024-06-300001716621us-gaap:RetainedEarningsMember2024-06-300001716621us-gaap:AdditionalPaidInCapitalMember2024-06-300001716621us-gaap:CommonStockMember2024-06-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2024-06-300001716621vtak:SeriesXConvertiblePreferredStockMember2024-06-3000017166212024-04-012024-06-300001716621us-gaap:RetainedEarningsMember2024-04-012024-06-300001716621us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001716621us-gaap:CommonStockMember2024-04-012024-06-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2024-04-012024-06-300001716621vtak:SeriesXConvertiblePreferredStockMember2024-04-012024-06-3000017166212024-03-310001716621us-gaap:RetainedEarningsMember2024-03-310001716621us-gaap:AdditionalPaidInCapitalMember2024-03-310001716621vtak:PreferredStockSharesSeriesAConvertibleMember2024-03-310001716621vtak:SeriesXConvertiblePreferredStockMember2024-03-3100017166212024-03-310001716621us-gaap:RetainedEarningsMember2024-03-310001716621us-gaap:AdditionalPaidInCapitalMember2024-03-310001716621us-gaap:CommonStockMember2024-03-310001716621vtak:PreferredStockSharesSeriesAConvertibleMember2024-03-310001716621vtak:SeriesXConvertiblePreferredStockMember2024-03-310001716621vtak:SeriesXConvertiblePreferredStockMember2024-01-012024-03-310001716621us-gaap:RetainedEarningsMember2023-12-310001716621us-gaap:AdditionalPaidInCapitalMember2023-12-310001716621us-gaap:CommonStockMember2023-12-310001716621vtak:PreferredStockSharesSeriesAConvertibleMember2023-12-310001716621us-gaap:RetainedEarningsMember2023-09-300001716621us-gaap:AdditionalPaidInCapitalMember2023-09-300001716621us-gaap:CommonStockMember2023-09-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2023-09-300001716621vtak:SeriesXConvertiblePreferredStockMember2023-09-300001716621us-gaap:RetainedEarningsMember2023-07-012023-09-300001716621us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001716621us-gaap:CommonStockMember2023-07-012023-09-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2023-07-012023-09-3000017166212023-06-300001716621us-gaap:RetainedEarningsMember2023-06-300001716621us-gaap:AdditionalPaidInCapitalMember2023-06-300001716621us-gaap:CommonStockMember2023-06-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2023-06-300001716621vtak:SeriesXConvertiblePreferredStockMember2023-06-3000017166212023-04-012023-06-300001716621us-gaap:RetainedEarningsMember2023-04-012023-06-300001716621us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001716621us-gaap:CommonStockMember2023-04-012023-06-300001716621vtak:PreferredStockSharesSeriesAConvertibleMember2023-04-012023-06-300001716621vtak:SeriesXConvertiblePreferredStockMember2023-04-012023-06-3000017166212023-03-310001716621us-gaap:RetainedEarningsMember2023-03-310001716621us-gaap:AdditionalPaidInCapitalMember2023-03-31000171662

[illegible]

The reported amounts of revenues and expenses during the reporting periods may differ materially from those estimates. The Company's unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the accounting for the Old Catheter business combination (see Note 3, Business Combination), allowance for credit losses, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, fair value of royalties payable, evaluation of probable loss contingencies, fair value of preferred stock and warrants issued, and the fair value of equity awards granted. A Concentrations of Credit Risk. The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent short-term, highly liquid investments with maturities of 90 days or less at the date of purchase. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. The Company had three and five customers that represented 90% and 86% of the Company's consolidated revenue for the three and nine months ended September 30, 2024, respectively; and three and four customers that represented 71% and 73% of the Company's consolidated revenue for the three and nine months ended September 30, 2023, respectively. Reclassifications. Certain prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Segment Reporting. The Company's Board of Directors and executive management team represents the entity's chief operating decision makers. To date, the Company's executive management team has viewed the Company's operations as one segment that includes the marketing, sales, and development of medical technologies in the field of cardiac electrophysiology. As a result, the financial information disclosed materially represents all of the financial information related to the Company's sole operating segment. Table of Contents. Cash and Cash Equivalents. Cash equivalents primarily represent funds invested in readily available checking and money market accounts. The Company maintains deposits in financial institutions in excess of federally insured limits of \$250,000, in the amount of \$987 thousand at September 30, 2024. Fair Value Measurements. Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to identify inputs used in measuring fair value as follows:

	Level 1 - Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets	Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities;	Level 3 - Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.
Cash equivalents			
Prepaid expenses, trade accounts receivable, accounts payable, and accrued expenses are reported on the condensed consolidated balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments.			
The following table details the fair value measurements within the fair value hierarchy of the Company's financial instruments:			
At September 30, 2024	\$1,237A	\$1,237A	\$1,237A
At December 31, 2023	\$1,237A	\$1,237A	\$1,237A

Royalties payable. Royalties payable have significant unobservable inputs that are not supported by any market data. As such, the Company developed its own assumptions and identified the inputs as Level 3. The revenue adjusted discount rate (RADR) was calculated using a weighted average cost of capital (WACC) approach for the measurement of the Level 3 liability. The RADR considers the WACC from the Company's impairment analysis and adjusts certain inputs to represent the risk profile of the revenue. Under the cost of equity section, the risk-free rate has changed to be commensurate with the royalties payable term. Additionally, the Beta and Company Specific Risk Premium have been adjusted to Revenue Beta and Revenue Specific Risk Premium, respectively. This adjustment was calculated by multiplying the respective metric by the quotient of equity volatility over revenue volatility. The remaining inputs from the Impairment WACC have remained unchanged. The following table summarizes the significant unobservable inputs used in the fair value measurement of Level 3 instruments as of September 30, 2024 and December 31, 2023:

	September 30, 2024	December 31, 2023
Input Range	20% to 28%	20% to 28%
Discounted future cash flows	Revenue adjusted discount rate	Revenue adjusted discount rate
Unobservable Input	20% to 28%	20% to 28%

Increases or decreases in the fair value of the royalties payable can result from updates to assumptions, such as changes in discount rates, project cash flows, among other assumptions. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Changes or updates to assumptions could have a material impact on the reported fair value, the change in fair value, and the results of operations in any given period. Accounts Receivable and Allowances for Credit Losses. Under the Current Expected Credit Loss ("CECL") impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on three portfolio segments: Hospitals - United States, Hospitals - Europe, and Distributors. The determination of portfolio segments is based primarily on the customers' industry and geographical location. Trade accounts receivable are recorded at invoiced amounts, net of allowance for credit losses, if applicable, and are unsecured and do not bear interest. The allowance for credit losses is based on the probability of future collection under the CECL impairment model in which the Company determines its estimated loss rates based on an aging schedule. The Company also considers reasonable and supportable current information in determining its estimated loss rates, such as external forecasts, macroeconomic trends or other factors, including customers' credit risk and historical loss experience. The adequacy of the allowance is evaluated on a regular basis. Trade account balances are written off after all means of collection are exhausted and the balance is deemed uncollectible. Subsequent recoveries are credited to the allowance for credit losses, if any. Changes in the allowance are recorded as adjustments to bad debt expense in the period incurred. The allowance for credit losses within trade accounts receivable was not material as of September 30, 2024 and December 31, 2023. Inventories. Inventories are stated at the lower of cost (determined by the first-in, first-out method) or net realizable value. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially in excess, obsolete or slow-moving based on changes in customer demand, technological developments or other economic factors. Property and Equipment. Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives as follows:

Asset Class	Useful Life
Machinery and equipment	2-5 years
Computer hardware and software	1-5 years
VIVO DEMO/Clinical Systems	1-5 years
Leasehold improvements	Depreciated over the shorter of the useful life of the leasehold improvement or the term of the underlying property's lease

The Company periodically reviews the residual values and estimated useful lives of each class of its property and equipment for ongoing reasonableness, considering long-term views on its intended use of each class of property and equipment and the planned level of improvements to maintain and enhance assets within those classes. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the account balances and any resulting gain or loss is recognized in income for the period. The cost of repairs and maintenance is expensed as incurred, whereas significant betterments are capitalized. Impairment of Long-Lived Assets. In accordance with ASC 360, Impairment and Disposals of Long-Lived Assets, the Company periodically reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value of the long-lived assets may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the assets carrying value over its fair value is recorded in the Company's consolidated statements of operations at that date. Goodwill and Other. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired. Goodwill, which represents the excess of purchase price of Old Catheter over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. The Company reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using a combination of an income and market approach. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. These assumptions require significant judgment. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. There were impairment charges of \$60.9 million recognized during the nine months ended September 30, 2023 (see Note 3, Business Combination and Note 7, Goodwill for additional details). As of December 31, 2023, goodwill was fully impaired. Royalties Payable. The Company is obligated to pay royalties under various royalty agreements executed by Old Catheter. On January 9, 2023, prior to the consummation of the Merger, Old Catheter entered in an agreement with its Convertible Promissory Noteholders (Noteholders), which substantially consisted of amounts due to David A. Jenkins, previously Old Catheter's Chairman of the Board of Directors, and currently, the Company's Executive Chairman of the Board of Directors and Chief Executive Officer, to forgive all accrued interest and future interest expense in exchange for a future royalty right. The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of Lockt, commencing on the first commercial sale through December 31, 2035 (see Note 10, Royalties Payable). The Company recognizes a current liability for royalty fees incurred and payable to the Noteholders based on actual sales of Lockt devices. The liability is recorded as current portion of royalties payable in the condensed consolidated balance sheet. The Company further recognizes a liability for future, estimated royalty payments to the Noteholders at fair value, which is recorded as royalties payable in the condensed consolidated balance sheet (the "Royalties Payable"). The fair value of the Royalties Payable is an estimate that is based on the projected sales of Lockt through the end of 2035. The projected sales are then multiplied by the royalty rate of 11.82% and discounted back to their present value using the RADR. At each reporting date, the fair value of the Royalty Payable is remeasured in connection with any changes to Management's projections as a change in estimate. Product Warranty. The Company offers product warranties against defects in material and workmanship when properly the products are used for their intended purpose and properly maintained. Warranty expenses are included in cost of revenues in the accompanying unaudited condensed consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense. As of September 30, 2024 and December 31, 2023, there was no accrued warranty balance. Distinguishing Liabilities from Equity. The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under ASC Topic 480, Distinguishing Liabilities from Equity (ASC 480). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company's equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company's equity shares, or variations inversely related to changes in fair value of the Company's equity shares. If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to ASC 815-40, Derivatives and Hedging (ASC 815-40). The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with ASC 480. Otherwise, the freestanding financial instruments is classified in permanent equity. Revenue Recognition. In accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), the Company accounts for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenue is measured as the amount of consideration expected to be received in exchange for transferring promised goods or services. The amount of consideration to be received and revenue recognized may vary due to discounts. A performance obligation is a promise in a contract to transfer a distinct good or service. If there are multiple performance obligations in the customer contract, the Company allocates the transaction price in the contract to each performance obligation based on the relative standalone selling price. Revenue is recognized when performance obligations in the customer contract are satisfied. This generally occurs when the customer obtains control of a promised good at a point in time or when a customer receives a promised service over time. A Pursuant to ASC 606, the Company applies the following five steps to each customer contract:

- Step 1: Identify the contract with the customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price in the contract
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognize revenue when the Company satisfies a performance obligation

The VIVO System. The VIVO System offers 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. Customers are provided with VIVO Positioning Patch Sets, which are custom patches, that are used in conjunction with the VIVO System. The VIVO Positioning Patch Sets are integral to the functionality of the VIVO System. The VIVO System, including the VIVO Positioning Patch Sets, represents the Company's primary performance obligation. The Company recognizes revenue when physical possession and control of the VIVO System is transferred to the customer upon delivery. The Company also offers customers software upgrades for the VIVO System, which may be purchased and paid in advance at contract inception. Software upgrades represent stand-ready services, whereby the Company promises to provide software upgrades to the customer when and as upgrades are available. Software upgrade services may be offered for initial contract terms of one to multiple years. Customers have the option to

by distributing sutures tension over a larger area, the patient in conjunction with a figure of eight suture closure. LockeT is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. The LockeT device represents a performance obligation in the customer contract. The Company recognizes revenue when it transfers control of the LockeT device to the customer, which happens when the Company delivers the product to the customer.Â For both LockeT and VIVO System, the Company has elected the practical expedient to expense costs incurred to obtain a contract, rather than recognizing these costs as an asset at the time of occurrence.Â A 16Table of ContentsA Disaggregation of RevenueÂ The following table summarizes disaggregated product sales by geographic area (in thousands):Â A A For the Three Months Ended September 30,Â A A For the Nine Months Ended September 30,Â A A 2024Â A 2023Â A 2024Â A 2023A Product SalesÂ A A A A A A A A A A USA \$62A Â \$110A Â \$129A Â \$241A EuropeÂ A 34A Â A 23A Â A 142A Â A 73A Â A \$96A Â \$133A Â \$271A Â \$314A Shipping and Handling Costs Â Shipping and handling costs charged to customers are included in net product sales, while all other shipping and handling costs are included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. A Advertising and Marketing A Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were \$31 thousand and \$127 thousand during the three and nine months ended September 30, 2024, respectively. Advertising costs were \$309 thousand and \$914 thousand during the three and nine months ended September 30, 2023, respectively. A PatentsA The Company expenses patent costs, including related legal costs, as incurred and records such costs as selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. A Research and DevelopmentA Major components of research and development costs include consulting, research grants, supplies and clinical trial expenses. Research and development expenses are charged to operations in the period incurred. A Stock-Based CompensationA The Company records stock-based compensation expense associated with stock options, restricted stock awards (â€œRSAsâ€) and restricted stock units (â€œRSUsâ€) issued to employees, members of the Companyâ€™s board of directors and consultants in accordance with the guidance under ASC Topic 718, Compensation â€œ Stock Compensation (â€œASC 718â€). The Company evaluates whether an award should be classified and accounted for as a liability award or equity award for all stock-based compensation awards granted. Stock-based compensation expense for stock options is measured at the grant date based on the estimated fair value of the award using the Black-Scholes option pricing valuation model (â€œBlack-Scholes modelâ€), which incorporates various assumptions, including expected term, volatility and risk-free interest rate. Stock-based compensation expense for stock options is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting period of the respective award. Share-based compensation for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not probable or is not met, no stock-based compensation expense is recognized, and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. A 17Table of ContentsA As a result of the Merger, all unvested Old Catheter stock options were subject to accelerated vesting and became fully vested as of the closing date of the business combination. The Company recognized the fair value of the replacement options as included in consideration transferred to the extent they do not exceed the fair value of the equivalent Old Catheter options. Any incremental fair value was recognized in compensation expense in the post-combination period, with this recognized as a Day 1 expense due to the Old Catheter options becoming fully vested concurrent with the closing of the business combination. A Income TaxesA The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. A The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively. A Basic and Diluted Net Loss per Share of Common StockA Earnings per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Companyâ€™s common shares and participating securities. The Companyâ€™s Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and outstanding warrants contain participating rights in distributions made to common stockholders and, therefore, are participating securities. The Company did not declare nor pay any dividends nor distributions in the current period. Furthermore, the participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per common share. A Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic net loss per share for the periods presented herein because common stock equivalent shares from warrants, stock options, non-vested restricted stock awards, restricted stock units, Series A Convertible Preferred Stock, and Series X Convertible Preferred Stock A were antidilutive (see Note 12, Net Loss per Share). A 18Table of ContentsA Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed dividends declared. The Company recorded a deemed dividend for the modification of existing warrants and issuance of new warrants during the three and nine months ended September 30, 2023 of \$0 and \$0.8 million, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders for the three and nine months ended September 30, 2023. There was no deemed dividend for the three and nine months ended September 30, 2024. A Recently Announced Accounting PronouncementsA In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 require disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entityâ€™s CODM. The amendments in this update also expand the interim segment disclosure requirements. These amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently reviewing the impact that the adoption of ASU 2023-07 may have on our consolidated financial statements and disclosures. A In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is required to adopt this standard prospectively in fiscal year 2025 for the annual reporting period ending December 31, 2025. The Company does not believe the impact of the new guidance and related codification improvements will have material impact to its financial position, results of operations and cash flows. A Note 3. Business CombinationA On January 9, 2023, the Company completed the acquisition of Old Catheter for the purpose of acquiring Old Catheterâ€™s existing and developing product lines based on unique electrophysiology technology. A Pursuant to the Merger Agreement, all Old Catheter common stock shares issued and outstanding and convertible promissory notes, representing an aggregate principal of \$25.2 million, were converted into a right to receive 14,649,592 shares of a new class of the Companyâ€™s preferred stock, designated Series X Convertible Preferred Stock. Additionally, all outstanding stock options to purchase Old Catheter common stock were assumed and converted into options to purchase approximately 75,367 shares of the Company's common stock. A The total purchase consideration for the Merger was \$72.5 million which represents the sum of the (i) estimated fair value of the 14,649,592 Series X Convertible Preferred Stock issued and (ii) the portion of the estimated fair value of \$3.4 million representing the Company stock options issued in replacement of Old Catheter share-based payment awards as required under FASB Topic 805, A Business Combinations ("Topic 805"). A The fair value of the Series X Convertible Preferred Stock includes certain discounts applied to the closing stock price of the Company, on January 9, 2023, of \$60.90 per share. A 19Table of ContentsA The following table summarizes the fair value of the consideration associated with the Merger (\$ in thousands): A DescriptionA Fair Value as of January 9, 2023A Fair Value of 14,649,592 Series X convertible preferred stock issuedA \$69,140A Fair value of Old Catheterâ€™s fully vested stock optionsA 3,404A Total Purchase PriceA \$72,544A The Merger was accounted for as a business combination in accordance with Topic 805, and the Company has been determined to be the accounting acquirer. A The Company allocated the purchase price to the assets acquired and liabilities assumed at fair value. The purchase price allocation reflects various fair value estimates and analyses, including certain tangible assets acquired and liabilities assumed, the valuation of intangible assets acquired, liabilities assumed, and goodwill, which were subject to change within the measurement period as valuations were being finalized (generally one year from the acquisition date). Measurement period adjustments were recorded in the reporting period in which the estimates are finalized, and adjustment amounts were determined. During the three months ended June 30, 2023, the Company recorded measurement period adjustments based on changes to certain estimates and assumptions and their related impact to the purchase price allocation. Developed technology was revised from \$35.1 million to \$27.0 million; trademarks were revised from \$1.7 million to \$1.3 million; customer relationships were revised from \$220 thousand to \$62 thousand; goodwill was revised from \$56.0 million to \$60.9 million; and royalties payable were revised from \$7.6 million to \$14.2 million. A 20Table of ContentsA The following table summarizes the final purchase price allocations relating to the Merger (in thousands): A DescriptionA Fair ValueA Assets acquired: A Cash and cash equivalentsA 15A Accounts receivableA 71A InventoriesA 52A Prepaid expenses and other current assetsA 23A Property and equipment, netA 26A Lease right-of-use assetsA 119A Other assetsA 8A Developed technologyA 27,014A Customer relationshipsA 62A TrademarksA 1,285A GoodwillA 60,934A Total assets acquiredA \$89,609A A A A Liabilities assumed: A A Accounts payableA 922A Accrued expensesA 1,389A Lease liabilityA 124A Interest payableA 198A Convertible promissory notesA 250A Royalties payableA 14,182A Total liabilities assumedA 17,065A Total purchase priceA 72,544A All intangible assets acquired are subject to amortization and their associated acquisition date fair values and useful lives are as follows: A Intangible AssetsA Fair ValueA Useful LifeA Developed technology- VIVOA \$8,244A A 15A Developed technology- LockeTA 18,770A A 14A Customer relationshipsA 62A A 6A Trademark- VIVOA 876A A 9A Trademark- LockeTA 409A A 9A A \$28,361A A A A Notwithstanding the above, as described in Note 7, management determined that there were indicators of asset impairment during the nine months ended September 30, 2023, and assessed the carrying values of the Companyâ€™s intangible assets and goodwill. As a result of the impairment analysis in prior periods, the Company recorded an impairment charge of \$60.9 million for the nine months ended September 30, 2023. This amount represented the purchase price amount ascribed to goodwill. A 21Table of ContentsA Transaction costs incurred in connection with this business combination amounted to approximately \$0 and \$1.7 million during the three and nine months ended September 30, 2023, respectively. A Pro Forma Financial InformationA The following table represents the revenue, net loss and net loss per share effect of the acquired company, as reported on a pro forma basis as if the acquisition occurred on January 1, 2023. These pro forma results are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the first day of the period presented, nor does the pro forma financial information purport to represent the results of operations for future periods. The following information for the three and nine months ended September 30, 2023 is presented in thousands except for the per share data (in thousands, except per share data): A A Three Months Ended September 30, A Nine Months Ended September 30, A A 2023A RevenuesA \$133A Â \$317A Net lossA \$(1,927)A Â \$(7,073)Net loss attributable to common stockholdersA \$(1,927)A Â \$(7,073)Basic and diluted net loss per share â€œ on a pro forma basisA \$(0.28)A Â \$(1.07)A Note 4. InventoriesA Inventories consisted of the following (in thousands): A A September 30, 2024A A December 31, 2023A Raw materialsA 44A Â 27A Finished goodsA 28A Â 17A InventoriesA 32A Â 44A A There were no charges for inventory obsolescence or allowance recorded during the three and nine months ended September 30, 2024 and 2023. A Note 5. Property and Equipment, netA Property and equipment, net consisted of the following (in thousands): A A September 30, 2024A A December 31, 2023A Machinery and equipmentA 29A Â 16A Computer hardware and softwareA 29A Â 17A LockeT Animation VideoA 29A Â 29A A A VIVO DEMO/Clinical SystemsA 101A Â A 69A Property and equipment, grossA 188A Â A 102A Accumulated depreciationA (77)A Â (32)Property and equipment, netA 111A Â 70A A A 22Table of ContentsA Depreciation expense was \$19 thousand and \$45 thousand for the three and nine months ended September 30, 2024, respectively. Depreciation expense was \$9 thousand and \$26 thousand for the three and nine months ended September 30, 2023, respectively. A Note 6. Intangible AssetsA The following table summarizes the Companyâ€™s intangible assets as of September 30, 2024 (in thousands): A A Estimated Useful Life in YearsA Gross Carrying Amount at January 9, 2024A A Accumulated AmortizationA Net Book Value at September 30, 2024A Developed technology â€œ VIVOA 15A Â \$8,244A Â \$(962)A 7,282A Developed technology â€œ LockeTA 14A Â 18,770A Â A (2,347)A 16,423A Customer relationshipsA 6A Â 62A Â A (1

Company’s single reporting unit and no goodwill remains as of this date. Note 8. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2024 December 31, 2023 Legal expenses \$60A \$102A Offering costs \$1,356A \$1,356A Compensation and related benefits \$33A \$43A Other accrued expenses \$48A \$1,232A Accrued expenses \$1,497A \$1,733A The product warranty accrual related to the voluntary recall of DABRA catheters was initiated in September 2019. The recall was closed by the FDA in July 2023 and no claims have been submitted in approximately 2 years. As such, the Company derecognized the warranty liability of \$192 thousand as of December 31, 2023. As of September 30, 2024 and December 31, 2023, the accrued warranty balance was \$0.A 24Table of ContentsA Note 9. Notes Payable Note Payable - Director & Officer Liability Insurance The Company purchased director and officer liability insurance coverage on October 16, 2023 for \$447 thousand. A down payment of \$157 thousand was made and the remaining balance of \$291 thousand was financed over 8 months through a short-term financing arrangement with its insurance carrier. The interest rate on the loan is 8.990%. Interest expense on this loan was \$1 thousand and \$4 thousand for the three and nine months ended September 30, 2024, respectively. The loan balance was \$184 thousand as of December 31, 2023. The loan balance was paid off in May of 2024 and therefore there is no balance as of September 30, 2024. A The Company purchased director and officer liability insurance coverage on September 26, 2024 for \$293 thousand. A down payment of \$44 thousand was made and the remaining balance of \$249 thousand was financed over 10 months through a short-term financing arrangement with its insurance carrier. The interest rate on the loan is 9.990%. Interest expense on this loan was \$0 for the three and nine months ending September 30, 2024. The loan balance was \$249 thousand as of September 30, 2024. A Short Term Promissory Notes (collectively, the Related Party Notes) On May 30, 2024, David A. Jenkins loaned \$500,000 to the Company in exchange for a short-term promissory note. On June 25, 2024, an entity controlled by Mr. Jenkins loaned \$150,000 to the Company in exchange for a short-term promissory note. On July 1, 2024 and July 18, 2024, the Company entered into two short-term promissory notes with an affiliate of Mr. Jenkins, where the affiliate loaned \$250,000 and \$100,000, respectively, to the Company in exchange for the notes. A On July 25, 2024, the Company entered into a short-term promissory note with a Trust, of which Mr. Jenkins’ adult daughter is the trustee, where the Trust loaned \$500,000 to the Company in exchange for the note. A All of these short-term promissory notes (the Related Party Notes) had a maturity date of August 30, 2024, and bear interest at the rate of 8% per annum. A On August 23, 2024, the Company entered in the first amendment of the Related Party Notes, which extended the maturity date to January 31, 2026 and increased the interest rate to 12% per annum after August 31, 2024. All other terms and conditions remained substantially unchanged. As part of the amendment, the Company paid down all accrued interest to date of \$21 thousand. The first amendment was accounted for as a debt modification in accordance with ASC 470-50, Debt Modifications and Extinguishment (ASC 470-50). Since the modified terms and conditions were not substantially different from the prior terms and conditions, the Company accounted for the debt modification as a continuation of the original debt instrument. The Company further concluded that the debt modification did not result in any adjustments to the carrying value of the Notes. A The Related Party Notes and the debt evidenced thereby, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owing when due, material breach of representations or warranties by the Company (unless waived by the holder of the Related Party Note or cured within 10 days following notice) and/or certain events involving a discontinuation of the Company’s business or certain types of proceedings involving insolvency, bankruptcy, receivership and the like. A Interest expense on the Related Party Notes was \$33 thousand and \$36 thousand for the three and nine months ended September 30, 2024, respectively. The balance of the Related Party Notes and accrued interest was \$1.5 million as of September 30, 2024, \$16 thousand of which relates to accrued interest and is recorded under interest payable to related parties on the condensed consolidated balance sheets. A See Note 19, Related Parties for additional details. A 25Table of ContentsA Note 10. Royalties Payable Lockt Royalty On January 9, 2023, Old Catheter entered into an agreement with the Noteholders to forgive all accrued interest and future interest expense in exchange for a future royalty right. Under these agreements, the Company is obligated to pay the Noteholders a total royalty equal to approximately 12% of net sales of its Lockt device on a quarterly basis, commencing upon the first commercial sale through December 31, 2035. A An additional royalty will be paid to the inventor of the Lockt device as detailed in the Royalty Agreement. In exchange for the assignment and all rights to Lockt, the Company will pay a 5% royalty on net sales up to \$1.0 million in royalties, payable annually in arrears, starting with the year ending December 31, 2022. After \$1.0 million has been paid, and if, and only if, a US patent is granted by the United States Patent and Trademark Office, the Company will continue to pay a royalty at a rate of 2% of net sales, until total cumulative royalties of \$10.0 million have been paid. The royalty payments will apply to revenues through December 31, 2033, then will terminate regardless of whether the full \$10.0 million has been paid. A The Lockt device had sales during the three and nine months ended September 30, 2024, and as such the Company owes the first royalty payment in relation to the Royalty Agreement. As of September 30, 2024, the Company owes \$17 thousand in relation to Lockt sales. A AMIGO System Royalty During 2006 and 2007, Old Catheter entered into two investment grant agreements with a non-profit foundation for the purpose of funding the initial development of Old Catheter’s AMIGO System, receiving a total of \$1.6 million from the foundation. A The agreement calls for the payment of the following sales-based royalties, by Old Catheter, to the foundation, upon successful commercialization of the AMIGO System: A Royalty Percentage A Until Royalty Payment Reaches a Total of 4% \$1,589,500 2% \$3,179,000 1% A In perpetuity A The Company is not actively marketing and selling the AMIGO System. There was no royalty expense recorded for the three and nine months ended September 30, 2024 and 2023 in relation to the AMIGO System. The AMIGO System royalty has been earned and payment has been deferred to a future date. A 26Table of ContentsA The table below represents the change in fair value of Level 3 royalties payable for the nine months ended September 30, 2024 and 2023 (\$ in thousands). See Note 2, Summary of Significant Accounting Policies, for valuation techniques. A A 2024 A 2023 A Beginning Balance, January 1 A \$6,974 A \$ A AMIGO royalty payable recognized in connection with the Merger A A 159A Lockt royalty payable recognized in connection with the Merger A A 14,022 A Payments owed on royalties payable A 17A A A Change in fair value of royalties payable A 2,823A A (5,333) Ending Balance, September 30, A \$9,814A A \$8,848A A Note 11. Leases For the three and nine months ended September 30, 2024 and 2023 operating lease expense and cash paid for leases were as follows: A A For the Three Months Ended September 30, A A For the Nine Months Ended September 30, A A 2024 A 2023 A Operating lease expense A 288A A 233A A 80A A \$52A Cash paid for leases A 25A A \$32 A A \$78A A 62A A The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies with similar credit ratings and of comparable quality and derived an imputed rate, which was used in a portfolio approach to discount its real estate lease liabilities. Management used an estimated incremental borrowing rate as detailed below for each lease. A Lease Terms and Discount Rate A The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating leases, as of September 30, 2024: A Weighted average remaining lease term (in years) - operating leases A 1.37A Weighted average discount rate - operating leases A 8.65% A South Carolina Office Lease Agreement A On September 27, 2022, Old Catheter entered into a lease agreement for office space located in Fort Mill, South Carolina. The space is used for office and general use. The term of the lease began on October 1, 2022, is 38 months, and includes two months of free rent from the commencement date of the lease. The lease contains two separate 36 month renewal periods, which require 180 days’ notice of the Company’s intention to exercise. As of the date of these condensed consolidated financial statements, the Company does not intend to exercise either of the two extension options. Total rent is \$3,435 per month for the first ten months following the two months of free rent, with annual increases on the anniversary of the effective date. The Company has adopted the practical expedient under Topic 842, which permits the Company to account for each separate lease component of a contract and its associated non-lease components as a single lease payment. As a result, beginning at lease inception on October 1, 2022, the Company recognized the lease payments and associated common area maintenance payments as a single lease payment. A 27Table of ContentsA New Jersey Office Lease Agreement A On December 7, 2022, Old Catheter entered into a lease agreement for office space located in Augusta, New Jersey. The space is used for office and general use. The term of the lease is 24 months and began on January 1, 2023. The lease contains one 24 month renewal period, which requires 9 months’ notice if the Company intends to exercise. In March 2024, the Company notified the landlord of its intent to extend the lease for a 12-month period. A In April 2024, a lease extension agreement was entered into extending the lease through December 31, 2025. A Total rent is \$1,207 per month through December 31, 2024, and \$1,267 for the remaining term of the extended lease. A Park City Office Lease Agreement A On March 19, 2023, the Company entered into a lease agreement for office space located in Park City, Utah. A The space is used for office and general use. The term of the lease is for 36 months and began on May 1, 2023. The lease contains one 36 month renewal period, which requires 180 days’ notice of the Company’s intention to exercise. As of the date of these unaudited condensed consolidated financial statements, the Company does not intend to exercise the extension option. Total rent is \$3,200 per month for the first year with an annual increase of three percent per year on the anniversary of the effective date. A Future lease payments for all lease obligations for the following five fiscal years and thereafter are as follows (in thousands): A Years ending December 31: A Operating Lease A Remainder of 2024 A 24A 2025 A 98A 2026 A 14A Total minimum lease payments A 136A Less effects of discounting A (1) Present value of future minimum lease payments A 135A A Operating lease right-of-use assets and lease liabilities for the Company’s operating leases were recorded in the condensed consolidated balance sheets as follows: A A September 30, A A December 31, A A A 2024 A 2023 A Assets A A A A Operating lease right-of-use assets, net A 127A A 179A Total lease liabilities A 127A A 179A A A A A Liabilities A A A A A Current liabilities: A A A A A Current portion of operating lease liabilities A 99A A 91A Non-current liabilities: A A A A A Operating lease liabilities A 36A A 97A Total lease liabilities A 135A A 188A A 28Table of ContentsA Note 12. Net Loss per Share The Company’s Series A Convertible Preferred Stock, Series X Convertible Preferred Stock and outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. A Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at September 30, 2024, consisted of Series X Convertible Preferred Stock of 1,265,601 shares, warrants of 13,170,652, stock options of 95,813, and no Series A convertible preferred stock, restricted stock awards or restricted stock units. A Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at September 30, 2023, consisted of Series A convertible preferred stock of 286,125 shares, Series X convertible preferred stock of 1,267,469 shares, warrants of 1,104,215, stock options of 21,465, and restricted stock units of 2. A Net loss attributable to common stockholders for the nine months ended September 30, 2023, consists of net loss, as adjusted for deemed dividends. The Company recorded a deemed dividend for the modification of existing warrants and issuance of the Series E warrants (see Note 13, Equity Offerings) of \$0.8 million, during the nine months ended September 30, 2023. A Note 13. Equity Offerings Warrant Inducement Offer A On January 9, 2023, the Company reduced the exercise price of all existing warrants (the “Existing Warrants”), exercisable for 33,161 shares of the Company’s common stock held by an investor (the “Investor”), with exercise prices ranging from \$140.00 to \$5,265 per share to \$40.00 per share (the “2023 Warrant Repricing”). In connection with the 2023 Warrant Repricing, the Company entered into a Warrant Inducement Offer Letter (the “2023 Inducement Letter”) with the Investor pursuant to which it would exercise up to all of the 33,161 Existing Warrants (the “Inducement Offer”). In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company received approximately \$1.3 million in gross proceeds. The Company paid placement agent aggregate cash fees plus other offering costs of approximately \$0.2 million related to the Inducement Offer, resulting in net proceeds to the Company of \$1.1 million. In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company issued the Investor a new Series E common stock purchase warrant (the “Series E Warrant”) to purchase 33,161 shares of common stock at an exercise price of \$40.00 per share. The Series E Warrant is exercisable for five years from the date of stockholder approval. Exercise of the Series E Warrant in full was subject to approval of the Company’s stockholders other than the Investor, which was obtained at a special meeting of the Company’s stockholders held on March 21, 2023 (the “Stockholders’ Meeting”). The incremental fair value of the repriced warrants amounted to \$0.3 million and the fair value of Series E warrant totaled \$1.9 million. The relative fair value of such amounts were recorded to additional paid-in capital concurrent with the exercise of the Existing Warrants. A As a result of the 2023 Warrant Repricing and Inducement Offer, the Company presents a deemed dividend for the modification of Existing Warrants and issuance of the Series E Warrants of \$0 and \$0.8 million during the three and nine months ended September 30, 2023, respectively. The deemed dividend was included in net loss attributable to common stockholders in the calculation of net loss per share in the unaudited consolidated condensed statements of operations. A 29Table of ContentsA The warrants, other than the Series E Warrants that are presented in a separate table below, were valued on the date of the 2023 Warrant Repricing using the Black-Scholes model based on the following assumptions: A A 5/22/2020 Raise A 8/3/2020 Raise A Series B A Series C A Risk-free interest rate A 4.06% A 4.06% A 3.60% A 3.66% Volatility A 135.35% A 132.55% A 115.42% A 127.65% Expected dividend yield A 0.00% A 0.00% A 0.00% A 0.00% Expected life (in years) A 2.4 A 2.6 A 6.5 A 4.5 A The Series E warrants were also valued on the date of the 2023 Warrant Repricing at approximately \$1.9 million using the Black-Scholes model based on the following assumptions: A Risk-free interest rate A 3.66% Volatility A 124.07% Expected dividend yield A 0.00% Expected life (in years) A 5.0 A Private Placement A On January 9, 2023, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”), with the Investor. Pursuant to the Securities Purchase Agreement, the Investor agreed to purchase, for an aggregate purchase price of approximately \$8.0 million, (a) Class A units at a price that was the lower of \$3.00 per unit and 90% of the 5 day volume weighted average price of the Company’s common stock immediately prior to obtaining of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants (as each are defined below), without adjusting such price for the reverse stock split, each consisting of one tenth of one share of common stock, one tenth of one Series F common stock purchase warrant (the “Series F Warrant”), and one tenth of one Series G common stock purchase warrant (the “Series G Warrant”), and together with the Series F Warrants (the “PIPE Warrants”) and (b) Class B units at a price of \$1,000 per unit, each consisting of one share of a new series of the Company’s preferred stock, designated as Series A Convertible Preferred Stock (the “PIPE Preferred Stock”), par value \$0.0001, and one tenth of one Series F Warrant and one tenth of one Series G Warrant for each one-tenth of one share of the Company’s common stock underlying the PIPE Preferred Stock (each share of which is convertible into a number of shares of the Company’s common stock equal to \$1,000 divided by the lower of \$30.00 and 90% of the 5 day volume weighted average closing price, multiplied by ten in order to reflect the impact of the reverse stock split of the Company’s common stock immediately prior to the obtaining of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants, or the Preferred Conversion Rate). The closing under the Securities Purchase Agreement and the sale and issuance of the Class A units and Class B units (and the issuance of any underlying common stock) were approved at the Stockholders’ Meeting. At the closing of the Private Placement, the Company issued 497,908 Class A units for proceeds of approximately \$0.9 million and 7,203 Class B units for proceeds of approximately \$7.1 million which contained preferred shares that were convertible into up to 450,123 shares of common stock, as well as the issuance of warrants described below. A The PIPE Warrants, including Series F warrants and Series G warrants, are exercisable at an exercise price of \$30.00 per share, subject to adjustments as provided under the terms of the PIPE Warrants. The PIPE Warrants are exercisable at any time on or after the closing date of the Private Placement until the expiration thereof, except that the PIPE Warrants cannot be exercised if, after giving effect thereto, the purchaser would beneficially own more than 4.99%, or the Maximum Percentage, of the outstanding shares of common stock of the Company, which Maximum Percentage may be increased or decreased by the purchaser with written notice to the Company to any other percentage specified not in excess of 9.99%. The Series F Warrants have a term of two years from the date of stockholder approval, and the Series G Warrants have a term of six years from the date of stockholder approval. The Series F Warrants and Series G Warrants were approved at the Stockholders’ Meeting. A 30Table of ContentsA The Series F warrants and Series G warrants were valued, in aggregate, at approximately \$5.5 million using the Black-Scholes model based on the following assumptions: A A Series F A Series G A Risk-free interest rate A 3.8% A 3.4% Volatility A 80.0% A 74.0% Expected dividend yield A 0.0% A 0.0% Expected life (in years) A 2.0 A 6.0 A The proceeds from the Securities Purchase Agreement were allocated to the equity instruments issued based on their relative fair values and recorded in additional paid-in capital. A Shares of PIPE Preferred Stock, the conversion of which was approved at the Stockholders’ Meeting, convert into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. A Subject to limited exceptions, holders of shares of PIPE Preferred Stock will not have the right to convert any portion of their Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or up to 9.99% at the election of the holder) of the number of shares of the

Company’s common stock outstanding immediately after giving effect to its conversion. Holders of PIPE Preferred Stock will be entitled to receive dividends on shares of PIPE Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the PIPE Preferred Stock does not have voting rights. The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the resale of the shares of common stock, the shares issuable upon exercise of the Warrants and the shares issuable upon the conversion of the PIPE Preferred Stock. A Placement Fees In connection with offerings completed by the Company in 2022, (the “2022 Offerings”), the Company entered into an agreement with a placement agent that, subject to satisfaction of the requirements contained therein, called for a placement fee payable based on capital raised from certain investors for a definitive time following the expiration of the agreement. The accrued placement fee of approximately \$1.4 million related to the 2022 Offerings is included in accrued expenses in the consolidated balance sheets as of September 30, 2024. Additionally, the agreement called for the issuance of warrants with the following terms: A Number of shares Exercise Price Expiration 3,300A \$312.50A 5 years3,100A \$175.00A 5 yearsA 31Table of ContentsA The warrants were valued on the date of the 2022 Offerings using the Black-Scholes model based on the following assumptions: A Value (\$ in millions)A Expected VolatilityA Risk-Free Interest RateA Expected Dividend YieldA Expected Term (years)\$0.4A 93.25%A 1.81%A 0%A 5.0\$0.2A 96.70%A 2.87%A 0%A 5.0A September 2024 Public OfferingA On September 3, 2024, in connection with the September Public Offering (see Note 1), the Company sold an aggregate of 805,900 Common Stock Units and 2,773,000 Pre-Funded Warrant Units at a public offering price of \$1.00 per Common Stock Unit and \$0.9999 per Pre-Funded Warrant Unit. The Company received gross proceeds of approximately \$3.6 million less underwriting discounts and commissions of \$1.0 million, resulting in net proceeds of \$2.6 million. A Each Common Stock Unit consists of: (i) one share of the Company’s Common Stock, (ii) a Series H Warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires six months from the date of issuance, (iii) a Series I Warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires eighteen months from the date of issuance, and (iv) a Series J Warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires five years from the date of issuance. A Each Pre-Funded Warrant Unit consists of: (i) a Pre-Funded Warrant to purchase one share of Common Stock at an exercise price of \$0.0001 per share with no expiration date, (ii) one Series H Warrant, (iii) one Series I Warrant (iv) and one Series J Warrant. A Pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day Overallotment Option to purchase up to (i) 468,041 additional shares of Common Stock, (ii) 468,041 additional Series H Warrants, (iii) 468,041 additional Series I Warrants, and/or (iv) 468,041 additional Series J Warrants, solely to cover over-allotments. On August 30, 2024, the Underwriters partially exercised the Overallotment Option to purchase an additional 458,623 shares of Common Stock, 458,623 Series H Warrants, 458,623 Series I Warrants, and 458,623 Series J Warrants, or 458,623 Common Stock Units. The Common Stock Units issued through the exercise of the Overallotment Option are included in the 805,900 Common Stock Units noted above. The Overallotment Option expires on October 14, 2024, and is not expected to be exercised. The remaining balance of the Overallotment Option is not material to the condensed consolidated financial statements as of September 30, 2024. A Furthermore, at the closing date, the Company agreed to deliver warrants to purchase an aggregate number of shares of Common Stock equal to 6% of the shares of Common Stock (i) issued in connection with the September 2024 Public Offering and (ii) issuable upon the exercise of the Pre-Funded Warrants. Therefore, the Company issued 214,734 warrants to the Representative and its designees (the “Representative Warrants”). The Representative Warrants are part of the underwriter costs and commissions incurred in connection with the September 2024 Public Offering. The Representative Warrants may be exercised to purchase one share of Common Stock at an exercise price of \$1.55 per share and expires five years from the date of issuance. A Each Series H Warrant, Series I Warrant, Series J Warrant (collectively, the “Series Warrants”), and Pre-Funded Warrant is immediately exercisable. The exercise price of the Series Warrants and Pre-Funded Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s Common Stock. Subject to limited exceptions, a holder of the Series Warrants will not have the right to exercise any portion of its Series Warrants if the holder (together with such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% of the shares of Common Stock then outstanding (the “Beneficial Ownership Limitation”). Similarly, a holder of the Pre-Funded Warrants has a Beneficial Ownership Limitation of 9.99%. At the holder’s option, the holder of the Series Warrants may increase the beneficial ownership limitation to 19.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days’ prior notice to the Company. A The Representative Warrants are exercisable after six months from the effective date of the Registration Statement filed by the Company on August 29, 2024. The Representative Warrants further have a Beneficial Ownership Limitation of 4.99%, which may be increased to 9.99% of the shares of Common Stock then outstanding at the option of the Representative. Any increase in the Beneficial Ownership Limitation will become effective upon 61 days’ prior notice to the Company. A The Company assessed the Series Warrants, Pre-Funded Warrants, and Representative Warrants issued in connection with the September 2024 Public Offering (collectively, the “September 2024 Warrants”) and determined that they do not require liability classification pursuant to ASC 480. Furthermore, the September 2024 Warrants do not have any net cash settlement provisions that would preclude equity classification under ASC 815-40. Accordingly, the September 2024 Warrants were recorded to additional paid-in capital in the condensed consolidated balance sheets. A 32Table of ContentsA WarrantsA The following table presents the number of common stock warrants outstanding: A Warrants outstanding, December 31, 2023A 1,104,217A IssuedA 13,724,435A ExercisedA 1,658,000A ExpiredA 6A Warrants outstanding, September 30, 2024A 13,170,652A 33Table of ContentsA As of September 30, 2024, and December 31, 2024, all warrants outstanding are recorded in additional paid-in capital in the condensed consolidated balance sheets. The following table presents the number and type of common stock warrants outstanding, their exercise price, and expiration dates as of September 30, 2024: A Warrant TypeA Warrants OutstandingA Exercise PriceA Expiration DateA May 2020 WarrantsA 1,275A \$5,625.00A 5/20/2025A May 2020 Placement Agent WarrantsA 124A \$7,031.25A 5/20/2025A August 2020 WarrantsA 1,943A \$4,375.00A 8/3/2025A August 2020 Placement Agent WarrantsA 192A \$5,468.75A 7/30/2025A August 2021 Pharos Banker WarrantsA 148A \$1,495.00A 8/16/2026A February 2022 Series B WarrantsA 39,153A \$140.00A 2/4/2029A July 2022 Series C WarrantsA 28,404A \$140.00A 7/22/2027A January 2023 Series E WarrantsA 33,161A \$40.00A 3/21/2028A March 2023 Series F WarrantsA 499,909A \$30.00A 3/21/2025A March 2023 Series G WarrantsA 499,909A \$30.00A 3/21/2029A September 2024 Pre-Funded WarrantsA 1,115,000A \$0.00A NoneA September 2024 Series H WarrantsA 3,578,900A \$1.00A 3/3/2025A September 2024 Series I WarrantsA 3,578,900A \$1.00A 3/3/2026A September 2024 Series J WarrantsA 3,578,900A \$1.00A 9/3/2029A September 2024 Representative WarrantsA 214,734A \$1.55A 8/29/2029A A A 13,170,652A A A A A A A As of September 30, 2024, the warrants issued by the Company had a weighted average exercise price of \$5.29. A Note 14. Preferred Stock A Series X Convertible Preferred Stock As described in Note 3, above, pursuant to the Merger Agreement, all Old Catheter common stock shares issued and outstanding and convertible promissory notes, representing an aggregate principal of \$25.2 million, were converted into a right to receive 14,649,592 shares of a new class of the Company’s preferred stock, designated Series X Convertible Preferred Stock. A Series X Convertible Preferred Stock has no voting rights prior to the conversion into common stock. While there are generally no voting rights of the Series X Convertible Preferred Stock, there are protective rights regarding the sales of the company, change of control, etc. Series X Preferred Stock may convert into common stock only if the Company’s common stock has been delisted from the NYSE American or has been approved for initial listing on the NYSE American or another stock exchange, at a rate of 100 shares of common stock for each share of Series X Convertible Preferred Stock. A Other than dividends payable in shares of Common Stock, Holders of Series X Convertible Preferred Stock will be entitled to receive dividends on shares of Series X Convertible Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of Common Stock. A Upon consummation of the Merger, each holder of Old Catheter convertible promissory notes received, in exchange for discharge of the principal of his or its Notes, a number of shares of the Company’s Series X Convertible Preferred Stock representing a potential right to convert into the Company’s common stock in an amount equal to one common share for each \$32.00 of principal amount. A 34Table of ContentsA On March 21, 2023, the Company held the Stockholders’ Meeting, at which the stockholders approved, among other things, the issuance of 199,359 shares of common stock upon the conversion of 1,993,581 of Series X Convertible Preferred Stock which were issued upon the closing of the Merger, see Note 3, Business Combination. On March 23, 2023, the Company issued 197,491 shares of common stock upon the conversion of 1,974,905 of Series X Convertible Preferred Stock. On October 24, 2023, the remaining 1,868 shares of common stock were issued upon the conversion of 18,676 shares of Series X Convertible Preferred Stock. The remaining 12,656.011 shares of Series X Convertible Preferred Stock are expected to remain outstanding until the Company meets the initial listing standards of the NYSE American or another national securities exchange or is delisted from the NYSE American, at which time they will convert into common stock. A Series A Convertible Preferred Stock As described in Note 13, on January 9, 2023, the Company entered into a Securities Purchase Agreement for a Private Placement with the Investor. Pursuant to the Securities Purchase Agreement, shares of Series A Convertible Preferred Stock were issued, the conversion of which was approved at the Stockholders’ Meeting. The Series A Convertible Preferred Stock converts into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. A Subject to limited exceptions, holders of shares of Series A Convertible Preferred Stock will not have the right to convert any portion of their Series A Convertible Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to its conversion. A Holders of Series A Convertible Preferred Stock will be entitled to receive dividends on shares of Series A Convertible Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Convertible Preferred Stock does not have voting rights. A The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the shares of common stock, issuable upon the conversion of the Series A Convertible Preferred Stock. The shares have been registered for resale on an effective registration statement on Form S-1. A The following conversions of Series A Convertible Preferred Stock occurred subsequent to the issuance and prior to September 30, 2024: A Date of ConversionA Series A Shares ConvertedA Common Shares IssuedJuly 25, 2003A 1,750A 109,355July 24, 2023A 875A 54,678January 24, 2024A 875A 54,678July 1, 2024A 1,303A 81,423July 11, 2024A 1,000A 62,489July 22, 2024A 1,000A 62,500July 23, 2024A 400A 25,000A Each share of Series A Convertible Preferred Stock is convertible into approximately 62.5 shares of common stock. The common stock was issued pursuant to the exemption contained in Section 3(a)(9) of the Securities Act of 1933, as amended (the “Act”), which applies to transactions in which a security is exchanged by an issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. A The shares issued have been registered for resale on an effective registration statement on Form S-1. A 35Table of ContentsA After the final conversion on July 23, 2024, the Company had no shares of Series A Convertible Preferred Stock outstanding. A Note 15. Stock-Based Compensation A 2018 Equity Incentive Plan In September 2018, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2018 Equity Incentive Plan (the “2018 Plan”) which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company’s employees, directors and consultants. In July 2023, the 2018 Plan was replaced by the 2023 Equity Incentive Plan (the “2023 Plan”), as described below. As of July 2023, no additional awards could be made under the 2018 Plan and no shares of common stock were reserved for future issuance. As of September 30, 2024, there are 7 non-statutory stock options outstanding under the 2018 Plan. A Three expire in June 2028 and four expire in January 2030. A 2018 Employee Stock Purchase Plan In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the “ESPP”) which permitted eligible employees to purchase the Company’s common stock at a discount through payroll deductions during defined offering periods. Eligible employees could elect to withhold up to 15% of their base earnings to purchase shares of the Company’s common stock at a price equal to 85% of the fair market value on the first day of the offering period or the purchase date, whichever was lower. The number of shares of common stock reserved for issuance under the ESPP automatically increased on January 1 of each fiscal year by the lesser of (1) 23 shares, (2) 1.25% of the total number of shares outstanding on December 31 of the preceding fiscal year, or (3) such other amount as the Company’s board of directors may determine. A In April 2024, the Company formally terminated the ESPP. For the three and nine months ended September 30, 2024 and 2023, no cash was received from the exercise of purchase rights under the ESPP in each respective period. A As of September 30, 2024, the Company had issued 95 shares of common stock since inception of the ESPP, and no shares were reserved for future issuance. A As of December 31, 2023, the Company had issued 95 shares of common stock since inception of the ESPP, and 2 shares were reserved for future issuance. A Upon termination of the ESPP in April 2024, the reserved shares were released back to the authorized pool. A 2020 Inducement Equity Incentive Plan In March 2020, the Company adopted the 2020 Inducement Equity Incentive Plan (the “2020 Plan”) for the purpose of attracting, retaining and incentivizing employees in furtherance of the Company’s success. The 2020 Plan was adopted without stockholder approval pursuant to Rule 303A.08 of the New York Stock Exchange. The 2020 Plan is used to offer equity awards as material inducements for new employees to join the Company. Upon adoption of the 2020 Plan, 64 shares of common stock were reserved for the granting of inducement stock options, restricted stock awards, restricted stock units and other forms of equity awards. As of September 30, 2024 and December 31, 2023, zero and 54 shares of common stock were reserved for future issuance under the 2020 Plan. In April 2024, the Company terminated the 2020 Plan at which time the reserved shares were released back to the authorized pool. A 36Table of ContentsA Stock Options Assumed in Merger (See Note 3, Business Combination) A At the closing of the Merger, each outstanding option to purchase Old Catheter common stock that had not previously been exercised prior to the closing of the Merger was assumed and converted into options to purchase 75,365 shares of the Company’s common stock (the “Replacement Options”). Additionally, no Old Catheter options were amended in connection with the Merger. All the Replacement Options vested in accordance with the original terms of the grants in place at the time of the Merger. As a result, \$3.4 million of purchase price consideration, which represented the estimated fair value of Old Catheter’s assumed stock options, and \$1.1 million of stock-based compensation expense, which represents the excess of the estimated fair value of the Replacement Options over the assumed Old Catheter stock options, were recognized upon the closing of the Merger. A 2023 Equity Incentive Plan In July 2023, the Company’s stockholders approved, the 2023 Plan, as defined above, which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company’s employees, directors and consultants. Stock options granted under the 2023 Plan to employees and consultants generally will vest annually over a five-year period or as determined by the Board’s Compensation Committee, while grants to non-employee directors generally vest quarterly over a three-year period. A As of September 30, 2024 and December 31, 2023, 225,085 and 50,186 shares of common stock were reserved for future issuance pursuant to the 2023 Plan. The number of shares available for issuance under the 2023 Plan also includes a quarterly increase commencing on September 1, 2023 by an amount equal to the lesser of (i) 10% of the number equal to the number of shares of common stock outstanding on the applicable adjustment date less the number of shares of common stock outstanding at the beginning of the fiscal quarter immediately preceding the adjustment date, but if such number is a negative number, then the increase will be zero; or (ii) such lesser number of shares as may be determined by the Board. A On January 8, 2024, the Board approved the issuance of a total of 28,500 non-qualified stock options under the 2023 Plan. 7,500 of these non-qualified options were issued to non-employee directors that vest at 8 1/3% per quarter for 3 years with an exercise price of \$4.00 and expiration date of January 8, 2034. The remaining 21,000 non-qualified options were issued to employees and consultants and vest at 20% per year for 5 years with an exercise price of \$4.00 and expiration date of January 8, 2034. A On February 26, 2024, the Board approved the issuance of a total of 15,000 incentive stock options under the 2023 Plan. All options were issued to employees and vest at 20% per year for 5 years with an exercise price of \$4.20 and expiration date of February 26, 2034. A On April 24, 2024, the Board approved the issuance of a total of 12,500 incentive stock options under the 2023 Plan. A All options were issued to employees and vest at 20% per year for 5 years with an exercise price of \$4.60 and expiration date of April 24, 2034. A On July 9, 2024, the Board approved the issuance of a total of 10,000 incentive stock options under the 2023 Plan. A All options were issued to employees and vest at 20% per year for 5 years with an exercise price of \$3.50 and expiration date of July 9, 2034. A 37Table of ContentsA The options issued during the three and nine months ended September 30, 2024 were valued at approximately \$262 thousand using the Black-Scholes model based on the following assumptions on the date of issue: A A Non-Employee Director Options Issued January 8, 2024A A Employee Options Issued January 8, 2024A A Employee Options Issued February 26, 2024A A Employee Options Issued April 24, 2024A A Employee Options Issued July 9, 2024A Risk-free interest

rateÄ 4.01%Ä 4.01%Ä 4.01%Ä 4.28%Ä 4.65%Ä 4.30%VolatilityÄ 175.36%Ä 175.36%Ä 178.14%Ä 211.61%Ä 214.61%Expected dividend yieldÄ 0.0%Ä 0%Ä 0%Ä 0%Ä 0%Ä 0%Expected life (in years)Ä 6.5Ä 6.5Ä 6.5Ä 6.5Ä 6.5Ä 6.5Ä Non-Plan Options IssuedÄ On April 24, 2024, the Board approved the issuance of a total of 25,000 Non-Plan Options as an employment incentive for the position of Chief Commercial Officer. The options were issued on May 1, 2024, the first day of employment and vest at 20% per year for 5 years with an exercise price of \$5.321 and an expiration date of May 1, 2034.Ä The non plan options issued were valued at approximately \$131 thousand using the Black-Scholes model based on the following assumptions on the date of issue:Ä Non-Plan Options Issued May 1, 2024Ä Risk-free interest rateÄ 4.63%VolatilityÄ 211.61%Expected dividend yieldÄ 0%Expected life (in years)Ä 6.5Ä The following is a summary of stock option activity for the nine months ended September 30, 2024:Ä Ä Ä Stock OptionsÄ Ä Weighted Average Exercise PriceÄ Ä Weighted Average Remaining Life (in years)Ä Ä Aggregate Intrinsic Value (in thousands)Ä Outstanding at December 31, 2023Ä 21,465Ä Ä \$64.71Ä Ä 6.38Ä Ä \$äcÄ Ä Options exercisedÄ äcÄ Ä \$äcÄ Ä Ä Ä Ä Ä Ä Ä Options grantedÄ 91,000Ä Ä 4.42Ä Ä Ä Ä Ä Ä Ä Ä Canceled/forfeitedÄ (16,652)Ä Ä \$4.50Ä Ä Ä Ä Ä Ä Ä Ä Ä Ä Outstanding at September 30, 2024Ä 95,813Ä Ä \$17.92Ä Ä Ä 8.86Ä Ä Ä \$4,510.00Ä Vested and expected to vest at September 30, 2024Ä 95,813Ä Ä \$17.92Ä Ä Ä 8.86Ä Ä \$4,510.00Ä Exercisable at September 30, 2024Ä 18,148Ä Ä \$75.35Ä Ä Ä 6.07Ä Ä \$äcÄ Ä Ä Restricted Stock UnitsÄ All restricted stock units have been forfeited or vested as of December 31, 2023.Ä Ä Ä 38Table of ContentsÄ Restricted Stock AwardsÄ All restricted stock awards have been forfeited or vested as of December 31, 2023.Ä Stock-based compensation expense for the three and nine months ended September 30, 2024 was \$17 thousand and \$36 thousand, respectively, in selling, general and administrative expenses in the condensed consolidated statements of operations. Stock-based compensation expense for the three and nine months ended September 30, 2023 was \$2 thousand and \$1.2 million respectively, in the Company's condensed consolidated statements of operations.Ä Total unrecognized estimated stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized at September 30, 2024 was as follows:Ä Ä Ä Unrecognized Expense (in thousands)Ä Ä Remaining Weighted Average Recognition Period (in years)Ä Stock optionsÄ \$309Ä Ä 4.4Ä Restricted stock awardsÄ \$äcÄ Ä Ä Ä Ä Restricted stock unitsÄ \$äcÄ Ä Ä Ä Ä Ä Note 16. Income TaxesÄ The provision for income taxes for interim periods is determined using an estimated annual effective tax rate. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where the Company conducts business.Ä For the three and nine months ended September 30, 2024 and 2023, the Company did not record any federal or state income tax provision or benefit due to net losses incurred for all periods presented. The Companyäc™s net deferred tax assets generated mainly from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.Ä As of September 30, 2024, the Company has an open sales and use tax audit with the California Department of Tax and Fee Administration covering the period from October 1, 2020 through March 31, 2023.Ä Note 17. Commitments and ContingenciesÄ In the normal course of business, the Company is at times subject to pending and threatened legal actions. In managementäc™s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company.Ä As of September 30, 2024, the Company had no outstanding litigation.Ä Ä 39Table of ContentsÄ Note 18. Employee Benefit PlanÄ In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (äcä01(k) Planäc). Under the terms of the 401(k) Plan, all full-time employees were eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company made matching contributions based on 100% of each employeeäc™s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employeeäc™s eligible compensation. The Company cancelled the 401(k) Plan effective March 10, 2023 and distributed all assets held by the 401(k) Plan to the participants. The Company had no expenses related to the matching contributions for the three and nine months ended September 30, 2024 and 2023.Ä Note 19. Related PartiesÄ Prior to the Merger, David A. Jenkins, the Companyäc™s current Executive Chairman of the Board and Chief Executive Officer, and Old Catheteräc™s then Chairman of the Board of Directors, and his affiliates held approximately \$25.1 million of Old Catheteräc™s Convertible Promissory Notes, or the Notes, that were converted in the Old Catheter merger into 7,856.251 shares of Series X Convertible Preferred Stock (see Note 3, Business Combination, and Note 14, Preferred Stock). In consideration for forgiving the interest accrued but remaining unpaid under the Notes in an aggregate amount of approximately \$13.9 million, Mr. Jenkins and his affiliates also received royalty rights equal to approximately 12% of the net sales, if any, of LockeT, commencing upon the first commercial sale and through December 31, 2035 (see Note 10, Royalties Payable).Ä In addition to the shares described above that were issued in connection with the Notes, Mr. Jenkins and his affiliates received 1,325.838 shares of Series X Convertible Preferred Stock in the merger, and Mr. Jenkinsäc™ adult children received 1,284.344 shares of Series X Convertible Preferred Stock in the merger, all in exchange for their equity interests in Old Catheter in accordance with the merger exchange ratio.Ä In connection with the Merger (see Note 3, Business Combination), the Company assumed \$1.4 million of accrued expenses and advances, of which \$1.1 million was due to Mr. Jenkins and was paid on January 10, 2023.Ä Mr. Jenkinsäc™ daughter, the Companyäc™s non-executive Chief Operating Officer, received options to purchase 14,416 shares of the Companyäc™s common stock upon the closing of the merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the merger. Of the total options to purchase 14,416 shares of the Companyäc™s common stock, 14,081 options have an exercise price of \$5.90 per share, and the remaining 335 options have an exercise price of \$20.20 per share.Ä Margrit Thomassen, the Companyäc™s Interim Chief Financial Officer, received options to purchase 1,676 shares of the Companyäc™s common stock upon the closing of the merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the merger.Ä The options have an exercise price of \$5.90 per share.Ä In January 2024, she received an option to purchase 2,500 shares of the Companyäc™s common stock under the 2023 Plan.Ä The options have an exercise price of \$4.00 per share, vest at 20% per year for 5 years and expire in January 2034.Ä Following stockholder approval on March 21, 2023, the Company issued 99,182 shares of common stock to Mr. Jenkins and affiliates upon conversion of 991.828 shares of Series X Convertible Preferred Stock, and 23,532 shares of common stock to his adult children upon conversion of 235.320 shares of Series X Convertible Preferred Stock.Ä On May 1, 2024, Marie-Claude Jacques, the Companyäc™s Chief Commercial Officer, received a non-plan option to purchase 25,000 shares of the Companyäc™s common stock.Ä The options have an exercise price of \$5.321 per share, vest at 20% per year for 5 years and expire in May 2034.Ä During the three months ended September 30, 2024, the Company entered into various short-term promissory notes with various related parties (the äcäRelated Party Notesäc). These Related Party Notes had a maturity date of August 30, 2024 and interest rates of 8% per annum. On August 23, 2024, the Notes were amended to extend the maturity date to January 31, 2026 and increase the interest rate to 12% per annum effective August 31, 2024. See Note 9, Notes Payable for further information.Ä Ä 40Table of ContentsÄ The related parties and the amounts owed to each related party are summarized in the following table (in thousands):Ä Related Party Issuance DateÄ Principal AmountÄ Interest PaidÄ Interest AccruedÄ David JenkinsÄ 5/30/2024Ä \$500Ä Ä \$10Ä Ä \$5Ä FatBoy CapitalÄ 6/25/2024Ä \$150Ä Ä \$2Ä Ä \$2Ä FatBoy CapitalÄ 7/1/2024Ä \$250Ä Ä \$3Ä Ä \$3Ä FatBoy CapitalÄ 7/18/2024Ä \$100Ä Ä \$1Ä Ä \$1Ä Jenkins Family Charitable InstituteÄ 7/25/2024Ä \$500Ä Ä \$4Ä Ä \$5Ä Ä On September 3, 2024, the Jenkins Family Charitable Institute also invested approximately \$500,000 in the Companyäc™s public offering and received 265,000 shares of common stock; 235,000 pre funded warrants with an exercise price of \$0.0001 and no expiration date; 500,000 Series H Warrants with an exercise price of \$1.00 per share that expire on March 3, 2025; 500,000 Series I Warrants with an exercise price of \$1.00 per share that expire on March 3, 2026; and 500,000 Series J Warrants with an exercise price of \$1.00 per share that expire on September 3, 2029.Ä Note 20. Subsequent EventsÄ 2024 Warrant Inducement OfferÄ On October 24, 2024, the Company executed the 2024 Inducement Offer with certain holders of the Existing Warrants. The Existing Warrants had exercise prices ranging from \$1.00 to \$40.00 per share. Following the closing of the 2024 Inducement Offer, such holders immediately exercised an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants to purchase up to 5.3 million shares of Common Stock at a reduced exercise price of \$0.70 per share.Ä In consideration for the immediate exercise of the Existing Warrants for cash, the Company issued unregistered new Series K Common Stock Purchase Warrants (äcäSeries K Warrantsäc) to purchase up to a number of shares equal to 200% of the number of shares of Common Stock issued pursuant to the exercise of the Existing Warrants. The Series K Warrants have an exercise price of \$0.70 per share, a term of 5.5 years following stockholder approval, and are not exercisable until such approval is obtained.Ä As additional consideration, the company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is \$1.085 per share and have a termination date of October 28, 2029.Ä The Company received aggregate gross proceeds of approximately \$3.7 million in cash from the exercise of the Existing Warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expenses of \$0.4 million. As of the date of the 2024 Inducement Offer, 578,900 Series H and 1,078,900 Series I warrants remained unexercised.Ä Prior to the repricing and execution of the 2024 Inducement Offer, the Company received additional gross proceeds of approximately \$1.2 million from the exercise of 1,010,000 Series H Warrants and 175,000 Series I Warrants in accordance with their original terms (as summarized below).Ä Ä Issuance of Securities from Warrant ExercisesÄ Aside from the common stock issued in connection with the 2024 Warrant Inducement Offer, the Company also issued common stock in connection with the following exercises of warrants (in thousands):Ä Name of WarrantÄ Exercise DateÄ Issue DateÄ Shares Common Stock IssuedÄ Number of Warrants ExercisedÄ Ä ProceedsÄ September 2024Ä Pre-Funded Warrant. Ä 10/3/2024Ä 10/4/2024Ä Ä 250,000Ä Ä Ä 250,000Ä Ä \$äcÄ Ä September 2024Ä Pre-Funded WarrantÄ 10/16/2024Ä 10/16/2024Ä Ä 196,000Ä Ä Ä 196,000Ä Ä \$äcÄ Ä September 2024Ä Pre-Funded Warrant Ä 10/18/2024Ä 10/21/2024Ä Ä 434,000Ä Ä Ä 434,000Ä Ä \$äcÄ Ä September 2024Ä Series H WarrantÄ 10/18/2024Ä 10/21/2024Ä Ä 1,010,000Ä Ä Ä 1,010,000Ä Ä \$1,010Ä September 2024Ä Series I WarrantÄ 10/18/2024Ä 10/21/2024Ä Ä 175,000Ä Ä Ä 175,000Ä Ä \$175Ä September 2024Ä Pre-Funded WarrantÄ 10/29/2024Ä 10/29/2024Ä Ä 235,000Ä Ä Ä 235,000Ä Ä \$äcÄ Ä Ä Ä Ä 41Table of ContentsÄ ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSÄ Special Note Regarding Forward Looking StatementsÄ This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that are based on our managementäc™s beliefs and assumptions and on information currently available. This section should be read in conjunction with our unaudited condensed financial statements and related notes included in Part I, Item 1 of this report. The statements contained in this Quarterly Report that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.Ä Forward-looking statements can be identified by words such as äcäbelieve,äc äcäanticipate,äc äcäömay,äc äcäömight,äc äcäöcan,äc äcäöcould,äc äcäöcontinue,äc äcäödepends,äc äcäöexpect,äc äcäöexpand,äc äcäöforecast,äc äcäöintend,äc äcäöpredict,äc äcäöplan,äc äcäörely,äc äcäöshould,äc äcäöwill,äc äcäömay,äc äcäöseek,äc or the negative of these terms or and other similar expressions, although not all forward-looking statements contain these words. These statements include, but are not limited to, our expectations regarding CE Mark approval for LockeT. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other äcäforward-lookingäc information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements.Ä These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including, but not limited to, those described in Item 1A, Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2023. These risks include, but are not limited to, that: our ability to obtain CE Mark approval for LockeT is subject to the discretion of EU regulators, and they may require additional information from us or that we conduct additional studies or trials that we may not be able to easily or cost effectively provide or complete, we will be required to raise additional funds to finance our operations and continue as a going concern, and we may not be able to do so when necessary, and/or the terms of any financings may not be advantageous to us, our business has a history of losses, will incur additional losses, and may never achieve profitability, we have identified material weaknesses in our internal control over financial reporting and these material weaknesses could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner, compliance with Sarbanes-Oxley Act Section 404 could have a material adverse impact on our business, we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals; our VIVO launch plans require significant investment in infrastructure and sales representatives, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to LockeT, the surgical vessel closing pressure device, will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business,Ä Ä if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, our revenues may depend on our customersäc™ receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any,Ä Ä a variety of risks associated with marketing our products internationally could materially adversely affect our business, the impact of the military conflicts in Ukraine and Israel, and the actions that have been and could be taken by other countries, including new and stricter sanctions and actions taken in response to such sanctions, have affected, and may continue to affect, our business and results of operations, including our supply chain, if the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for or commercialize our product candidates, we may be adversely affected by product liability claims, unfavorable court decisions or legal settlements, our ability to use our net operating loss carryforwards may be limited, we may have to make milestone payments under the Settlement Agreement we entered into with the Department of Justice (äcäDOJäc), we are subject to pervasive and continuing regulation by the FDA and other regulatory agencies. Our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the United States (äcäU.S.äc) and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results, product clearances and approvals can often be denied or significantly delayed, although we have obtained regulatory clearance for our VIVO and LockeT products in the U.S. and certain non-U.S. jurisdictions, our business plans include expanding uses for our products, which will require additional clearances; and even after clearance is obtained, our products remain subject to extensive regulatory scrutiny, if we or our suppliers fail to comply with the FDAäc™s Quality System Regulation, or QSR, or any applicable state equivalent, our operations could be interrupted, and our potential product sales and operating results could suffer, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, if any of our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be required to report under applicable medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions, healthcare reform initiatives and other administrative and legislative proposals may adversely affect our business, financial condition, results of operations and cash flows in our key markets, and if we are unable to obtain and maintain patent protection for our products, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our existing products and any products we may develop, and our technology may be adversely affected.Ä Ä 42Table of ContentsÄ These forward-looking statements reflect our beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Quarterly Report and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We qualify all of the

forward-looking statements in this Quarterly Report by these cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.Â This Quarterly Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.Â References to âââ, âââââ, âââââ and âââââ Companyâ refer to Catheter Precision, Inc.Â OverviewÂ Catheter Precision, Inc. ("Catheter" or the "Company") was incorporated in California on September 4, 2002, and reincorporated in Delaware in July 2018. Catheter was initially formed to develop, commercialize, and market its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases.Â On January 9, 2023, the Company merged with the former Catheter Precision, Inc., or ââOld Catheterâ, a privately-held Delaware corporation (the ââMergerâ), and the business of Old Catheter became a wholly owned subsidiary of the Company, which today is our only operating subsidiary. Following the Merger, we discontinued the Companyâââs legacy lines of business and the use of any of its DABRA-related assets. For further information about these historical lines of business, see ââItem 1. Businessâ of the Companyâââs Form 10-K for the fiscal year ended December 31, 2021.Â Since the Merger, we have shifted the focus of our operations to Old Catheterâââs product lines. Accordingly, our current activities primarily relate to Old Catheterâââs historical business which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology, or ââEP.âÂ A 43Table of ContentsÂ One of our two primary products is the View into Ventricular Onset (ââVIVOâ or ââVIVO Systemâ). VIVO is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures.Â Our newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. LockeT is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently.Â Our product portfolio also includes the AmigoÂ® Remote Catheter System, or Amigo, a robotic arm that serves as a catheter control device. Prior to 2018, Old Catheter marketed Amigo. We own the intellectual property related to Amigo, and this product is under consideration for future research and development of a generation 2 product.Â A Pre-Merger Operations Â The Company owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. The Destruction of Arteriosclerotic Blockages by laser Radiation Ablation, laser and single-use catheter, together referred to as the DABRA Excimer Laser System or DABRA, was developed as a tool in the treatment of Peripheral Artery Disease which commonly occurs in the legs. The Company also previously marketed the Pharos laser which was used to treat proliferative skin conditions. The Company completed the sale of its Pharos laser business, or Dermatology Business, to STRATA Skin Sciences, Inc. on August 16, 2021. Â In June 2022, the board of directors reviewed strategic alternatives, and as a result, the Company paused all engineering activities related to DABRA in June 2022. The Company ceased marketing the DABRA Excimer Laser System and does not currently intend to commercialize the DABRA 2.0 catheter.Â A Post-Merger OperationsÂ Looking forward, we do not expect to use our legacy DABRA-related assets or continue the Company's legacy lines of business, but instead have shifted the focus of our operations to Old Catheterâââs product lines. Accordingly, our current activities primarily relate to Old Catheterâââs historical business, which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology, or EP.Â One of our two primary products is the VIVO System. We are focused on the design, market development and usage adoption of our VIVO System by cardiac electrophysiologists to enhance their ability to diagnose and treat cardiac arrhythmias. We have completed development, received regulatory clearance, and initiated sales of the VIVO System in the U.S., Europe (ââEUâ) and the Middle East.Â Our business strategy is to become a leading medical imaging company in the field of cardiac electrophysiology, and we are dedicated to developing and delivering electrophysiology products to provide patients, hospitals, and physicians with novel technologies and solutions to improve the lives of patients with cardiac arrhythmias. We aim to establish VIVO as an integral tool used by cardiac electrophysiologists during ablation treatment of ventricular arrhythmias by reducing procedure time and patient complications and increasing procedural success.Â We have received FDA clearance to market and promote the VIVO System in the U.S. as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment for idiopathic ventricular arrhythmias. VIVO allows for the acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician. We began a limited commercial launch of VIVO in 2021 and to date, VIVO has been utilized in more than 1,000 procedures in the U.S. and EU by over 30 physicians, with no reported device-related complications. Â A 44Table of ContentsÂ We have been cleared to label the VIVO System with the CE Mark in the EU and certain other countries. The CE Mark designation, which affirms the productââs conformity with European health, safety, and environmental protection standards, allows us to market that product in countries that are members of the EU and the European Free Trade Association. Catheter has commenced limited sales of the VIVO System in Europe and the UK through independent distributors. Catheterââs international distributors are supported by two EU based full time consultants.Â In addition, our newest product is LockeT, a suture retention device. LockeT is indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure, and it is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. LockeT is a sterile Class I product that was registered with the FDA in February 2023, at which time we began initial shipments to distributors. In May 2024, we recognized our first sale of LockeT. In May 2023, Catheter submitted LockeT for CE Mark approval. CE Mark approval is expected in March 2025, at which time initial international shipments to distributors will begin. In September 2024, we received notification of the issuance of our first LockeT patent in the country of China and we also completed a Middle East distribution agreement for LockeT.Â A Clinical studies for LockeT began during the year ended December 31, 2023. The three phases of the current studies are planned to show the productââs effectiveness and benefits, including faster wound closure, earlier ambulation, potentially leading to early hospital discharge, and lower costs for the healthcare provider and/or insurance payor. This data is intended to provide crucial data for marketing and to expand our indications for use with the FDA.Â A Recent DevelopmentsÂ September 2024 Public OfferingÂ On August 30, 2024, the Company entered into an underwriting agreement to issue and sell in a public offering (i) 347,277 Common Stock Units, priced at a public offering price of \$1.00 per unit, with each unit consisting of (a) one share of Common Stock, (b) one warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires on the six month anniversary of the date of issuance (a ââSeries H Warrantâ), (c) one warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires on the eighteenth month anniversary of the date of issuance (a ââSeries I Warrantâ), and (d) one warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires on the five year anniversary of the date of issuance (a ââSeries J Warrantâ), and (ii) 2,773,000 Pre-Funded Warrant Units, priced at a public offering price of \$0.9999 per unit, with each unit consisting of (a) one pre-funded warrant to purchase one share of Common Stock at an exercise price of \$0.0001 per share that has no expiration date (a ââPre-Funded Warrantâ), (b) one Series H Warrant, (c) one Series I Warrant, and (d) one Series J Warrant.Â In addition to the securities described above, the Company granted the underwriter a 45-day Overallotment Option to purchase up to (i) 468,041 additional shares of Common Stock, (ii) 468,041 additional Series H Warrants, (iii) 468,041 additional Series I Warrants, and/or (iv) 468,041 additional Series J Warrants, solely to cover over-allotments. On August 30, 2024, the Underwriters partially exercised the Overallotment Option to purchase an additional 458,623 shares of Common Stock, 458,623 Series H Warrants, 458,623 Series I Warrants, and 458,623 Series J Warrants.Â In the aggregate, the Company issued and sold (i) 805,900 Common Stock Units, (ii) 2,773,000 Pre-Funded Warrant Units, and (iii) 214,734 warrants that were issued as part of the underwriterââs compensation, which have an exercise price of \$1.55, are not exercisable until March 1, 2025 and expire on August 29, 2029. The public offering closed on September 3, 2024. The net proceeds to the Company, after deducting the underwriting discount, commissions, and management fee and offering expenses payable by the Company, were approximately \$2.6 million. Â A Debt ModificationÂ Between May 30, 2024 and July 25, 2024, the Company issued five short-term promissory notes to related parties totaling \$1.5 million with an 8% interest rate and a maturity date of August 30, 2024. On August 23, 2024, the Company amended the promissory notes to extend the maturity date to January 31, 2026. As part of the amendment, all interest accrued as of the amendment date was repaid to the notes holders and the contractual interest rate increased to 12% per annum as of the amendment date. The modified terms and conditions were not substantially different from the original terms and conditions, and the Company applied modification accounting, which resulted in the new carrying amount of the debt being equal to the remaining principal balance of the old debt. The previously outstanding accrued interest through August 30, 2024 was repaid in accordance with the terms of the amendment. Â A 45Table of ContentsÂ Issuance of Securities from Warrant ExercisesÂ Aside from the common stock issued in connection with the 2024 Warrant Inducement Offer, the Company also issued common stock in connection with the following exercises of warrants (in thousands):Â Name of WarrantÂ Exercise DateÂ Issue DateÂ Shares Common Stock IssuedÂ A Number of Warrants Exercised Â A ProceedsÂ September 2024 Pre FundedÂ 10/3/2024Â 10/4/2024Â A 250,000Â A \$âÂ A September 2024 Pre FundedÂ 10/16/2024Â 10/16/2024Â A 196,000Â A \$âÂ A September 2024 Pre FundedÂ 10/18/2024Â 10/21/2024Â A 434,000Â A \$âÂ A September 2024 Series HA 10/18/2024Â 10/21/2024Â A 1,010,000Â A \$1,010,000Â A \$1,010,000Â A September 2024 Series IA 10/18/2024Â 10/21/2024Â A 175,000Â A \$175,000Â A \$175,000Â A September 2024 Pre-FundedÂ 10/29/2024Â 10/29/2024Â A 235,000Â A \$âÂ A Reverse Stock SplitÂ On July 3, 2024, at the annual meeting of shareholders of the Company, the shareholders approved an amendment to the Amended and Restated Certificate of Incorporation of the Company (the ââAmendmentâ) which included a decrease in the authorized common stock and authorization for the Board, in its discretion, to effect a reverse stock split within specified parameters.Â The Amendment was effective July 15, 2024, reducing the authorized common stock to 30 million shares and effecting a reverse stock split in which each ten (10) shares of the Companyââs common stock, par value \$0.0001 per share, issued and outstanding immediately prior to the effective time automatically combined into one (1) validly issued, fully paid and non-assessable share of common stock, par value \$0.0001 per share.Â A No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive a fractional share were entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). The financial statements and all share and per share information contained in this Form 10-Q have been retrospectively adjusted to reflect the Reverse Stock Split of the Companyââs common stock for all periods presented.Â A Expansion of Sales ForceÂ Beginning in the first quarter of 2024, we began to rejuvenate our sales force with plans to engage a new Chief Commercial Officer ("CCO"). As of November 2024, the sales force is placed fully in service and ten sales people and three clinical support staff have been hired, along with the new CCO.Â A Settlement Agreements with the Department of Justice and Participating StatesÂ On December 28, 2020, the Company entered into a settlement agreement with the U.S., acting through the Department of Justice ("DOJ") and on behalf of the Office of Inspector General, and other settlement agreements with certain state attorneys general (collectively the "Settlement Agreements"), to resolve investigations and a related civil action concerning its marketing of the DABRA laser system and DABRA-related remuneration to certain physicians. Pursuant to the terms of the Settlement Agreements, if the Company was acquired or was otherwise involved in a change in control transaction (as defined in the Settlement Agreements) before the end of 2024, the Company was required to pay a settlement amount of \$5.0 million. As a result of the Merger, the Company made payments of \$4.7 million and \$0.3 million to the DOJ and participating states, respectively, in February 2023. Additional contingent payments may be required in the future if certain revenue milestones are achieved. However, no liability has been recorded for additional payments based on the Companyââs determination that additional future payments are not probable at this time.Â A 46Table of ContentsÂ Warrant Inducement OffersÂ On January 9, 2023, we reduced the exercise price of certain existing warrants, exercisable for 33,161 shares of the Company's common stock held by a certain investor (the ââInvestorâ), with exercise prices ranging from \$140 to \$5,265 per share to \$40 per share, or the Warrant Repricing. In connection with the Warrant Repricing, we entered into a warrant inducement offer letter (the ââInducement Letterâ), with the Investor pursuant to which it would exercise up to all of the 33,161 existing warrants (the ââInducement Offerâ). In consideration for exercising the existing warrants pursuant to the terms of the Inducement Letter, we received approximately \$1.3 million in gross proceeds. We paid the placement agent aggregate cash fees of approximately \$0.2 million related to the Inducement Offer which represented 8.0% of the gross proceeds received from the Inducement Offer plus other offering costs. In consideration for exercising the existing warrants pursuant to the terms of the Inducement Letter, we issued the Investor a new Series E common stock purchase warrant (ââSeries E Warrantâ), to purchase 33,161 shares of common stock at an exercise price of \$40 per share. The Series E Warrant is exercisable for five years from the date of stockholder approval. Exercise of the Series E Warrant in full was approved by the Company's stockholders at the special Stockholdersââ Meeting held on March 21, 2023. The incremental fair value of the repriced warrants amounted to \$0.3 million and the fair value of Series E warrant totaled \$1.9 million.Â The relative fair values of such amounts were recorded to additional paid-in capital concurrent with the exercise of the existing warrants. We registered the shares of common stock underlying the Series E Warrant for resale in February 2023.Â On October 24, 2024, we entered into Warrant Inducement Offer Letters (the ââ2024 Inducement Offerâ) with certain holders of the Companyââs existing warrants. Following the closing of the 2024 Inducement Offer, such warrant holders immediately exercised up to an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants to purchase up to approximately 5.3 million shares of the Companyââs Common Stock at a reduced exercise price of \$0.70 per share. In consideration for the immediate exercise of the existing warrants for cash, the Company agreed to issue unregistered new Series K Common Stock Purchase Warrants (ââSeries K Warrantsâ) to purchase up to 10.7 million shares of common stock. We received aggregate gross proceeds of approximately \$3.7 million in cash from the exercise of these warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expense of \$0.4 million. Due to beneficial ownership blockers we have issued 2,251,981 shares of common stock and 3,096,000 outstanding pre-funded warrants related to the 2024 Inducement Offer as of November 1, 2024. The Series K Warrants are not exercisable unless and untilÂ we obtain stockholder approval of their exercise. In connection with the 2024 Inducement Offer, we repriced all outstanding Series A H and Series I Warrants to \$0.70 per share, including those that were not exercised. As partial consideration to the placement agent, we issued placement agent warrants to purchase up to 320,879 shares of common stock on substantially the same terms as the Series K warrants, except the exercise price is \$1.085 per share and they have a termination date of October 28, 2029.Â A Securities Purchase AgreementÂ On January 9, 2023, we entered into a Securities Purchase Agreement (the "Securities Purchase Agreement"), for a private placement (the "Private Placement"), with the Investor. Pursuant to the Securities Purchase Agreement, on March 23, 2023, the Investor purchased, for an aggregate purchase price of approximately \$8.0 million, (a) 497,908 Class A Units at a price of \$1.60029 per Class A Unit, each consisting of one tenth of one share of common stock, one tenth of one Series F Common Stock Purchase Warrant, or Series F Warrant, and one tenth of one Series G Common Stock Purchase Warrant, or Series G Warrant, and together with the Series F Warrant, the PIPE Warrants, and (b) 4,501,060 Class B Units at a price of \$1,000 per unit, each consisting of one share of a new series of the Companyââs preferred stock, designated as Series A Convertible Preferred Stock, par value \$0.0001, or the PIPE Preferred Stock, and one tenth of one Series F Warrant and one tenth of one Series G Warrant for each share of the Companyââs common stock underlying the PIPE Preferred Stock, each share of which is convertible into approximately 62.5 shares of the Companyââs common stock (the ââPreferred Conversion Rateâ). The closing under the Securities Purchase Agreement and the sale and issuance of the Class A Units and Class B Units (and the issuance of any underlying common stock) was approved at the special Stockholdersââ Meeting held March 21, 2023. We paid placement agent aggregate cash fees plus other offering costs of approximately \$0.2 million related to the Inducement Offer, resulting in net proceeds of \$1.1 million.Â A 47Table of ContentsÂ The PIPE Warrants are exercisable at any time until the expiration thereof, except that the PIPE Warrants cannot be exercised if, after giving effect thereto, the purchaser would beneficially own more than 4.99% (the ââMaximum Percentageâ), of the outstanding shares of common stock of the Company, which Maximum Percentage may be increased or decreased by the purchaser with written notice to the Company to any other percentage specified not in excess of 9.99%. The Series F Warrants have a term of two years from the date of stockholder approval, and the Series G Warrants have a term of six years from the date of stockholder approval. Stockholder approval of the Series F Warrants and Series G Warrants was obtained at the special Stockholdersââ Meeting held on March 21, 2023.Â A Shares of PIPE Preferred Stock, the conversion of which was approved at the special Stockholdersââ Meeting held on March 21, 2023, convert into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to

adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.Â Subject to limited exceptions, holders of shares of PIPE Preferred Stock do not have the right to convert any portion of their Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to its conversion.Â Holders of PIPE Preferred Stock are entitled to receive dividends on shares of PIPE Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the PIPE Preferred Stock does not have voting rights. However, as long as any shares of PIPE Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the PIPEA Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the PIPE Preferred Stock, (b) alter or amend the Certificate of Designation for the PIPE Preferred Stock, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of PIPE Preferred Stock, (d) increase the number of authorized shares of PIPE Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing. The PIPE Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. The holders of PIPE Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of the Company's common stock would receive if the PIPE Preferred Stock were fully converted (disregarding for such purposes any conversion limitations) to the Company's common stock, which amounts will be paid pari passu with all holders of the Company's common stock.Â The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the resale of the shares of its common stock, the shares issuable upon exercise of the PIPE Warrants and the shares issuable upon the conversion of the PIPE Preferred Stock. These registration statements were declared effective in April 2023.Â The net proceeds from the Private Placement and the Warrant Repricing have been used to advance the development and commercialization of our novel electrophysiology technologies and solutions and to support general corporate purposes.Â Conversion of Series X Convertible Preferred Stock Â On March 21, 2023, the Company held a special meeting of stockholders (the "Stockholders' Meeting"), at which the stockholders approved, among other things, the issuance of 199,359 shares of common stock upon conversion of 1,993,581 shares of Series X Convertible Preferred Stock which were issued upon the closing of the Merger (see Note 3, Business Combination of our accompanying unaudited condensed consolidated financial statements). On March 23, 2023, the Company issued 197,491 shares of common stock upon the conversion of 1,974,905 shares of Series X Convertible Preferred Stock. On October 24, 2023, the remaining 1,868 shares of common stock were issued upon the conversion of 18,676 shares of Series X Convertible Preferred Stock. As of September 30, 2024, 12,656,011 shares of Series X Convertible Preferred Stock remain outstanding. These shares will convert up to 1,265,601 shares of common stock, only if the Company meets the initial listing standards of the NYSE American or another national securities exchange or is delisted from the NYSE American.Â Â 48Table of ContentsÂ Issuance of Securities upon Conversion of Series A Preferred Â The following conversions of Series A Convertible Preferred Stock occurred subsequent to issuance:Â Conversion DateÂ Shares Common Stock IssuedÂ Shares of Series A Convertible Preferred Converted7/3/2023Â 109,355Â 1,7507/24/2023Â 54,678Â 8751/24/2024Â 54,678Â 8757/1/2024Â 81,423Â 1,3037/11/2024Â 62,489Â 1,0007/22/2024Â 62,500Â 1,0007/24/2024Â 25,000Â 400Â Each share of Series A Convertible Preferred Stock is convertible into approximately 62.5 shares of common stock. All series A Convertible Preferred Stock has been converted and no shares are outstanding subsequent to the last conversion on July 24, 2024.Â 2023 Equity Incentive PlanÂ On July 11, 2023, we held an Annual Meeting where our stockholders approved the 2023 Equity Incentive Plan ("2023 Plan") that authorizes us to grant options, restricted stock and other equity-based awards. No issuance of options were granted under the 2023 Plan during the year ended December 31, 2023. In July 2024, the shareholders approved an additional 200,000 shares of common stock for issuance under the plan. As of September 30, 2024, options to purchase an aggregate of 53,709 shares were outstanding and 225,085 shares remain available for grant under the 2023 Plan.Â The number of shares available for grant under the 2023 Plan also includes a quarterly increase commencing on September 1, 2023 by an amount equal to the lesser of (i) 10% of the number equal to the number of shares of common stock outstanding on the applicable adjustment date less the number of shares of common stock outstanding at the beginning of the fiscal quarter immediately preceding the adjustment date, but if such number is a negative number, then the increase will be zero; or (ii) such lesser number of shares as may be determined by the Board.Â Components of our Results of Operations for the Three and Nine Months Ended September 30, 2024 and 2023Â RevenuesÂ A Product sales revenues prior to the Merger consisted of sales of catheters for use with the DABRA laser in our atherectomy clinical trials.Â After the Merger, our legacy DABRA laser is no longer in use and we have shifted the focus of our operations to Old Catheter's product lines. Accordingly, our current activities primarily relate to Old Catheter's historical business which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology, or EP. Â One of our two primary products in 2024 is the VIVO System. The VIVO System offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. In addition to the VIVO System, customers are provided with VIVO Positioning Patch Sets, which are custom patches, that are used in conjunction with the VIVO System to complete the intended output of the VIVO System. The delivery of the VIVO System, including the VIVO Positioning Patch Sets, represents our primary performance obligation. We recognize revenue upon the delivery of the VIVO system. We also provide customers with the option to pay for software upgrades in advance at the time of the contract's inception. Software upgrades are stand-ready services, whereby we will provide software upgrade services to the customer when and as upgrades are available. Terms of the period covered by the payment of software upgrades in advance can range from one year to multiple years. Customers have the option to renew terms covered by software upgrades at the end of each term. The stand-ready software upgrades represent our second separate performance obligation and revenue is recognized over the term of the period. Â 49Table of ContentsÂ We invoice the customers after physical possession and control of the VIVO System is transferred to the customer and recognize revenue upon delivery. The timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. We invoice customers who pay for software upgrades in advance in conjunction with the invoice for the delivery of the VIVO System, and subsequent renewals of software upgrades are invoiced at the inception of the term. Revenue for these stand-ready services is recognized evenly over the term of the upgrade period, consistently with similar stand-ready services under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. Similar to the delivery of the VIVO System, the timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. We have elected the practical expedient to expense costs to obtain a contract, as incurred, as opposed to recognizing the cost as an asset upon occurrence. Â Our second primary product is LockET. We recognize sales of LockET at the point in time that the product is delivered to the customer.Â We are a business that has operations within multiple countries. During the three and nine months ended September 30, 2024, approximately 35% and 52%, respectively, of our sales were derived from customers outside the United States.Â Cost of RevenuesÂ Cost of revenues for product sales consisted primarily of costs of components for use in our products, the labor used to produce our products, and the manufacturing overhead that supports production.Â Selling, General and Administrative ExpensesÂ Selling, general and administrative ("SG&A"), expenses consist of employee-related costs, including salaries, benefits and stock-based compensation expenses. Other SG&A expenses include amortization of intangible assets, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses and facility-related expenses.Â Research and Development ExpensesÂ Research and development ("R&D"), expenses are expensed as incurred and include the following: research grants paid to other parties; product development; cost of clinical studies to support new products and product enhancements, including expanded indications; supplies used for internal R&D and clinical activities; and cost of outside consultants who assist with technology development and clinical affairs.Â Results of Operations for the Three and Nine Months Ended September 30, 2024 and 2023Â The following table sets forth the results of the Company's operations for the periods presented (\$ in thousands):Â Â 3 Three Months Ended September 30, 2024 Â 3 Nine Months Ended September 30, 2024 Â 4 2024 Â 2023 Â Change Â 2024 Â 2023 Â Change Â Revenues Â \$96A Â \$133A Â \$(37) Â \$271A Â \$314A Â \$(43) Â Cost of revenues Â \$10A Â \$6A Â \$4A Â \$31A Â \$23A Â \$8A Â Selling, general and administrative expenses Â \$2,882A Â \$2,745A Â \$137A Â \$8,251A Â \$14,393A Â \$(6,142) Â Research and development expenses Â \$63A Â \$112A Â \$(49) Â \$A Â \$181A Â \$486A Â \$(305) Â Loss on impairment of goodwill Â \$A Â \$A Â \$A Â \$A Â \$A Â \$60,934A Â \$(60,934) Â Change in fair value of royalties payable Â \$(1,223) Â \$A Â \$716A Â \$(1,949) Â \$A Â \$(2,823) Â \$A Â \$5,333A Â \$(8,156) Â Other income, net (1) Â \$A Â (28) Â \$A Â \$87A Â \$(115) Â \$A Â \$A Â \$286A Â \$(286) Â \$A Â (1) Â Constitutes the operating activities within other income, net, except for the change in fair value of royalties payable component which is presented separately. Â 50Table of ContentsÂ RevenuesÂ The decrease in revenues of approximately \$37 thousand and \$43 thousand for the three and nine months ended September 30, 2024 as compared to the corresponding periods in the prior year was due to lower product sales of the VIVO System products that was partially offset by our first LockET product sales in 2024. LockET sales for the three and nine months ended September 30, 2024 were approximately \$62 thousand and \$100 thousand. The decrease in VIVO System product sales was caused mainly by on hospital, who accounted for the most VIVO disposable sales in 2023 and place a large order in late 2023.Â Therefore, this hospital did not need to place additional orders prior to September 30, 2024, despite regular use of the product. In October 2024, this hospital placed an order of disposable VIVO patches totaling \$30 thousand.Â Cost of RevenuesÂ The increase in cost of revenues of approximately \$4 thousand for the three months ended September 30, 2024 as compared to the corresponding period in the prior year was due to order fulfillment charges that are now being incurred for LockET.Â The increase in cost of revenues of approximately \$8 thousand for the nine months ended September 30, 2024 as compared to the corresponding period in the prior year was due to order fulfillment charges that are now being incurred for LockET, offset by the lower cost of revenues of the VIVO Positioning Patches. During 2024 the manufacturing process was changed from 3D printing components of the VIVO Positioning Patches to the use of a more cost effective specialized mold.Â This new process also allowed for larger build quantities which in turn further reduced production costs and led to a reduction in the manufacturing cost of VIVO Positioning Patches of approximately 40%.Â Selling, General and Administrative ExpensesÂ The increase in selling, general and administrative expenses of approximately \$0.1 million for the three months ended September 30, 2024 as compared to the corresponding period in the prior year was due primarily to an increase in salaries and benefits of \$0.6 million relating to the Company hiring additional sales force and a CCO, partially offset by a decrease in professional accounting, consulting, investor relations fees, and insurance services totaling \$0.5 million.Â The decrease in selling, general and administrative expenses of approximately \$6.1 million for the nine months ended September 30, 2024 as compared to the corresponding period in the prior year was due primarily to a decrease in legal fees of \$2.1 million and a decrease in professional accounting fees of \$1.1 million that were primarily incurred in connection with the Merger in 2023. Further, there was a decrease in salaries and benefits of \$1.1 million, resulting from a \$1.7 million decrease in costs related to the Company's former Chief Executive Officer's compensation, partially offset by a \$0.6 increase in salaries and benefits for increasing other departmental headcount. Additionally, the decrease in selling, general and administrative expenses was impacted by a decrease in stock based compensation of \$1.2 million relating to the one time stock compensation for Old Catheter stock options assumed in the Merger during 2023, an additional decrease of approximately \$0.6 million in other consulting services, as a result of certain efforts being absorbed by internal employees, lower investor relations fees as a result of fewer 2024 year to date special stockholder meetings relative to the year to date 2023 period, and lower insurance premiums during the 2024 period.Â Research and Development ExpensesÂ The decrease in research and development expenses of approximately \$49 thousand for the three months ended September 30, 2024 as compared to the corresponding period in the prior year was due primarily to a decrease in regulatory affairs related expenditures, product development costs, and clinical studies, as to which \$89 thousand was incurred, partially offset by an increase of \$40 thousand in consulting fees.Â The decrease in research and development expenses of approximately \$0.3 million for the nine months ended September 30, 2024 as compared to the corresponding period in the prior year was primarily due to a decrease in salaries and benefits of \$0.1 million, a decrease in product development costs of \$0.1 million, and a decrease in regulatory affairs related expenditures of \$0.1 million, partially offset by an increase in professional fees of \$0.1 million. The net decreases were primarily the result of the discontinuation of the historical products of the Company that were previously under development.Â 51Table of ContentsÂ Loss on Impairment of GoodwillÂ We test for goodwill impairment at the reporting level annually in the fourth quarter or more frequently if a change in circumstances or the occurrence of events indicates that potential impairment exists. As a result of the Merger with Old Catheter the Company recognized \$60.9 million of goodwill. Due to a sustained decrease in our share price during 2023, we concluded that in accordance with ASC 350 a triggering event occurred indicating that potential impairment exists that required us to assess if impairment during 2023. In accordance with ASC 350 we performed a quantitative goodwill impairment test, which resulted in the carrying amount of the reporting unit exceeding its fair value, indicating that the goodwill of the reporting unit was impaired. We utilized a combination of an income and market approach to assess the fair value of the reporting unit during 2023. The income approach considered the discounted cash flow model, considering projected future cash flows (including timing and profitability), discount rate reflecting the risk inherent in future cash flows, perpetual growth rate, and projected future economic and market conditions while the guideline public company market approach considered marketplace earnings multiples from within a peer public company group.Â We recorded the impairment charge of \$0.0 million and \$60.9 million for the three and nine months ended September 30, 2023 within loss on impairment of goodwill in the consolidated statement of operations. There was no remaining goodwill balance as of December 31, 2023.Â Change in Fair Value of Royalties PayableÂ As of the date of the Merger, the royalties payable were calculated using a discounted cash flow method utilizing a discount rate of 24.1%. At each reporting period, the fair value of the royalties payable is calculated using the discounted cash flow method. At September 30, 2024, the discount rate was 20.0%. The change in fair value of the royalties payable for the three and nine months ended September 30, 2024 as compared to the corresponding periods in the prior year was a decrease of \$1.9 million and \$8.2 million, respectively. The change between the three and nine months ended September 30, 2024 and 2023 is driven by the change in fair value of the royalties payable.Â Other Income, NetÂ The decrease in other income (expense), net of approximately \$0.1 million and \$0.3 million for the three and nine months ended September 30, 2024, respectively, as compared to the corresponding periods in the prior year was primarily due to a decrease in investment income.Â Liquidity and Capital ResourcesÂ As of September 30, 2024, we had cash and cash equivalents of approximately \$1.3 million and an accumulated deficit of approximately \$286.7 million. For the nine months ended September 30, 2024, net cash used from operating activities was approximately \$6.4 million. We have incurred recurring net losses from operations and negative cash flows from operating activities since inception. We received a total of \$1.5 million of loans in Q2 and Q3 2024 that will become due and payable on January 31, 2026.Â We expect operating losses and negative cash flows to continue for the foreseeable future as we invest in our commercial capabilities. These negative cash flows and additional costs associated with the Merger paid during the year ended December 31, 2023 have substantially depleted our cash. Following the Merger with Old Catheter, we further reduced staff and other costs while assuming the operating costs of Old Catheter. Since the first quarter of 2024, we've begun to rejuvenate our sales force and hired a CCO. We will continue to monitor our operating costs and seek to reduce our current liabilities. Such actions may impair our ability to proceed with certain strategic activities. We believe that our current cash on hand of \$4.4 million as of November 1, 2024 will not be sufficient to fund our operations through the end of November 2025, including without limitation, to repay our outstanding short-term notes that will become due and payable on January 31, 2026. Because expected revenues are not adequate to fund our planned expenditures and anticipated operating costs and liabilities beyond such point, we are currently evaluating potential means of raising cash through future capital transactions and additional bridge loans. If we are unable to do so, we will be required to reduce our spending rate to align with expected revenue levels and cash reserves, although there can be no guarantee that we will be successful in doing so. Accordingly, we will likely be required to raise additional cash through debt or equity transactions and bridge loans to continue our operations and pay our debts as they come due, and if we are unable to do so, we will be required to suspend a portion or all of our operations and/or potentially seek relief from our creditors. We may not be able to secure financing in a timely manner or on favorable terms, if at all.Â 52Table of ContentsÂ As a result of these factors, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of one year after the date the unaudited condensed consolidated financial statements for the quarter ended September 30, 2024 are issued. The Company's unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.Â 3 Cash Flows for the Nine Months Ended September 30, 2024 (\$ in thousands)Â 3 For the Nine Months Ended September 30, 2024 Â Net cash provided by (used in): Â 2024 Â 2023 Â Operating activities Â \$(6,407) Â \$(18,730) Â Investing activities Â \$(67) Â \$(43) Â Financing activities Â \$4,177A Â \$8,493A Â Net change in cash and cash equivalents Â \$(2,297) Â \$(10,280) Â Net Cash Used in Operating ActivitiesÂ During the nine months ended September 30, 2024, net cash used in operating activities of \$6.4 million primarily consisted of a net loss of \$11.0 million, partially offset by depreciation and amortization of \$1.6 million, a change in fair value of royalties payable of \$2.8 million, and an increase in non-cash changes in operating assets and liabilities of \$0.2 million.Â During the nine months ended September 30, 2023, net cash used in operating activities of \$18.7 million primarily consisted of a net

loss of \$69.9 million, a decrease in non-cash changes in operating assets and liabilities of \$7.2 million, partially offset by non-cash expenses of \$58.5 million, consisting primarily of a loss on impairment of goodwill of \$60.9 million, non-cash stock-based compensation of \$1.2 million, depreciation and amortization of \$1.6 million, offset by a change in fair value of royalties payable of 5.3 million.Â Net Cash Used in Investing ActivitiesÂ During the nine months ended September 30, 2024, net cash used in investing activities of \$67 thousand consisted of purchases of property and equipment.Â During the nine months ended September 30, 2023, net cash used in investing activities of \$43 thousand consisted of purchases of property and equipment of approximately \$58 thousand, offset by proceeds from cash acquired as part of the Merger of approximately \$15 thousand.Â Net Cash Provided by Financing ActivitiesÂ During the nine months ended September 30, 2024, net cash provided by financing activities of \$4.2 million primarily consisting of proceeds from issuance of common stock and warrants of \$2.6 million, proceeds from notes payable from related parties of \$1.5 million, proceeds from notes payable of \$0.3 million, partially offset by payments on notes payable of \$0.2 million. Â The Recent Developments section describes our material financing activities that have occurred subsequent to September 30, 2024. Â 53Table of ContentsÂ During the nine months ended September 30, 2023, net cash provided by financing activities of \$8.5 million, consisted of cash proceeds from the private placement of \$8.0 million, proceeds from issuance of common stock and warrants of \$0.2 million and proceeds from the exercise of warrants of \$1.3 million, offset by the payment of offering costs of \$0.6 million, the payment of costs related to the warrant repricing of \$0.2 million and the payment of convertible promissory notes of \$0.3 million.Â Off-Balance Sheet ArrangementsÂ We do not engage in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, as a part of our ongoing business. Accordingly, we did not have any off-balance sheet arrangements during any of the periods presented.Â The Companyâ€™s Critical Accounting EstimatesÂ The information set forth below relates to the Companyâ€™s critical accounting policies and estimates. The discussion and analysis of our financial position and results of operations is based on our interim unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report, which have been prepared in accordance with U.S. GAAP. We believe certain of our accounting policies are critical to understanding our financial position and results of operations. Â The preparation of these unaudited consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We regularly evaluate estimates and assumptions related to business combinations, including the determination of the purchase price and related allocations to the fair value of assets acquired and liabilities assumed, provisions for legal contingencies, income taxes, deferred income tax asset valuation allowances, valuation of warranties liabilities, royalties payable, share based compensation and revenues. Our estimates are based on current facts, historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.Â We believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.Â Accounting for Long-Lived Assets-Useful LivesÂ Intangible assets acquired from business combinations are initially measured at their estimated fair values and are then amortized on a straight-line basis over their estimated useful lives. Management evaluates whether events or circumstances have occurred that indicate the remaining useful life or carrying value of the amortizing intangible should be revised and adjusted, if necessary. Should the sum of the undiscounted expected future net cash flows be less than the carrying value, the Company would recognize an impairment loss at that date.Â Stock-Based CompensationÂ We calculate the cost of awards of equity instruments based on the grant date fair value of the option awards issued to employees, members of our board of directors and nonemployee consultants using the Black-Scholes option pricing valuation model, or Black-Scholes model, which incorporates various assumptions including volatility, expected term and risk-free interest rate. The expected term of the options is the estimated period of time until exercise and was determined using the SECâ€™s safe harbor rules, using an average of vesting and contractual terms, as we did not have sufficient historical experience of similar awards. Expected stock price volatility is based on historical volatilities of certain â€œguidelineâ€ companies, as the Company does not have sufficient historical stock price data. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent term. The estimated fair value of stock-based compensation awards is amortized on a straight-line basis over the relevant vesting period, adjusted for actual forfeitures at the time they occur.Â 54Table of ContentsÂ Royalties PayableÂ We are obligated to pay royalties under various royalty agreements Old Catheter had entered into. On January 9, 2023, prior to the consummation of the Merger, Old Catheter entered in an agreement with its convertible promissory noteholders, which substantially consisted of amounts due to David A. Jenkins, previously Old Catheter's Chairman of the Board of Directors prior to the Merger, and, currently, the Companyâ€™s Executive Chairman of the Board of Directors and Chief Executive Officer, to forgive all accrued interest and future interest expense in exchange for a future royalty right. We will pay to the noteholders a total royalty equal to approximately 12% of net sales of LockeT, commencing upon the first commercial sale, through December 31, 2035. Â In addition, the Company finalized an Invention Assignment and Royalty Agreement (the "Royalty Agreement") that had previously been entered into by Old Catheter with the inventor of LockeT in exchange for the assignment and all rights to LockeT. Pursuant to the agreement, we will pay a 5% royalty on net sales up to \$1 million in royalties. After \$1 million has been paid, and if, and only if, a U.S. patent is granted by the United States Patent and Trademark Office, then we will continue to pay a royalty at a rate of 2% of LockeT net sales, until total cumulative royalties of \$10 million have been paid. No further royalty payments will be due under this Royalty Agreement after December 31, 2033.Â During 2006 and 2007, Old Catheter entered into two investment grant agreements with a non-profit foundation for the purpose of funding the initial development of Old Catheter's AMIGO System. The agreement calls for the payment of sales-based royalties to the foundation, upon successful commercialization of the AMIGO System. We are not currently selling the AMIGO System.Â New Accounting PronouncementsÂ In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 require disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entityâ€™s CODM. The amendments in this update also expand the interim segment disclosure requirements. These amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently reviewing the impact that the adoption of ASU 2023-07 may have on our consolidated financial statements and disclosures.Â In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is required to adopt this standard prospectively in fiscal year 2025 for the annual reporting period ending December 31, 2025. The accounting pronouncement is not expected to have a material impact on the Company's related disclosures.Â 55Table of ContentsÂ ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKÂ Not applicable.Â ITEM 4. CONTROLS AND PROCEDURESÂ Evaluation of Disclosure Controls and ProceduresÂ Our management, with the participation of our Executive Chairman of the Board and Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2024. Our objective in designing our disclosure controls and procedures is that they provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon this evaluation, due to the existence of the material weaknesses found in our internal controls over financial reporting described below, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of September 30, 2024, our disclosure controls and procedures were not effective at the reasonable assurance level. As disclosed in our Form 10-K for the year ended December 31, 2023 and Forms 10-Q for the quarters ended March 31, 2024 and June 30, 2024, for the reasons set forth therein, our Chief Executive Officer and Interim Chief Financial Officer had previously concluded our disclosure controls and procedures were not effective at the reasonable assurance level.Â A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. The Company has developed a plan to remediate the internal control weaknesses that were previously identified and we continue to make progress to implement the plan.Â The plan includes a change in the Companyâ€™s Chief Financial Officer, hiring additional accounting staff and changing the third-party technical accounting consultants.Â The material weaknessesÂ in internal control over financial reporting related to our control environment that were previously identified are described below.Â A Specifically, we identified material weaknessesÂ with respect to (1) the lack of segregation of duties, (2) the lack of designed and operating review controls with respect to oversight of the financial reporting process, (3) errors with respect to the review of work performed by service providers, (4) errors in connection with accounting for the royalty obligation acquired in the merger with Old Catheter, (5) use of an incorrect discount rate in calculating the fair value of the royalty obligation,Â 6 and (6) timing of revenue recognition.Â Notwithstanding the identified material weaknesses, management believes that the Financial Statements and related financial information included in this Quarterly Report, its quarterly report for the quarters ended March 31, 2024 and June 30, 2024, and in its Quarterly and Annual Reports filed during and with respect to the year ended December 31, 2023, fairly present, in all material respects, our consolidated balance sheets, statements of operations, stockholdersâ€™ equity and cash flows as of and for the periods presented.Â Remediation PlanÂ Management is in the process of implementing a remediation plan and believes significant progress has been made, including the following remediation items:Â 1. Segregation of duties â€œWe have added additional professional accounting personnel and have retained a new third party technical accounting consultant. In addition, we have reviewed and updated our accounting systems descriptions for sales/accounts receivable/cash receipts and purchasing/accounts payable and cash disbursements/payroll process and general ledger process and all employees have been trained on the updated procedures.Â 56Table of ContentsÂ 2. Lack of designed and operating review controls with respect to oversight of the financial reporting process â€œWe have recently changed our third party technical accounting consultants who assist in the financial reporting process.Â We believe that the new consulting group will improve our financial reporting process.Â 3. Errors with respect to the review of work performed by service providers â€œ work performed by service providers is reviewed and any errors identified are sent back to service provider for resolution before being incorporated into the companyâ€™s financial reports.Â In addition, we have recently changed third party technical consultants, and we believe that the new consulting group will improve our financial reporting process.Â 4. Errors in connection with accounting for the royalty obligations acquired in the merger with Old Catheter â€œ the initial royalty calculations did not include the royalty payable to the LockeT inventor. The process includes review by the Interim Chief Financial Officer of material contracts for any assets, liabilities or disclosures that would need to be recorded.Â 5. Use of an incorrect discount rate in calculating the fair value of the royalty obligation in the draft financial statements (which were corrected prior to release) â€œ Calculations are reviewed by management to ensure inputs are reasonable prior to incorporating the calculations into the Companyâ€™s financial reports.Â We have recently changed third party technical consultants, and we believe that the new consulting group will improve our financial reporting process. Â 6. Timing of revenue recognition â€œ Revenue is recognized when product is delivered to the customer. We have implemented a tracking spreadsheet for all shipments which contains delivery date, and invoicing/recognition of revenue is then dated to match the delivery date. This is reviewed at month end by the Interim Chief Financial Officer to ensure revenue is recognized in the proper period.Â The material weaknesses will not be considered remediated until management designs and implements effective controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. The Company will monitor the effectiveness of its remediation plans and will make changes management determines to be appropriate.Â Additional anticipated remediation measures include continuing assessment of the need to expand the Companyâ€™s current accounting and financial reporting teams to include individuals with requisite experience to meet the requirements associated with the increasing operations of a publicly traded company, establishment of policies and procedures to ensure full review and sign offs with respect to the inputs sent to third-party service providers as well as the reports and documentation upon the completion of their work prior to any adjustments being made to the financial statements, establishment of policies and procedures related to the review of all contracts the Company enters into to ensure any terms or conditions are evaluated for any accounting required or accounting treatment or disclosure, and establishment of policies and procedures to review the inputs to royalties payable and other fair value calculations as well as the outputs impacting the balance at each reporting period.Â Â Changes in Internal Control over Financial ReportingÂ Except as noted above, there have been no changes in the Companyâ€™s internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting. Â Inherent Limitations on Effectiveness of ControlsÂ Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.Â 57Table of ContentsÂ PART II. â€œ OTHER INFORMATIONÂ ITEM 1. LEGAL PROCEEDINGS Â Reference is made to the information disclosed under ItemÂ 3A â€œ "Legal Proceedings" in the Fiscal 2023 10-K.Â ITEM 1A. RISK FACTORSÂ There have been no material changes from the risk factors previously disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Report on Form 10-Q filed for the period ended June 30, 2024.Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â Previously Reported.Â ITEM 3. DEFAULTS UPON SENIOR SECURITIESÂ None.Â ITEM 4. MINE SAFETY DISCLOSURESÂ Not applicable.Â ITEM 5. OTHER INFORMATIONÂ None.Â 58Table of ContentsÂ ITEM 6. EXHIBITSÂ ExhibitÂ A Incorporated by ReferenceÂ NumberDescriptionFormÂ File No.Â A ExhibitÂ A Filing DateÂ A A A A A A A A A A 3.1.1Â Amended and Restated Certificate of Incorporation of the Registrant.Â 8-KÂ 001-38677Â 3.1Â 10/1/2018Â A A A A A A A A A A 3.1.2Â Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.Â (effective 11/16/20)Â 8-KÂ 001-38677Â 3.1Â 11/17/2020Â A A A A A A A A A A 3.1.3Â Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.Â (effective 09/30/22)Â 8-KÂ 001-38677Â 3.1Â 9/20/2022Â A A A A A A A A A A 3.1.4Â Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.Â (filed 08/01/23, effective 08/17/23)Â 8-KÂ 001-38677Â 3.1Â 8/4/2023Â A A A A A A A A A A 3.1.5Â Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (filed 07/11/2024, effective 07/15/2024)Â 8-KÂ 001-38677Â 3.1Â 7/12/2024Â A A A A A A A A A A 5Â Certificate of Designation of Series X Convertible Preferred Stock.Â 8-KÂ 001-38677Â 3.1Â 1/13/2023Â A A A A A A A A A A 6Â Certificate of Designation of Series A Preferred Stock.Â 8-KÂ 001-38677Â 3.2Â 1/13/2023Â A A A A A A A A A A 3.2.1Â Amended and Restated Bylaws of the Registrant.Â 8-KÂ 001-38677Â 3.2Â 10/1/2018Â A A A A A A A A A A 3.2.2Â Amendment to Amended and Restated Bylaws of the Registrant.Â 8-KÂ 001-38677Â 3.1Â 8/17/2022Â A A A A A A A A A A 4.1Â Specimen common stock certificate of the Registrant.Â S-1Â 333-226191Â 4.1Â 7/16/2018Â A A A A A A A A A A 4.2Â [omitted].Â A A A A A A A A A A 4.3Â Form of warrant issued in May 2020.Â 8-KÂ 001-38677Â 4.1Â 5/22/2020Â A A A A A A A A A A 4.4Â Form of pre-funded warrant issued in May 2020.Â 8-KÂ 001-38677Â 4.2Â 5/22/2020Â A A A A A A A A A A 4.5Â Form of placement agent

[illegible]

000067 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 000068 - Disclosure - Leases (Details 3) link:presentationLink link:calculationLink link:definitionLink 000069 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000070 - Disclosure - Net Loss per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000071 - Disclosure - Equity Offerings (Details) link:presentationLink link:calculationLink link:definitionLink 000072 - Disclosure - Equity Offerings (Details 1) link:presentationLink link:calculationLink link:definitionLink 000073 - Disclosure - Equity Offerings (Details 2) link:presentationLink link:calculationLink link:definitionLink 000074 - Disclosure - Equity Offerings (Details 3) link:presentationLink link:calculationLink link:definitionLink 000075 - Disclosure - Equity Offerings (Details 4) link:presentationLink link:calculationLink link:definitionLink 000076 - Disclosure - Equity Offerings (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000077 - Disclosure - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 000078 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000079 - Disclosure - StockBased Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 000080 - Disclosure - StockBased Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 000081 - Disclosure - StockBased Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 000082 - Disclosure - StockBased Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 000083 - Disclosure - StockBased Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000084 - Disclosure - Employee Benefit Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000085 - Disclosure - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 000086 - Disclosure - Related Parties (Details narrative) link:presentationLink link:calculationLink link:definitionLink 000087 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 000088 - Disclosure - Subsequent Events (Details narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 vtaK-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Document Quarterly Report Document Transition Report Entity Interactive Data Current Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Class of Stock [Axis] Series A convertible preferred stocks [Member] Series X convertible preferred stocks [Member] ASSETS Current Assets Cash and cash equivalents Accounts receivable Inventories [Inventory, Net] Prepaid expenses and other current assets Total current assets [Assets, Current] Property and equipment, net Operating lease right-of-use assets, net Intangible assets, net Other non-current assets TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable Accrued expenses Notes payable Interest payable to related parties Current portion of royalties payable Current portion of operating lease liabilities Total current liabilities [Liabilities, Current] Royalties payable Notes payable due to related parties Operating lease liabilities Total liabilities [Liabilities] Commitments and contingencies (see Note 17) Stockholders' Equity Common stock, \$0.0001 par value, 30,000,000 shares authorized; 3,452,652 and 702,662 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity [Equity, Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Preferred Stock, value Statement Equity Components [Axis] Series X Convertible Preferred Stock [Member] Series A convertible preferred stock [Member] Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Preferred stock, shares designated Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares Outstanding Condensed Consolidated Statements of Operations (Unaudited) Revenue Cost of revenues Gross profit [Gross Profit] Operating expenses Loss on impairment of goodwill Selling, general and administrative Research and development Total operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Other income (expense), net Interest income Interest expense [Interest Expense, Operating and Nonoperating] Other expense, net Change in fair value of royalties payable Total other income (expense), net [Other Operating Income (Expense), Net] Net loss [Net Income (Loss) Attributable to Parent] Deemed dividend - warrant inducement offer Net loss attributable to common stockholders [Net Income (Loss) Available to Common Stockholders, Diluted] Net loss per share attributable to common stockholders, basic and diluted Weighted average common shares used in computing net loss per share, basic and diluted Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Series A Convertible Preferred Stock Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount Common stock issued upon the exercise of options, shares Common stock issued upon the exercise of options, amount Restricted stock awards cancelled, shares Restricted stock awards cancelled, amount Stock-based compensation Issuance of Series X Convertible Preferred Stock in merger, shares Issuance of Series X Convertible Preferred Stock in merger, amount Conversion of Series X Convertible Preferred Stock, shares Conversion of Series X Convertible Preferred Stock, amount Issuance of Series A Convertible Preferred Stock in connection with private placement, net, shares Issuance of Series A Convertible Preferred Stock in connection with private placement, net, amount Warrants exercised (see Note 13), shares Warrants exercised (see Note 13), amount Net loss Adjustment of fair value of Series X Convertible Preferred Stock in merger Adjustment of fair value of stock-based compensation related to merger Conversion of Series A Convertible Preferred Stock, shares Conversion of Series A Convertible Preferred Stock, amount Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, shares Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, amount Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), shares Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), amount Balance, shares Balance, amount Condensed Consolidated Statements of Cash Flows (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES: Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Loss on impairment of goodwill Depreciation and amortization Stock-based compensation [Share-Based Payment Arrangement, Noncash Expense] Change in fair value of royalties payable [Change in fair value of royalties payable] Changes in operating assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Inventories [Increase (Decrease) in Inventories] Prepaid expenses and other assets [Increase (Decrease) in Prepaid Expense and Other Assets] Operating lease right-of-use assets and lease liabilities Current portion of royalties payable [Increase (Decrease) in Royalties Payable] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Interest payable to related parties [Increase (Decrease) in Interest Payable, Net] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Cash acquired as part of business combination [Payments to Acquire Businesses, Net of Cash Acquired] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs Proceeds from notes payable due to related parties Payment on note payable [Repayments of Notes Payable] Proceeds from note payable Proceeds from exercise of warrants Payments of costs related to the warrant repricing [Payments of costs related to the warrant repricing] Payments of convertible promissory notes and accrued interest [Payments of convertible promissory notes and accrued interest] Proceeds from the private placement of securities Payments of offering costs related to the private placement of securities [Payments of offering costs related to the private placement of securities] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET CHANGE IN CASH AND CASH EQUIVALENTS [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] CASH AND CASH EQUIVALENTS, beginning of period [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash payments for interest SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING AND INVESTING ACTIVITIES Non-cash consideration for Catheter acquisition Property and equipment reclassified from inventories Conversion of Series A Convertible Preferred Stock for common stock Organization and Nature of Operations Organization and Nature of Operations Nature of Operations [Text Block] Summary of Significant Accounting Policies Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Business Combination Business Combination Business Combination Disclosure [Text Block] Inventories Inventories Inventory Disclosure [Text Block] Property and Equipment Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Intangible Assets Intangible Assets Intangible Assets Disclosure [Text Block] Goodwill Goodwill Goodwill Disclosure [Text Block] Accrued Expenses Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Notes Payable Notes Payable [Notes Payable] Royalties Payable Royalties Payable [Royalties Payable] Leases Leases Lessee, Finance Leases [Text Block] Net Loss per Share Net Loss per Share Earnings Per Share [Text Block] Equity Offerings Equity Offerings Preferred Stock [Text Block] Preferred Stock Preferred Stock Equity Method Investments [Table Text Block] StockBased Compensation Stock-Based Compensation Income Taxes Income Taxes Income Tax Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Employee Benefit Plan Employee Benefit Plan Defined Benefit Plan [Text Block] Related Parties Related Parties Related Party Transactions Disclosure [Text Block] Subsequent Events Subsequent Events Subsequent Events [Text Block] Principles of Consolidation Basis of Presentation Use of Estimates Concentrations of Credit Risk Reclassifications Segment Reporting Cash and Cash Equivalents Fair Value Measurements Accounts Receivable and Allowances for Credit Losses Inventories Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Impairment of Long-lived Assets Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Royalties Payable Oil and Gas, Royalty Trust, Distributable Income [Policy Text Block] Product Warranty Distinguishing Liabilities from Equity Revenue Recognition Shipping and Handling Costs Advertising and Marketing Patents Research and Development Stock-based Compensation Income Taxes Income Tax, Policy [Policy Text Block] Basic and Diluted Net Loss per Share of Common Stock Recently Announced Accounting Pronouncements Schedule of the fair value measurements within the fair value hierarchy of the Company's financial instruments Schedule of Significant unobservable inputs used in the fair value measurement Schedule of Property and Equipment Estimated Useful Lives Schedule of disaggregated product sales by geographic area summary the preliminary estimated fair value summary Of preliminary purchase price allocations Schedule of acquisition date fair values and estimated useful lives Schedule of Inventories Schedule of Property and Equipment, Net Schedule of Intangible Assets Schedule of estimated future amortization expense Schedule of Accrued Expenses summary of sales-based royalties summary of roll forward of the royalty payable Schedule of operating lease expense and cash paid for leases Schedule of weighted average discount rate Schedule of Future lease payments for all lease Schedule of Right of use lease assets and lease liabilities Schedule of Black-Scholes Model Based on Assumptions Schedule of issuance of warrants Schedule of Black-Scholes Model Based on Assumptions for placement fees Schedule of common stock warrants outstanding Schedule of Series A Convertible Preferred Stock occurred subsequent to the issuance Schedule of Options Activity Schedule of Unrecognized Estimated Stock Based Compensation Expense by Award Type Schedule of Related parties and the amounts owed to each related party Schedule of Issuance of Securities from Warrant Exercises Plan Name [Axis] Related Party Notes [Member] Reverse Stock Split [Member] September 2024 Public Offering [Member] 2024 Inducement Offer [Member] Cash flows used in operating activities Common Stock, shares authorized Common stock, Par value Effected reverse stock split shares Non assessable share of common stock, per share Cash and cash equivalents [Cash Equivalents, at Carrying Value] Short-term promissory notes Interest Rate Common Stock Units Pre-Funded Units Gross proceeds Equity Offerings Costs Description of warrant inducement Accumulated deficit [Cumulative Earnings (Deficit)] Fair Value By Fair Value Hierarchy Level Axis Level 1 [Member] Level 2 [Member] Level 3 [Member] Mutual fund Money market fund Total assets Royalties payable [Royalties payable] Total liabilities [Other Liabilities] Valuation Technique Unobservable Input Input Range Long-Lived Tangible Asset [Axis] Computer Hardware And Software [Member] Minimum [Member] Maximum [Member] VIVO DEMO/Clinical Systems[Member] Locket Animation Video [Member] Machinery And Equipment [Member] Estimated useful lives Geographical [Axis] Europe [Member] US [Member] Revenue by location Concentration Risk Type [Axis] Revenue Member Three and Five Customers Member Three and Four Customers [Member] Impairment charges Deemed dividend amount for existing warrants and issuance of new warrants Description of legal limit Concentration risk Royalty liability description Royalty rate Advertising and marketing Business Acquisition [Axis] Convertible Series X Preferred Stock [Member] Catheter's [Member] Total Purchase Price fair value of convertible preferred stock issued fair value of options issued Liabilities assumed [Member] Assets Acquired [Member] Accounts payable Accrued expenses Lease liability Interest payable Convertible promissory note Royalties payable Total liabilities assumed Total purchase price Cash and cash equivalents Accounts receivable [Accounts Receivable, after Allowance for Credit Loss] Inventories Prepaid expenses and other current assets Property and equipment, net Lease right of use assets Other assets Developed technology Customer relationships Trademarks Goodwill [Goodwill] Total assets acquired Finite Lived Intangible Assets By Major Class Axis Developed Technology - VIVO [Member] Developed technology- Locket [Member] Customer Relationships [Member] Trademark- VIVO [Member] Trademark- Locket [Member] Intangible assets acquired Estimated Useful Life Financial Instrument Performance Status Axis Pro Forma Financial Information [Member] Revenues Net loss Net loss attributable to common stockholders [Net Income (Loss) Available to Common Stockholders, Basic] Basic and diluted net loss per share - on a pro forma basis Merger Agreement [Member] Merger Agreement One [Member] Developed technologies assets Trademarks [Indefinite-Lived Trademarks] Customer relationships Goodwill [Business Acquisition, Goodwill, Expected Tax Deductible Amount] Royalties payable [Accrued Royalties, Current] Total Impairment charge Transaction costs for the merger Convertible promissory note [Convertible Notes Payable, Noncurrent] Series X preferred stock shares Purchase shares of common stock Total purchase consideration Estimated fair value of the Convertible Preferred Stock issued Value of stock option issued Closing stock price Raw materials Finished goods Computer Hardware And Software [Member] [Computer Hardware And Software [Member]] VIVO DEMO/Clinical Systems[Member] Machinery And Equipment [Member] Property and equipment, gross Accumulated depreciation [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Property and equipment, net Depreciation expense Trademarks/trade Names - VIVO [Member] Trademarks/trade Names - Locket [Member] Gross Carrying Amount Accumulated Amortization Net Book Value Estimated Useful Life in Years Remainder of 2024 2025 2026 2027 2028 Thereafter Total Amortization expense Weighted average remaining amortization period Goodwill Cumulative goodwill impairment charges Legal expenses Offering costs Compensation and related benefits Other accrued expenses Accrued expenses Removal of accrued warranty [Removal of accrued warranty] Accrued warranty balance Pledging Purpose Axis Financial Instrument [Axis] Related Party Transaction [Axis] Notes Payable Director And Officer [Member] Short Term Promissory Notes [Member] David A Jenkin [Member] Mr. Jenkins [Member] Short term loan Note payable to third party Short-term financing Down payment against purchase of director and officer liability insurance coverage Purchase of director and officer liability insurance coverage Interest expenses Interest expense on loan Interest payable to related parties [Interest payable to related parties] Interest rate of loan Loan to company Maturity date of related party notes Interest rate of related party Interest payable [Interest payable] Notes payable Notes Payable and accrued interest Award Type Axis Product Or Service Axis Royalty One [Member] Royalty Two [Member] Royalty Three [Member] Royalty Percentage Royalty Payment Royalty Payment [Royalty Payment] Balance at beginning of period [Balance at beginning of period] AMIGO royalty payable recognized in connection with the Merger Locket royalty payable recognized in connection with the Merger Payments owed on royalties payable Change in fair value of royalties payable [Change in fair value of royalties payable 1] Balance at end of period Locket Royalty [Member] AMIGO System Royalty [Member] Royalty payable, Percentage Payments for Royalties Termination payments for Royalties Royalty payments description Royalty of net sales Description of lockeT device inventor Investment amount received Operating lease expense Cash paid for leases Weighted average discount rate - operating leases Weighted average remaining lease term (in years) - operating leases Remainder of 2024 [Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year] 2025 [Lessee, Operating Lease, Liability, to be Paid, Year One] 2026 [Lessee, Operating Lease, Liability, to be Paid, Year Two] Total minimum lease payments Less effects of discounting Present value of future minimum lease payments Lease right-of-use assets Total lease assets Lease liability - current portion Lease liability - net of current portion Total lease liabilities South Carolina Office Lease Agreement [Member] New Jersey Office Lease Agreement [Member] Park City Office Lease Agreement [Member] Total rent expense per month Rent expense for extended period per month Lease agreement term Lease agreement term extended period Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Stock Options [Member] Series x convertible preferred stocks [Member] Warrants [Member] Restricted Stock Units [Member] Anti-dilutive common share equivalents excluded from computation of diluted net loss per share Convertible preferred stock [Conversion of Stock, Shares Converted] Convertible preferred stock Deemed dividend amount Subsidiary Sale Of Stock Axis Series B Warrants [Member] 2023 Warrant Repricing [Member] Series C Warrants [Member] 2023 Warrant Repricing [Member] [2023 Warrant Repricing [Member]] Series E Warrants [Member] 5/22/2020 Raise

[Member] 8/3/20 Raise [Member] Risk-free interest rate Volatility Expected dividend yield Expected life (in years) Series F Warrants [Member] Private Placement [Member] Series G Warrants [Member] Risk-free interest rate Volatility Expected dividend yield Expected life (in years) Class of Warrant or Right [Axis] 2022 Offering [Member] Warrant One [Member] Warrant Two [Member] Warrants outstanding Exercise Price Expiration Date Warrants outstanding, value Risk-free interest rate Volatility Expected dividend yield Expected life (in years) Warrants outstanding, Beginning balance Issued Exercised [Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised] Expired [Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations] Warrants outstanding, Ending balance Pre-Funded Warrants Series H Warrants [Member] Series I Warrants [Member] Series J Warrants [Member] May 2020 Warrants May 2020 Placement Agent Warrants August 2020 Warrants August 2020 Placement Agent Warrants August 2021 Pharos Banker Warrants February 2022 Series B Warrants July 2022 Series C Warrants January 2023 Series E Warrants March 2023 Series F Warrants March 2023 Series G Warrants Representative Warrants [Member] Warrants outstanding Exercise Price Expiration Date Underwriting Agreement [Member] Warrant Repricing [Member] Common Stocks At The Market Offerings. Series A Warrants [Member] Series B Warrants [Member] Securities Purchase AgreeMent [Member] Series A convertible preferred stock [Member] Private Placement [Member] Securities Purchase AgreeMent Class B [Member] Series F and Series G Warrants. 2022 Offering [Member] Series E Warrants [Member] Series H Warrant, Series I Warrant, Series J Warrant 2024 Public Offering [Member] Existing warrants. Minimum [Member] Maximum [Member] Warrants exercise price Option to purchase additional shares of Common Stock Common Stock Units [Common Unit, Issued] Common stock, weighted average exercise price Repriced warrants Stock Issued During Period Shares New Issues Public offering price Underwriting discounts and commissions Pre-Funded Warrant Units Pre-Funded Warrant Units Issued Incremental fair value of the repriced warrants Aggregate purchase price Fair value of Series E warrant Proceeds From Issuance Of Common Stock Payments Of Stock Issuance Costs Weighted average exercise price Deemed dividend amount Valuation of warrants Fee withheld Percentage of shares exercised Percentage of shares exercised beneficially Gross proceeds [Proceeds from Issuance Initial Public Offering] Net proceeds from public offering Stock issued during period, warrants exercised Class B preferred stock issued and converted to Series A preferred stock Issuance of warrants Net proceeds Common Shares Issued Convertible promissory notes, representing an aggregate principal Description of convertible Preferred Stock Principal amount per share Initial rate of share listing price Common stock share issued Conversion of preferred stock Common stock Convertible Preferred Stock description Description of private investment in public equity Title Of Individual Axis Non-Employee Director Options Issued [Member] Employees [Member] Award Date [Axis] Non-Plan Options Issued [Member] May 1, 2024 [Member] Stock option outstanding beginning of the period [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Stock option options exercised Stock option options granted Stock option canceled/forfeited [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period] Stock option outstanding end of the period Vested and expected to vest at September 30, 2024 [Vested and expected to vest at September 30, 2024] Exercisable at September 30, 2024 [Exercisable at September 30, 2024] Weighted average exercised price outstanding beg of period [Weighted average exercised price outstanding beg of period] Weighted average exercised price Options exercised Weighted average exercised price options granted Weighted average exercised price canceled/forfeited Weighted average exercised price outstanding end of period [Weighted average exercised price outstanding end of period] Weighted average exercised price vested and expected to vest end of the period [Weighted average exercised price vested and expected to vest end of the period] Weighted average exercised price exercisable at September 30, 2024 [Weighted average exercised price exercisable at September 30, 2024] Weighted Average Remaining Life end of period exercisable, begin Weighted Average Remaining Life end of period exercisable, end Weighted Average Remaining Life Vested and expected to vest end of period Weighted Average Remaining Life end of period Aggregate Intrinsic Value outstanding ending balance [Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding] Aggregate Intrinsic Value outstanding beginning balance Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2024 Aggregate Intrinsic Value, Exercisable at September 30, 2024 [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value] Restricted Stock Awards [Member] Stock options [Member] Remaining Weighted Average Recognition Period Total unrecognized estimated stock-based compensation expense Stock Options Assumed in Merger [Member] 2018 Equity Stock Purchase Plan [Member] 2020 Stock Option Plan [Member] 2018 Stock Compensation Plan [Member] 2023 Stock Option Plan [Member] Restricted Stock Awards [Member] 2023 Equity Incentive Plan [Member] Director [Member] Employees And Consultants [Member] Employees [Member] Non-Plan Options Issued [Member] Equity Incentive Plan description Value of options issued Issuance of options Issuances of options Issuances of options for employment incentive Exercise price Options to purchase Stock-based compensation [Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture] Stock-based compensation [Stock-based compensation] Purchase price consideration Shares issued under employee stock purchase plan Percentage of fair market value of share of common stock to purchase Eligible employees withhold percentage of earnings to purchase shares of common stock Maximum annual increase of outstanding stock reserved for future issuance, Percentage Common stock reserve for issuance Vesting [Axis] Second Contribution [Member] First Contribution [Member] Third Contribution [Member] Maximum contribution per employee (percentage) Employer matching contribution, maximum (percentage) David Jenkins [Member] FatBoy Capital [Member] FatBoy Capital One [Member] FatBoy Capital Two [Member] Jenkins Family Charitable Institute [Member] Issuance Date Principal Amount Interest Paid Interest Accrued Principal Amount [Principal Amount] Chief Commercial Officer [Member] May 01, 2024 [Member] Margrit Thomassen [Member] Mr. Jenkins [Member] Pre-Funded Warrants Series H Warrants [Member] Series I Warrants [Member] Series J Warrants [Member] Received options to purchase common stock Option exercise price Vested period percentage Vested period Expiration period Interest rate Maturity date Warrants issued Business Combination, Description Convertible Promissory Notes Convertible Notes Interest accrued Accrued expenses [Accrued expenses] Options to purchase [Options to purchase] Public offering Number of options Remaining number of options Conversion of stock description Exercise price [Warrant, Exercise Price, Increase] Remaining number of options exercise price Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Pre-Funded Warrant Units Issued Subsequent Event Type [Axis] Subsequent Event [Member] Pre-Funded Warrant [Member] Pre-Funded Warrant One [Member] Pre-Funded Warrant Two [Member] Series H Warrant [Member] Series I Warrant [Member] Pre-Funded Warrant Three [Member] Exercise Date Issue Date Shares Common Stock Issued Number of Warrants Exercised Proceeds Subsequent Event [Member] Series K Warrants [Member] 2024 Inducement Offer [Member] [2024 Inducement Offer [Member]] Reverse stock split description Exercise price [Shares Issued, Price Per Share] Warrants remained outstanding after inducement offer Warrants exercised Placement agent warrants description Warrants Term description Gross proceeds from warrants Agent fees and offering expenses Proceeds from issuance of common stock and warrants, net of fees withheld. Shipping and handling costs. Patents Property and equipment estimated useful lives. EX-101.CAL 8 vtak-20240930 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 vtak-20240930 pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 vtak-20240930 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Cover [Abstract] A Entity Registrant Name Catheter Precision, Inc. A Entity Central Index Key 0001716621 A Document Type 10-Q A Amendment Flag false A Current Fiscal Year End Date -12-31 A Entity Small Business true A Entity Shell Company false A Entity Emerging Growth Company false A Entity Current Reporting Status Yes A Document Period End Date Sep. 30, 2024 A Entity Filer Category Non-accelerated Filer A Document Fiscal Period Focus Q3 A Document Fiscal Year Focus 2024 A Entity Common Stock Shares Outstanding A 8,004,633 Entity File Number 001-38677 A Entity Incorporation State Country Code DE A Entity Tax Identification Number 38-3661826 A Entity Address Address Line 1 1670 Highway 160 West A Entity Address Address Line 2 Suite 205 A Entity Address City Or Town Fort Mill A Entity Address State Or Province SC A Entity Address Postal Zip Code 29708 A City Area Code 973 A Local Phone Number 691-2000 A Security 12b Title Common stock, par value 0.0001 per share A Trading Symbol VTAK A Security Exchange Name NYSE A Document Quarterly Report true A Document Transition Report false A Entity Interactive Data Current Yes A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format -MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei Data Type: dei:submissionItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityFilerCategory Namespace Prefix: dei Data Type: dei:fileCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityRegistrantName Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityShellCompany Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntitySmallBusiness Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei Security12bTitle Namespace Prefix: dei Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei SecurityExchangeName Namespace Prefix: dei Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Current Assets A Cash and cash equivalents \$ 1,268 \$ 3,565 Accounts receivable 107

137 Inventories 32 44 Prepaid expenses and other current assets 307 415 Total current assets 1,714 4,161 Property and equipment, net 111 70 Operating lease right-of-use assets, net 127 179 Intangible assets, net 24,785 26,318 Other non-current assets 8 8 TOTAL ASSETS 26,745 30,736 Current Liabilities Â Â Accounts payable 708 464 Accrued expenses 1,497 1,733 Notes payable 249 184 Interest payable to related parties 16 0 Current portion of royalties payable 17 0 Current portion of operating lease liabilities 99 91 Total current liabilities 2,586 2,472 Royalties payable 9,797 6,974 Notes payable due to related parties 1,500 0 Operating lease liabilities 36 97 Total liabilities 13,919 9,543 Stockholders' Equity Â Â Common stock, \$0.0001 par value, 30,000,000 shares authorized: 3,452,652 and 702,662 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 0 0 Additional paid-in capital 299,550 296,902 Accumulated deficit (286,724) (275,779) Total stockholders' equity 12,826 21,193 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 26,745 30,736 Series A convertible preferred stocks [Member] Â Â Stockholders' Equity Â Â Preferred Stock, value 0 0 Series X convertible preferred stocks [Member] Â Â Stockholders' Equity Â Â Preferred Stock, value \$ 0 \$ 0 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (i)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (i)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl](http://www.xbrl.org/2003/role/exampleRef)

<http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details> Name: us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details) Name: us-gaap InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details](http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details) Name: us-gaap InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: [Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: \[Name: us-gaap NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\(b\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details\\) Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\(b\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details\\) Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\(a\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details\\) Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\(SX 210.5-02\\\(17\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(17\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details\\) Name: us-gaap OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock \\(or preferred stock redeemable solely at the option of the issuer\\). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef>\]\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: <a href=\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <a href=)

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Publisher FASB -URI

Paragraph 2 - Subparagraph (SX 210.5-03(2)) - Publisher FASB - URI

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income \(loss\) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SAB Topic 6.B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNoncashIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income \(expense\) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain \(loss\). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses \(for example, credit, warranty, and advertising\) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalIncomeStatementElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_ChangeInFairValueOfRoyalty Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_DeemedDividendsWarrantInducementOffer Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_EarningsPerSharesBasicAndDiluted Namespace Prefix: vtak_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted Namespace Prefix: vtak_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity \(Unaudited\) - USD \(\\$\) \\$ in Thousands Total Series X Convertible Preferred Stock \[Member\] Series A Convertible Preferred Stock Common Stock Additional Paid-In Capital Retained Earnings \(Accumulated Deficit\) Balance, shares at Dec. 31, 2022 Å 0 216,127 Å Å Balance, amount at Dec. 31, 2022 Å 9,260 \\$ 0 \\$ 0 \\$ 214,397 \\$ \(205,137\) Common stock issued upon the exercise of options, shares Å Å 30,175 Å Å Common stock issued upon the exercise of options, amount 179 0 0 \\$ 0 179 0 Restricted stock awards cancelled, shares Å Å 36 Å Å Restricted stock awards cancelled, amount 0 0 \\$ 0 0 Stock-based compensation 1,394 \\$ 0 0 0 1,394 0 Issuance of Series X Convertible Preferred Stock in merger, shares Å 14,650 Å Å Issuance of Series X Convertible Preferred Stock in merger, amount 82,925 \\$ 0 0 \\$ 0 82,925 0 Conversion of Series X Convertible Preferred Stock, shares Å \(1,975\) Å 197,491 Å Å Conversion of Series X Convertible Preferred Stock, amount 0 \\$ 0 0 0 Issuance of Series A Convertible Preferred Stock in connection with private placement, net, shares Å Å 7,203 49,791 Å Å Issuance of Series A Convertible Preferred Stock in connection with private placement, net, amount 7,360 \\$ 0 0 \\$ 0 7,360 0 Warrants exercised \(see Note 13\), shares Å Å 33,161 Å Å Warrants exercised \(see Note 13\), amount 1,145 0 \\$ 0 1,145 0 Net loss \(66,400\) \\$ 0 0 \\$ 0 \(66,400\) Balance, shares at Mar. 31, 2023 Å 12,675 7,203 526,709 Å Å Balance, amount at Mar. 31, 2023 35,863 \\$ 0 0 \\$ 0 307,400 \(271,537\) Balance, shares at Dec. 31, 2022 Å 0 216,127 Å Å Balance, amount at Dec. 31, 2022 9,260 \\$ 0 0 \\$ 0 214,397 \(205,137\) Net loss \(69,903\) Å Å Å Å Balance, shares at Sep. 30, 2023 Å 12,675 4,578 700,800 Å Å Balance, amount at Sep. 30, 2023 21,867 \\$ 0 0 \\$ 1 296,906 \(275,040\) Balance, shares at Mar. 31, 2023 Å 12,675 7,203 526,709 Å Å Balance, amount at Mar. 31, 2023 35,863 \\$ 0 0 \\$ 0 307,400 \(271,537\) Common stock issued upon the exercise of options, shares Å Å 10,058 Å Å Common stock issued upon the exercise of options, amount 59 0 0 \\$ 0 59 0 Net loss \(1,576\) 0 0 0 \(1,576\) Adjustment of fair value of Series X Convertible Preferred Stock in merger \(10,381\) 0 0 0 \(10,381\) 0 Adjustment of fair value of stock-based compensation related to merger \(174\) \\$ 0 0 \\$ 0 \(174\) 0 Balance, shares at Jun. 30, 2023 Å 12,675 7,203 536,767 Å Å Balance, amount at Jun. 30, 2023 23,791 \\$ 0 0 \\$ 0 296,904 \(273,113\) Stock-based compensation 2 0 0 2 0 Net loss \(1,927\) 0 0 \\$ 0 \(1,927\) Conversion of Series A Convertible Preferred Stock, shares Å Å 2,625 164,033 Å Å Conversion of Series A Convertible Preferred Stock, amount 1 \\$ 0 0 1 0 Balance, shares at Sep. 30, 2023 Å 12,675 4,578 700,800 Å Å Balance, amount at Sep. 30, 2023 21,867 \\$ 0 0 \\$ 1 296,906 \(275,040\) Balance, shares at Dec. 31, 2023 Å 12,656 4,578 702,662 Å Å Balance, amount at Dec. 31, 2023 21,193 \\$ 0 0 \\$ 0 296,902 \(275,709\) Stock-based compensation 6 0 0 0 6 Net loss \(2,675\) 0 0 0 \(2,675\) Conversion of Series A Convertible Preferred Stock, shares Å Å 875 54,678 Å Å Conversion of Series A Convertible Preferred Stock, amount 0 0 \\$ 0 0 0 Balance, shares at Mar. 31, 2024](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32:)

A 12,656 3,703 757,340 Â Balance, amount at Mar. 31, 2024 18,524 \$ 0 \$ 0 \$ 0 296,908 (278,384) Balance, shares at Mar. 31, 2023 12,656 4,578 702,662 Â Balance, amount at Dec. 31, 2023 \$ 21,193 \$ 0 \$ 0 \$ 0 296,902 (275,709) Common stock issued upon the exercise of options, shares 0 Â Â Â Net loss \$ (11,015) Â Â Â Balance, shares at Sep. 30, 2024 12,656 0 3,452,652 Â Balance, amount at Sep. 30, 2024 12,826 \$ 0 \$ 0 \$ 0 299,550 (286,724) Balance, shares at Mar. 31, 2024 12,656 3,703 757,340 Â Balance, amount at Mar. 31, 2024 18,524 \$ 0 \$ 0 \$ 0 296,908 (278,384) Stock-based compensation 13 0 0 13 0 Net loss (4,220) \$ 0 \$ 0 0 (4,220) Balance, shares at Jun. 30, 2024 12,656 3,703 757,340 Â Balance, amount at Jun. 30, 2024 14,317 \$ 0 \$ 0 \$ 0 296,921 (282,604) Stock-based compensation 17 0 0 17 0 Net loss (4,120) 0 \$ 0 \$ 0 0 (4,120) Conversion of Series A Convertible Preferred Stock, shares Â A 3,703 231,412 Â Conversion of Series A Convertible Preferred Stock, amount 0 0 \$ 0 \$ 0 0 Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, shares Â Â Â 805,900 Â Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, amount 2,612 0 0 \$ 0 2,612 0 Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), amount 0 \$ 0 \$ 0 0 0 Balance, shares at Sep. 30, 2024 12,656 0 3,452,652 Â Balance, amount at Sep. 30, 2024 \$ 12,826 \$ 0 \$ 0 \$ 0 299,550 \$ (286,724) X - DefinitionAmount of expense for employee benefit and equity-based compensation. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1:

Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08)(g)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_ConversionOfSeriesAConvertiblePreferredStockForCommonStock Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_FairValueOfRoyaltiesPayableIncreaseDecrease Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_PaymentsOfConvertiblePromissoryNotesAndAccruedInterest Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_PaymentsOfCostsRelatedToTheWarrantRepricing Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_PaymentsOfOfferingCostsRelatedToThePrivatePlacementOfSecurities Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_ProceedsFromIssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCosts Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock and warrants, net of fees withheld. + ReferencesNo definition available. + Details Name: vtak_ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_ProceedsFromNotesPayableDueToRelatedParties Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_ProceedsFromThePrivatePlacementOfSecurities Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_PropertyAndEquipmentReclassifiedFromInventories Namespace Prefix: vtak_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML R7.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Nature of Operations 9 Months Ended Sep. 30, 2024 Organization and Nature of Operations 4 Organization and Nature of Operations Note 1. Organization and Nature of Operations 5 The Company 6 Catheter Precision, Inc. ("Catheter" or the "Company") was incorporated in California on September 4, 2002, and reincorporated in Delaware in July 2018. Catheter was initially formed to develop, commercialize and market its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. 7 On January 9, 2023, Catheter entered into the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement") with Catheter Precision, Inc. (the "Old Catheter"), a privately held Delaware corporation. Under the terms of the Merger Agreement, Old Catheter became a wholly owned subsidiary of Catheter, together referred to as the Company, in a stock-for-stock merger transaction (the "Merger"). 8 Prior to the Merger, Catheter developed an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases designed to be used as a tool in the treatment of Peripheral Artery Disease, which commonly occurs in the legs. After the Merger, and looking forward, this legacy Destruction of Arteriosclerotic Blockages by laser Radiation Ablation laser and single-use catheter (together referred to as "DABRA") and related assets were no longer used. The Company ceased operations and marketing with respect to DABRA, and Catheter's legacy lines of business were discontinued. Instead, the Company shifted the focus of its operations to Old Catheter's product lines. Accordingly, the Company's current activities primarily relate to Old Catheter's historical business, which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology (the "EP"). 9 One of the Company's two primary products is the VIVO System, which is an acronym for View into Ventricular Onset (the "VIVO"). VIVO is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO System is commercially available in the European Union and has been placed at several hospitals in Europe. 10 United States Food and Drug Administration ("FDA") 510(k) clearance was received, and the Company began a limited commercial release of VIVO in 2021 in the United States. 11 The Company's newest product, LockT (the "LockT"), is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure and is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. In addition, LockT is a sterile, Class I product that was registered with the FDA in February 2023, at which time initial shipments began to distributors. Clinical studies for LockT began during the year ended December 31, 2023. These studies are planned to show the product's effectiveness and benefits, including faster wound closure, earlier ambulation, potentially leading to early hospital discharge, and cost benefits. This information is intended to provide crucial data for marketing. 12 The Company's product portfolio also includes the Amigo Remote Catheter System (the "AMIGO" or "AMIGO System"), a robotic arm that serves as a catheter control device. Prior to 2018, Old Catheter marketed Amigo. The Company owns the intellectual property related to Amigo, and this product is under consideration for future research and development of a generation 2 product. 13 Reverse Stock Split 14 On July 3, 2024, at the annual meeting of stockholders of the Company, the stockholders approved an amendment to the Amended and Restated Certificate of Incorporation of the Company (the "Amendment"), which included a decrease in the authorized common stock and authorization for the Board, in its discretion, to effect a reverse stock split within specified parameters. The Amendment was effective July 15, 2024, reducing the authorized common stock to 30 million shares and effecting a reverse stock split in which each ten (10) shares of the Company's common stock, par value \$0.0001 per share, issued and outstanding immediately prior to the effective time, automatically combined into one (1) validly issued, fully paid and non-assessable share of the Company's common stock, par value \$0.0001 per share. 15 A No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive a fractional share were entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). All references to share and per share amounts for all periods presented in the unaudited condensed consolidated financial statements have been retrospectively restated to reflect this Reverse Stock Split. All rights to receive shares of common stock under outstanding securities, including but not limited to, warrants and options were adjusted to give effect to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise price and the number of shares of Common Stock that may be purchased upon exercise of outstanding warrants and stock options granted by the Company, and the number of shares of Common Stock reserved for future issuance under the Company's Equity Incentive Plan. 16 A Going Concern 17 The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the

[illegible]

Our rates. Comparative multiple, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. There were impairment charges of \$60.9 million recognized during the nine months ended September 30, 2023 (see Note 3, Business Combination and Note 7, Goodwill for additional details). As of December 31, 2023, goodwill was fully impaired. Royalties Payable The Company is obligated to pay royalties under various royalty agreements executed by Old Catheter. On January 9, 2023, prior to the consummation of the Merger, Old Catheter entered in an agreement with its Convertible Promissory Noteholders (the Noteholders), which substantially consisted of amounts due to David A. Jenkins, previously Old Catheter's Chairman of the Board of Directors, and, currently, the Company's Executive Chairman of the Board of Directors and Chief Executive Officer, to forgive all accrued interest and future interest expense in exchange for a future royalty right. The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of Lockt, commencing on the first commercial sale through December 31, 2035 (see Note 10, Royalties Payable). The Company recognizes a current liability for royalty fees incurred and payable to the Noteholders based on actual sales of Lockt devices. The liability is recorded as current portion of royalties payable in the condensed consolidated balance sheet. The Company further recognizes a liability for future, estimated royalty payments to the Noteholders at fair value, which is recorded as royalties payable in the condensed consolidated balance sheet (the Royalties Payable). The fair value of the Royalties Payable is an estimate that is based on the projected sales of Lockt through the end of 2035. The projected sales are then multiplied by the royalty rate of 11.82% and discounted back to their present value using the RADR. At each reporting date, the fair value of the Royalty Payable is re-measured in connection with any changes to Management's projections as a change in estimate. Product Warranty The Company offers product warranties against defects in material and workmanship when properly the products are used for their intended purpose and properly maintained. Warranty expenses are included in cost of revenues in the accompanying unaudited condensed consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense. As of September 30, 2024 and December 31, 2023, there was no accrued warranty balance. Distinguishing Liabilities from Equity The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under ASC Topic 480, Distinguishing Liabilities from Equity (ASC 480). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company's equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company's equity shares, or variations inversely related to changes in fair value of the Company's equity shares. If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to ASC 815-40, Derivatives and Hedging (ASC 815). The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with ASC 480. Otherwise, the freestanding financial instruments is classified in permanent equity. Revenue Recognition In accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), the Company accounts for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenue is measured as the amount of consideration expected to be received in exchange for transferring promised goods or services. The amount of consideration to be received and revenue recognized may vary due to discounts. A performance obligation is a promise in a contract to transfer a distinct good or service. If there are multiple performance obligations in the customer contract, the Company allocates the transaction price in the contract to each performance obligation based on the relative standalone selling price. Revenue is recognized when performance obligations in the customer contract are satisfied. This generally occurs when the customer obtains control of a promised good at a point in time or when a customer receives a promised service over time. Pursuant to ASC 606, the Company applies the following five steps to each customer contract: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price in the contract Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the Company satisfies a performance obligation VIVO System The VIVO System offers 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. Customers are provided with VIVO Positioning Patch Sets, which are custom patches, that are used in conjunction with the VIVO System. The VIVO Positioning Patch Sets are integral to the functionality of the VIVO System. The VIVO System, including the VIVO Positioning Patch Sets, represents the Company's primary performance obligation. The Company recognizes revenue when physical possession and control of the VIVO System is transferred to the customer upon delivery. The Company also offers customers software upgrades for the VIVO System, which may be purchased and paid in advance at contract inception. Software upgrades represent stand-ready services, whereby the Company promises to provide software upgrades to the customer when and as upgrades are available. Software upgrade services may be offered for initial contract terms of one to multiple years. Customers have the option to renew terms for software upgrades services at the end of each term. The software upgrade services represent the Company's second performance obligation, which is recognized evenly over time over the contract term. A The Company invoices the customer after physical possession and control of the VIVO System is transferred to the customer and recognizes revenue upon delivery. The timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. The Company invoices customers who pay for software upgrades in advance in conjunction with the invoice for the delivery of the VIVO System, and subsequent renewals of software upgrades are invoiced at the inception of the term. Revenue for these stand-ready services is recognized evenly over the term of the upgrade period, consistently with similar stand-ready services under ASC 606. Similar to the delivery of the VIVO System, the timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. Revenue is recognized at the point in time that the product is delivered to the customer. Lockt Lockt was launched by the Company in February 2023 and is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Lockt is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. The Lockt device represents a performance obligation in the customer contract. The Company recognizes revenue when it transfers control of the Lockt device to the customer, which happens when the Company delivers the product to the customer. For both Lockt and VIVO System, the Company has elected the practical expedient to expense costs incurred to obtain a contract, rather than recognizing these costs as an asset at the time of occurrence. Disaggregation of Revenue The following table summarizes disaggregated product sales by geographic area (in thousands): For the Three Months Ended September 30, 2024 For the Nine Months Ended September 30, 2024 For the Three Months Ended September 30, 2023 For the Nine Months Ended September 30, 2023 Sales USA \$62A \$110A \$129A \$241A Europe \$34A \$23A \$142A \$73A \$96A \$133A \$271A \$314A Shipping and Handling Costs Shipping and handling costs charged to customers are included in net product sales, while all other shipping and handling costs are included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Advertising and Marketing Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were \$31 thousand and \$127 thousand during the three and nine months ended September 30, 2024, respectively. Advertising costs were \$309 thousand and \$914 thousand during the three and nine months ended September 30, 2023, respectively. Patents The Company expenses patent costs, including related legal costs, as incurred and records such costs as selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Research and Development Major components of research and development costs include consulting, research grants, supplies and clinical trial expenses. Research and development expenses are charged to operations in the period incurred. A Stock-Based Compensation The Company records stock-based compensation expense associated with stock options, restricted stock awards (RSAs) and restricted stock units (RSUs) issued to employees, members of the Company's board of directors and consultants in accordance with the guidance under ASC Topic 718, Compensation - Stock Compensation (ASC 718). The Company evaluates whether an award should be classified and accounted for as a liability award or equity award for all stock-based compensation awards granted. Stock-based compensation expense for stock options is measured at the grant date based on the estimated fair value of the award using the Black-Scholes option pricing valuation model (the Black-Scholes model), which incorporates various assumptions, including expected term, volatility and risk-free interest rate. Stock-based compensation expense for stock options is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting period of the respective award. Share-based compensation for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not probable or is not met, no stock-based compensation expense is recognized, and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. As a result of the Merger, all unvested Old Catheter stock options were subject to accelerated vesting and became fully vested as of the closing date of the business combination. The Company recognized the fair value of the replacement options as included in consideration transferred to the extent they do not exceed the fair value of the equivalent Old Catheter options. Any incremental fair value was recognized in compensation expense in the post-combination period, with this recognized as a Day 1 expense due to the Old Catheter options becoming fully vested concurrent with the closing of the business combination. A Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. A The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively. A Basic and Diluted Net Loss per Share of Common Stock Earnings per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Company's common shares and participating securities. The Company's Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and outstanding warrants contain participating rights in distributions made to common stockholders and, therefore, are participating securities. The Company did not declare nor pay any dividends nor distributions in the current period. Furthermore, the participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per common share. A Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic net loss per share for the periods presented herein because common stock equivalent shares from warrants, stock options, non-vested restricted stock awards, restricted stock units, Series A Convertible Preferred Stock, and Series X Convertible Preferred Stock are antidilutive (see Note 12, Net Loss per Share). Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed dividends declared. The Company recorded a deemed dividend for the modification of existing warrants and issuance of new warrants during the three and nine months ended September 30, 2023 of \$0 and \$0.8 million, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders for the three and nine months ended September 30, 2023. There was no deemed dividend for the three and nine months ended September 30, 2024. Recently Announced Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 require disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. These amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently reviewing the impact that the adoption of ASU 2023-07 may have on our consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is required to adopt this standard prospectively in fiscal year 2025 for the annual reporting period ending December 31, 2025. The Company does not believe the impact of the new guidance and related codification improvements will have material impact to its financial position, results of operations and cash flows. X - References No definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:string Item Type Balance Type: na:Period Type: duration X - Definition The entire disclosure for all significant accounting policies of the reporting entity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483426/235-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 - Name Accounting Standards Codification - Publisher FASB - URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_Significant Accounting Policies Text Block Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlock Item Type Balance Type: na:Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combination 9 Months Ended Sep. 30, 2024 Business Combination A Business Combination Note 3. Business Combination A On January 9, 2023, the Company completed the acquisition of Old Catheter for the purpose of acquiring Old Catheter's existing and developing product lines based on unique electrophysiology technology. A Pursuant to the Merger Agreement, all Old Catheter common stock shares issued and outstanding and convertible promissory notes, representing an aggregate principal of \$25.2 million, were converted into a right to receive 14,649,592 shares of a new class of the Company's preferred stock, designated Series X Convertible Preferred Stock

Effects various fair value estimates and analyses, including certain tangible assets acquired and liabilities assumed, the valuation of intangible assets acquired, goodwill, which were subject to change within the measurement period as valuations were being finalized (generally one year from the acquisition date). Measurement period adjustments were recorded in the reporting period in which the estimates are finalized, and adjustment amounts were determined. During the three months ended June 30, 2023, the Company recorded measurement period adjustments based on changes to certain estimates and assumptions and their related impact to the purchase price allocation. Developed technology was revised from \$35.1 million to \$27.0 million; trademarks were revised from \$1.7 million to \$1.3 million; customer relationships were revised from \$220 thousand to \$62 thousand; goodwill was revised from \$56.0 million to \$60.9 million; and royalties payable were revised from \$7.6 million to \$14.2 million. The following table summarizes the final purchase price allocations relating to the Merger (in thousands):

Description
A Fair Value Assets acquired:
A A Cash and cash equivalents
A Accounts receivable
A Inventories
A Prepaid expenses and other current assets
A Property and equipment,
A Lease right-of-use assets
A Other assets
A Developed technology
A Customer relationships
A Trademarks
A Goodwill
A Total assets acquired
A Liabilities assumed:
A Accounts payable
A Accrued expenses
A Lease liability
A Interest payable
A Convertible promissory notes
A Royalties payable
A Total liabilities assumed
A Total purchase price
A All intangible assets acquired are subject to amortization and their associated acquisition date fair values and useful lives are as follows:
A Intangible Assets
A Useful Life
A Developed technology - VIVO
A Lock eT
A Customer relationships
A Trade mark - VIVO
A Trade mark - Locke T
A Notwithstanding the above, as described in Note 7, management determined that there were indicators of asset impairment during the nine months ended September 30, 2023, and assessed the carrying values of the Company's intangible assets and goodwill. As a result of the impairment analysis in prior periods, the Company recorded an impairment charge of \$60.9 million for the nine months ended September 30, 2023. This amount represented the purchase price amount ascribed to goodwill. Transaction costs incurred in connection with this business combination amounted to approximately \$0 and \$1.7 million during the three and nine months ended September 30, 2023, respectively.

Pro Forma Financial Information The following table represents the revenue, net loss and net loss per share effect of the acquired company, as reported on a pro forma basis as if the acquisition occurred on January 1, 2023. These pro forma results are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the first day of the period presented, nor does the pro forma financial information purport to represent the results of operations for future periods. The following information for the three and nine months ended September 30, 2023 is presented in thousands except for the per share data (in thousands, except per share data):

Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Revenue	\$133A
Net loss	\$(1,927)A
Net loss attributable to common stockholders	\$(1,927)A
Basic and diluted net loss per share	\$(0.28)A (\$14.07) X

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

References

Reference 1:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 805 - SubTopic 20 - Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474779907/805-20-50](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 - SubTopic 20 - Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/21474779907/805-20-50)

Reference 2:

thereby, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owing when due, material breach of representations or warranties by the Company (unless waived by the holder of the Related Party Note or cured within 10 days following notice) and/or certain events involving a discontinuation of the Company’s business or certain types of proceedings involving insolvency, bankruptcy, receivership and the like. A Interest expense on the Related Party Notes was \$33 thousand and \$36 thousand for the three and nine months ended September 30, 2024, respectively. The balance of the Related Party Notes and accrued interest was \$1.5 million as of September 30, 2024, \$16 thousand of which relates to accrued interest and is recorded under interest payable to related parties on the condensed consolidated balance sheets. A See Note 19, Related Parties for additional details. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_NotesPayableDisclosureTextBlock Namespace Prefix: vtak_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Royalties Payable 9 Months Ended Sep. 30, 2024 Royalties Payable A Royalties Payable Note 10. Royalties PayableA LockET RoyaltyA On January 9, 2023, Old Catheter entered into an agreement with the Noteholders to forgive all accrued interest and future interest expense in exchange for a future royalty right. Under these agreements, the Company is obligated to pay the Noteholders a total royalty equal to approximately 12% of net sales of its LockET device on a quarterly basis, commencing upon the first commercial sale through DecemberA 31, 2035. A An additional royalty will be paid to the inventor of the LockET device as detailed in the Royalty Agreement. In exchange for the assignment and all rights to LockET, the Company will pay a 5% royalty on net sales up to \$1.0 million in royalties, payable annually in arrears, starting with the year ending December 31, 2022. After \$1.0 million has been paid, and if, and only if, a US patent is granted by the United States Patent and Trademark Office, the Company will continue to pay a royalty at a rate of 2% of net sales, until total cumulative royalties of \$10.0 million have been paid. The royalty payments will apply to revenues through December 31, 2033, then will terminate regardless of whether the full \$10.0 million has been paid.A The LockET device had sales during the three and nine months ended September 30, 2024, and as such the Company owes the first royalty payment in relation to the Royalty Agreement. As of September 30, 2024, the Company owes \$17 thousand in relation to LockET sales. A A AMIGO System RoyaltyA During 2006 and 2007, Old Catheter entered into two investment grant agreements with a non-profit foundation for the purpose of funding the initial development of Old Catheter’s AMIGO System, receiving a total of \$1.6 million from the foundation.A The agreement calls for the payment of the following sales-based royalties, by Old Catheter, to the foundation, upon successful commercialization of the AMIGO System: A Royalty PercentageA A Until Royalty Payment Reaches a Total of4%\$1,589,5002%A \$3,179,0001%A A In perpetuityA The Company is not actively marketing and selling the AMIGO System. There was no royalty expense recorded for the three and nine months ended September 30, 2024 and 2023 in relation to the AMIGO System. The AMIGO System royalty has been earned and payment has been deferred to a future date.The table below represents the change in fair value of Level 3 royalties payable for the nine months ended September 30, 2024 and 2023 (\$ in thousands). See Note 2, Summary of Significant Accounting Policies, for valuation techniques. A A A 2024A A 2023A Beginning Balance, January 1, A \$6,974A A \$6“A AMIGO royalty payable recognized in connection with the MergerA A A A A 159A LockET royalty payable recognized in connection with the MergerA A A A A A 14,022A Payments owed on royalties payableA A 17A A A A A Change in fair value of royalties payableA A 2,823A A A (5,333)Ending Balance, September 30, A \$9,814A A \$8,848A X - ReferencesNo definition available. + Details Name: vtak_RoyaltiesPayableAbstract Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_RoyaltiesPayableTextBlock Namespace Prefix: vtak_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases 11. LeasesA For the three and nine months ended September 30, 2024 and 2023 operating lease expense and cash paid for leases were as follows: A A A For the Three Months Ended September 30, A A For the Nine Months Ended September 30, A A 2024A A 2023A A 2024A A 2023A Operating lease expenseA \$28A A 23A A \$80A A \$52A Cash paid for leasesA \$25A A \$32 A A \$78A A \$62A A The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies with similar credit ratings and of comparable quality and derived an imputed rate, which was used in a portfolio approach to discount its real estate lease liabilities. Management used an estimated incremental borrowing rate as detailed below for each lease. A Lease Terms and Discount RateA The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating leases, as of September 30, 2024: A Weighted average remaining lease term (in years) - operating leasesA A 1.37A Weighted average discount rate - operating leasesA A 8.65%A South Carolina Office Lease AgreementA On September 27, 2022, Old Catheter entered into a lease agreement for office space located in Fort Mill, South Carolina. The space is used for office and general use. The term of the lease began on October 1, 2022, is 38 months, and includes two months of free rent from the commencement date of the lease. The lease contains two separate 36 month renewal periods, which require 180 days’ notice of the Company’s intention to exercise. As of the date of these condensed consolidated financial statements, the Company does not intend to exercise either of the two extension options. Total rent is \$3,435 per month for the first ten months following the two months of free rent, with annual increases on the anniversary of the effective date. The Company has adopted the practical expedient under Topic 842, which permits the Company to account for each separate lease component of a contract and its associated non-lease components as a single lease payment. As a result, beginning at lease inception on October 1, 2022, the Company recognized the lease payments and associated common area maintenance payments as a single lease payment. New Jersey Office Lease AgreementA On December 7, 2022, Old Catheter entered into a lease agreement for office space located in Augusta, New Jersey. The space is used for office and general use. The term of the lease is 24 months and began on January 1, 2023. The lease contains one 24 month renewal period, which requires 9 months’ notice if the Company intends to exercise. In March 2024, the Company notified the landlord of its intent to extend the lease for a 12-month period. A In April 2024, a lease extension agreement was entered into extending the lease through December 31, 2025. A Total rent is \$1,207 per month through December 31, 2024, and \$1,267 for the remaining term of the extended lease. A Park City Office Lease AgreementA On March 19, 2023, the Company entered into a lease agreement for office space located in Park City, Utah. A The space is used for office and general use. The term of the lease is for 36 months and began on May 1, 2023. The lease contains one 36 month renewal period, which requires 180 days’ notice of the Company’s intention to exercise. As of the date of these unaudited condensed consolidated financial statements, the Company does not intend to exercise the extension option. Total rent is \$3,200 per month for the first year with an annual increase of three percent per year on the anniversary of the effective date. A Future lease payments for all lease obligations for the following five fiscal years and thereafter are as follows (in thousands): A Years ending December 31: A Operating LeaseA Remainder of 2024A 2024A 2025A A 98A 2026A A 14A Total minimum lease paymentsA A 136A Less effects of discountingA A (1)Present value of future minimum lease paymentsA \$135A A Operating lease right-of-use assets and lease liabilities for the Company’s operating leases were recorded in the condensed consolidated balance sheets as follows: A A A September 30, A A December 31, A A A 2024A A 2023A AssetsA A A A A Operating lease right-of-use assets, netA \$127A A \$179A Total lease assetsA \$127A A \$179A A A A A A LiabilitiesA A A A A A Current liabilities: A A A A A Current portion of operating lease liabilitiesA \$99A A \$91A Non-current liabilities: A A A A A A Operating lease liabilitiesA \$36A A A 97A Total lease liabilitiesA \$135A A \$188A X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee’s finance lease and maturity analysis of finance lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap_LesseeFinanceLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share 9 Months Ended Sep. 30, 2024 Net Loss per Share A Net Loss per Share Note 12. Net Loss per ShareA The Company’s Series A Convertible Preferred Stock, Series X Convertible Preferred Stock and outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. A Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at September 30, 2024, consisted of Series X Convertible Preferred Stock of 1,265,601 shares, warrants of 13,170,652, stock options of 95,813, and no Series A convertible preferred stock, restricted stock awards or restricted stock units.A Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at September 30, 2023, consisted of Series A convertible preferred stock of 286,125 shares, Series X convertible preferred stock of 1,267,469 shares, warrants of 1,104,215, stock options of 21,465, and restricted stock units of 2 A Net loss attributable to common stockholders for the nine months ended September 30, 2023, consists of net loss, as adjusted for deemed dividends. The Company recorded a deemed dividend for the modification of existing warrants and issuance of the Series E warrants (see Note 13, Equity Offerings) of \$0.8 million, during the nine months ended September 30, 2023. X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3> + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_NetLossPerShareAbstract Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Offerings 9 Months Ended Sep. 30, 2024 Equity Offerings A Equity OfferingsA Warrant Inducement OfferA On January 9, 2023, the Company reduced the exercise price of all existing warrants (the "Existing Warrants"), exercisable for 33,161 shares of the Company’s common stock held by an investor (the “Investor”), with exercise prices ranging from \$140.00 to \$5,265 per share to \$40.00 per share (the "2023 Warrant Repricing"). In connection with the 2023 Warrant Repricing, the Company entered into a Warrant Inducement Offer Letter (the "2023 Inducement Letter") with the Investor pursuant to which it would exercise up to all of the 33,161 Existing Warrants (the "Inducement Offer"). In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company received approximately \$1.3 million in gross proceeds. The Company paid placement agent aggregate cash fees plus other offering costs of approximately \$0.2 million related to the Inducement Offer, resulting in net proceeds to the Company of \$1.1 million. In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company issued the Investor a new Series E common stock purchase warrant (the "Series E Warrant") to purchase 33,161 shares of common stock at an exercise price of \$40.00 per share. The Series E Warrant is exercisable for five years from the date of stockholder approval. Exercise of the Series E Warrant in full was subject to approval of the Company’s stockholders other than the Investor, which was obtained at a special meeting of the Company’s stockholders held on March 21, 2023 (the "Stockholders’ Meeting"). The incremental fair value of the repriced warrants amounted to \$0.3 million and the fair value of Series E warrant totaled \$1.9 million. The relative fair value of such amounts were recorded to additional paid-in capital concurrent with the exercise of the Existing Warrants.A As a result of the 2023 Warrant Repricing and Inducement Offer, the Company presents a deemed dividend for the modification of Existing Warrants and issuance of the Series E Warrants of \$0 and \$0.8 million during the three and nine months ended September 30, 2023, respectively. The deemed dividend was included in net loss attributable to common stockholders in the calculation of net loss per share in the unaudited consolidated condensed statements of operations. The warrants, other than the Series E Warrants that are presented in a separate table below, were valued on the date of the 2023 Warrant Repricing using the Black-Scholes model based on the following assumptions: A A A 5/22/2020 RaiseA A 8/3/2020 RaiseA A Series BA A Series CA Risk-free interest rateA A 4.06%A A 4.06%A A 3.60%A A 3.66%VolatilityA A 135.35%A A 132.55%A A 115.42%A A 127.65%Expected dividend yieldA A 0.00%A A 0.00%A A 0.00%A A 0.00%Expected life (in years)A A 2.4A A 2.4A A 2.6A A 2.6A A 4.5A A 4.5A The Series E warrants were also valued on the date of the 2023 Warrant Repricing at approximately \$1.9 million using the Black-Scholes model based on the following assumptions: A Risk-free interest rateA A 3.66%VolatilityA A 124.07%Expected dividend yieldA A 0.00%Expected life (in years)A A 5.0A A Private PlacementA On January 9, 2023, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”), with the Investor. Pursuant to the Securities Purchase Agreement, the Investor agreed to purchase, for an aggregate purchase price of approximately \$8.0 million, (a) Class A units at a price that was the lower of \$3.00 per unit and 90% of the 5 day volume weighted average price of the Company’s common stock immediately prior to obtaining of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants (as each are defined below), without adjusting such price for the reverse stock split, each consisting of one tenth of one share of common stock, one tenth of one Series F common stock purchase warrant (the “Series F Warrant”), and one tenth of one Series G common stock purchase warrant (the “Series G Warrant”), and together with the Series F Warrants (the “PIPE Warrants”), and (b) Class B units at a price of \$1,000 per unit, each consisting of one share of a new series of the Company’s preferred stock, designated as Series A Convertible Preferred Stock (the “PIPE Preferred Stock”), par value \$0.0001, and one tenth of one Series F Warrant and one tenth of one Series G Warrant for each one-tenth of one share of the Company’s common stock underlying the PIPE Preferred Stock (each share of which is convertible into a number of shares of the Company’s common stock equal to \$1,000 divided by the lower of \$30.00 and 90% of the 5 day volume weighted average closing price, multiplied by ten in order to reflect the impact of the reverse stock split of the Company’s common stock immediately prior to the obtaining of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants, or the Preferred Conversion Rate). The closing under the Securities Purchase Agreement and the sale and issuance of the Class A units and Class B units (and the issuance of any underlying common stock) were approved at the Stockholders’ Meeting. At the closing of the Private Placement, the Company issued 497,908 Class A units for proceeds of approximately \$0.9 million and 7,203 Class B units for proceeds of approximately \$7.1 million which contained preferred shares that were convertible into up to 450,123 shares of common stock, as well as the issuance of warrants described below.A The PIPE Warrants, including Series F warrants and Series G warrants, are exercisable at an exercise price of \$30.00 per share, subject to adjustments as provided under the terms of the PIPE Warrants. The PIPE Warrants are exercisable at any time on or after the closing date of the Private Placement until the expiration thereof, except that the PIPE Warrants cannot be exercised if, after giving effect thereto, the purchaser would beneficially own more than 4.99%, or the Maximum Percentage, of the outstanding shares of common stock of the Company, which Maximum Percentage may be increased or decreased by the purchaser with written notice to the Company to any other percentage specified not in excess of 9.99%. The Series F Warrants have a term of two years from the date of stockholder approval, and the Series G Warrants have a term of six years from the date of stockholder approval. The Series F Warrants and Series G Warrants were approved at the Stockholders’ Meeting. The Series F warrants and Series G warrants were valued, in aggregate, at approximately \$5.5 million using the Black-Scholes model based on the following assumptions: A A A Series FA A Series GA Risk-free interest rateA A 3.8%A A 3.4%VolatilityA A 80.0%A A 74.0%Expected dividend yieldA A 0.0%A A 0.0%Expected life (in years)A A 2.0A A 6.0A The proceeds from the Securities Purchase Agreement were allocated to the equity instruments issued based on their relative fair values and recorded in additional paid-in capital.A Shares of PIPE Preferred Stock, the conversion of which was approved at the Stockholders’ Meeting, convert into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.A Subject to limited exceptions, holders of shares of PIPE Preferred Stock will not have the right to convert any portion of their Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or up to 9.99% at the election of the holder) of the number of shares of the Company’s common stock outstanding immediately after giving effect to its conversion.A Holders of PIPE Preferred Stock will be entitled to receive dividends on shares of PIPE Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the PIPE Preferred Stock does not have voting rights.A The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the resale of the shares of common stock, the shares issuable upon exercise of the Warrants and the shares issuable upon the conversion of the PIPE Preferred Stock. A Placement FeesA In connection with offerings

completed by the Company in 2022, (the "2022 Offerings"), the Company entered into an agreement with a placement agent that, subject to satisfaction of the requirements contained therein, called for a placement fee payable based on capital raised from certain investors for a definitive time following the expiration of the agreement. The accrued placement fee of approximately \$1.4 million related to the 2022 Offerings is included in accrued expenses in the consolidated balance sheets as of September 30, 2024. Additionally, the agreement called for the issuance of warrants with the following terms: A Number of sharesÂ Exercise PriceÂ Expiration 3,300Â \$312.50Â 5 years 3,100Â \$175.00Â 5 years The warrants were valued on the date of the 2022 Offerings using the Black-Scholes model based on the following assumptions: A Value (\$ in millions)Â Expected VolatilityÂ Risk-Free Interest RateÂ Expected Dividend YieldÂ Expected Term (years) \$0.44 93.25%Â 1.81%Â 0%Â 5.0 \$0.2Â 96.70%Â 2.87%Â 0%Â 5.0 Pursuant to the 2024 Public Offering On September 3, 2024, in connection with the September Public Offering (see Note 1), the Company sold an aggregate of 805,900 Common Stock Units and 2,773,000 Pre-Funded Warrant Units at a public offering price of \$1.00 per Common Stock Unit and \$0.9999 per Pre-Funded Warrant Unit. The Company received gross proceeds of approximately \$3.6 million less underwriting discounts and commissions of \$1.0 million, resulting in net proceeds of \$2.6 million. A Each Common Stock Unit consists of: (i) one share of the Company's Common Stock, (ii) a Series H Warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires six months from the date of issuance, (iii) a Series I Warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires eighteen months from the date of issuance, and (iv) a Series J Warrant to purchase one share of Common Stock at an exercise price of \$1.00 per share that expires five years from the date of issuance. A Each Pre-Funded Warrant Unit consists of: (i) a Pre-Funded Warrant to purchase one share of Common Stock at an exercise price of \$0.0001 per share with no expiration date, (ii) one Series H Warrant, (iii) one Series I Warrant (iv) and one Series J Warrant. A Pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day Overallotment Option to purchase up to (i) 468,041 additional shares of Common Stock, (ii) 468,041 additional Series H Warrants, (iii) 468,041 additional Series I Warrants, and/or (iv) 468,041 additional Series J Warrants, solely to cover over-allotments. On August 30, 2024, the Underwriters partially exercised the Overallotment Option to purchase an additional 458,623 shares of Common Stock, 458,623 Series H Warrants, 458,623 Series I Warrants, and 458,623 Series J Warrants, or 458,623 Common Stock Units. The Common Stock Units issued through the exercise of the Overallotment Option are included in the 805,900 Common Stock Units noted above. The Overallotment Option expires on October 14, 2024, and is not expected to be exercised. The remaining balance of the Overallotment Option is not material to the condensed consolidated financial statements as of September 30, 2024. A Furthermore, at the closing date, the Company agreed to deliver warrants to purchase an aggregate number of shares of Common Stock equal to 6% of the shares of Common Stock (i) issued in connection with the September 2024 Public Offering and (ii) issuable upon the exercise of the Pre-Funded Warrants. Therefore, the Company issued 214,734 warrants to the Representative and its designees (the "Representative Warrants"). The Representative Warrants are part of the underwriter costs and commissions incurred in connection with the September 2024 Public Offering. The Representative Warrants may be exercised to purchase one share of Common Stock at an exercise price of \$1.55 per share and expires five years from the date of issuance. A Each Series H Warrant, Series I Warrant, Series J Warrant (collectively, the "Series Warrants"), and Pre-Funded Warrant is immediately exercisable. The exercise price of the Series Warrants and Pre-Funded Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company's common stock. Subject to limited exceptions, a holder of the Series Warrants will not have the right to exercise any portion of its Series Warrants if the holder (together with such holder's affiliates) would beneficially own a number of shares of common stock in excess of 4.99% of the shares of Common Stock then outstanding (the "Beneficial Ownership Limitation"). Similarly, a holder of the Pre-Funded Warrants has a Beneficial Ownership Limitation of 9.99%. At the holder's option, the holder of the Series Warrants may increase the beneficial ownership limitation to 19.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days' prior notice to the Company. A The Representative Warrants are exercisable after six months from the effective date of the Registration Statement filed by the Company on August 29, 2024. The Representative Warrants further have a Beneficial Ownership Limitation of 4.99%, which may be increased to 9.99% of the shares of Common Stock then outstanding at the option of the Representative. Any increase in the Beneficial Ownership Limitation will become effective upon 61 days' prior notice to the Company. A The Company assessed the Series Warrants, Pre-Funded Warrants, and Representative Warrants issued in connection with the September 2024 Public Offering (collectively, the "September 2024 Warrants") and determined that they do not require liability classification pursuant to ASC 480. Furthermore, the September 2024 Warrants do not have any net cash settlement provisions that would preclude equity classification under ASC 815-40. Accordingly, the September 2024 Warrants were recorded to additional paid-in capital in the condensed consolidated balance sheets. Warrants A The following table presents the number of common stock warrants outstanding: A Warrants outstanding, December 31, 2023 A 1,104,217 A Issued A 13,724,435 A Exercised A (1,658,000) A Expired A 0 A Warrants outstanding, September 30, 2024 A 13,170,652 A As of September 30, 2024, and December 31, 2024, all warrants outstanding are recorded in additional paid-in capital in the condensed consolidated balance sheets. The following table presents the number and type of common stock warrants outstanding, their exercise price, and expiration dates as of September 30, 2024: A Warrant Type A Warrants Outstanding A Exercise Price A Expiration Date A May 2020 Warrants A 1,275 A \$5,625.00 A 5/20/2025 A May 2020 Placement Agent Warrants A 124 A \$7,031.25 A 5/20/2025 A August 2020 Warrants A 1,943 A \$4,375.00 A 8/3/2025 A August 2020 Placement Agent Warrants A 192 A \$5,468.75 A 7/30/2025 A August 2021 Pharos Banker Warrants A 148 A \$1,495.00 A 8/16/2026 A February 2022 Series B Warrants A 39,153 A \$140.00 A 2/4/2022 A July 2022 Series C Warrants A 28,404 A \$140.00 A 7/22/2027 A January 2023 Series E Warrants A 33,161 A \$40.00 A 3/21/2028 A March 2023 Series F Warrants A 499,909 A \$30.00 A 3/21/2025 A March 2023 Series G Warrants A 499,909 A \$30.00 A 3/21/2029 A September 2024 Pre-Funded Warrants A 1,115,000 A \$0.00 A None A September 2024 Series H Warrants A 3,578,900 A \$1.00 A 3/3/2025 A September 2024 Series I Warrants A 3,578,900 A \$1.00 A 3/3/2026 A September 2024 Series J Warrants A 3,578,900 A \$1.00 A 9/3/2029 A September 2024 Representative Warrants A 214,734 A \$1.55 A 8/29/2029 A A A A A A As of September 30, 2024, the warrants issued by the Company had a weighted average exercise price of \$5.29. X - Definition The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details Name: us-gaap -PreferredStockTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X R220.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred Stock 9 Months Ended Sep. 30, 2024 Preferred Stock A Preferred Stock Note 14. Preferred Stock A Series X Convertible Preferred Stock A As described in Note 3, above, pursuant to the Merger Agreement, all Old Catheter common stock shares issued and outstanding and convertible promissory notes, representing an aggregate principal of \$25.2 million, were converted into a right to receive 14,649,592 shares of a new class of the Company's preferred stock, designated Series X Convertible Preferred Stock. A Series X Convertible Preferred Stock has no voting rights prior to the conversion into common stock. While there are generally no voting rights of the Series X Convertible Preferred Stock, there are protective rights regarding the sales of the company, change of control, etc. Series X Preferred Stock may convert into common stock only if the Company's common stock has been delisted from the NYSE American or has been approved for initial listing on the NYSE American or another stock exchange, at a rate of 100 shares of common stock for each share of Series X Convertible Preferred Stock. A Other than dividends payable in shares of Common Stock, Holders of Series X Convertible Preferred Stock will be entitled to receive dividends on shares of Series X Convertible Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of Common Stock. A Upon consummation of the Merger, each holder of Old Catheter convertible promissory notes received, in exchange for discharge of the principal of his or its Notes, a number of shares of the Company's Series X Convertible Preferred Stock representing a potential right to convert into the Company's common stock in an amount equal to one common share for each \$32.00 of principal amount. On March 21, 2023, the Company held the Stockholders' Meeting, at which the stockholders approved, among other things, the issuance of 199,359 shares of common stock upon the conversion of 1,993,581 of Series X Convertible Preferred Stock which were issued upon the closing of the Merger, see Note 3, Business Combination. On March 23, 2023, the Company issued 197,491 shares of common stock upon the conversion of 1,974,905 of Series X Convertible Preferred Stock. On October 24, 2023, the remaining 1,868 shares of common stock were issued upon the conversion of 18,676 shares of Series X Convertible Preferred Stock. The remaining 12,656,011 shares of Series X Convertible Preferred Stock are expected to remain outstanding until the Company meets the initial listing standards of the NYSE American or another national securities exchange or is delisted from the NYSE American, at which time they will convert into common stock. A Series A Convertible Preferred Stock A As described in Note 13, on January 9, 2023, the Company entered into a Securities Purchase Agreement for a Private Placement with the Investor. Pursuant to the Securities Purchase Agreement, shares of Series A Convertible Preferred Stock were issued, the conversion of which was approved at the Stockholders' Meeting. The Series A Convertible Preferred Stock converts into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. A Subject to limited exceptions, holders of shares of Series A Convertible Preferred Stock will not have the right to convert any portion of their Series A Convertible Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to its conversion. A Holders of Series A Convertible Preferred Stock will be entitled to receive dividends on shares of Series A Convertible Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Convertible Preferred Stock does not have voting rights. A The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the shares of common stock, issuable upon the conversion of the Series A Convertible Preferred Stock. The shares have been registered for resale on an effective registration statement on Form S-1. A The following conversions of Series A Convertible Preferred Stock occurred subsequent to the issuance and prior to September 30, 2024: A Date of Conversion A Series A Shares Converted A Common Shares Issued July 5, 2023 A 1,750 A 109,355 July 24, 2023 A 875 A 54,678 January 24, 2024 A 875 A 54,678 July 1, 2024 A 1,303 A 81,423 July 1, 2024 A 1,000 A 62,489 July 22, 2024 A 1,000 A 62,500 July 23, 2024 A 400 A 25,000 A Each share of Series A Convertible Preferred Stock is convertible into approximately 62.5 shares of common stock. The common stock was issued pursuant to the exemption contained in Section 3(a)(9) of the Securities Act of 1933, as amended (the "Act"), which applies to transactions in which a security is exchanged by an issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. A The shares issued have been registered for resale on an effective registration statement on Form S-1. After the final conversion on July 23, 2024, the Company had no shares of Series A Convertible Preferred Stock outstanding. X - Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap -EquityMethodInvestmentsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X R221.htm IDEA: XBRL DOCUMENT v3.24.3 StockBased Compensation 9 Months Ended Sep. 30, 2024 StockBased Compensation A Stock-Based Compensation Note 15. Stock-Based Compensation A 2018 Equity Incentive Plan A In September 2018, the Company's board of directors adopted, and the Company's stockholders approved, the 2018 Equity Incentive Plan (the "2018 Plan") which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company's employees, directors and consultants. In July 2023, the 2018 Plan was replaced by the 2023 Equity Incentive Plan (the "2023 Plan"), as described below. As of July 2023, no additional awards could be made under the 2018 Plan and no shares of common stock were reserved for future issuance. As of September 30, 2024, there are 7 non-statutory stock options outstanding under the 2018 Plan. A A Three expire in June 2028 and four expire in January 2030. A 2018 Employee Stock Purchase Plan A In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "ESPP") which permitted eligible employees to purchase the Company's common stock at a discount through payroll deductions during defined offering periods. Eligible employees could elect to withhold up to 15% of their base earnings to purchase shares of the Company's common stock at a price equal to 85% of the fair market value on the first day of the offering period or the purchase date, whichever was lower. The number of shares of common stock reserved for issuance under the ESPP automatically increased on January 1 of each fiscal year by the lesser of (1) 23 shares, (2) 1.25% of the total number of shares outstanding on December 31 of the preceding fiscal year, or (3) such other amount as the Company's board of directors may determine. A In April 2024, the Company formally terminated the ESPP. For the three and nine months ended September 30, 2024 and 2023, no cash was received from the exercise of purchase rights under the ESPP in each respective period. A As of September 30, 2024, the Company had issued 95 shares of common stock since inception of the ESPP, and no shares were reserved for future issuance. A As of December 31, 2023, the Company had issued 95 shares of common stock since inception of the ESPP, and 2 shares were reserved for future issuance. A Upon termination of the ESPP in April 2024, the reserved shares were released back to the authorized pool. A 2020 Inducement Equity Incentive Plan A In March 2020, the Company adopted the 2020 Inducement Equity Incentive Plan (the "2020 Plan") for the purpose of attracting, retaining and incentivizing employees in furtherance of the Company's success. The 2020 Plan was adopted without stockholder approval pursuant to Rule 303A.08 of the New York Stock Exchange. The 2020 Plan is used to offer equity awards as material inducements for new employees to join the Company. Upon adoption of the 2020 Plan, 64 shares of common stock were reserved for the granting of inducement stock options, restricted stock awards, restricted stock units and other forms of equity awards. As of September 30, 2024 and December 31, 2023, zero and 54 shares of common stock were reserved for future issuance under the 2020 Plan. In April 2024, the Company terminated the 2020 Plan at which time the reserved shares were released back to the authorized pool. Stock Options Assumed in Merger (See Note 3, Business Combination) A At the closing of the Merger, each outstanding option to purchase Old Catheter common stock that had not previously been exercised prior to the closing of the Merger was assumed and converted into options to purchase 75,365 shares of the Company's common stock (the "Replacement Options"). Additionally, no Old Catheter options were amended in connection with the Merger. All the Replacement Options vested in accordance with the original terms of the grants in place at the time of the Merger. As a result, \$3.4 million of purchase price consideration, which represented the estimated fair value of Old Catheter's assumed stock options, and \$1.1 million of stock-based compensation expense, which represents the excess of the estimated fair value of the Replacement Options over the assumed Old Catheter stock options, were recognized upon the closing of the Merger. A 2023 Equity Incentive Plan A In July 2023, the Company's stockholders approved, the 2023 Plan, as defined above, which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company's employees, directors and consultants. Stock options granted under the 2023 Plan to employees and consultants generally will vest annually over a five-year period or as determined by the Board's Compensation Committee, while grants to non-employee directors generally vest quarterly over a three-year period. A As of September 30, 2024 and December 31, 2023, 225,085 and 50,186 shares of common stock were reserved for future issuance pursuant to the 2023 Plan. The number of shares available for issuance under the 2023 Plan also includes a quarterly increase commencing on September 1, 2023 by an amount equal to the lesser of (i) 10% of the number equal to the number of shares of common stock outstanding on the applicable adjustment date less the number of shares of common stock outstanding at the beginning of the fiscal quarter immediately preceding the adjustment date, but if such number is a negative number, then the increase will be zero; or (ii) such lesser number of shares as may be determined by the Board. A On January 8, 2024, the Board approved the issuance of a total of 28,500 non-qualified stock options under the 2023 Plan. 7,500 of these non-qualified options were issued to non-employee directors that vest at 8 1/3% per quarter for 3 years with an exercise price of \$4.00 and expiration date of January 8, 2034. The remaining 21,000 non-qualified options were issued to employees and consultants and vest at 20% per year for 5 years with an exercise price of \$4.00 and expiration date of January 8, 2034. A On February 26, 2024, the Board approved the issuance of a total of 15,000 incentive stock options under the 2023 Plan. All options were issued to employees and vest at 20% per year for 5 years with an exercise price of \$4.20 and expiration date of February 26, 2034. A On April 24, 2024, the Board approved the issuance of a total of 12,500 incentive stock options under the 2023 Plan. A All options were issued to employees and vest at 20% per year for 5 years with an

exercise price of \$4.60 and expiration date of April 24, 2034.Â On July 9, 2024, the Board approved the issuance of a total of 10,000 incentive stock options under the 2023 Plan.Â All options were issued to employees and vest at 20% per year for 5 years with an exercise price of \$3.50 and expiration date of July 9, 2034. The options issued during the three and nine months ended September 30, 2024 were valued at approximately \$262 thousand using the Black-Scholes model based on the following assumptions on the date of issue:Â Â Â Non-Employee Director Options Issued January 8, 2024Â Â Employee Options Issued January 8, 2024Â Â Employee Options Issued February 26, 2024Â Â Employee Options Issued April 24, 2024Â Â Employee Options Issued July 9, 2024Â Risk-free interest rateÂ Â 4.01%Â Â 4.01%Â Â 4.28%Â Â 4.65%Â Â 4.30%VolatilityÂ Â 175.36%Â Â 175.36%Â Â 178.14%Â Â 211.61%Â Â 214.61%Expected dividend yieldÂ Â 0%Â Â 0%Â Â 0%Â Â 0%Â Â 0%Expected life (in years)Â Â 6.5Â Â 6.5Â Â 6.5Â Â 6.5Â Â 6.5Â Â 6.5Â Â Non-Plan Options IssuedÂ On April 24, 2024, the Board approved the issuance of a total of 25,000 Non-Plan Options as an employment incentive for the position of Chief Commercial Officer. The options were issued on May 1, 2024, the first day of employment and vest at 20% per year for 5 years with an exercise price of \$5.321 and an expiration date of May 1, 2034.Â The non plan options issued were valued at approximately \$131 thousand using the Black-Scholes model based on the following assumptions on the date of issue:Â Â Â Non-Plan Options Issued May 1, 2024Â Risk-free interest rateÂ Â 4.63%VolatilityÂ Â 211.61%Expected dividend yieldÂ Â 0%Expected life (in years)Â Â 6.5Â Â The following is a summary of stock option activity for the nine months ended September 30, 2024:Â Â Â Stock OptionsÂ Â Weighted Average Exercise PriceÂ Â Weighted Average Remaining Life (in years)Â Â Aggregate Intrinsic Value (in thousands)Â Outstanding at December 31, 2023Â Â 21,465Â Â \$64.71Â Â 6.38Â Â \$â€Â Â Options exercisedÂ Â â€Â Â \$â€Â Â Â Â Â Options grantedÂ Â 91,000Â Â \$4.42Â Â â€Â Â Â Â Â Canceled/forfeitedÂ Â (16,652)Â Â \$4.50Â Â Â Â Â Â Â Â Outstanding at September 30, 2024Â Â 95,813Â Â \$17.92Â Â Â 8.86Â Â \$4,510.00Â Vested and expected to vest at September 30, 2024Â Â 95,813Â Â \$17.92Â Â Â 8.86Â Â \$4,510.00Â Exercisable at September 30, 2024Â Â 18,148Â Â \$75.35Â Â 6.07Â Â \$â€Â Â Restricted Stock UnitsÂ All restricted stock units have been forfeited or vested as of December 31, 2023. Restricted Stock AwardsÂ All restricted stock awards have been forfeited or vested as of December 31, 2023.Â A Stock-based compensation expense for the three and nine months ended September 30, 2024 was \$17 thousand and \$36 thousand, respectively, in selling, general and administrative expenses in the condensed consolidated statements of operations. Stock-based compensation expense for the three and nine months ended September 30, 2023 was \$2 thousand and \$1.2 million respectively, in the Company's condensed consolidated statements of operations.Â Total unrecognized estimated stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized at September 30, 2024 was as follows:Â Â Â Unrecognized Expense (in thousands)Â Â Remaining Weighted Average Recognition Period (in years)Â Stock optionsÂ \$309Â Â 4.4Â Restricted stock awardsÂ \$â€Â Â Â Â Â Restricted stock unitsÂ \$â€Â Â Â Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Taxes 4 Income Taxes Note 16. Income TaxesÂ The provision for income taxes for interim periods is determined using an estimated annual effective tax rate. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. Â For the three and nine months ended September 30, 2024 and 2023, the Company did not record any federal or state income tax provision or benefit due to net losses incurred for all periods presented. The Companyâ€™s net deferred tax assets generated mainly from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.Â As of September 30, 2024, the Company has an open sales and use tax audit with the California Department of Tax and Fee Administration covering the period from October 1, 2020 through March 31, 2023. X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: vtak_IncomeTaxesAbstract Namespace Prefix: vtak_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies A Commitments and Contingencies Note 17. Commitments and ContingenciesÂ In the normal course of business, the Company is at times subject to pending and threatened legal actions. In managementâ€™s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company.Â As of September 30, 2024, the Company had no outstanding litigation. X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <a href=)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 6: [http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: vtak_CommitmentsAndContingenciesAbstract Namespace Prefix: vtak_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plan 9 Months Ended Sep. 30, 2024 Employee Benefit Plan A Employee Benefit Plan Note 18. Employee Benefit PlanÂ In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (â€œ401(k) Planâ€). Under the terms of the 401(k) Plan, all full-time employees were eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company made matching contributions based on 100% of each employeeâ€™s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employeeâ€™s eligible compensation. The Company cancelled the 401(k) Plan effective March 10, 2023 and distributed all assets held by the 401(k) Plan to the participants. The Company had no expenses related to the matching contributions for the three and nine months ended September 30, 2024 and 2023. X - DefinitionThe entire disclosure for defined benefit plan. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 715 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477317/912-715-50-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715-20/tableOfContent + Details Name: us-gaap_DefinedBenefitPlanTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: vtak_EmployeeBenefitPlanAbstract Namespace Prefix: vtak_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties 9 Months Ended Sep. 30, 2024 Related Parties A Related Parties Note 19. Related PartiesÂ Prior to the Merger, David A. Jenkins, the Companyâ€™s current Executive Chairman of the Board and Chief Executive Officer, and Old Catheterâ€™s then Chairman of the Board of Directors, and his affiliates held approximately $25.1 million of Old Catheterâ€™s Convertible Promissory Notes, or the Notes, that were converted in the Old Catheter merger into 7,856,251 shares of Series X Convertible Preferred Stock (see Note 3, Business Combination, and Note 14, Preferred Stock). In consideration for forgiving the interest accrued but remaining unpaid under the Notes in an aggregate amount of approximately $13.9 million, Mr. Jenkins and his affiliates also received royalty rights equal to approximately 12% of the net sales, if any, of LockeT, commencing upon the first commercial sale and through December 31, 2035 (see Note 10, Royalties Payable).Â In addition to the shares described above that were issued in connection with the Notes, Mr. Jenkins and his affiliates received 1,325,838 shares of Series X Convertible Preferred Stock in the merger, and Mr. Jenkinsâ€™ adult children received 1,284,344 shares of Series X Convertible Preferred Stock in the merger, all in exchange for their equity interests in Old Catheter in accordance with the merger exchange ratio. Â In connection with the Merger (see Note 3, Business Combination), the Company assumed $1.4 million of accrued expenses and advances, of which $1.1 million was due to Mr. Jenkins and was paid on January 10, 2023.Â (Mr. Jenkinsâ€™ daughter, the Companyâ€™s non-executive Chief Operating Officer, received options to purchase 14,416 shares of the Companyâ€™s common stock upon the closing of the merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the merger. Of the total options to purchase 14,416 shares of the Companyâ€™s common stock, 14,081 options have an exercise price of $5.90 per share, and the remaining 335 options have an exercise price of $20.20 per share.Â Margrit Thomassen, the Companyâ€™s Interim Chief Financial Officer, received options to purchase 1,676 shares of the Companyâ€™s common stock upon the closing of the merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the merger.Â The options have an exercise price of $5.90 per share.Â In January 2024, she received an option to purchase 2,500 shares of the Companyâ€™s common stock under the 2023 Plan.Â The options have an exercise price of $4.00 per share, vest at 20% per year for 5 years and expire in January 2034.Â Following stockholder approval on March 21, 2023, the Company issued 99,182 shares of common stock to Mr. Jenkins and affiliates upon conversion of 991,828 shares of Series X Convertible Preferred Stock, and 23,532 shares of common stock to his adult children upon conversion of 235,320 shares of Series X Convertible Preferred Stock. Â On May 1, 2024, Marie-Claude Jacques, the Companyâ€™s Chief Commercial Officer, received a non-plan option to purchase 25,000 shares of the Companyâ€™s common stock.Â The options have an exercise price of $5.321 per share, vest at 20% per year for 5 years and expire in May 2034.Â During the three months ended September 30, 2024, the Company entered into various short-term promissory notes with various related parties (the â€œRelated Party Notesâ€). These Related Party Notes had a maturity date of August 30, 2024 and interest rates of 8% per annum. On August 23, 2024, the Notes were amended to extend the maturity date to January 31, 2026 and increase the interest rate to 12% per annum effective August 31, 2024. See Note 9, Notes Payable for further information. The related parties and the amounts owed to each related party are summarized in the following table (in thousands):Â Related PartyÂ Issuance DateÂ Principal AmountÂ A Interest PaidÂ A Interest AccruedÂ David JenkinsÂ 5/30/2024Â $500Â A $10Â A $5Â FatBoy CapitalÂ 6/25/2024Â $150Â A $2Â A $2Â FatBoy CapitalÂ 7/1/2024Â $250Â A $3Â A $3Â FatBoy CapitalÂ 7/18/2024Â $100Â A $1Â A $1Â Jenkins Family Charitable InstituteÂ 7/25/2024Â $500Â A $4Â A $5Â A On September 3, 2024, the Jenkins Family Charitable Institute also invested approximately $500,000 in the Companyâ€™s public offering and received 265,000 shares of common stock; 235,000 pre funded warrants with an exercise price of $0.0001 and no expiration date; 500,000 Series H Warrants with an exercise price of $1.00 per share that expire on March 3, 2025; 500,000 Series I Warrants with an exercise price of $1.00 per share that expire on March 3, 2026; and 500,000 Series J Warrants with an exercise price of $1.00 per share that expire on September 3, 2029. X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/214747968/946-235-50-6>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/214747968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(g\)\(3\)\) -Publisher](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher)

ASB - URL https://asc.fasb.org/1943274/21474734/4946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474734/4946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474734/4946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_RelatedPartiesAbstract Namespace Prefix: vtak_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events A Subsequent Events Note 20. Subsequent EventsA 2024 Warrant Inducement OfferA On October 24, 2024, the Company executed the 2024 Inducement Offer with certain holders of the Existing Warrants. The Existing Warrants had exercise prices ranging from \$1.00 to \$40.00 per share. Following the closing of the 2024 Inducement Offer, such holders immediately exercised an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants to purchase up to 5.3 million shares of Common Stock at a reduced exercise price of \$0.70 per share.Â In consideration for the immediate exercise of the Existing Warrants for cash, the Company issued unregistered new Series K Common Stock Purchase Warrants (â€œSeries K Warrantsâ€) to purchase up to a number of shares equal to 200% of the number of shares of Common Stock issued pursuant to the exercise of the Existing Warrants. The Series K Warrants have an exercise price of \$0.70 per share, a term of 5.5 years following stockholder approval, and are not exercisable until such approval is obtained. Â As additional consideration, the company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is \$1.085 per share and have a termination date of October 28, 2029.Â The Company received aggregate gross proceeds of approximately \$3.7 million in cash from the exercise of the Existing Warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expenses of \$0.4 million. As of the date of the 2024 Inducement Offer, 578,900 Series H and 1,078,900 Series I warrants remained unexercised.Â Prior to the repricing and execution of the 2024 Inducement Offer, the Company received additional gross proceeds of approximately \$1.2 million from the exercise of 1,010,000 Series H Warrants and 175,000 Series I Warrants in accordance with their original terms (as summarized below).Â A Issuance of Securities from Warrant ExercisesA Aside from the common stock issued in connection with the 2024 Warrant Inducement Offer, the Company also issued common stock in connection with the following exercises of warrants (in thousands):Â Name of WarrantA Exercise DateA Issue DateA Shares Common Stock IssuedA Number of Warrants Exercised A A ProceedsA September 2024A Pre-Funded Warrant A 10/3/2024A 10/4/2024A A 250,000A A \$â€A A September 2024A Pre-Funded WarrantA 10/16/2024A 10/16/2024A A 196,000A A A 196,000A A \$â€A A September 2024A Pre-Funded Warrant A 10/18/2024A 10/21/2024A A 434,000A A A 434,000A A \$â€A A September 2024A Series H WarrantA 10/18/2024A 10/21/2024A A 1,010,000A A A 1,010,000A A \$1,010.00A September 2024A Series I WarrantA 10/18/2024A 10/21/2024A A 175,000A A A 175,000A A \$175.00A September 2024A Pre-Funded WarrantA 10/29/2024A 10/29/2024A A 235,000A A A 235,000A A \$â€A X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies A Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of the Company and Old Catheter. All intercompany transactions have been eliminated in consolidation. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). The Financial Accounting Standards Board (â€œFASBâ€) establishes these principles to ensure financial condition, results of operations, and cash flows are consistently reported. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the FASB Accounting Standards Codification (â€œASCâ€). Certain footnotes and other financial information normally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, such statements include all adjustments which are considered necessary for fair presentation of the unaudited condensed consolidated financial statements of the Company. The operating results presented herein are not necessarily an indication of the results that may be expected for the year. The unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (â€œSECâ€) on April 1, 2024. Use of Estimates The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ materially from those estimates. The Companyâ€™s unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the accounting for the Old Catheter business combination (see Note 3, Business Combination), allowance for credit losses, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, fair value of royalties payable, evaluation of probable loss contingencies, fair value of preferred stock and warrants issued, and the fair value of equity awards granted. Concentrations of Credit Risk The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent short-term, highly liquid investments with maturities of 90 days or less at the date of purchase. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.Â The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.Â The Company had three and five customers that represented 90% and 86% of the Company's consolidated revenue for the three and nine months ended September 30, 2024, respectively; and three and four customers that represented 71% and 73% of the Company's consolidated revenue for the three and nine months ended September 30, 2023, respectively. Reclassifications Certain prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Segment Reporting The Companyâ€™s Board of Directors and executive management team represents the entityâ€™s chief operating decision makers. To date, the Companyâ€™s executive management team has viewed the Companyâ€™s operations as one segment that includes the marketing, sales, and development of medical technologies in the field of cardiac electrophysiology. As a result, the financial information disclosed materially represents all of the financial information related to the Companyâ€™s sole operating segment. Cash and Cash Equivalents Cash equivalents primarily represent funds invested in readily available checking and money market accounts. The Company maintains deposits in financial institutions in excess of federally insured limits of \$250,000, in the amount of \$987 thousand at September 30, 2024. Fair Value Measurements Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to identify inputs used in measuring fair value as follows: Â Level 1 - Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;Â Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Â Level 3 - Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Â Cash equivalents, prepaid expenses, trade accounts receivable, accounts payable, and accrued expenses are reported on the condensed consolidated balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments. Â The following table details the fair value measurements within the fair value hierarchy of the Companyâ€™s financial instruments: Â A A A Fair value at September 30, 2024A A A A TotalA A Level 1A A Level 2A A Level 3A Assets: A A A A A A A A A A Cash EquivalentsA A A A A A A A A A Mutual FundsA \$1,237A A \$â€A A Money Market FundsA 18A A A 18A A A â€A A A A A Total assetsA \$1,255A A \$1,255A A \$â€A A Liabilities: A A A A A A A A A A Royalties payableA 9,797A A \$â€A A \$â€A A \$9,797A A Total liabilitiesA \$9,797A A \$â€A A \$â€A A \$9,797A A A A A Fair value at December 31, 2023A A A TotalA A Level 1A A Level 2A A Level 3A Assets: A A A A A A A A A A Cash EquivalentsA A A A A A A A A A Mutual FundsA \$3,397A A \$3,397A A \$â€A A Money Market FundsA 10A A A 10A A A â€A A Total assetsA \$3,407A A \$3,407A A \$â€A A A A A A A A A A Liabilities: A A A A A A A A A A Royalties payableA 6,974A A \$â€A A \$â€A A \$6,974A A Total liabilitiesA \$6,974A A \$â€A A \$â€A A \$6,974A The royalties payable have significant unobservable inputs that are not supported by any market data. As such, the Company developed its own assumptions and identified the inputs as Level 3. The revenue adjusted discount rate (â€œRADRâ€) was calculated using a weighted average cost of capital (â€œWACCâ€) approach for the measurement of the Level 3 liability. The RADR considers the WACC from the Companyâ€™s impairment analysis and adjusts certain inputs to represent the risk profile of the revenue. Under the cost of equity section, the risk-free rate has changed to be commensurate with the royalties payable term. Additionally, the Beta and Company Specific Risk Premium have been adjusted to Revenue Beta and Revenue Specific Risk Premium, respectively. This adjustment was calculated by multiplying the respective metric by the quotient of equity volatility over revenue volatility. The remaining inputs from the Impairment WACC have remained unchanged.Â The following table summarizes the significant unobservable inputs used in the fair value measurement of Level 3 instruments as of September 30, 2024 and December 31, 2023:Â A A September 30, 2024

Level 3 inputs. The inputs for the market capitalization calculation are considered Level 4 inputs. There were impairment charges of \$60.9 million recognized during the nine months ended September 30, 2023 (see Note 3, Business Combination and Note 7, Goodwill for additional details). As of December 31, 2023, goodwill was fully impaired. Royalties Payable The Company is obligated to pay royalties under various royalty agreements executed by Old Catheter. On January 9, 2023, prior to the consummation of the Merger, Old Catheter entered in an agreement with its Convertible Promissory Noteholders ("Noteholders"), which substantially consisted of amounts due to David A. Jenkins, previously Old Catheter's Chairman of the Board of Directors, and, currently, the Company's Executive Chairman of the Board of Directors and Chief Executive Officer, to forgive all accrued interest and future interest expense in exchange for a future royalty right. The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of Lockt, commencing on the first commercial sale through December 31, 2035 (see Note 10, Royalties Payable). The Company recognizes a current liability for royalty fees incurred and payable to the Noteholders based on actual sales of Lockt devices. The liability is recorded as current portion of royalties payable in the condensed consolidated balance sheet. The Company further recognizes a liability for future, estimated royalty payments to the Noteholders at fair value, which is recorded as royalties payable in the condensed consolidated balance sheet (the "Royalties Payable"). The fair value of the Royalties Payable is an estimate that is based on the projected sales of Lockt through the end of 2035. The projected sales are then multiplied by the royalty rate of 11.82% and discounted back to their present value using the RADR. At each reporting date, the fair value of the Royalty Payable is re-measured in connection with any changes to Management's projections as a change in estimate. Product Warranty The Company offers product warranties against defects in material and workmanship when properly the products are used for their intended purpose and properly maintained. A Warranty expenses are included in cost of revenues in the accompanying unaudited condensed consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense. As of September 30, 2024 and December 31, 2023, there was no accrued warranty balance. Distinguishing Liabilities from Equity The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480"). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company's equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company's equity shares, or variations inversely related to changes in fair value of the Company's equity shares. If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to ASC 815-40, Derivatives and Hedging ("ASC 815-40"). The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with ASC 480. Otherwise, the freestanding financial instruments is classified in permanent equity. Revenue Recognition In accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company accounts for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenue is measured as the amount of consideration expected to be received in exchange for transferring promised goods or services. The amount of consideration to be received and revenue recognized may vary due to discounts. A performance obligation is a promise in a contract to transfer a distinct good or service. If there are multiple performance obligations in the customer contract, the Company allocates the transaction price in the contract to each performance obligation based on the relative standalone selling price. Revenue is recognized when performance obligations in the customer contract are satisfied. This generally occurs when the customer obtains control of a promised good at a point in time or when a customer receives a promised service over time. A Pursuant to ASC 606, the Company applies the following five steps to each customer contract: Step 1: Identify the contract with the customer; Step 2: Identify the performance obligations in the contract; Step 3: Determine the transaction price in the contract; Step 4: Allocate the transaction price to the performance obligations in the contract; Step 5: Recognize revenue when the Company satisfies a performance obligation. VIVO System The VIVO System offers 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. Customers are provided with VIVO Positioning Patch Sets, which are custom patches, that are used in conjunction with the VIVO System. The VIVO Positioning Patch Sets are integral to the functionality of the VIVO System. The VIVO System, including the VIVO Positioning Patch Sets, represents the Company's primary performance obligation. The Company recognizes revenue when physical possession and control of the VIVO System is transferred to the customer upon delivery. The Company also offers customers software upgrades for the VIVO System, which may be purchased and paid in advance at contract inception. Software upgrades represent stand-ready services, whereby the Company promises to provide software upgrades to the customer when and as upgrades are available. Software upgrade services may be offered for initial contract terms of one to multiple years. Customers have the option to renew terms for software upgrade services at the end of each term. The software upgrade services represent the Company's second performance obligation, which is recognized evenly over time over the contract term. A The Company invoices the customer after physical possession and control of the VIVO System is transferred to the customer and recognizes revenue upon delivery. The timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. The Company invoices customers who pay for software upgrades in advance in conjunction with the invoice for the delivery of the VIVO System, and subsequent renewals of software upgrades are invoiced at the inception of the term. Revenue for these stand-ready services is recognized evenly over the term of the upgrade period, consistently with similar stand-ready services under ASC 606. Similar to the delivery of the VIVO System, the timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. Revenue is recognized at the point in time that the product is delivered to the customer. A Lockt Lockt was launched by the Company in February 2023 and is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Lockt is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. The Lockt device represents a performance obligation in the customer contract. The Company recognizes revenue when it transfers control of the Lockt device to the customer, which happens when the Company delivers the product to the customer. For both Lockt and VIVO System, the Company has elected the practical expedient to expense costs incurred to obtain a contract, rather than recognizing these costs as an asset at the time of occurrence. Disaggregation of Revenue The following table summarizes disaggregated product sales by geographic area (in thousands):

	For the Three Months Ended September 30,	For the Nine Months Ended September 30,
Sales	\$62A	\$110A
Americas	\$62A	\$110A
Europe	\$129A	\$241A
Asia	\$34A	\$23A
Oceania	\$142A	\$73A
Shipping and Handling Costs	\$96A	\$133A
Shipping and handling costs charged to customers are included in net product sales, while all other shipping and handling costs are included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.		
Advertising and Marketing Expenses	\$31 thousand	\$127 thousand
Advertising costs were \$31 thousand and \$127 thousand during the three and nine months ended September 30, 2024, respectively. Advertising costs were \$309 thousand and \$914 thousand during the three and nine months ended September 30, 2023, respectively. Patents The Company expenses patent costs, including related legal costs, as incurred and records such costs as selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Research and Development Major components of research and development costs include consulting, research grants, supplies and clinical trial expenses. Research and development expenses are charged to operations in the period incurred. Stock-based Compensation The Company records stock-based compensation expense associated with stock options, restricted stock awards ("RSAs") and restricted stock units ("RSUs") issued to employees, members of the Company's board of directors and consultants in accordance with the guidance under ASC Topic 718, Compensation - Stock Compensation ("ASC 718"). The Company evaluates whether an award should be classified and accounted for as a liability award or equity award for all stock-based compensation awards granted. Stock-based compensation expense for stock options is measured at the grant date based on the estimated fair value of the award using the Black-Scholes option pricing valuation model ("Black-Scholes model"), which incorporates various assumptions, including expected term, volatility and risk-free interest rate. Stock-based compensation expense for stock options is recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting period of the respective award. Share-based compensation for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not probable or is not met, no stock-based compensation expense is recognized, and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. As a result of the Merger, all unvested Old Catheter stock options were subject to accelerated vesting and became fully vested as of the closing date of the business combination. The Company recognized the fair value of the replacement options as included in consideration transferred to the extent they do not exceed the fair value of the equivalent Old Catheter options. Any incremental fair value was recognized in compensation expense in the post-combination period, with this recognized as a Day 1 expense due to the Old Catheter options becoming fully vested concurrent with the closing of the business combination. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. A The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively. Basic and Diluted Net Loss per Share of Common Stock Earnings per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Company's common shares and participating securities. The Company's Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and outstanding warrants contain participating rights in distributions made to common stockholders and, therefore, are participating securities. The Company did not declare nor pay any dividends nor distributions in the current period. Furthermore, the participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per common share. A Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic net loss per share for the periods presented herein because common stock equivalent shares from warrants, stock options, non-vested restricted stock awards, restricted stock units, Series A Convertible Preferred Stock, and Series X Convertible Preferred Stock were antidilutive (see Note 12, Net Loss per Share). Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed dividends declared. The Company recorded a deemed dividend for the modification of existing warrants and issuance of new warrants during the three and nine months ended September 30, 2023 of \$0 and \$0.8 million, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders for the three and nine months ended September 30, 2023. There was no deemed dividend for the three and nine months ended September 30, 2024. Recently Announced Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 require disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. These amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently reviewing the impact that the adoption of ASU 2023-07 may have on our consolidated financial statements and disclosures. A In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is required to adopt this standard prospectively in fiscal year 2025 for the annual reporting period ending December 31, 2025. The Company does not believe the impact of the new guidance and related codification improvements will have material impact to its financial position, results of operations and cash flows. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy		

consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap ConsolidationPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap FairValueMeasurementPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\(SAB Topic 5.CC\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-599-2\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 5.CC\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-599-2\)Reference 2: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: <a href=\)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25>Reference 4: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(h\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-599-3\)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9>Reference 7: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\(SX 210.5-02\\\(6\\\)\\\(b\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(6\\)\\(b\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1\\)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1>Reference 4: \\[http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \\\(d\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4\\]\\(http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \\(d\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4\\)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1>Reference 6: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4\\)Reference 8: \\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph \\(a\\) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap InventoryPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: <a href=\\)Reference 2: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\(SX 210.7-03\\\(a\\\)\\\(8\\\)\\\(a\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.7-03\\(a\\)\\(8\\)\\(a\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1\\)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477998/958-360-50-6>Reference 4: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\(SX 210.6-07\\\(1\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.6-07\\(1\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1\\)Reference 2: \\[http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \\\(f\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4\\]\\(http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4\\)Reference 3: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \\\(bb\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47">http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \\\(bb\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41\\)Reference 3: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(f\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\)Reference 4: \\[http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \\\(a\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54\\]\\(http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54\\)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36>Reference 6: \\[http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \\\(a\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47\\]\\(http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47\\)Reference 7: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(d\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(d\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\)Reference 8: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(a\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\)Reference 9: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(b\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\)Reference 10: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(c\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29\\)Reference 11: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(e\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(e\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 12: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\\(f\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-29\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-29\\)Reference 13: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(i\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(i\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 4: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(v\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(v\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 5: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(ii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(ii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 6: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(iii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(iii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 7: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(iv\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(iv\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 8: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(v\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(v\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 9: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(vi\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(vi\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 10: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(vii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(vii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 11: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(viii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(viii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 12: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(ix\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(ix\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 13: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(x\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(x\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 14: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xi\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xi\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 15: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 16: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xiii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xiii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 17: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xiv\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xiv\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 18: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xv\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xv\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 19: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xvi\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xvi\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 20: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xvii\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xvii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)Reference 21: \\[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(xviii\\\) -Publisher FASB -URI https://asc.fasb.org/194327\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(f\\)\\(2\\)\\(xviii\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2)

[illegible]

xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vtak ProceedsFromPublicOffering Namespace Prefix: vtak Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak ReverseStockSplitShares Namespace Prefix: vtak Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap StatementClassOfStockAxis=vtak ReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=vtak RelatedPartyNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=vtak SeptemberTwoThousandTwentyFourPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=vtak TwoThousandTwentyFourInducementOfferMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Mutual fund \$ 1,237 \$ 3,397 Money market fund 18 10 Total assets 1,255 3,407 Royalties payable 9,797 6,974 Total liabilities 9,797 6,974 Level 1 [Member] A Mutual fund 1,237 3,397 Money market fund 18 10 Total assets 1,255 3,407 Royalties payable 0 0 Total liabilities 0 0 Level 2 [Member] A Mutual fund 0 0 Money market fund 0 0 Total assets 0 0 Royalties payable 0 0 Total liabilities 0 0 Level 3 [Member] A Mutual fund A 0 Money market fund 0 0 Total assets 0 0 Royalties payable 9,797 6,974 Total liabilities \$ 9,797 \$ 6,974 X - DefinitionInvestment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + ReferencesNo definition available. + Details Name: us-gaap MoneyMarketFundsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap OtherAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap OtherLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak MutualFund Namespace Prefix: vtak Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details 1) 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Summary of Significant Accounting Policies A Valuation Technique Discounted future cash flows Discounted future cash flows Unobservable Input Revenue adjusted discount rate Revenue adjusted discount rate Input Range 20.00% 28.00% X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak InputRangeOfValueMeasurement Namespace Prefix: vtak Data Type: num:percentItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vtak UnobservableInput Namespace Prefix: vtak Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak ValuationTechnique Namespace Prefix: vtak Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details 2) 9 Months Ended Sep. 30, 2024 Computer Hardware And Software [Member] | Minimum [Member] A Estimated useful lives 1 year Computer Hardware And Software [Member] | Maximum [Member] A Estimated useful lives 5 years VIVO DEMO/Clinical Systems[Member] | Minimum [Member] A Estimated useful lives 1 year VIVO DEMO/Clinical Systems[Member] | Maximum [Member] A Estimated useful lives 5 years Locket Animation Video [Member] A Estimated useful lives 3 years Machinery And Equipment [Member] | Minimum [Member] A Estimated useful lives 2 years Machinery And Equipment [Member] | Maximum [Member] A Estimated useful lives 5 years X - ReferencesNo definition available. + Details Name: vtak PropertyPlantAndEquipmentEstimatedUsefulLives Namespace Prefix: vtak Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=us-gaap ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=vtak BottomMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=vtak TopMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=vtak VivoDemoClinicalSystemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=vtak LocketAnimationVideoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=us-gaap MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details 3) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue by location \$ 96 \$ 133 \$ 271 \$ 314 Europe [Member] A A A Revenue by location 34 23 142 73 US [Member] A A A Revenue by location \$ 62 \$ 110 \$ 129 \$ 241 X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477314/942-235-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap Revenues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Details Name: srt StatementGeographicalAxis=srt EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementGeographicalAxis=vtak USMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details Narrative) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Impairment charges A A \$ 60,900 Deemed dividend amount for existing warrants and issuance of new warrants A \$ 0 A 800 Description of legal limit A A The Company maintains deposits in financial institutions in excess of federally insured limits of \$250,000, in the amount of \$987 thousand A Royalty liability description A A The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of Locket, commencing on the first commercial sale through December 31, 2035 A Royalty rate A A 11.82% A Advertising and marketing \$ 31 \$ 309 \$ 127 \$ 914 Revenue Member | Three and Five Customers Member A A A Concentration risk 90.00% A 86.00% A Revenue Member | Three and Four Customers [Member] A A A Concentration risk A 71.00% A 73.00% X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap AssetImpairmentCharges Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-21>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap ConcentrationRiskPercentage1 Namespace Prefix: us-gaap Data Type: dt:types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe total expense recognized in the period for promotion, public relations, and brand or product advertising. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap MarketingAndAdvertisingExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak DeemedDividendAmountForExistingWarrantsAndIssuanceOfNewWarrants Namespace Prefix:

Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_DescriptionRelatedToRoyalty Namespace Prefix: vtak Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_LegalLimitDescription Namespace Prefix: vtak Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_RateOfRoyalty Namespace Prefix: vtak Data Type: num:percentItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=vtak_RevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vtak_ThreeAndFiveCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vtak_ThreeAndFourCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: vtak_XBRL_DOCUMENT v3.24.3 Business Combination (Details) \$ in Thousands Jan. 09, 2023 USD (\$ Total Purchase Price \$ 72,544 Catheter's [Member] A fair value of options issued 3,404 Convertible Series X Preferred Stock [Member] A fair value of convertible preferred stock issued \$ 69,140 X - ReferencesNo definition available. + Details Name: vtak_FairValueOfOptionsIssued Namespace Prefix: vtak Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak_FairValueOfPreferredStockIssued Namespace Prefix: vtak Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak_TotalPurchasePriceOfFairValue Namespace Prefix: vtak Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=vtak_CathetersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=vtak_ConvertiblePreferredStockSeriesXSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: vtak_XBRL_DOCUMENT v3.24.3 Business Combination (Details 1) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Jan. 09, 2023 Accounts payable \$ 708 \$ 464 A A A Accrued expenses 1,497 1,733 A A A Lease liability 99 91 A A A Interest payable 16 0 A A A Convertible promissory note A A A A \$ 25,100 Royalties payable 7,977 6,974 A A A Cash and cash equivalents 1,268 3,565 A A A Inventories 32 44 A A A Prepaid expenses and other current assets 307 415 A A A Property and equipment, net 111 70 A A A Lease right of use assets 127 179 A A A Other assets \$ 1,255 \$ 3,407 A A A Goodwill A A \$ 60,900 \$ 60,900 A A A Liabilities assumed [Member] A A A A Accounts payable A A A 922 Accrued expenses A A A 1,389 Lease liability A A A 124 Interest payable A A A 198 Convertible promissory note A A A 250 Royalties payable A A A 14,182 Total liabilities assumed A A A 17,065 Total purchase price A A A 72,544 Assets Acquired [Member] A A A A Cash and cash equivalents A A A 15 Accounts receivable A A A 71 Inventories A A A 52 Prepaid expenses and other current assets A A A 23 Property and equipment, net A A A 26 Lease right of use assets A A A 119 Other assets A A A 8 Developed technology A A A 27,014 Customer relationships A A A 62 Trademarks A A A 1,285 Goodwill A A A 60,934 Total assets acquired A A A \$ 89,609 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:> <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2:> <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 5:> <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1> + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1> + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1> + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:> <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3:> <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI

[to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.](#) - ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 4:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak RoyaltiesPayable Namespace Prefix: vtak Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap BusinessAcquisitionAxis=vtak LiabilitiesAssumedMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=vtak AssetsAcquiredMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combination (Details 2) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Jan. 09, 2023 Intangible assets acquired Á \$ 28,361 Customer Relationships [Member] Á Á Intangible assets acquired Á 62 Estimated Useful Life 6 years Á Developed Technology - VIVO [Member] Á Á Intangible assets acquired Á 8,244 Estimated Useful Life 15 years Á Developed technology- Lockett [Member] Á Á Intangible assets acquired Á 18,770 Estimated Useful Life 14 years Á Trademark- VIVO [Member] Á Á Intangible assets acquired Á 876 Estimated Useful Life 9 years Á Trademark- Lockett [Member] Á Á Intangible assets acquired Á \$ 409 Estimated Useful Life 9 years Á X - DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date. - ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak FiniteLivedIntangibleAssetUsefulLifes Namespace Prefix: vtak Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=vtak DevelopedTechnologyVivoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=vtak TrademarkVivoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=vtak TrademarkLockettMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combination (Details 3) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues \$ 96 Á Á \$ 133 Á Á \$ 271 Á 314 Net loss \$ (4,120) Á (4,220) Á (2,675) (1,927) Á (1,576) Á (66,400) Á (11,015) (69,903) Pro Forma Financial Information [Member] Á Á Á Á Á Revenues Á Á Á 133 Á Á 317 Net loss Á Á (1,927) Á Á (70,073) Net loss attributable to common stockholders Á Á \$ (1,927) Á Á \$ (70,873) Basic and diluted net loss per share - on a pro forma basis Á Á Á (0.28) Á Á Á (14.07) X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. - ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: [http://www.xbrl](http://www.xbrl.org/2003/role/disclosureRef)

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak BasicAndDilutedNetLossPerShareOnAProFormaBasisUnaudited Namespace Prefix: vtak_ Data Type: num-perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap FinancialInstrumentPerformanceStatusAxis=vtak ProFormaFinancialInformationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combination (Details Narrative) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended Jan. 09, 2023 Sep. 30, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Merger Agreement [Member] Á Á Á Á Developed technologies assets Á Á Á \$ 27,000 \$ 35,100 Trademarks Á Á Á 1,300 1,700 Customer relationships Á Á Á 62 220 Goodwill Á Á Á 60,900 56,000 Royalties payable Á Á Á \$ 14,200 \$ 7,600 Total Impairment charge Á Á Á \$ 60,900 Á Á Á Transaction costs for the merger Á Á \$ 0 \$ 1,700 Á Á Á Merger Agreement One [Member] Á Á Á Á Á Á Convertible promissory note \$ 25,200 Á Á Á Á Series X preferred stock shares 14,649 Á Á Á Á Purchase shares of common stock 75,367 Á Á Á Á Total purchase consideration \$ 72,500 Á Á Á Á Estimated fair value of the Convertible Preferred Stock issued 14,649 Á Á Á Á Value of stock option issued \$ 3,400 Á Á Á Á Closing stock price \$ 60.90 Á Á Á Á X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of goodwill arising from a business combination that is expected to be deductible for tax purposes. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap ConvertibleLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before amortization, of finite-lived asset representing customer relationship acquired in business combination, asset acquisition, and from joint venture formation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap FiniteLivedCustomerRelationshipsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap IndefiniteLivedTrademarks Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of cash paid during the reporting period for charges associated with the mergers. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap PaymentsForMergerRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak ImpairmentCharge Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak IndefiniteLivedDevelopedTechnologiesAssets Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak PurchaseConsideration Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak PurchaseSharesOfCommonStock Namespace Prefix: vtak_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak SeriesXPreferredStockShares Namespace Prefix: vtak_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap PlanNameAxis=vtak MergerAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=vtak MergerAgreementOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventories Á Á Á Raw materials \$ 4 \$ 27 Finished goods 28 17 Inventories \$ 32 \$ 44 X - ReferencesNo definition available. + Details Name: us-gaap InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property and equipment, gross \$ 188 \$ 102 Accumulated depreciation (77) (32) Property and equipment, net 111 70 Locket Animation Video [Member] Á Á Property and equipment, gross 29 0 Computer Hardware And Software [Member] Á Á Property and equipment, gross 29 17 VIVO DEMO/Clinical Systems[Member] Á Á Property and equipment, gross 101 69 Machinery And Equipment [Member] Á Á Property and equipment, gross \$ 29 \$ 16 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=vtak LocketAnimationVideoMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=vtak VIVO DemoClinicalSystemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=us-gaap MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment (Details narrative) - USD (\$) \$ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Property and Equipment Á Á Á Depreciation expense \$ 19 \$ 9 \$ 45 \$ 26 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets (Details) - USD (\$) \$ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Jan. 09, 2024 Jan. 09, 2023 Gross Carrying Amount Á Á \$ 28,361 \$ 28,361 Accumulated Amortization Á Á \$ (2,043) (3,576) Net Book Value \$ 24,785 26,318 Á 24,785 Customer Relationships [Member] Á Á Á Á Gross Carrying Amount Á Á 62 62 Accumulated Amortization (18) (10) Á Á Á Net Book Value \$ 44 \$ 52 Á Á Á Estimated Useful Life in Years 6 years 6 years Á Á Trademarks/Trade Names - VIVO [Member] Á Á Á Á Gross Carrying Amount Á Á 876 876 Accumulated Amortization \$ (170) (97) Á Á Á Net Book Value \$ 706 \$ 779 Á Á Á Estimated Useful

Life in Years 9 years 9 years [A](#) [A](#) Trademarks/trade Names - LockeT [Member] [A](#) [A](#) [A](#) Gross Carrying Amount [A](#) [A](#) 409 409 Accumulated Amortization [A](#) [A](#) 79) [A](#) 45) [A](#) [A](#) Net Book Value [A](#) 330 [A](#) 364 [A](#) [A](#) Estimated Useful Life in Years 9 years 9 years [A](#) [A](#) Developed Technology - VIVO [Member] [A](#) [A](#) [A](#) Gross Carrying Amount [A](#) [A](#) 8,244 8,244 Accumulated Amortization [A](#) 962) [A](#) 550) [A](#) [A](#) Net Book Value [A](#) 7,282 [A](#) 7,694 [A](#) [A](#) Estimated Useful Life in Years 15 years 15 years [A](#) [A](#) Developed technology - LockeT [Member] [A](#) [A](#) [A](#) Gross Carrying Amount [A](#) [A](#) 18,770 [A](#) 18,770 Accumulated Amortization [A](#) 2,347) [A](#) 1,341) [A](#) [A](#) Net Book Value [A](#) 16,423 [A](#) 17,429 [A](#) [A](#) Estimated Useful Life in Years 14 years 14 years [A](#) [A](#) [A](#) [X](#) - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> - Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480265/350-10-545-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap FinitelivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480265/350-10-S45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478859/928-340-50-1> + Details Name: us-gaap FinitelivedIntangibleAssetsGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap FinitelivedIntangibleAssetsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak EstimatedUsefulLifeYears Namespace Prefix: vtak Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap FinitelivedIntangibleAssetsByMajorClassAxis=us-gaap CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FinitelivedIntangibleAssetsByMajorClassAxis=vtak TrademarksTradeNamesVivoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=vtak DevelopedTechnologyVivoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=vtak DevelopedTechnologyLockeTMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets (Details 1) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Jan. 09, 2023 Intangible Assets [A](#) [A](#) Remainder of 2024 [A](#) 510 [A](#) [A](#) 2025 2,043 [A](#) [A](#) 2026 2,043 [A](#) [A](#) 2027 2,043 [A](#) [A](#) 2028 2,043 [A](#) [A](#) Thereafter 16,103 [A](#) [A](#) Total [A](#) 24,785 [A](#) 26,318 [A](#) 24,785 [X](#) - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap FinitelivedIntangibleAssetsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets (Details narrative) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Intangible Assets [A](#) [A](#) [A](#) Amortization expense [A](#) 500,000 [A](#) 500,000.0 [A](#) 1,500,000.0 [A](#) 1,500,000 Weighted average remaining amortization period [A](#) [A](#) 12 years 3 months 25 days [A](#) [X](#) - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap AmortizationOfIntangibleAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak FinitelivedIntangibleAssetsWeightedAverageRemainingAmortizationPeriod1 Namespace Prefix: vtak Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill (Details Narrative) - USD (\$) in Millions Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Goodwill [A](#) [A](#) [A](#) Goodwill [A](#) [A](#) 60.9 [A](#) 60.9 [A](#) 56.0 Cumulative goodwill impairment charges [A](#) 60.9 [A](#) [A](#) [X](#) - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482548/350-20-55-24>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482598/350-20-45-1>Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Goodwill Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak CumulativeGoodwillImpairmentsCharges Namespace Prefix: vtak Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak GoodwillAbstract Namespace Prefix: vtak Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Details) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Expenses [A](#) [A](#) Legal expenses [A](#) 60 [A](#) 102 Offering costs 1,356 1,356 Compensation and related benefits 33 43 Other accrued expenses 48 232 Accrued expenses [A](#) 1,497 [A](#) 1,733 [X](#) - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI [https://asc.fasb.org](https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak AccruedExpensesAbstract Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak AccruedOfferingCostsCurrent Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Details Narrative) - USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023 Sep. 30, 2024 Accrued Expenses Á Á Removal of accrued warranty \$ 192 Á Accrued warranty balance Á \$ 0 X - ReferencesNo definition available. + Details Name: vtak AccruedExpensesAbstract Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak AccruedWarranty Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak RemovalOfAccruedWarranty Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Notes Payable (Details Narrative) - USD (\$) 1 Months Ended 3 Months Ended 9 Months Ended Sep. 26, 2024 Jul. 18, 2024 Jun. 25, 2024 May 30, 2024 Oct. 16, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jul. 02, 2024 Jun. 30, 2024 Dec. 31, 2023 Interest expenses Á Á Á \$ 32,000 \$ 0 \$ 40,000 \$ 18,000 Á Á Á Loan to company Á Á \$ 150,000 Á Á Á Á Á Notes payable Á Á Á Á 249,000 Á 249,000 Á Á Á \$ 184,000 Short Term Promissory Notes [Member] Á Á Á Á Á Á Á Interest expenses Á Á Á Á 33,000 Á 36,000 Á Á Á Á Interest payable to related parties Á Á Á Á 16,000 Á \$ 16,000 Á Á Á Á Loan to company Á Á \$ 500,000 Á Á Á Á Á Á Á Maturity date of related party notes Á Á Á Á Á August 30, 2024 Á Á Á Interest rate of related party Á Á 12.00% Á Á Á 8.00% Á Á Á Á Interest payable Á Á Á Á Á Á Á \$ 4,000 Á Notes Payable and accrued interest \$ 21,000 Á Á Á 1,500,000 Á 1,500,000 Á Á Á Short Term Promissory Notes [Member] | David A Jenkin [Member] Á Á Á Á Á Á Á Á Á Á Loan to company Á \$ 100,000 Á \$ 500,000 Á Á Á Á Á Short Term Promissory Notes [Member] | Mr. Jenkins [Member] Á Á Á Á Á Á Á Á Á Short term loan Á Á Á Á Á Á Á \$ 250,000 Á Á Notes Payable Director And Officer [Member] Á Á Á Á Á Á Á Note payable to third party Á Á Á \$ 291,000 249,000 Á 249,000 Á Á Á Short-term financing Á Á Á Á Á 249,000 Á Á Á Down payment against purchase of director and officer liability insurance coverage 44,000 Á Á Á 157,000 Á Á Á Á Purchase of director and officer liability insurance coverage \$ 293,000 Á Á \$ 447,000 Á Á Á Á Interest expenses Á Á Á 1,000 Á Á Á Interest expense on loan Á Á Á Á \$ 0 Á \$ 0 Á Á Á Interest rate of loan 9.99% Á Á Á 8.99% Á Á Á Á Á Notes payable Á Á Á Á Á Á Á Á \$ 184,000 X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInterest and debt related expenses associated with nonoperating financing activities of the entity. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(8\)\)](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap InterestAndDebtExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrli.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrli.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1) + Details Name: us-gaap InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of loans assumed in noncash investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap LoansAssumed1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22))) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(17\)\)](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(1\)\)](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIdentify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties. + ReferencesNo definition available. + Details Name: us-gaap RelatedPartyTransactionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(13\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: <http://www.xbrli.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(1\)\)](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-4> + Details Name: us-gaap ShortTermDebtRefinancedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStated interest rate of the subordinated debt. + ReferencesNo definition available. + Details Name: us-gaap SubordinatedBorrowingInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak CashDownPaymentAmount Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak InterestPayableOfRelatedPartyCurrent Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak InterestPayableToRelatedParties Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak LiabilityInsuranceCoveragePurchasedByCompany Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak MaturityDate Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak NotePayableToThirdParty Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap FinancialInstrumentAxis=us-gaap ShortTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RelatedPartyTransactionAxis=vtak MrJenkinsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PledgingPurposeAxis=vtak NotesPayableDirectorAndOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Royalties Payable (Details) 9 Months Ended Sep. 30, 2024 USD (\$) \$ Royalty Payment \$ 10,000.000 Royalty Two [Member] Á Royalty Percentage 2.00% Royalty Payment \$ 3,179,000 Royalty One [Member] Á Royalty Percentage 4.00% Royalty Payment \$ 1,589,500 Royalty Three [Member] Á Royalty Percentage 1.00% Royalty Payment In perpetuity X - DefinitionThe amount of cash paid for royalties during the current period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RoyaltyPayment Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RoyaltyPercentage Namespace Prefix: vtak_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Details Name: srt ProductOrServiceAxis=vtak RoyaltyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=vtak RoyaltyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=vtak RoyaltyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Royalties Payable (Details 1) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Royalties Payable Á Á Balance at beginning of period \$ 6,974 \$ 0 AMIGO royalty payable recognized in connection with the Merger 0 159 LockeT royalty payable recognized in connection with the Merger 0 14,022 Payments owed on royalties payable 17 0 Change in fair value of royalties payable 2,823 (5,333) Balance at end of period \$ 9,814 \$ 8,848 X - ReferencesNo definition available. + Details Name: vtak AmigoRoyaltyPayableRecognizedInConnectionWithTheMerger Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak ChangeInFairValueOfRoyaltiesPayable Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak LocketRoyaltyPayableRecognizedInConnectionWithTheMerger Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak PaymentsOwedOnRoyaltiesPayable Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RoyaltiesPayableAbstract Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RoyaltyPayable Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Royalties Payable (Details Narrative) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Royalties payable \$ 9,797 \$ 6,974 Payments for Royalties 10,000 Á Termination payments for Royalties \$ 10,000 Á Royalty payments description The royalty payments will apply to revenues through December 31, 2033 Á Royalty of net sales 2.00% Á LockeT Royalty [Member] Á Á Royalty payable, Percentage 12.00% Á Royalties payable \$ 17 Á Description of LockeT device inventor the inventor of the LockeT device as detailed in the Royalty Agreement. In exchange for the assignment and all rights to LockeT, the Company will pay a 5% royalty on net sales up to \$1.0 million in royalties Á AMIGO System Royalty [Member] Á Á Investment amount received \$ 1,600 Á X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef-Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14>Reference 2: <http://www.xbrli.org/2003/role/exampleRef-Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(1\)\(h\)\)](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(1\)\(6\)\)](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of cash paid for royalties during the current period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak DescriptionRelatedToRoyaltyPayments Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak InventorOfDeviceDescription Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RoyaltiesPayable Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak RoyaltyOfNetSalesPercentage Namespace Prefix: vtak_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RoyaltyPayablePercentageFigures Namespace Prefix: vtak_ Data Type: num:percentItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vtak TerminatePayment Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap RelatedPartyTransactionAxis=vtak LockeTRoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: us-gaap RelatedPartyTransactionAxis=vtak AMIGOSystemRoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases Á Á Á Operating lease expense \$ 28 \$ 23 \$ 80 \$ 52 Cash paid for leases \$ 25 \$ 32 \$ 78 \$ 62 X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4) + Details Name: us-gaap OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the

lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement. + ReferencesNo definition available. + Details Name: us-gaap PaymentsForLeasingCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details 1) 9 Months Ended Sep. 30, 2024 Leases 4 Weighted average discount rate - operating leases 8.65% Weighted average remaining lease term (in years) - operating leases 1 year 4 months 13 days X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap Data Type: dt-types:percentItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: vtak OperatingLeaseWeightedAverageRemainingLeaseTerm Namespace Prefix: vtak Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details 2) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases 4 A Remainder of 2024 \$ 24 A 2025 98 A 2026 14 A Total minimum lease payments 136 A Less effects of discounting (1) A Present value of future minimum lease payments \$ 135 \$ 188 X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterFiscalYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak FinanceLeaseLiabilityDiscountedAmount Namespace Prefix: vtak Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details 3) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases 4 A Lease right-of-use assets \$ 127 \$ 179 Total lease assets 127 179 Lease liability - current portion 99 91 Lease liability - net of current portion 36 97 Total lease liabilities \$ 135 \$ 188 X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details Narrative) 9 Months Ended Sep. 30, 2024 USD (\$) South Carolina Office Lease Agreement [Member] A Total rent expense per month \$ 3,435 Lease agreement term 36 years New Jersey Office Lease Agreement [Member] A Total rent expense per month \$ 1,207 Rent expense for extended period per month \$ 1,267 Lease agreement term 24 years Lease agreement term extended period 12 years Park City Office Lease Agreement [Member] A Total rent expense per month \$ 3,200 Lease agreement term 36 years X - ReferencesNo definition available. + Details Name: vtak LeaseAgreementDuration Namespace Prefix: vtak Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak LeaseAgreementDurationExtended Namespace Prefix: vtak Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RentExpense Namespace Prefix: vtak Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak RentExpenseforExtendedPeriod Namespace Prefix: vtak Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=vtak SouthCarolinaOfficeLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=vtak NewJerseyOfficeLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=vtak ParkCityOfficeLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Details Narrative) - USD (\$) in Millions 1 Months Ended 3 Months Ended 9 Months Ended Jul. 11, 2024 Jul. 02, 2024 Jul. 05, 2023 Jul. 23,

of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem) Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem) Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap StatementClassOfStockAxis=vtak SeriesFWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=vtak SeriesGWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Offerings (Details 2) - USD ($) $ / shares in Units, $ in Millions 12 Months Ended Dec. 31, 2022 Sep. 30, 2024 Warrants outstanding $ 13,170,652 2022 Offering [Member] | Warrant One [Member] $ Warrants outstanding 3,300 $ Exercise Price $ 312.50 $ Expiration Date 5.0 $ Warrants outstanding, value $ 0.4 $ Risk-free interest rate 1.81% $ Volatility 93.25% $ Expected dividend yield 0.00% $ Expected life (in years) 5 years $ 2022 Offering [Member] | Warrant Two [Member] $ Warrants outstanding 3,100 $ Exercise Price $ 175.00 $ Expiration Date 5.0 $ Warrants outstanding, value $ 0.2 $ Risk-free interest rate 2.87% $ Volatility 96.70% $ Expected dividend yield 0.00% $ Expected life (in years) 5 years $ X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap Data Type: dr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <a href=) Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem) Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dr-types:percentItem) Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1:

[illegible]

"non-affiliate" refers to that portion of the transaction or transactions resulting in cash receipts or cash payments during the period.

+ ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50](#) + Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50](#)

3Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5](#) + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Balance Type: na Period Type: duration X -Details Name: us-gaap_StatementClassOfStockAxis=vtask SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML R87.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred Stock (Details Narrative) -USD (\$) \$ / shares in Units, \$ in Millions 9 Months Ended Jan. 09, 2023 Sep. 30, 2024 Dec. 31, 2023 Oct. 24, 2023 Mar. 23, 2023 Mar. 21, 2023 Common stock share issued A 3,452,652 702,662 A A Conversion of preferred stock 7,856 A A A Series X convertible preferred stocks [Member] A A A Convertible promissory notes, representing an aggregate principal \$ 25.2 A A A Description of convertible Preferred Stock were converted into a right to receive 14,649,592 shares of a new class of the Company's preferred stock, designated Series X Convertible Preferred Stock A A A Principal amount per share \$ 32.00 A A A Initial rate of share listing price A \$ 100 A A A Common stock share issued A A 1,868 197,491 199,359 Conversion of preferred stock A A 18 1,974 1,993 Common stock Convertible Preferred Stock description A The remaining 12,656.011 shares of Series X Convertible Preferred Stock are expected to remain outstanding until the Company meets the initial listing standards of the NYSE American or another national securities exchange or is delisted from the NYSE American, at which time they will convert into common stock A A A Series A convertible preferred stock [Member] A A A Description of private investment in public equity Series A Convertible Preferred Stock will not have the right to convert any portion of their Series A Convertible Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to its conversion A A A X -DefinitionThe price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/21474811138/505-30-25-5](#) + Details Name: us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Balance Type: na Period Type: duration X -DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Balance Type: na Period Type: instant X -DefinitionNumber of shares issued for each share of convertible preferred stock that is converted. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](#) + Details Name: us-gaap_ConvertiblePreferredStockTermsOfConversion Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Balance Type: na Period Type: instant X -DefinitionDescription of conversion terms for preferred stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](#) + Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6](#) + Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](#) + Details Name: us-gaap_ConvertiblePreferredStockTermsOfConversion Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Balance Type: na Period Type: instant X -ReferencesNo definition available. + Details Name: vtak_CommonStockConvertiblePreferredStockDescription Namespace Prefix: vtak_Data Type: xbrli:stringItem Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: vtak_ConvertiblePromissoryNoteValue Namespace Prefix: vtak_Data Type: xbrli:monetaryItem Balance Type: credit Period Type: instant X -ReferencesNo definition available. + Details Name: vtak_PrincipalAmountPerShares Namespace Prefix: vtak_Data Type: num-perShareItem Balance Type: na Period Type: instant X -ReferencesNo definition available. + Details Name: vtak_PrivateInvestmentInPublicEquityDescription Namespace Prefix: vtak_Data Type: xbrli:stringItem Balance Type: na Period Type: duration X -Details Name: us-gaap_StatementClassOfStockAxis=vtak SeriesXConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X -Details Name: us-gaap_StatementClassOfStockAxis=vtak SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.3 StockBased Compensation (Details) 1 Months Ended Jul. 09, 2024 Jan. 08, 2024 Apr. 24, 2024 Feb. 26, 2024 Employees [Member] A A A Risk-free interest rate 4.30% 4.01% 4.65% 4.28% Volatility 214.61% 175.36% 211.61% 178.14% Expected dividend yield 0.00% 0.00% 0.00% 0.00% Expected life (in years) 6 years 6 months 6 years 6 months 6 years 6 months Non-Employee Director Options Issued [Member] A A A Risk-free interest rate 4.01% A A Volatility 175.36% A A Expected dividend yield 0.00% A A Expected life (in years) 6 years 6 months A A X -DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](#) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Balance Type: na Period Type: duration X -DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](#) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Balance Type: na Period Type: duration X -DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](#) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Balance Type: na Period Type: duration X -DefinitionExpected term of award under share-based payment arrangement, in "PnYmNdTnHnMns" format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](#) + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:drationItem Balance Type: na Period Type: duration X -Details Name: srt_TermOfIndividualAxis=vtak_EmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.3 StockBased Compensation (Details) 1 -Non-Plan Options Issued [Member] -May 1, 2024 [Member] 9 Months Ended Sep. 30, 2024 Risk-free interest rate 4.63% Volatility 211.61% Expected dividend yield 0.00% Expected life (in years) 6 years 6 months X -DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](#) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Balance Type: na Period Type: duration X -Definition

[illegible]

Type: Period Type: X - Details Name: srt TitleOfIndividualAxis=vtak EmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vtak NonPlanOptionsIssuedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=vtak StockOptionsAssumedInMergerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 95 R84.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plan (Details Narrative) 9 Months Ended Sep. 30, 2024 Second Contribution [Member] Â Employer matching contribution, maximum (percentage) 4.00% Second Contribution [Member] | Maximum [Member] Â Maximum contribution per employee (percentage) 50.00% Second Contribution [Member] | Minimum [Member] Â Maximum contribution per employee (percentage) 3.00% First Contribution [Member] Â Maximum contribution per employee (percentage) 3.00% Employer matching contribution, maximum (percentage) 100.00% Third Contribution [Member] Â Maximum contribution per employee (percentage) 5.00% X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum percentage of employee gross pay the employee may contribute to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=vtak BottomMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 96 R85.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties (Details) \$ in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) David Jenkins [Member] Â Issuance Date 5/30/2024 Principal Amount \$ 500 Interest Paid 10 Interest Accrued \$ 5 FatBoy Capital [Member] Â Issuance Date 6/25/2024 Principal Amount \$ 150 Interest Paid 2 Interest Accrued \$ 2 FatBoy Capital One [Member] Â Issuance Date 7/1/2024 Principal Amount \$ 250 Interest Paid 3 Interest Accrued \$ 3 FatBoy Capital Two [Member] Â Issuance Date 7/18/2024 Principal Amount \$ 100 Interest Paid 1 Interest Accrued \$ 1 Jenkins Family Charitable Institute [Member] Â Issuance Date 7/25/2024 Interest Paid 4 Interest Accrued 5 Principal Amount \$ 500 X - DefinitionAmount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount, classified as operating and investing activities. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_InterestPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_DepositLiabilitiesAccruedInterst Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: vtak_IssuanceDate Namespace Prefix: vtak_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_PrincipalAmountOfRelatedPartyDebt Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: vtak_PrincipalAmountOfRelatedPartyDebt Namespace Prefix: vtak_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionAxis=vtak DavidJenkinsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=vtak FatBoyCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=vtak FatBoyCapitalOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=vtak FatBoyCapitalTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=vtak JenkinsFamilyCharitableInstituteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 97 R86.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties (Details narrative) - USD (\$) 1 Months Ended 3 Months Ended 9 Months Ended Sep. 03, 2024 Jan. 09, 2023 Aug. 23, 2024 Jan. 31, 2024 Mar. 21, 2023 Sep. 30, 2024 Sep. 30, 2024 Business Combination, Description Â Mr. Jenkins and his affiliates received 1,325,838 shares of Series X Convertible Preferred Stock in the merger, and Mr. Jenkinsâ€™ adult children received 1,284,344 shares of Series X Convertible Preferred Stock in the merger, all in exchange for their equity interests in Old Catheter in accordance with the merger exchange ratio Â Â Â Â Â Convertible Promissory Notes Â \$ 25,100,000 Â Â Â Â Convertible Notes Â 7,856 Â Â Â Â Interest accrued Â \$ 13,900,000 Â Â Â Â Accrued expenses Â \$ 1,400,000 Â Â Â Â Â Options to purchase Â 14,416 Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights \$ 0.0001 Â Â Â Â Series H Warrants [Member] Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights 1.00 Â Â Â Â Series I Warrants [Member] Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights 1.00 Â Â Â Â Series J Warrants [Member] Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights \$ 1.00 Â Â Â Â Â Chief Commercial Officer [Member] | May 01, 2024 [Member] Â Â Â Â Â Received options to purchase common stock Â Â Â Â Â 25,000 Option exercise price Â Â Â Â Â \$ 5.321 Vested percentage Â Â Â Â Â 20.00% Vested period Â Â Â Â Â 5 years Expiration period Â Â Â Â Â expire in May 2034 Margrit Thomassen [Member] Â Â Â Â Â Received options to purchase common stock Â Â Â Â Â 2,500 Â Â Â Â 1,676 Option exercise price Â Â Â Â Â \$ 4.00 Â Â Â Â 5.90 Vested percentage Â Â Â Â 20.00% Â Â Vested period Â Â Â Â 5 years Â Â Â Â Expiration period Â Â Â Â expire in January 2034 Â Â Â Mr. Jenkins [Member] | Pre-Funded Warrants Â Â Â Â Â Interest rate 8.00% Â 12.00% Â Â Â Maturity date Â Â Jan. 31, 2026 Â Â Aug. 30, 2024 Â Warrants issued 265,000 Â Â Â 99,182 Â Â Â Accrued expenses Â \$ 1,100,000 Â Â Â Â Options to purchase Â 14,416 Â Â Â Â Public offering \$ 500,000 Â Â Â Â Â Number of options Â 14,081 Â Â Â Â Â Remaining number of options Â 335 Â Â Â Â Â Conversion of stock description Â Â Â Â conversion of 991,828 shares of Series X Convertible Preferred Stock, and 23,532 shares of common stock to his adult children upon conversion of 235,320 shares of Series X Convertible Preferred Stock Â Â Exercise price Â \$ 5.90 Â Â Â Â Â Remaining number of options exercise price Â \$ 20.20 Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights \$ 0.0001 Â Â Â Â Â Pre-Funded Warrant Units Issued 235,000 Â Â Â Â Â Mr. Jenkins [Member] | Series H Warrants [Member] Â Â Â Â Â Expiration period expire on March 3, 2025 Â Â Â Â Â Warrants issued 500,000 Â Â Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights \$ 1.00 Â Â Â Â Â Mr. Jenkins [Member] | Series I Warrants [Member] Â Â Â Â Â Expiration period expire on March 3, 2026 Â Â Â Â Â Warrants issued 500,000 Â Â Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights \$ 1.00 Â Â Â Â Â Mr. Jenkins [Member] | Series J Warrants [Member] Â Â Â Â Â Expiration period expire on September 3, 2029 Â Â Â Â Â Warrants issued 500,000 Â Â Â Â Â Class Of Warrant Or Right Exercise Price Of Warrants Or Rights \$ 1.00 Â Â Â Â Â X - DefinitionThis element represents a description of how the entity obtained control of the acquired entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2) + Details Name: us-gaap_BusinessCombinationControlObtainedDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe type of stock (i.e. preferred, common, treasury, etc.) being converted in a noncash (or part noncash) transaction. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 34: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 38: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 39: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 40: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 41: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 42: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 43: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 44: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3)Reference 45:

[illegible]

[illegible]

[illegible]

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~%FKPD\@/B?H13,03I^7/K^M-WXB4S-D\J(28PLAK\0ZW\$)M,H^J-ZIS-JL@>69E^3X50&BDA3+D\@>P(E2-R\,ZMLM250P3)M\5Q@,R8V6J(=H^IAAF+W80L3/B~%G&JUGO-VHS^KCHO?3.TL\VLZ\K^S\I,M\35\H^46RE><^ECTSH-WBYW\A(R^T5?C^BSY^M&S&C^3XYH)E^F20#,"X0?1-2U4-Q0?E=ID&LSKX\Q5Z^?K9^2,N-75MR-M^N8HJ\IIO.50.D\$!M^<=YPSZ^?+#+<=M5R8R^5ZU8Z)5HO>7FT\KJQZ,L\H\XK3^R0=IY@6(GMW6+>H^,0\H1!^6+49&62\J@I9Y\V5D DBG^C^F3Z? MRP2(8^>+TQ46?T^A1.3)2 M-C9IG+>OUU^M^G^B80=9P<C^D^RDX,2)M1<^<FFL\UC9.RX=^@E^3>1+I^N090\$M+2+43XQDEK7^I?M^BY2V^F3D^C^KXJN24V,<#E^5XKP^E,KKR\X^4M#E^")PH\@I&L;J+>6\UIQ\DRXDA,MS56&R^3(6ML48% H89,EIS^#17%JP-M35DQ.MG\A(\$,PI-<K9\U\G,H,B(U<^C^f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|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

[illegible]

[illegible]

[illegible]

[illegible]

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how:is IDEA: XBRL DOCUMENT //Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=f;Show.LastAR=null;Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!="TABLE")e=e.nextSibling;if(e.nodeName!="TABLE")var re=(window)?w.document.document.getElementById(e.id):e.removeAttribute("id");a.parentNode.appendChild(e)} if(e.style.display='block';Show.LastAR=e;Show.hideAR=function() {Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!="DIV")e=e.nextSibling;if(!e.style){} else if(e.style.display){} else {var d,p;if(e.style.display=="none"){d='block';p='-'} else {d='none';p='+'} e.style.display=d;if(a.textContent) fa.textContent=p+a.textContent.substring(1)} else {a.innerHTMLText=p+a.innerHTMLText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } report table.authRefData a { display: block; font-weight: bold; } report table.authRefData p { margin-top: 0px; } report table.authRefData { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } report table.authRefData { background-color: #2F4497; } report table.authRefData { background-color: #2F4497; padding: 1px 3px 0px 0px; } report table.authRefData { font-size: 1em; } /* Report Styles */ .pl a { visited { color: black; text-decoration: none; } } table { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } report hr { border: 1px solid #acf; } /* Top labels */ report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } report th { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } word-wrap: break-word; } report td .pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; } report td .pl div a { width: 200px; } report td .pl a { hover { background-color: #ffc; } } Header rows... */ report tr { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ report .rc { background-color: #f0f0f0; } /* Even rows... */ report .re, report .reu { background-color: #def; } report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ report .ro, report .rou { background-color: white; } report .rou td { border-bottom: 1px solid black; } report .rou table td, report .rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */ report .fn { white-space: nowrap; } /* styles for numeric types */ report .num, report .nump { text-align: right; white-space: nowrap; } report .nump { padding-left: 2em; } report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ report .text { text-align: left; white-space: normal; } report .text .big { margin-bottom: 1em; width: 17em; } report .text .more { display: none; } report .text .note { font-style: italic; font-weight: bold; } report .text .small { width: 10em; } report .text .sup { font-style: italic; } report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html3954531false1320false4 falsefalseR1.htm000001- Document - CoverSheethttp://vtak.com/role/CoverCoverCover1 falsefalseR2.htm000002- Statement - Condensed Consolidated Balance SheetsSheethttp://vtak.com/role/CondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm000003- Statement - Consolidated Balance Sheets (Parenthetical)Sheethttp://vtak.com/role/ConsolidatedBalanceSheetsParentheticalConsolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm000004- Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnauditedCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm000005- Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)Sheethttp://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedCondensed Consolidated Statements of Stockholders' Equity (Unaudited)Statements5 falsefalseR6.htm000006- Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements6 falsefalseR7.htm000007- Disclosure - Organization and Nature of OperationsSheethttp://vtak.com/role/OrganizationAndNatureOfOperationsOrganization and Nature of OperationsNotes7 falsefalseR8.htm000008- Disclosure - Summary of Significant Accounting PoliciesSheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes8 falsefalseR9.htm000009- Disclosure - Business CombinationSheethttp://vtak.com/role/BusinessCombinationBusiness CombinationNotes9 falsefalseR10.htm000010- Disclosure - InventoriesSheethttp://vtak.com/role/InventoriesInventoriesNotes10 falsefalseR11.htm000011- Disclosure - Property and EquipmentSheethttp://vtak.com/role/PropertyAndEquipmentProperty and EquipmentNotes11 falsefalseR12.htm000012- Disclosure - Intangible AssetsSheethttp://vtak.com/role/IntangibleAssetsIntangible AssetsNotes12 falsefalseR13.htm000013- Disclosure - GoodwillSheethttp://vtak.com/role/GoodwillGoodwillNotes13 falsefalseR14.htm000014- Disclosure - Accrued ExpensesSheethttp://vtak.com/role/AccruedExpensesAccrued ExpensesNotes14 falsefalseR15.htm000015- Disclosure - Notes PayableNoteshttp://vtak.com/role/NotesPayableNotes PayableNotes15 falsefalseR16.htm000016- Disclosure - Royalties PayableSheethttp://vtak.com/role/RoyaltiesPayableRoyalties PayableNotes16 falsefalseR17.htm000017- Disclosure - LeasesSheethttp://vtak.com/role/LeasesLeasesNotes17 falsefalseR18.htm000018- Disclosure - Net Loss per ShareSheethttp://vtak.com/role/NetLossPerShareNet Loss per ShareNotes18 falsefalseR19.htm000019- Disclosure - Equity OfferingsSheethttp://vtak.com/role/EquityOfferingsEquity OfferingsNotes19 falsefalseR20.htm000020- Disclosure - Preferred StockSheethttp://vtak.com/role/PreferredStockPreferred StockNotes20 falsefalseR21.htm000021- Disclosure - StockBased CompensationSheethttp://vtak.com/role/StockbasedCompensationStockBased CompensationNotes21 falsefalseR22.htm000022- Disclosure - Income TaxesSheethttp://vtak.com/role/IncomeTaxesIncome TaxesNotes22 falsefalseR23.htm000023- Disclosure - Commitments and ContingenciesSheethttp://vtak.com/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes23 falsefalseR24.htm000024- Disclosure - Employee Benefit PlanSheethttp://vtak.com/role/EmployeeBenefitPlanEmployee Benefit PlanNotes24 falsefalseR25.htm000025- Disclosure - Related PartiesSheethttp://vtak.com/role/RelatedPartiesRelated PartiesNotes25 falsefalseR26.htm000026- Disclosure - Subsequent EventsSheethttp://vtak.com/role/SubsequentEventsSubsequent EventsNotes26 falsefalseR27.htm000027- Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies27 falsefalseR28.htm000028- Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables28 falsefalseR29.htm000029- Disclosure - Business Combination (Tables)Sheethttp://vtak.com/role/BusinessCombinationTablesBusiness Combination (Tables)Tableshttp://vtak.com/role/BusinessCombinationTables29 falsefalseR30.htm000030- Disclosure - Inventories (Tables)Sheethttp://vtak.com/role/InventoriesTablesInventories (Tables)Tableshttp://vtak.com/role/Inventories30 falsefalseR31.htm000031- Disclosure - Property and Equipment (Tables)Sheethttp://vtak.com/role/PropertyAndEquipmentTablesProperty and Equipment (Tables)Tableshttp://vtak.com/role/PropertyAndEquipment31 falsefalseR32.htm000032- Disclosure - Intangible Assets (Tables)Sheethttp://vtak.com/role/IntangibleAssetsTablesIntangible Assets (Tables)Tableshttp://vtak.com/role/IntangibleAssets32 falsefalseR33.htm000033- Disclosure - Accrued Expenses (Tables)Sheethttp://vtak.com/role/AccruedExpensesTablesAccrued Expenses (Tables)Tableshttp://vtak.com/role/AccruedExpenses33 falsefalseR34.htm000034- Disclosure - Royalties Payable (Tables)Sheethttp://vtak.com/role/RoyaltiesPayableTablesRoyalties Payable (Tables)Tableshttp://vtak.com/role/RoyaltiesPayable34 falsefalseR35.htm000035- Disclosure - Leases (Tables)Sheethttp://vtak.com/role/LeasesTablesLeases (Tables)Tableshttp://vtak.com/role/Leases35 falsefalseR36.htm000036- Disclosure - Equity Offerings (Tables)Sheethttp://vtak.com/role/EquityOfferingsTablesEquity Offerings (Tables)Tableshttp://vtak.com/role/EquityOfferings36 falsefalseR37.htm000037- Disclosure - Preferred Stock (Tables)Sheethttp://vtak.com/role/PreferredStockTablesPreferred Stock (Tables)Tableshttp://vtak.com/role/PreferredStock37 falsefalseR38.htm000038- Disclosure - StockBased Compensation (Tables)Sheethttp://vtak.com/role/StockbasedCompensationTablesStockBased Compensation (Tables)Tableshttp://vtak.com/role/StockbasedCompensation38 falsefalseR39.htm000039- Disclosure - Related Parties (Tables)Sheethttp://vtak.com/role/RelatedPartiesTablesRelated Parties (Tables)Tableshttp://vtak.com/role/RelatedParties39 falsefalseR40.htm000040- Disclosure - Subsequent Events (Tables)Sheethttp://vtak.com/role/SubsequentEventsTablesSubsequent Events (Tables)Tableshttp://vtak.com/role/SubsequentEvents40 falsefalseR41.htm000041- Disclosure - Organization and Nature of Operations (Details Narrative)Sheethttp://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrativeOrganization and Nature of Operations (Details Narrative)Detailshttp://vtak.com/role/OrganizationAndNatureOfOperations41 falsefalseR42.htm000042- Disclosure - Summary of Significant Accounting Policies (Details)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsSummary of Significant Accounting Policies (Details)Detailshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails42 falsefalseR43.htm000043- Disclosure - Summary of Significant Accounting Policies (Details 1)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails1Summary of Significant Accounting Policies (Details 1)Detailshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables43 falsefalseR44.htm000044- Disclosure - Summary of Significant Accounting Policies (Details 2)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2Summary of Significant Accounting Policies (Details 2)Detailshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables44 falsefalseR45.htm000045- Disclosure - Summary of Significant Accounting Policies (Details 3)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails3Summary of Significant Accounting Policies (Details 3)Detailshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables45 falsefalseR46.htm000046- Disclosure - Summary of Significant Accounting Policies (Details Narrative)Sheethttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeSummary of Significant Accounting Policies (Details Narrative)Detailshttp://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables46 falsefalseR47.htm000047- Disclosure - Business Combination (Details)Sheethttp://vtak.com/role/BusinessCombinationDetailsBusiness Combination (Details)Detailshttp://vtak.com/role/BusinessCombinationTables47 falsefalseR48.htm000048- Disclosure - Business Combination (Details 1)Sheethttp://vtak.com/role/BusinessCombinationDetails1Business Combination (Details 1)Detailshttp://vtak.com/role/BusinessCombinationTables48 falsefalseR49.htm000049- Disclosure - Business Combination (Details 2)Sheethttp://vtak.com/role/BusinessCombinationTables49 falsefalseR50.htm000050- Disclosure - Business Combination (Details 3)Sheethttp://vtak.com/role/BusinessCombinationDetails3Business Combination (Details 3)Detailshttp://vtak.com/role/BusinessCombinationTables50 falsefalseR51.htm000051- Disclosure - Business Combination (Details Narrative)Sheethttp://vtak.com/role/BusinessCombinationDetailsNarrativeBusiness Combination (Details Narrative)Detailshttp://vtak.com/role/BusinessCombinationTables51 falsefalseR52.htm000052- Disclosure - Inventories (Details)Sheethttp://vtak.com/role/InventoriesDetailsInventories (Details)Detailshttp://vtak.com/role/InventoriesTables52 falsefalseR53.htm000053- Disclosure - Property and Equipment (Details)Sheethttp://vtak.com/role/PropertyAndEquipmentDetailsProperty and Equipment (Details)Detailshttp://vtak.com/role/PropertyAndEquipmentTables53 falsefalseR54.htm000054- Disclosure - Property and Equipment (Details Narrative)Sheethttp://vtak.com/role/PropertyAndEquipmentDetailsNarrativeProperty and Equipment (Details Narrative)Detailshttp://vtak.com/role/PropertyAndEquipmentTables54 falsefalseR55.htm000055- Disclosure - Intangible Assets (Details)Sheethttp://vtak.com/role/IntangibleAssetsDetailsIntangible Assets (Details)Detailshttp://vtak.com/role/IntangibleAssetsTables55 falsefalseR56.htm000056- Disclosure - Intangible Assets (Details 1)Sheethttp://vtak.com/role/IntangibleAssetsDetailsIntangible Assets (Details 1)Detailshttp://vtak.com/role/IntangibleAssetsTables56 falsefalseR57.htm000057- Disclosure - Intangible Assets (Details Narrative)Sheethttp://vtak.com/role/IntangibleAssetsDetailsNarrativeIntangible Assets (Details Narrative)Detailshttp://vtak.com/role/IntangibleAssetsTables57 falsefalseR58.htm000058- Disclosure - Goodwill (Details Narrative)Sheethttp://vtak.com/role/GoodwillDetailsNarrativeGoodwill (Details Narrative)Detailshttp://vtak.com/role/Goodwill58 falsefalseR59.htm000059- Disclosure - Accrued Expenses (Details)Sheethttp://vtak.com/role/AccruedExpensesDetailsAccrued Expenses (Details)Detailshttp://vtak.com/role/AccruedExpensesTables59 falsefalseR60.htm000060- Disclosure - Accrued Expenses (Details Narrative)Sheethttp://vtak.com/role/AccruedExpensesDetailsNarrativeAccrued Expenses (Details Narrative)Detailshttp://vtak.com/role/AccruedExpensesTables60 falsefalseR61.htm000061- Disclosure - Notes Payable (Details Narrative)Noteshttp://vtak.com/role/NotesPayableDetailsNarrativeNotes Payable (Details Narrative)Detailshttp://vtak.com/role/NotesPayable61 falsefalseR62.htm000062- Disclosure - Royalties Payable (Details)Sheethttp://vtak.com/role/RoyaltiesPayableDetailsRoyalties Payable (Details)Detailshttp://vtak.com/role/RoyaltiesPayableTables62 falsefalseR63.htm000063- Disclosure - Royalties Payable (Details 1)Sheethttp://vtak.com/role/RoyaltiesPayableDetails1Royalties Payable (Details

1)Detailshttp://vtak.com/role/RoyaltiesPayableTables63 falsefalseR64.htm000064 - Disclosure - Royalties Payable (Details Narrative)Sheethttp://vtak.com/role/RoyaltiesPayableDetailsNarrativeRoyalties Payable (Details Narrative)Detailshttp://vtak.com/role/RoyaltiesPayableTables64 falsefalseR65.htm000065 - Disclosure - Leases (Details)Sheethttp://vtak.com/role/LeasesDetailsLeases (Details)Detailshttp://vtak.com/role/LeasesTables65 falsefalseR66.htm000066 - Disclosure - Leases (Details 1)Sheethttp://vtak.com/role/LeasesDetails1Leases (Details 1)Detailshttp://vtak.com/role/LeasesTables66 falsefalseR67.htm000067 - Disclosure - Leases (Details 2)Sheethttp://vtak.com/role/LeasesDetails2Leases (Details 2)Detailshttp://vtak.com/role/LeasesTables67 falsefalseR68.htm000068 - Disclosure - Leases (Details 3)Sheethttp://vtak.com/role/LeasesDetails3Leases (Details 3)Detailshttp://vtak.com/role/LeasesTables68 falsefalseR69.htm000069 - Disclosure - Leases (Details Narrative)Sheethttp://vtak.com/role/LeasesDetailsNarrativeLeases (Details Narrative)Detailshttp://vtak.com/role/LeasesTables69 falsefalseR70.htm000070 - Disclosure - Net Loss per Share (Details Narrative)Sheethttp://vtak.com/role/NetLossPerShareDetailsNarrativeNet Loss per Share (Details Narrative)Detailshttp://vtak.com/role/NetLossPerShare70 falsefalseR71.htm000071 - Disclosure - Equity Offerings (Details)Sheethttp://vtak.com/role/EquityOfferingsDetailsEquity Offerings (Details)Detailshttp://vtak.com/role/EquityOfferingsTables71 falsefalseR72.htm000072 - Disclosure - Equity Offerings (Details 1)Sheethttp://vtak.com/role/EquityOfferingsDetails1Equity Offerings (Details 1)Detailshttp://vtak.com/role/EquityOfferingsTables72 falsefalseR73.htm000073 - Disclosure - Equity Offerings (Details 2)Sheethttp://vtak.com/role/EquityOfferingsDetails2Equity Offerings (Details 2)Detailshttp://vtak.com/role/EquityOfferingsTables73 falsefalseR74.htm000074 - Disclosure - Equity Offerings (Details 3)Sheethttp://vtak.com/role/EquityOfferingsDetails3Equity Offerings (Details 3)Detailshttp://vtak.com/role/EquityOfferingsTables74 falsefalseR75.htm000075 - Disclosure - Equity Offerings (Details 4)Sheethttp://vtak.com/role/EquityOfferingsDetails4Equity Offerings (Details 4)Detailshttp://vtak.com/role/EquityOfferingsTables75 falsefalseR76.htm000076 - Disclosure - Equity Offerings (Details Narrative)Sheethttp://vtak.com/role/EquityOfferingsDetailsNarrativeEquity Offerings (Details Narrative)Detailshttp://vtak.com/role/EquityOfferingsTables76 falsefalseR77.htm000077 - Disclosure - Preferred Stock (Details)Sheethttp://vtak.com/role/PreferredStockDetailsPreferred Stock (Details)Detailshttp://vtak.com/role/PreferredStockTables77 falsefalseR78.htm000078 - Disclosure - Preferred Stock (Details Narrative)Sheethttp://vtak.com/role/PreferredStockDetailsNarrativePreferred Stock (Details Narrative)Detailshttp://vtak.com/role/PreferredStockTables78 falsefalseR79.htm000079 - Disclosure - StockBased Compensation (Details)Sheethttp://vtak.com/role/StockbasedCompensationDetailsStockBased Compensation (Details)Detailshttp://vtak.com/role/StockbasedCompensationTables79 falsefalseR80.htm000080 - Disclosure - StockBased Compensation (Details 1)Sheethttp://vtak.com/role/StockbasedCompensationDetails1StockBased Compensation (Details 1)Detailshttp://vtak.com/role/StockbasedCompensationTables80 falsefalseR81.htm000081 - Disclosure - StockBased Compensation (Details 2)Sheethttp://vtak.com/role/StockbasedCompensationDetails2StockBased Compensation (Details 2)Detailshttp://vtak.com/role/StockbasedCompensationTables81 falsefalseR82.htm000082 - Disclosure - StockBased Compensation (Details 3)Sheethttp://vtak.com/role/StockbasedCompensationDetails3StockBased Compensation (Details 3)Detailshttp://vtak.com/role/StockbasedCompensationTables82 falsefalseR83.htm000083 - Disclosure - StockBased Compensation (Details Narrative)Sheethttp://vtak.com/role/StockbasedCompensationDetailsNarrativeStockBased Compensation (Details Narrative)Detailshttp://vtak.com/role/StockbasedCompensationTables83 falsefalseR84.htm000084 - Disclosure - Employee Benefit Plan (Details Narrative)Sheethttp://vtak.com/role/EmployeeBenefitPlanDetailsNarrativeEmployee Benefit Plan (Details Narrative)Detailshttp://vtak.com/role/EmployeeBenefitPlan84 falsefalseR85.htm000085 - Disclosure - Related Parties (Details)Sheethttp://vtak.com/role/RelatedPartiesDetailsRelated Parties (Details)Detailshttp://vtak.com/role/RelatedPartiesTables85 falsefalseR86.htm000086 - Disclosure - Related Parties (Details Narrative)Sheethttp://vtak.com/role/RelatedPartiesDetailsNarrativeRelated Parties (Details Narrative)Detailshttp://vtak.com/role/RelatedPartiesTables86 falsefalseR87.htm000087 - Disclosure - Subsequent Events (Details)Sheethttp://vtak.com/role/SubsequentEventsDetailsSubsequent Events (Details)Detailshttp://vtak.com/role/SubsequentEventsTables87 falsefalseR88.htm000088 - Disclosure - Subsequent Events (Details Narrative)Sheethttp://vtak.com/role/SubsequentEventsDetailsNarrativeSubsequent Events (Details Narrative)Detailshttp://vtak.com/role/SubsequentEventsTables88 falsefalseAll ReportsBookAll Reports vtab-20240930.xsdvtak-20240930_cal.xmlvtak-20240930_def.xmlvtak-20240930_lab.xmlvtak-20240930_pre.xmlvtak-10q.htm http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": "vtak-10q.htm": { "nsPrefix": "vtak", "nsuri": "http://vtak.com/20240930", "dts": { "schema": { "vtak-20240930.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrldt-2005.xsd", "http://www.xbrl.org/2006/rdf-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/ir/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/ir/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ir/role/net-2009-12-16.xsd", "http://www.xbrl.org/ir/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" }, "calculationLink": { "local": { "vtak-20240930_cal.xml" }, "definitionLink": { "local": { "vtak-20240930_def.xml" }, "labelLink": { "local": { "vtak-20240930_lab.xml" } }, "presentationLink": { "local": { "vtak-20240930_pre.xml" } }, "inline": { "local": { "vtak-10q.htm" } } }, "keyStandard": 287, "keyCustom": 166, "axisStandard": 22, "axisCustom": 0, "memberStandard": 18, "memberCustom": 112, "hidden": { "total": 27, "http://vtak.com/20240930": 3, "http://fasb.org/us-gaap/2024": 19, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 395, "entityCount": 1, "segmentCount": 132, "elementCount": 669, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 886, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://vtak.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "strong", "p": "td", "tr": "tbody", "table": "body", "html": "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "strong", "p": "td", "tr": "tbody", "table": "body", "html": "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "R2": { "role": "http://vtak.com/role/ConsolidatedConsolidatedBalanceSheets", "longName": "000002 - Statement - Consolidated Consolidated Balance Sheets", "shortName": "Consolidated Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "statement", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "unique": true }, "R3": { "role": "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "td", "tr": "tbody", "table": "body", "html": "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "td", "tr": "tbody", "table": "body", "html": "reportCount": 1, "baseRef": "vtak-10q.htm", "unique": true }, "R4": { "role": "http://vtak.com/role/ConsolidatedConsolidatedStatementsOfOperationsUnaudited", "longName": "000004 - Statement - Consolidated Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "statement", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "unique": true }, "R5": { "role": "http://vtak.com/role/ConsolidatedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "000005 - Statement - Consolidated Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Consolidated Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "statement", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "strong": "td", "tr": "tbody", "table": "body", "html": "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-03-31", "name": "us-gaap:CommonStockMember", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "unique": true }, "R6": { "role": "http://vtak.com/role/ConsolidatedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "000006 - Statement - Consolidated Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "statement", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "R7": { "role": "http://vtak.com/role/SummaryOfSignificantAccountingPolicies", "longName": "000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "R9": { "role": "http://vtak.com/role/BusinessCombination", "longName": "000009 - Disclosure - Business Combination", "shortName": "Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "R10": { "role": "http://vtak.com/role/Inventories", "longName": "000010 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "R11": { "role": "http://vtak.com/role/PropertyAndEquipment", "longName": "000011 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "vtak-10q.htm", "first": true, "unique": true }, "R12": { "role": "http://vtak.com/role/IntangibleAssets", "longName": "000012 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "12", "firstAnchor": {

[illegible]

```
"AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R34":{"role":"http://vtak.com/role/RoyaltiesPayableTables","longName":"000034-Disclosure-Royalties Payable (Tables)","shortName":"Royalties Payable (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"34","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:SummaryofsalesbasedroyaliestableTextblock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["vtak:RoyaltiesPayableTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R35":{"role":"http://vtak.com/role/LeasesTables","longName":"000035-Disclosure-Leases (Tables)","shortName":"Leases (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"35","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfOperatingLeaseExpenseAndCashPaidForLeasesTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["us-gaap:LesseeFinanceLeasesTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfOperatingLeaseExpenseAndCashPaidForLeasesTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["us-gaap:LesseeFinanceLeasesTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R36":{"role":"http://vtak.com/role/EquityOfferingsTables","longName":"000036-Disclosure-Equity Offerings (Tables)","shortName":"Equity Offerings (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"36","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R37":{"role":"http://vtak.com/role/PreferredStockTables","longName":"000037-Disclosure-Preferred Stock (Tables)","shortName":"Preferred Stock (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"37","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfSeriesAConvertiblePreferredStockOccurredSubsequentToTheIssuanceTablTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfSeriesAConvertiblePreferredStockOccurredSubsequentToTheIssuanceTablTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R38":{"role":"http://vtak.com/role/StockbasedCompensationTables","longName":"000038-Disclosure-Stock Based Compensation (Tables)","shortName":"Stock Based Compensation (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"38","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R39":{"role":"http://vtak.com/role/RelatedPartiesTables","longName":"000039-Disclosure-Related Parties (Tables)","shortName":"Related Parties (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"39","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfRelatedPartiesAndTheAmountsOwedToEachRelatedPartyTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfRelatedPartiesAndTheAmountsOwedToEachRelatedPartyTableTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R40":{"role":"http://vtak.com/role/SubsequentEventsTables","longName":"000040-Disclosure-Subsequent Events (Tables)","shortName":"Subsequent Events (Tables)","isDefault":"false","groupType":"disclosure","subGroupType":"tables","menuCat":"Tables","order":"40","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfIssuanceOfSecuritiesFromWarrantExercisesTableTextblock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["us-gaap:SubsequentEventsTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ScheduleOfIssuanceOfSecuritiesFromWarrantExercisesTableTextblock","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["us-gaap:SubsequentEventsTextBlock","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R41":{"role":"http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative","longName":"000041-Disclosure-Organization and Nature of Operations (Details Narrative)","shortName":"Organization and Nature of Operations (Details Narrative)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"41","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:CashFlowsUsedInOperatingActivities","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":5,"ancestors":["p","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:CashFlowsUsedInOperatingActivities","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":5,"ancestors":["p","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R42":{"role":"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails","longName":"000042-Disclosure-Summary of Significant Accounting Policies (Details)","shortName":"Summary of Significant Accounting Policies (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"42","firstAnchor":{"contextRef":"AsOf2024-09-30","name":"vtak:MutualFund","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":3,"ancestors":["td","tr","tbody","table","us-gaap:ScheduleOfDerivativeInstrumentsInStatementOffinancialPositionFairValueTableTextBlock","us-gaap:Fair Value Measurement PolicyPolicyTextBlock","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"AsOf2024-09-30","name":"vtak:MutualFund","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":3,"ancestors":["td","tr","tbody","table","us-gaap:ScheduleOfDerivativeInstrumentsInStatementOffinancialPositionFairValueTableTextBlock","us-gaap:Fair Value Measurement PolicyPolicyTextBlock","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R43":{"role":"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails1","longName":"000043-Disclosure-Summary of Significant Accounting Policies (Details 1)","shortName":"Summary of Significant Accounting Policies (Details 1)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"43","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ValuationTechnique","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["p","td","tr","tbody","table","vtak:ScheduleOfSignificantUnobservableInputsUsedInTheFairValueMeasurementTableTextBlock","ix:continuation","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30","name":"vtak:ValuationTechnique","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["p","td","tr","tbody","table","vtak:ScheduleOfSignificantUnobservableInputsUsedInTheFairValueMeasurementTableTextBlock","ix:continuation","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R44":{"role":"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2","longName":"000044-Disclosure-Summary of Significant Accounting Policies (Details 2)","shortName":"Summary of Significant Accounting Policies (Details 2)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"44","firstAnchor":{"contextRef":"From2024-01-01to2024-09-30 us-gaap:ComputerEquipmentMember vtak Bottom Member","name":"vtak:PropertyPlantAndEquipmentEstimatedUsefulLives","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["p","td","tr","tbody","table","vtak:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock","us-gaap:PropertyPlantAndEquipmentPolicyTextBlock","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-01-01to2024-09-30 us-gaap:ComputerEquipmentMember vtak Bottom Member","name":"vtak:PropertyPlantAndEquipmentEstimatedUsefulLives","unitRef":null,"xsiNil":"false","lang":"en-US"},"decimals":null,"ancestors":["p","td","tr","tbody","table","vtak:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock","us-gaap:PropertyPlantAndEquipmentPolicyTextBlock","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R45":{"role":"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails3","longName":"000045-Disclosure-Summary of Significant Accounting Policies (Details 3)","shortName":"Summary of Significant Accounting Policies (Details 3)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"45","firstAnchor":{"contextRef":"From2024-07-01to2024-09-30","name":"us-gaap:Revenues","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":3,"ancestors":["td","tr","tbody","table","us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2024-07-01to2024-09-30","name":"us-gaap:Revenues","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":3,"ancestors":["td","tr","tbody","table","us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"From2023-01-01to2023-09-30","name":"us-gaap:AssetImpairmentCharges","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":5,"ancestors":["p","us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy","ix:continuation","body","html","reportCount":1,"baseRef":"vtak-10q.htm","first":true,"unique":true},"R47":{"role":"http://vtak.com/role/BusinessCombinationDetails","longName":"000047-Disclosure-Business Combination (Details)","shortName":"Business Combination (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"47","firstAnchor":{"contextRef":"AsOf2023-01-09","name":"vtak:TotalPurchasePriceOffFairValue","unitRef":"USD","xsiNil":"false","lang":"en-US"},"decimals":3,"ancestors":["td","tr
```

[illegible]

```
"vtab_10q.htm", "first": true, "unique": true }, { "uniqueAnchor": f "contextRef": "AsOf2024-09-30", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "USD", "xsiNil": false, "lang": null, "decimals": 3, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R69": f "role": "http://vtak.com/role/LeasesDetailsNarrative", "longName": "000069 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 69, "firstAnchor": f "contextRef": "From2024-01-01to2024-09-30 vtak_SouthCarolinaOfficeLeaseAgreementMember", "name": "vtak:RentExpense", "unitRef": "USD", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "p": us-gaap:LesseesFinanceLeasesTextBlock, "body": html 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true }, { "uniqueAnchor": f "contextRef": "From2024-01-01to2024-09-30 vtak_SouthCarolinaOfficeLeaseAgreementMember", "name": "vtak:RentExpense", "unitRef": "USD", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "p": us-gaap:LesseesFinanceLeasesTextBlock, "body": html 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R70": f "role": "http://vtak.com/role/NetLossPerShareDetailsNarrative", "longName": "000070 - Disclosure - Net Loss per Share (Details Narrative)", "shortName": "Net Loss per Share (Details Narrative)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 70, "firstAnchor": f "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": false, "lang": null, "decimals": 6, "ancestors": f "p": us-gaap:PreferredStockTextBlock, "body": html 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true }, { "uniqueAnchor": f "contextRef": "From2024-01-01to2024-09-30 vtak_SeriesXConvertiblePreferredStocksMember", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "p": us-gaap:EarningsPerShareTextBlock, "body": html 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "unique": true } }, "R71": f "role": "http://vtak.com/role/EquityOfferingsDetails", "longName": "000071 - Disclosure - Equity Offerings (Details)", "shortName": "Equity Offerings (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 71, "firstAnchor": f "contextRef": "From2023-01-01to2023-01-09 vtak_SeriesBWarrantsMember vtak_TwoThousandTwentyThreeWarrantRepricingMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R72": f "role": "http://vtak.com/role/EquityOfferingsDetails1", "longName": "000072 - Disclosure - Equity Offerings (Details 1)", "shortName": "Equity Offerings (Details 1)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 72, "firstAnchor": f "contextRef": "From2023-01-01to2023-01-09 vtak_SeriesFWarrantsMember us-gaap:PrivatePlacementMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R73": f "role": "http://vtak.com/role/EquityOfferingsDetails2", "longName": "000073 - Disclosure - Equity Offerings (Details 2)", "shortName": "Equity Offerings (Details 2)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 73, "firstAnchor": f "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R74": f "role": "http://vtak.com/role/EquityOfferingsDetails3", "longName": "000074 - Disclosure - Equity Offerings (Details 3)", "shortName": "Equity Offerings (Details 3)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 74, "firstAnchor": f "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R75": f "role": "http://vtak.com/role/EquityOfferingsDetails4", "longName": "000075 - Disclosure - Equity Offerings (Details 4)", "shortName": "Equity Offerings (Details 4)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 75, "firstAnchor": f "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R76": f "role": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "longName": "000076 - Disclosure - Equity Offerings (Details Narrative)", "shortName": "Equity Offerings (Details Narrative)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 76, "firstAnchor": f "contextRef": "AsOf2024-09-03", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "p": ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R77": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000077 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 77, "firstAnchor": f "contextRef": "From2024-07-01to2024-07-11 vtak_SeriesAConvertiblePreferredStockMember", "name": "us-gaap:ConversionOfStockSharesIssued1", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "p": td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R78": f "role": "http://vtak.com/role/PreferredStockDetailsNarrative", "longName": "000078 - Disclosure - Preferred Stock (Details Narrative)", "shortName": "Preferred Stock (Details Narrative)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 78, "firstAnchor": f "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "p": td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R79": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000079 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 79, "firstAnchor": f "contextRef": "From2024-07-01to2024-07-09 vtak_EmployeesMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R80": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000080 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 80, "firstAnchor": f "contextRef": "From2024-01-01to2024-09-30 vtak_NonPlanOptionsIssuedMember vtak_MayOneTwoZeroTwoFourMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R81": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000081 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 81, "firstAnchor": f "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R82": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000082 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 82, "firstAnchor": f "contextRef": "From2024-01-01to2024-09-30 vtak_StockOptionsMember", "name": "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R83": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000083 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 83, "firstAnchor": f "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": false, "lang": null, "decimals": 0, "ancestors": f "td": tr, tbody": table, "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "vtak_10q.htm", "first": true, "unique": true } }, "R84": f "role": "http://vtak.com/role/PreferredStockDetails", "longName": "000084 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 84, "firstAnchor": f "contextRef": "From2024-01-01to2024-09-30 vtak_StockOptionsMember", "name": "us-gaap:Schedule
```

```
"Details Narrative", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30-us-gaap:ShareBasedCompensationAwardTrancheTwoMember", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DefinedBenefitPlanTextBlock", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ], "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30-us-gaap:ShareBasedCompensationAwardTrancheTwoMember", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DefinedBenefitPlanTextBlock", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ] }, "R85": { "role": "http://vtak.com/role/RelatedPartiesDetails", "longName": "000085 - Disclosure - Related Parties (Details)", "shortName": "Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30-vtak-DavidJenkinsMember", "name": "vtak:IssuanceDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "vtak:ScheduleOfRelatedPartiesAndTheAmountsOwedToEachRelatedPartyTableTextBlock", "ix:continuation", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ], "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30-vtak-DavidJenkinsMember", "name": "vtak:IssuanceDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "vtak:ScheduleOfRelatedPartiesAndTheAmountsOwedToEachRelatedPartyTableTextBlock", "ix:continuation", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ] }, "R86": { "role": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "longName": "000086 - Disclosure - Related Parties (Details narrative)", "shortName": "Related Parties (Details narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "From2023-01-01to2023-01-09", "name": "us-gaap:BusinessCombinationControlObtainedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ], "uniqueAnchor": { "contextRef": "From2023-01-01to2023-01-09", "name": "us-gaap:BusinessCombinationControlObtainedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ] }, "R87": { "role": "http://vtak.com/role/SubsequentEventsDetails", "longName": "000087 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "id", "tr", "tbody", "table", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ], "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30-us-gaap:SubsequentEventMember vtak PreFundedWarrantMember", "name": "vtak:ExerciseSharesDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "vtak:ScheduleOfIssuanceOfSecuritiesFromWarrantExercisesTableTextblock", "us-gaap:SubsequentEventsTextBlock", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "unique": true ] }, "R88": { "role": "http://vtak.com/role/SubsequentEventsDetailsNarrative", "longName": "000088 - Disclosure - Subsequent Events (Details narrative)", "shortName": "Subsequent Events (Details narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "From2024-01-01to2024-10-24-us-gaap:SubsequentEventMember", "name": "vtak:StockSplitDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html", "reportCount", "baseRef", "vtak 10q.htm", "first", true, "unique": true ] }, "tag": { "vtak:AMIGOSystemRoyaltyMember", "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "AMIGOSystemRoyaltyMember", "presentation": [ "http://vtak.com/role/RoyaltiesPayableDetailsNarrative", "lang": "en-us", "role": "label", "AMIGO System Royalty Member", "auth ref": [ "us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare", "presentation": [ "http://vtak.com/role/PreferredStockDetailsNarrative", "lang": "en-us", "role": "label", "Initial rate of share listing price", "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement." ] ], "auth ref": [ "r57", "r61", "r82" ] }, "us-gaap:Accounts Payable And Other Accrued Liabilities Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounting Policies Abstract", "lang": "en-us", "role": "label", "Summary of Significant Accounting Policies", "auth ref": [ "us-gaap:Accounts Payable And Other Accrued Liabilities Disclosure Text Block", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounts Payable And Other Accrued Liabilities Disclosure Text Block", "presentation": [ "http://vtak.com/role/AccruedExpenses", "lang": "en-us", "role": "label", "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." ] ], "auth ref": [ "r55", "r57", "r61", "r82" ] }, "us-gaap:Accounts Payable And Other Accrued Liabilities Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounts Payable And Other Accrued Liabilities Current", "crdr": "credit", "presentation": [ "http://vtak.com/role/Notes Payable Details Narrative", "lang": "en-us", "role": "label", "Notes Payable and accrued interest", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." ] ], "auth ref": [ "us-gaap:Accounts Payable Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounts Payable Current", "crdr": "debit", "calculation": [ "http://vtak.com/role/Condensed Consolidated Balance Sheets", "parentTag": "us-gaap:Liabilities Current", "weight": 1.0, "order": 16.0 ] ], "presentation": [ "http://vtak.com/role/Business Combination Details", "http://vtak.com/role/Condensed Consolidated Balance Sheets", "lang": "en-us", "role": "label", "Accounts payable", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." ] ], "auth ref": [ "r55", "r699" ] }, "us-gaap:Accounts Receivable Net", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounts Receivable Net", "crdr": "debit", "presentation": [ "http://vtak.com/role/Business Combination Details", "lang": "en-us", "role": "label", "Interest accrued", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." ] ], "auth ref": [ "r588", "r637", "r721", "r851", "r852" ] }, "us-gaap:Accounts Receivable Net Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounts Receivable Net Current", "crdr": "debit", "calculation": [ "http://vtak.com/role/Condensed Consolidated Balance Sheets", "parentTag": "us-gaap:Assets Current", "weight": 1.0, "order": 3.0 ] ], "presentation": [ "http://vtak.com/role/Condensed Consolidated Balance Sheets", "lang": "en-us", "role": "label", "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." ] ], "auth ref": [ "r768" ] }, "vtak:Accrued Expenses", "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "Accrued Expenses", "crdr": "credit", "presentation": [ "http://vtak.com/role/Related Parties Details Narrative", "lang": "en-us", "role": "label", "Accrued expenses", "label": "[Accrued expenses]", "auth ref": [ "vtak:Accrued Expenses Abstract", "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "Accrued Expenses Abstract", "lang": "en-us", "role": "label", "Accrued Expenses", "auth ref": [ "vtak:Accrued Interest On Convertible Promissory Note", "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "Accrued Interest On Convertible Promissory Note", "crdr": "credit", "presentation": [ "http://vtak.com/role/Related Parties Details Narrative", "lang": "en-us", "role": "label", "Interest accrued", "auth ref": [ "us-gaap:Accrued Liabilities Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accrued Liabilities Current", "crdr": "credit", "calculation": [ "http://vtak.com/role/Condensed Consolidated Balance Sheets", "parentTag": "us-gaap:Liabilities Current", "weight": 1.0, "order": 11.0 ] ], "presentation": [ "http://vtak.com/role/Accrued Expenses Details", "http://vtak.com/role/Business Combination Details", "http://vtak.com/role/Condensed Consolidated Balance Sheets", "http://vtak.com/role/Equity Offerings Details Narrative", "lang": "en-us", "role": "label", "Accrued expenses", "verboseLabel": "Accrued expenses", "terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." ] ], "auth ref": [ "r57" ] }, "vtak:Accrued Offering Costs Current", "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "Accrued Offering Costs Current", "crdr": "credit", "presentation": [ "http://vtak.com/role/Accrued Expenses Details", "lang": "en-us", "role": "label", "Offering costs", "auth ref": [ "us-gaap:Accrued Professional Fees Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accrued Professional Fees Current", "crdr": "credit", "presentation": [ "http://vtak.com/role/Accrued Expenses Details", "lang": "en-us", "role": "label", "Legal expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." ] ], "auth ref": [ "r57" ] }, "us-gaap:Accrued Royalties Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accrued Royalties Current", "crdr": "credit", "presentation": [ "http://vtak.com/role/Business Combination Details Narrative", "lang": "en-us", "role": "label", "Royalties payable", "label": "[Accrued Royalties Current]", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." ] ], "auth ref": [ "r57", "r65
```

[illegible]

"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "crdr": "debit", "presentation": "http://vtak.com/role/BusinessCombinationDetails1", "lang": "en-us", "role": "label", "label": "Total purchase price", "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree." }, {"auth_ref": "r45", "us-gaap-BusinessCombinationsAbstract": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": "en-us", "role": "label", "label": "Business Combination", "auth_ref": "r1", "us-gaap-CashAndCashEquivalentsAtCarryingValue": "stringItemType", "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 2.0, "presentation": "http://vtak.com/role/BusinessCombinationDetails1", "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." }, {"auth_ref": "r19", "r139", "r654", "us-gaap-CashAndCashEquivalentsPolicyTextBlock": "stringItemType", "textBlockItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPolicies", "lang": "en-us", "role": "label", "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." }, {"auth_ref": "r20", "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": "stringItemType", "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "periodStartLabel", "label": "CASH AND CASH EQUIVALENTS, beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }, {"auth_ref": "r19", "r81", "r166", "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": "stringItemType", "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "totalLabel", "label": "NET CHANGE IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }, {"auth_ref": "r2", "r81", "vtak-CashDownPaymentAmount": "stringItemType", "monetaryItemType": "nsuri": "http://vtak.com/20240930", "localname": "CashDownPaymentAmount", "crdr": "debit", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "label": "Down payment against purchase of director and officer liability insurance coverage", "auth_ref": "r1", "us-gaap-CashEquivalentsAtCarryingValue": "stringItemType", "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Cash and cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." }, {"auth_ref": "r747", "r850", "us-gaap-CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": "stringItemType", "stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "label": "SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING AND INVESTING ACTIVITIES", "auth_ref": "r1", "vtak-CashFlowsUsedInOperatingActivities": "stringItemType", "monetaryItemType": "nsuri": "http://vtak.com/20240930", "localname": "CashFlowsUsedInOperatingActivities", "crdr": "debit", "presentation": "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Cash flows used in operating activities", "auth_ref": "r1", "vtak-CathetersMember": "stringItemType", "domainItemType": "nsuri": "http://vtak.com/20240930", "localname": "CathetersMember", "presentation": "http://vtak.com/role/BusinessCombinationDetails", "lang": "en-us", "role": "label", "label": "Catheter's Member", "auth_ref": "r1", "vtak-ChangeInFairValueOfRoyaltiesPayable": "stringItemType", "monetaryItemType": "nsuri": "http://vtak.com/20240930", "localname": "ChangeInFairValueOfRoyaltiesPayable", "crdr": "debit", "presentation": "http://vtak.com/role/RoyaltiesPayableDetails1", "lang": "en-us", "role": "label", "label": "Change in fair value of royalties payable", "label": "Change in fair value of royalties payable", "auth_ref": "r1", "vtak-ChangeInFairValueOfRoyalty": "stringItemType", "monetaryItemType": "nsuri": "http://vtak.com/20240930", "localname": "ChangeInFairValueOfRoyalty", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "parentTag": "us-gaap-OtherOperatingIncomeExpenseNet", "weight": 1.0, "order": 10.0, "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "label": "Change in fair value of royalties payable", "auth_ref": "r1", "vtak-ChiefCommercialOfficerMember": "stringItemType", "domainItemType": "nsuri": "http://vtak.com/20240930", "localname": "ChiefCommercialOfficerMember", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Chief Commercial Officer", "auth_ref": "r1", "doi-CityAreaCode": "stringItemType", "normalizedStringItemType": "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "CityAreaCode", "presentation": "http://vtak.com/role/Cover", "lang": "en-us", "role": "label", "label": "City Area Code", "documentation": "Area code of city", "auth_ref": "r1", "us-gaap-ClassOfStockDomain": "stringItemType", "domainItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": "http://vtak.com/role/BusinessCombinationDetails", "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "http://vtak.com/role/CondensedConsolidatedBalanceSheetsParentetical", "http://vtak.com/role/EquityOfferingsDetails", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/NetLossPerShareDetailsNarrative", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://vtak.com/role/PreferredStockDetails", "http://vtak.com/role/PreferredStockDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetails", "http://vtak.com/role/StockbasedCompensationDetails1", "http://vtak.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." }, {"auth_ref": "r133", "r147", "r148", "r149", "r168", "r178", "r188", "r197", "r198", "r204", "r205", "r258", "r298", "r300", "r301", "r302", "r305", "r306", "r310", "r311", "r313", "r314", "r317", "r421", "r548", "r549", "r559", "r559", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r580", "r602", "r622", "r631", "r632", "r633", "r634", "r635", "r735", "r755", "r761", "us-gaap-ClassOfWarrantOrRightAxis": "stringItemType", "stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Class of Warrant or Right Axis", "documentation": "Information by type of warrant or right issued." }, {"auth_ref": "r38", "us-gaap-ClassOfWarrantOrRightDomain": "stringItemType", "domainItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." }, {"auth_ref": "r1", "us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": "stringItemType", "perShareItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/RelatedPartiesDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "lang": "en-us", "role": "label", "label": "Warrants exercise price", "verboseLabel": "Exercise price", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." }, {"auth_ref": "r318", "us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": "stringItemType", "sharesItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Option to purchase additional shares of Common Stock", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." }, {"auth_ref": "r1", "us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": "stringItemType", "sharesItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." }, {"auth_ref": "r310", "us-gaap-ClassOfWarrantOrRightOutstanding": "stringItemType", "sharesItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": "http://vtak.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Warrants remained outstanding after inducement offer", "documentation": "Number of warrants or rights outstanding." }, {"auth_ref": "r1", "vtak-CommitmentsAndContingenciesAbstract": "stringItemType", "stringItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommitmentsAndContingenciesAbstract", "lang": "en-us", "role": "label", "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." }, {"auth_ref": "r90", "r296", "r297", "r639", "r791", "r792", "us-gaap-CommonStockCapitalSharesReservedForFutureIssuance": "stringItemType", "sharesItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock reserve for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." }, {"auth_ref": "r65", "vtak-CommonStockCapitalSharesWeightedAverageExercisePrice": "stringItemType", "perShareItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommonStockCapitalSharesWeightedAverageExercisePrice", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock weighted average exercise price", "auth_ref": "r1", "vtak-CommonStockConvertiblePreferredStockDescription": "stringItemType", "stringItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommonStockConvertiblePreferredStockDescription", "presentation": "http://vtak.com/role/PreferredStockDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock convertible preferred stock description", "auth_ref": "r1", "us-gaap-CommonStockMember": "stringItemType", "domainItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." }, {"auth_ref": "r718", "r719", "r720", "r722", "r723", "r724", "r725", "r757", "r758", "r760", "r829", "r882", "r886", "us-gaap-CommonStockParOrStatedValuePerShare": "stringItemType", "perShareItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommonStockParOrStatedValuePerShare", "presentation": "http://vtak.com/role/ConsolidatedBalanceSheetsParentetical", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock, par value", "verboseLabel": "Common stock, Par value", "documentation": "Face amount or stated value per share of common stock." }, {"auth_ref": "r65", "us-gaap-CommonStockSharesAuthorized": "stringItemType", "stringItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommonStockSharesAuthorized", "presentation": "http://vtak.com/role/PreferredStockDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock reserve for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." }, {"auth_ref": "r65", "vtak-CommonStockParOrStatedValuePerShare": "stringItemType", "perShareItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommonStockParOrStatedValuePerShare", "presentation": "http://vtak.com/role/ConsolidatedBalanceSheetsParentetical", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock, par value", "verboseLabel": "Common stock, Par value", "documentation": "Face amount or stated value per share of common stock." }, {"auth_ref": "r65", "us-gaap-CommonStockSharesAuthorized": "stringItemType", "stringItemType": "nsuri": "http://vtak.com/20240930", "localname": "CommonStockSharesAuthorized", "presentation": "http://vtak.com/role/PreferredStockDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock reserve for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." }]

```

xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock, shares authorized", "verboseLabel": "Common Stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "auth ref": "r65", "r580", "us-gaap CommonStockSharesIssued", "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vtak.com/role/PreferredStockDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock, shares issued", "verboseLabel": "Common stock share issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "auth ref": "r65", "r580", "us-gaap CommonStockSharesOutstanding", "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vtak.com/role/PreferredStockDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "auth ref": "r8", "r65", "r580", "r599", "r886", "r887", "us-gaap CommonStockValue", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 22.0, "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Common stock, $0.0001 par value, 30,000,000 shares authorized; 3,452,652 and 702,662 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "auth ref": "r65", "r524", "r699", "vtak CommonStocksMember", "xbrlType": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "CommonStocksMember", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common Stocks", "auth ref": "us-gaap CommonUnitIssued", "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonUnitIssued", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "label": "Common Stock Units", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC).", "auth ref": "us-gaap ComputerEquipmentMember", "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "lang": "en-us", "role": "label", "label": "Computer Hardware And Software [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "auth ref": "vtak ComputerHardwareAndSoftwareMember", "xbrlType": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ComputerHardwareAndSoftwareMember", "presentation": "http://vtak.com/role/PropertyAndEquipmentDetails", "lang": "en-us", "role": "label", "label": "Computer Hardware And Software [Member]", "documentation": "Computer hardware and software used in the organization's operations.", "auth ref": "us-gaap ConcentrationRiskByTypeAxis", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Concentration Risk [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "auth ref": "r26", "r27", "r50", "r51", "r225", "r638", "r738", "us-gaap ConcentrationRiskCreditRisk", "xbrlType": "textBlockItemType", "nsuri": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "label": "Concentration Risk Credit Risk", "documentation": "Disclosure of accounting policy for credit risk.", "auth ref": "r54", "r126", "us-gaap ConcentrationRiskPercentage1", "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Concentration risk", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the 'benchmark' (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "auth ref": "r26", "r27", "r50", "r51", "r225", "us-gaap ConcentrationRiskTypeDomain", "xbrlType": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConcentrationRiskTypeDomain", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Concentration Risk", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "auth ref": "r26", "r27", "r50", "r51", "r225", "r638", "us-gaap ConsolidationPolicyTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConsolidationPolicyTextBlock", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "auth ref": "r48", "r659", "vtak ConversionOfSeriesAConvertiblePreferredStockAmount", "xbrlType": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConversionOfSeriesAConvertiblePreferredStockAmount", "crdr": "credit", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Conversion of Series A Convertible Preferred Stock, amount", "auth ref": "vtak ConversionOfSeriesAConvertiblePreferredStockForCommonStock", "xbrlType": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConversionOfSeriesAConvertiblePreferredStockForCommonStock", "crdr": "credit", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "label": "Conversion of Series A Convertible Preferred Stock for common stock", "auth ref": "vtak ConversionOfSeriesAConvertiblePreferredStockShares", "xbrlType": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConversionOfSeriesAConvertiblePreferredStockShares", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Conversion of Series A Convertible Preferred Stock, shares", "auth ref": "vtak ConversionOfSeriesXPreferredStockAmount", "xbrlType": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConversionOfSeriesXPreferredStockAmount", "crdr": "credit", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Conversion of Series X Convertible Preferred Stock, amount", "auth ref": "vtak ConversionOfSeriesXPreferredStockShares", "xbrlType": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConversionOfSeriesXPreferredStockShares", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Conversion of Series X Convertible Preferred Stock, shares", "auth ref": "us-gaap ConversionOfStockSharesConverted1", "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/NetLossPerShareDetailsNarrative", "http://vtak.com/role/PreferredStockDetails", "lang": "en-us", "role": "label", "label": "Convertible preferred stock", "verboseLabel": "Convertible preferred stock", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "auth ref": "r21", "r22", "r23", "us-gaap ConversionOfStockSharesIssued1", "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": "http://vtak.com/role/PreferredStockDetails", "lang": "en-us", "role": "label", "label": "Common Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "auth ref": "r21", "r22", "r23", "us-gaap ConversionOfStockTypeOfStockConverted", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockTypeOfStockConverted", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Conversion of stock description", "documentation": "The type of stock (i.e. preferred, common, treasury, etc.) being converted in a noncash (or part noncash) transaction.", "auth ref": "r21", "r22", "r23", "us-gaap ConvertibleLongTermNotesPayable", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "presentation": "http://vtak.com/role/BusinessCombinationDetailsNarrative", "lang": "en-us", "role": "label", "label": "Convertible promissory note", "verboseLabel": "Convertible promissory note", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "auth ref": "r13", "us-gaap ConvertibleNotesPayable", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": "http://vtak.com/role/BusinessCombinationDetails1", "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Convertible promissory note", "verboseLabel": "Convertible Promissory Notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "auth ref": "r13", "r110", "r848", "vtak ConvertiblePreferredStockSeriesXSharesMember", "xbrlType": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ConvertiblePreferredStockSeriesXSharesMember", "presentation": "http://vtak.com/role/BusinessCombinationDetails", "lang": "en-us", "role": "label", "label": "Convertible Series X Preferred Stock [Member]", "auth ref": "us-gaap ConvertiblePreferredStockSharesIssuedUponConversion", "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": "http://vtak.com/role/PreferredStockDetailsNarrative", "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "label": "Conversion of preferred stock", "verboseLabel": "Convertible Notes", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "auth ref": "r14", "r36", "r64", "r93", "r315", "us-gaap ConvertiblePreferredStockTermsOfConversion", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockTermsOfConversion", "presentation": "http://vtak.com/role/PreferredStockDetailsNarr
```

"http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 14.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Current portion of royalties payable" } } }, "auth ref": { "us-gaap CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": { "http://vtak.com/role/BusinessCombinationDetails2": { "http://vtak.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth ref": { "r46", "r780", "r781", "r782", "r783", "r784", "r785", "r788", "r789" } }, "vtak DavidAJenkinMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "DavidAJenkinMember", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "label": "David A Jenkin [Member]" } } }, "auth ref": { "vtak DavidJenkinsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "DavidJenkinsMember", "presentation": { "http://vtak.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "label": "David Jenkins [Member]" } } }, "auth ref": { "us-gaap DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "auth ref": { "us-gaap DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": { "http://vtak.com/role/RelatedPartiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Interest Rate", "verboseLabel": "Interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth ref": { "r359", "r308", "r837" } }, "us-gaap DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": { "http://vtak.com/role/RelatedPartiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth ref": { "r146", "r672", "r832", "r833" } }, "vtak DeemedDividendAmountForExistingWarrantsAndIssuanceOfNewWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "DeemedDividendAmountForExistingWarrantsAndIssuanceOfNewWarrants", "crdr": "debit", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Deemed dividend amount for existing warrants and issuance of new warrants" } } }, "auth ref": { "vtak DeemedDividendsWarrantInducementOffer": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "DeemedDividendsWarrantInducementOffer", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 16.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "label": "Deemed dividend - warrant inducement offer" } } }, "auth ref": { "us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth ref": { "r828" } }, "us-gaap DefinedBenefitPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanTextBlock", "presentation": { "http://vtak.com/role/EmployeeBenefitPlan": { "lang": { "en-us": { "role": { "label": "Employee Benefit Plan", "label": "Defined Benefit Plan [Text Block]", "documentation": "The entire disclosure for defined benefit plan." } } }, "auth ref": { "r320", "r479", "r679" } }, "us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Employer matching contribution, maximum (percentage)", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth ref": { "us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Maximum contribution per employee (percentage)", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth ref": { "vtak DepositiLiabilitiesaccruedinterst": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "DepositiLiabilitiesaccruedinterst", "crdr": "credit", "presentation": { "http://vtak.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "label": "Interest Accrued" } } }, "auth ref": { "us-gaap Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://vtak.com/role/PropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth ref": { "r6", "r32" } }, "us-gaap DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth ref": { "r6", "r32" } }, "vtak DescriptionOfWarrantInducement": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "DescriptionOfWarrantInducement", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Description of warrant inducement" } } }, "auth ref": { "vtak DescriptionRelatedToRoyalty": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "DescriptionRelatedToRoyalty", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Royalty liability description" } } }, "auth ref": { "vtak DescriptionRelatedToRoyaltyPayments": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "DescriptionRelatedToRoyaltyPayments", "presentation": { "http://vtak.com/role/RoyaltiesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Royalty payments description" } } }, "auth ref": { "vtak DescriptionofwarrantsTerm": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "DescriptionofwarrantsTerm", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrants Term description" } } }, "auth ref": { "vtak DevelopedTechnologyLockeTMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "DevelopedTechnologyLockeTMember", "presentation": { "http://vtak.com/role/BusinessCombinationDetails2": { "http://vtak.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "label": "Developed technology - LockeT [Member]" } } }, "auth ref": { "vtak DevelopedTechnologyVivoMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "DevelopedTechnologyVivoMember", "presentation": { "http://vtak.com/role/BusinessCombinationDetails2": { "http://vtak.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "label": "Developed Technology - Vivo [Member]" } } }, "auth ref": { "us-gaap DevelopmentInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopmentInProcess", "crdr": "debit", "presentation": { "http://vtak.com/role/BusinessCombinationDetails1": { "lang": { "en-us": { "role": { "label": "Developed technology", "documentation": "The current amount of expenditures for a real estate project that has not yet been completed." } } }, "auth ref": { "r845", "r846" } }, "rt DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth ref": { "r767", "r883" } }, "us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://vtak.com/role/StockbasedCompensation": { "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth ref": { "r327", "r328", "r358", "r359", "r361", "r682" } }, "us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "StockBased Compensation" } } }, "auth ref": { "vtak DistinguishingLiabilitiesFromEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "DistinguishingLiabilitiesFromEquityPolicyTextBlock", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Distinguishing Liabilities from Equity" } } }, "auth ref": { "dei DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth ref": { "dei DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth ref": { "dei DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth ref": { "dei DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth ref": { "dei DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth ref": { "dei DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth ref": { "us-gaap EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://vtak.com/role/NetLossPerShare": { "lang": { "en-us": { "role": { "label": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth ref": { "r183", "r199", "r200", "r201" } }, "vtak EarningsPerSharesBasicAndDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "EarningsPerSharesBasicAndDiluted", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "label": "Net loss per share attributable to common stockholders, basic and diluted" } } }, "auth ref": { "vtak EmployeeBenefitPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "EmployeeBenefitPlanAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefit Plan" } } }, "auth ref": { "us-gaap EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth ref": { "us-gaap EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://vtak.com/role/AccruedExpensesDetails": { "lang": { "en-us": { "role": { "label": "Compensation and related benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": { "us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails3": { "lang": { "en-us": { "role": { "label": "Remaining Weighted Average Recognition Period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnFnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth ref": { "us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails3": { "lang": { "en-us": { "role": { "label": "Total unrecognized estimated stock-based

compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth ref": { "r826" } } }, "us-gaap-EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://vtak.com/role/NetLossPerShareDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } }, "auth ref": { } }, "vtak-EmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "EmployeesAndConsultantsMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Employees And Consultants [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } }, "auth ref": { } }, "vtak-EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "EmployeesMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails": { "lang": { "en-us": { "role": { "label": "Employees [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } }, "auth ref": { } }, "vtak-EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } } }, "auth ref": { } }, "vtak-EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } } }, "auth ref": { } }, "vtak-EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } } }, "auth ref": { } }, "vtak-EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } } }, "auth ref": { } }, "vtak-EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } } }, "auth ref": { } }, "vtak-EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } }, "auth ref": { "r730" } } }, "vtak-EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } }, "auth ref": { } }, "vtak-EntityCurrentReportingStatus": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, "auth ref": { "r730" } } }, "vtak-EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } }, "auth ref": { "r730" } } }, "vtak-EntityFileNumber": { "xbrltype": "fileNumberItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits; the sequence number may contain 1-8 digits; the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } }, "auth ref": { "r730" } } }, "vtak-EntityFilerCategory": { "xbrltype": "filerCategoryItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, "auth ref": { "r730" } } }, "vtak-EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } }, "auth ref": { } }, "vtak-EntityInteractiveDataCurrent": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } }, "auth ref": { "r734" } } }, "vtak-EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } }, "auth ref": { "r730" } } }, "vtak-EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } } }, "auth ref": { "r730" } } }, "vtak-EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } }, "auth ref": { "r730" } } }, "vtak-EntityTaxIdentificationNumber": { "xbrltype": "employerIdItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://vtak.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } }, "auth ref": { "r730" } } }, "us-gaap-EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://vtak.com/role/ConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } }, "auth ref": { "r8", "r134", "r156", "r157", "r158", "r170", "r171", "r172", "r174", "r179", "r180", "r182", "r203", "r259", "r260", "r295", "r319", "r380", "r381", "r386", "r387", "r388", "r390", "r394", "r395", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r422", "r423", "r424", "r425", "r426", "r427", "r430", "r432", "r437", "r532", "r541", "r542", "r543", "r558", "r622" } } }, "vtak-EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "EquityIncentivePlanMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "2023 Equity Incentive Plan [Member]", "documentation": "Equity incentive plan details." } } } }, "auth ref": { } }, "us-gaap-EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": { "http://vtak.com/role/PreferredStock": { "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } } }, "auth ref": { "r257" } } }, "vtak-EquityOfferingsAbstract": { "xbrltype": "stringItem", "nsuri": "http://vtak.com/20240930", "localname": "EquityOfferingsAbstract", "presentation": { "http://vtak.com/role/EquityOfferingsAbstract": { "lang": { "en-us": { "role": { "label": "Equity Offerings", "documentation": "Equity Offerings Abstract." } } } }, "auth ref": { } }, "vtak-EstimatedUsefulLifeInYears": { "xbrltype": "durationItem", "nsuri": "http://vtak.com/20240930", "localname": "EstimatedUsefulLifeInYears", "presentation": { "http://vtak.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "label": "Estimated Useful Life in Years", "documentation": "Estimated Useful Life in Years." } } } }, "auth ref": { "r7", "srt-EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Europe [Member]", "documentation": "Summary of significant accounting policies." } } } }, "auth ref": { "r888", "r889", "r890", "r891" } } }, "vtak-ExerciseSharesDate": { "xbrltype": "dateItem", "nsuri": "http://vtak.com/20240930", "localname": "ExerciseSharesDate", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Exercise Date", "documentation": "Exercise Date." } } } }, "auth ref": { } }, "vtak-ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ExistingWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Existing warrants", "documentation": "Existing warrants." } } } }, "auth ref": { } }, "vtak-ExpirationDate": { "xbrltype": "stringItem", "nsuri": "http://vtak.com/20240930", "localname": "ExpirationDate", "presentation": { "http://vtak.com/role/EquityOfferingsDetails2": { "lang": { "en-us": { "role": { "label": "Expiration Date", "documentation": "Expiration Date." } } } }, "auth ref": { } }, "vtak-ExpirationPeriod": { "xbrltype": "stringItem", "nsuri": "http://vtak.com/20240930", "localname": "ExpirationPeriod", "presentation": { "http://vtak.com/role/RelatedPartiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Expiration period", "documentation": "Expiration period." } } } }, "auth ref": { } }, "us-gaap-FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Fair Value Adjustments of Warrants", "documentation": "Fair value adjustments of warrants." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueMeasurementPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyTextBlock", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } } }, "auth ref": { } }, "us-gaap-FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "vtak-FairValueOfOptionsIssued": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfOptionsIssued", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of options issued", "documentation": "Fair value of options issued." } } } }, "auth ref": { } }, "vtak-FairValueOfPreferredStockIssued": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfPreferredStockIssued", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of convertible preferred stock issued", "documentation": "Fair value of convertible preferred stock issued." } } } }, "auth ref": { } }, "vtak-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "lang": { "en-us": { "role": { "label": "Fair value of royalties payable increase/decrease", "documentation": "Fair value of royalties payable increase/decrease." } } } }, "auth ref": { "r307", "r321", "r322", "r323", "r324", "r325", "r326", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r450", "r451", "r452", "r673", "r674", "r677", "r678", "r679", "r688", "r691" } } }, "us-gaap-FairValueOfRoyaltiesPayableIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "FairValueOfRoyaltiesPayableIncreaseDecrease", "presentation": { "http://vtak.com/role

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

"Loss on impairment of goodwill", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth ref": { "r6": "r275", "r277", "r279", "r670", "r689" } }, "us-gaap GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "[Gross Profit]", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } } }, "auth ref": { "r74", "r75", "r115", "r168", "r258", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r421", "r663", "r666", "r762", "r763", "r764", "r765", "r766", "r796" } }, "vtak ImpairmentCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "ImpairmentCharge", "crdr": "debit", "presentation": { "http://vtak.com/role/BusinessCombinationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Total Impairment charge" } } } }, "auth ref": { } }, "us-gaap ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Impairment of Long-lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } } }, "auth ref": { "r0": "r89" } }, "us-gaap IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://vtak.com/role/IncomeTaxes": { "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } } }, "auth ref": { "r169", "r368", "r371", "r372", "r373", "r374", "r375", "r378", "r382", "r383", "r384", "r385", "r553", "r684" } }, "us-gaap IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Policy [Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } } }, "auth ref": { "r155", "r369", "r370", "r375", "r376", "r377", "r379", "r547" } }, "vtak IncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "IncomeTaxesAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } } }, "auth ref": { } }, "us-gaap IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "[Increase (Decrease) in Accounts Payable]", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } } }, "auth ref": { "r5" } }, "us-gaap IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "[Increase (Decrease) in Accounts Receivable]", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } } }, "auth ref": { "r5" } }, "us-gaap IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "[Increase (Decrease) in Accrued Liabilities]", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } } }, "auth ref": { "r5" } }, "us-gaap IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Interest payable to related parties", "label": "[Increase (Decrease) in Interest Payable, Net]", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } } }, "auth ref": { "r5" } }, "us-gaap IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "[Increase (Decrease) in Inventories]", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } } }, "auth ref": { "r5" } }, "us-gaap IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } } }, "auth ref": { } }, "us-gaap IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets and lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } } }, "auth ref": { "r739", "r753" } }, "us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } } }, "auth ref": { "r5" } }, "us-gaap IncreaseDecreaseInRoyaltiesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInRoyaltiesPayable", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Current portion of royalties payable", "label": "[Increase (Decrease) in Royalties Payable]", "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction." } } } }, "auth ref": { "r5" } }, "us-gaap IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "presentation": { "http://vtak.com/role/NetLossPerShareDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Convertible preferred stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } } }, "auth ref": { "r193", "r194", "r198" } }, "vtak IndefiniteLivedDevelopedTechnologiesAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "IndefiniteLivedDevelopedTechnologiesAssets", "crdr": "debit", "presentation": { "http://vtak.com/role/BusinessCombinationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Developed technologies assets" } } } }, "auth ref": { } }, "us-gaap IndefiniteLivedTrademarks": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedTrademarks", "crdr": "debit", "presentation": { "http://vtak.com/role/BusinessCombinationDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel": "Trademarks", "label": "[Indefinite-Lived Trademarks]", "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit." } } } }, "auth ref": { "r748", "r787" } }, "vtak InducementOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "InducementOfferMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel": "2024 Inducement Offer [Member]", "label": "[2024 Inducement Offer [Member]]" } } } }, "auth ref": { } }, "vtak InputRangeOfValueMeasurement": { "xbrltype": "percentItemType", "nsuri": "http://vtak.com/20240930", "localname": "InputRangeOfValueMeasurement", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Input Range" } } } }, "auth ref": { } }, "us-gaap IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": { "http://vtak.com/role/IntangibleAssets": { "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } } }, "auth ref": { "r280", "r293", "r294", "r649", "r650" } }, "us-gaap InterestAndDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndDebtExpense", "crdr": "debit", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Interest expense on loan", "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity." } } } }, "auth ref": { "r751" } }, "us-gaap InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap OtherOperatingIncomeExpenseNet", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } } }, "auth ref": { "r202", "r206", "r209", "r210", "r220", "r429", "r666", "r667" } }, "us-gaap InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap OtherOperatingIncomeExpenseNet", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } } }, "auth ref": { } }, "us-gaap InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaid", "crdr": "credit", "presentation": { "http://vtak.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "label": "Interest Paid", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount, classified as operating and investing activities." } } } }, "auth ref": { "r754" } }, "us-gaap InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Cash payments for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } } }, "auth ref": { "r161", "r164", "r165" } }, "us-gaap InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://vtak.com/role/BusinessCombinationDetails": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Interest payable to related parties", "verboseLabel": "Interest payable", "documentation": "Carrying value as of the balance sheet date of accrued interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth ref": { "r757" } }, "vtak InterestPayableOfRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "InterestPayableOfRelatedPartyCurrent", "crdr": "credit", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel": "Interest payable", "label": "Interest

payable"} } } },"auth ref":{ } } },"vtak InterestPayableToRelatedParties":{"xbrltype":"monetaryItemType","nsuri":"http://vtak.com/20240930","localname":"InterestPayableToRelatedParties","crdr":"credit","presentation":{"http://vtak.com/role/NotesPayableDetailsNarrative"},"lang":{"en-us":{"role":{"verboseLabel":"Interest payable to related parties"},"label":"Interest payable to related parties"} } } },"auth ref":{ } } },"vtak InventorOfDeviceDescription":{"xbrltype":"stringItemType","nsuri":"http://vtak.com/20240930","localname":"InventorOfDeviceDescription","presentation":{"http://vtak.com/role/RoyaltiesPayableDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Description of lockeT device inventor"} } } },"auth ref":{ } } },"us-gaap InventoryDisclosureAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryDisclosureAbstract","lang":{"en-us":{"role":{"label":"Inventories"} } } },"auth ref":{ } } },"us-gaap InventoryDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryDisclosureTextBlock","presentation":{"http://vtak.com/role/Inventories"},"lang":{"en-us":{"role":{"verboseLabel":"Inventories"},"label":"Inventory Disclosure [Text Block]"},"documentation":"The entire disclosure for inventory, includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } },"auth ref":{"r269"} } },"us-gaap InventoryFinishedGoodsNetOfReserves":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryFinishedGoodsNetOfReserves","crdr":"debit","presentation":{"http://vtak.com/role/InventoriesDetails"},"lang":{"en-us":{"role":{"label":"Finished goods"},"documentation":"Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } },"auth ref":{"r86","r657"} } },"us-gaap InventoryNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryNet","crdr":"debit","calculation":{"http://vtak.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":"us-gaap AssetsCurrent","weight":1.0,"order":4.0 } },"presentation":{"http://vtak.com/role/BusinessCombinationDetails1"},"http://vtak.com/role/CondensedConsolidatedBalanceSheets"},"http://vtak.com/role/InventoriesDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Inventories"},"label":"Inventory, Net"},"terseLabel":"Inventories"},"documentation":"Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } },"auth ref":{"r151","r655","r699"} } },"us-gaap InventoryPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryPolicyTextBlock","presentation":{"http://vtak.com/role/SummaryOfSignificantAccountingPolicies"},"lang":{"en-us":{"role":{"verboseLabel":"Inventories"},"label":"Inventory, Policy [Policy Text Block]"},"documentation":"Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } },"auth ref":{"r121","r138","r150","r269","r270","r271","r478","r660"} } },"us-gaap InventoryRawMaterialsNetOfReserves":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InventoryRawMaterialsNetOfReserves","crdr":"debit","presentation":{"http://vtak.com/role/InventoriesDetails"},"lang":{"en-us":{"role":{"label":"Raw materials"},"documentation":"Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } },"auth ref":{"r86","r658"} } },"us-gaap Investments":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Investments","crdr":"debit","presentation":{"http://vtak.com/role/RoyaltiesPayableDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Investment amount received"},"documentation":"Sum of the carrying amounts as of the balance sheet date of all investments." } } },"auth ref":{"r518","r519","r715","r717"} } },"vtak IssuanceDate":{"xbrltype":"stringItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceDate","presentation":{"http://vtak.com/role/RelatedPartiesDetails"},"lang":{"en-us":{"role":{"label":"Issuance Date"} } } },"auth ref":{ } } },"vtak IssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCostsAmount":{"xbrltype":"monetaryItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCostsAmount","crdr":"credit","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, amount"} } } },"auth ref":{ } } },"vtak IssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCostsShares":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCostsShares","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, shares"} } } },"auth ref":{ } } },"vtak IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount":{"xbrltype":"monetaryItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount","crdr":"credit","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), amount"} } } },"auth ref":{ } } },"vtak IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsShares":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsShares","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), shares"} } } },"auth ref":{ } } },"vtak IssuanceOfInstrumentsInConnectionWithPrivatePlacementNetAmount":{"xbrltype":"monetaryItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfInstrumentsInConnectionWithPrivatePlacementNetAmount","crdr":"debit","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of Series A Convertible Preferred Stock in connection with private placement, net, amount"} } } },"auth ref":{ } } },"vtak IssuanceOfInstrumentsInConnectionWithPrivatePlacementNetShares":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfInstrumentsInConnectionWithPrivatePlacementNetShares","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of Series A Convertible Preferred Stock in connection with private placement, net, shares"} } } },"auth ref":{ } } },"vtak IssuanceOfOptionsShares":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfOptionsShares","presentation":{"http://vtak.com/role/StockbasedCompensationDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Issuance of options"} } } },"auth ref":{ } } },"vtak IssuanceOfSeriesXPreferredStockInMergerAmount":{"xbrltype":"monetaryItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfSeriesXPreferredStockInMergerAmount","crdr":"credit","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of Series X Convertible Preferred Stock in merger, amount"} } } },"auth ref":{ } } },"vtak IssuanceOfSeriesXPreferredStockInMergerShares":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuanceOfSeriesXPreferredStockInMergerShares","presentation":{"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"label":"Issuance of Series X Convertible Preferred Stock in merger, shares"} } } },"auth ref":{ } } },"us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IssuanceOfStockAndWarrantsForServicesOrClaims","crdr":"debit","presentation":{"http://vtak.com/role/EquityOfferingsDetailsNarrative"},"http://vtak.com/role/NetLossPerShareDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Deemed dividend amount"},"verboseLabel":"Deemed dividend amount"},"documentation":"Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } },"auth ref":{"r6"} } },"vtak IssuancesOfOptionsForEmploymentIncentive":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuancesOfOptionsForEmploymentIncentive","presentation":{"http://vtak.com/role/StockbasedCompensationDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Issuances of options for employment incentive"} } } },"auth ref":{ } } },"vtak IssuancesOfOptionsShares":{"xbrltype":"sharesItemType","nsuri":"http://vtak.com/20240930","localname":"IssuancesOfOptionsShares","presentation":{"http://vtak.com/role/StockbasedCompensationDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Issuances of options"} } } },"auth ref":{ } } },"vtak IssueSharesDate":{"xbrltype":"dateTimeType","nsuri":"http://vtak.com/20240930","localname":"IssueSharesDate","presentation":{"http://vtak.com/role/SubsequentEventsDetails"},"lang":{"en-us":{"role":{"label":"Issue Date"} } } },"auth ref":{ } } },"vtak JanuaryTwoThousandTwentyThreeSeriesEWarrantsMember":{"xbrltype":"domainItemType","nsuri":"http://vtak.com/20240930","localname":"JanuaryTwoThousandTwentyThreeSeriesEWarrantsMember","presentation":{"http://vtak.com/role/EquityOfferingsDetails4"},"lang":{"en-us":{"role":{"label":"January 2023 Series E Warrants"} } } },"auth ref":{ } } },"vtak JenkinsFamilyCharitableInstituteMember":{"xbrltype":"domainItemType","nsuri":"http://vtak.com/20240930","localname":"JenkinsFamilyCharitableInstituteMember","presentation":{"http://vtak.com/role/RelatedPartiesDetails"},"lang":{"en-us":{"role":{"label":"Jenkins Family Charitable Institute [Member]"} } } },"auth ref":{ } } },"vtak JulyTwoThousandTwentyTwoSeriesCWarrantsMember":{"xbrltype":"domainItemType","nsuri":"http://vtak.com/20240930","localname":"JulyTwoThousandTwentyTwoSeriesCWarrantsMember","presentation":{"http://vtak.com/role/EquityOfferingsDetails4"},"lang":{"en-us":{"role":{"label":"July 2022 Series C Warrants"} } } },"auth ref":{ } } },"vtak LeaseAgreementDuration":{"xbrltype":"durationItemType","nsuri":"http://vtak.com/20240930","localname":"LeaseAgreementDuration","presentation":{"http://vtak.com/role/LeasesDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Lease agreement term"} } } },"auth ref":{ } } },"vtak LeaseAgreementDurationExtended":{"xbrltype":"durationItemType","nsuri":"http://vtak.com/20240930","localname":"LeaseAgreementDurationExtended","presentation":{"http://vtak.com/role/LeasesDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Lease agreement term extended period"} } } },"auth ref":{ } } },"us-gaap LeasesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeasesAbstract","lang":{"en-us":{"role":{"label":"Leases"} } } },"auth ref":{ } } },"vtak LegalLimitDescription":{"xbrltype":"stringItemType","nsuri":"http://vtak.com/20240930","localname":"LegalLimitDescription","presentation":{"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Description of legal limit"} } } },"auth ref":{ } } },"us-gaap LesseeFinanceLeasesTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeFinanceLeasesTextBlock","presentation":{"http://vtak.com/role/Leases"},"lang":{"en-us":{"role":{"verboseLabel":"Leases"},"label":"Lessee, Finance Leases [Text Block]"},"documentation":"The entire disclosure for finance leases of lessee, includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } },"auth ref":{"r431"} } },"us-gaap LesseeOperatingLeaseDiscountRate":{"xbrltype":"percentItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseDiscountRate","presentation":{"http://vtak.com/role/LeasesDetails1"},"lang":{"en-us":{"role":{"label":"Weighted average discount rate - operating leases"},"documentation":"Discount rate used by lessee to determine present value of operating lease payments." } } },"auth ref":{"r698"} } },"us-gaap LesseeOperatingLeaseLiabilityPaymentsDue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDue","crdr":"credit","presentation":{"http://vtak.com/role/LeasesDetails2"},"lang":{"en-us":{"role":{"label":"Total minimum lease payments"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease." } } },"auth ref":{"r435"} } },"us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths","crdr":"credit","presentation":{"http://vtak.com/role/LeasesDetails2"},"lang":{"en-us":{"role":{"label":"Lessee, Operating Lease, Liability, to be Paid, Year One"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } },"auth ref":{"r435"} } },"us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo","crdr":"credit","presentation":{"http://vtak.com/role/LeasesDetails2"},"lang":{"en-us":{"role":{"label":"Lessee, Operating Lease, Liability, to be Paid, Year Two"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } },"auth ref":{"r435"} } },"us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear","crdr":"credit","presentation":{"http://vtak.com/role/LeasesDetails2"},"lang":{"en-us":{"role":{"label":"Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year"},"documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } },"auth ref":{"r839"} } },"us-gaap Liabilities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Liabilities","crdr":"credit","calculation":{"http://vtak.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":"us-gaap LiabilitiesAndStockholdersEquity","weight":1.0,"order":25.0 } },"presentation":{"http://vtak.com/role/CondensedConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"totalLabel":"Total liabilities"},"label":"[Liabilities]"},"documentation":"Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } },"auth ref":{"r13","r56","r57","r58","r60","r61","r62","r63","r168","r258","r298","r299","r300","r301","r302","r303","r304","r305","r306","r398","r401","r402","r421","r570","r662","r728","r796","r842","r843"} } },"us-gaap LiabilitiesAndStockholdersEquity":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LiabilitiesAndStockholdersEquity","crdr":"credit","calculation":{"http://vtak.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":null,"weight":null,"order":null,"root":true } },"presentation":{"http://vtak.com/role/CondensedConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"totalLabel":"TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"},"label":"[Liabilities and Equity]"},"documentation":"Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } },"auth ref":{"r70","r111","r526","r699","r756","r776","r836"} } },"us-gaap LiabilitiesAndStockholdersEquityAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LiabilitiesAndStockholdersEquityAbstract","presentation":{"http://vtak.com/role/CondensedConsolidatedBalanceSheets"},"

"lang": "en-us", "role": "label", "LIABILITIES AND STOCKHOLDERS' EQUITY" }, "auth ref": "vtak LiabilitiesAssumedMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "LiabilitiesAssumedMember", "presentation": "http://vtak.com/role/BusinessCombinationDetails1", "lang": "en-us", "role": "label", "Liabilities assumed [Member]" }, "auth ref": "us-gaap LiabilitiesCurrent", "domainItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 17.0 }, "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "totalLabel", "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." }, "auth ref": "r58", "r137", "r168", "r258", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r398", "r401", "r402", "r421", "r699", "r796", "r842", "r843" }, "us-gaap LiabilitiesCurrentAbstract", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Current Liabilities" }, "auth ref": "vtak LiabilityInsuranceCoveragePurchasedByCompany", "domainItemType": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "LiabilityInsuranceCoveragePurchasedByCompany", "crdr": "credit", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Purchase of director and officer liability insurance coverage" }, "auth ref": "us-gaap LoansAssumed1", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAssumed1", "crdr": "credit", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Loan to company", "documentation": "The fair value of loans assumed in noncash investing or financing activities." }, "auth ref": "r21", "r22", "r23" }, "dei LocalPhoneNumber", "normalizedStringItemType": "nsuri", "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": "http://vtak.com/role/Cover", "lang": "en-us", "role": "label", "Local Phone Number", "documentation": "Local phone number for entity." }, "auth ref": "vtak LocketRoyaltyMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "LocketRoyaltyMember", "presentation": "http://vtak.com/role/RoyaltiesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Locket Royalty [Member]" }, "auth ref": "vtak LocketAnimationVideoMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "LocketAnimationVideoMember", "presentation": "http://vtak.com/role/PropertyAndEquipmentDetails", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "lang": "en-us", "role": "label", "Locket Animation Video [Member]" }, "auth ref": "vtak LocketRoyaltyPayableRecognizedInConnectionWithTheMerger", "domainItemType": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "LocketRoyaltyPayableRecognizedInConnectionWithTheMerger", "crdr": "debit", "presentation": "http://vtak.com/role/RoyaltiesPayableDetails1", "lang": "en-us", "role": "label", "Locket Royalty payable recognized in connection with the Merger" }, "auth ref": "us-gaap MachineryAndEquipmentMember", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": "http://vtak.com/role/PropertyAndEquipmentDetails", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "lang": "en-us", "role": "label", "Machinery And Equipment [Member]", "verboseLabel": "Machinery And Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." }, "auth ref": "us-gaap ManagementFeeExpense", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManagementFeeExpense", "crdr": "debit", "presentation": "http://vtak.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Agent fees and offering expenses", "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment." }, "auth ref": "r52", "r604", "r726", "r885" }, "vtak MarchTwoThousandTwentyThreeSeriesFWarrantsMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MarchTwoThousandTwentyThreeSeriesFWarrantsMember", "presentation": "http://vtak.com/role/EquityOfferingsDetails4", "lang": "en-us", "role": "label", "March 2023 Series F Warrants" }, "auth ref": "vtak MarchTwoThousandTwentyThreeSeriesGWarrantsMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MarchTwoThousandTwentyThreeSeriesGWarrantsMember", "presentation": "http://vtak.com/role/EquityOfferingsDetails4", "lang": "en-us", "role": "label", "March 2023 Series G Warrants" }, "auth ref": "vtak MargritThomassenMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MargritThomassenMember", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "Margrit Thomassen [Member]" }, "auth ref": "us-gaap MarketingAndAdvertisingExpense", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "lang": "en-us", "role": "label", "Advertising and marketing", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." }, "auth ref": "r77", "vtak MaturityDate", "stringItemType": "nsuri", "http://vtak.com/20240930", "localname": "MaturityDate", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Maturity date of related party notes" }, "auth ref": "vtak MayFirstTwentyTwentyFourMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MayFirstTwentyTwentyFourMember", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "May 01, 2024 [Member]" }, "auth ref": "vtak MayOneTwoZeroTwoFourMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MayOneTwoZeroTwoFourMember", "presentation": "http://vtak.com/role/StockbasedCompensationDetails1", "lang": "en-us", "role": "label", "May 1, 2024 [Member]" }, "auth ref": "vtak MayTwoThousandTwentyPlacementAgentWarrantsMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MayTwoThousandTwentyPlacementAgentWarrantsMember", "presentation": "http://vtak.com/role/EquityOfferingsDetails4", "lang": "en-us", "role": "label", "May 2020 Placement Agent Warrants" }, "auth ref": "vtak MayTwoThousandTwentyWarrantsMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MayTwoThousandTwentyWarrantsMember", "presentation": "http://vtak.com/role/EquityOfferingsDetails4", "lang": "en-us", "role": "label", "May 2020 Warrants" }, "auth ref": "vtak MergerAgreementMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MergerAgreementMember", "presentation": "http://vtak.com/role/BusinessCombinationDetailsNarrative", "lang": "en-us", "role": "label", "Merger Agreement [Member]" }, "auth ref": "vtak MergerAgreementOneMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MergerAgreementOneMember", "presentation": "http://vtak.com/role/BusinessCombinationDetailsNarrative", "lang": "en-us", "role": "label", "Merger Agreement One [Member]" }, "auth ref": "us-gaap MoneyMarketFundsAtCarryingValue", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "Money market fund", "documentation": "Investment in short-term money market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months." }, "auth ref": "vtak MrJenkinsMember", "domainItemType": "nsuri", "http://vtak.com/20240930", "localname": "MrJenkinsMember", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "Mr. Jenkins [Member]", "verboseLabel": "Mr. Jenkins [Member]" }, "auth ref": "vtak MutualFund", "domainItemType": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "MutualFund", "crdr": "debit", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "Mutual fund" }, "auth ref": "us-gaap NatureOfOperations", "domainItemType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": "http://vtak.com/role/OrganizationAndNatureOfOperations", "lang": "en-us", "role": "label", "Organization and Nature of Operations", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." }, "auth ref": "r122", "r132", "us-gaap NetCashProvidedByUsedInFinancingActivities", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 29.0 }, "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "totalLabel", "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." }, "auth ref": "r163", "us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "CASH FLOWS FROM FINANCING ACTIVITIES", "auth ref": "us-gaap NetCashProvidedByUsedInInvestingActivities", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 29.0 }, "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "totalLabel", "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." }, "auth ref": "r163", "us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "CASH FLOWS FROM OPERATING ACTIVITIES", "auth ref": "us-gaap NetIncomeLoss", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "parentTag": "us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 15.0 }, "presentation": "http://vtak.com/role/BusinessCombinationDetails3", "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "totalLabel", "Net loss", "label": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net loss", "terseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." }, "auth ref": "r76", "r83", "r112", "r135", "r153", "r154", "r158", "r168", "r173", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r195", "r258", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r389", "r395", "r411", "r421", "r531", "r601", "r620", "r621", "r726", "r796" }, "us-gaap NetIncomeLossAvailableToCommonStockholdersBasic", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": "http://vtak.com/role/BusinessCombinationDetails3", "lang": "en-us", "role": "label", "Net loss attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." }, "auth ref": "r160", "r175", "r176", "r177", "r178", "r184", "r185", "r196", "r198", "r395" }, "us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted", "domainItemType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "totalLabel", "Net loss attributable to common stockholders"

["Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." }, {"label": "Net Loss Per Share Abstract", "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "NetLossPerShareAbstract", "lang": "en-us", "role": "label", "Net Loss per Share", "auth ref": "11", "vtak Net Proceeds From Warrant Exercise", "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "NetProceedsFromWarrantExercise", "crdr": "debit", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "Net proceeds", "auth ref": "11", "us-gaap New Accounting Pronouncements Policy Policy Text Block", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "label", "Recently Announced Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "auth ref": "11", "vtak New Jersey Office Lease Agreement Member", "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "NewJerseyOfficeLeaseAgreementMember", "presentation": "http://vtak.com/role/LeasesDetailsNarrative", "lang": "en-us", "role": "label", "New Jersey Office Lease Agreement [Member]", "auth ref": "11", "vtak Non-Employee Director Options Issued Member", "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "NonEmployeeDirectorOptionsIssuedMember", "presentation": "http://vtak.com/role/StockbasedCompensationDetails", "lang": "en-us", "role": "label", "Non-Employee Director Options Issued [Member]", "auth ref": "11", "vtak Non-Plan Options Issued Member", "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "NonPlanOptionsIssuedMember", "presentation": "http://vtak.com/role/StockbasedCompensationDetails", "lang": "en-us", "role": "label", "Non-Plan Options Issued [Member]", "auth ref": "11", "vtak Note Payable To Third Party", "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "NotePayableToThirdParty", "crdr": "credit", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Note payable to third party", "auth ref": "11", "us-gaap Notes Payable", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap LiabilitiesCurrent", "weight": "1.0", "order": "12.0", "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Notes payable", "verboseLabel": "Notes payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "auth ref": "r13", "r110", "r48", "r49", "vtak Notes Payable Director And Officer Member", "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "NotesPayableDirectorAndOfficerMember", "presentation": "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": "en-us", "role": "label", "Notes Payable Director And Officer [Member]", "auth ref": "11", "vtak Notes Payable Disclosure Text Block", "xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "NotesPayableDisclosureTextBlock", "presentation": "http://vtak.com/role/NotesPayable", "lang": "en-us", "role": "label", "Notes Payable", "label": "Notes Payable", "auth ref": "11", "vtak Notes Payable Related Party Non Current", "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "NotesPayableRelatedPartyNonCurrent", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap Liabilities", "weight": "1.0", "order": "20.0", "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Notes payable due to related parties", "auth ref": "11", "vtak Number Of Warrants Exercised Shares", "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "NumberOfWarrantsExercisedShares", "presentation": "http://vtak.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "label", "Number of Warrants Exercised", "auth ref": "11", "vtak Number Of Warrants Issued", "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "NumberOfWarrantsIssued", "presentation": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "lang": "en-us", "role": "label", "Issuance of warrants", "auth ref": "11", "us-gaap Operating Expenses", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "parentTag": "us-gaap OperatingIncomeLoss", "weight": "1.0", "order": "8.0", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "auth ref": "11", "us-gaap Operating Expenses Abstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "Operating expenses", "auth ref": "11", "us-gaap Operating Income Loss", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "parentTag": "us-gaap NetIncomeLoss", "weight": "1.0", "order": "13.0", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "auth ref": "r15", "r66", "r72", "r73", "r74", "r75", "r76", "us-gaap Operating Lease Expense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": "http://vtak.com/role/LeasesDetails", "lang": "en-us", "role": "label", "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income.", "auth ref": "r38", "us-gaap Operating Lease Liability", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": "http://vtak.com/role/LeasesDetails2", "http://vtak.com/role/LeasesDetails3", "lang": "en-us", "role": "label", "Present value of future minimum lease payments", "verboseLabel": "Total lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "auth ref": "r43", "us-gaap Operating Lease Liability Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap LiabilitiesCurrent", "weight": "1.0", "order": "15.0", "presentation": "http://vtak.com/role/BusinessCombinationDetails", "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "http://vtak.com/role/LeasesDetails3", "lang": "en-us", "role": "label", "Current portion of operating lease liabilities", "verboseLabel": "Lease liability", "label": "Lease liability - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "auth ref": "r43", "us-gaap Operating Lease Liability Noncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap Liabilities", "weight": "1.0", "order": "6.0", "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "auth ref": "r43", "vtak Operating Lease Weighted Average Remaining Lease Term", "xbrltype": "durationItemType", "nsuri": "http://vtak.com/20240930", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": "http://vtak.com/role/LeasesDetails1", "lang": "en-us", "role": "label", "Weighted average remaining lease term (in years) - operating leases", "auth ref": "11", "vtak Option Exercise Price", "xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "OptionExercisePrice", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "Option exercise price", "auth ref": "11", "vtak Options To Purchase", "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "OptionsToPurchase", "presentation": "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": "en-us", "role": "label", "Options to purchase", "label": "Options to purchase", "auth ref": "11", "vtak Organization And Nature Of Operations Abstract", "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "OrganizationAndNatureOfOperationsAbstract", "lang": "en-us", "role": "label", "Organization and Nature of Operations", "auth ref": "11", "us-gaap Other Accrued Liabilities Current", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": "http://vtak.com/role/AccruedExpensesDetails", "lang": "en-us", "role": "label", "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "auth ref": "r57", "us-gaap Other Assets", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": "http://vtak.com/role/BusinessCombinationDetails", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "Total assets", "verboseLabel": "Other assets", "documentation": "Amount of assets classified as other.", "auth ref": "r105", "r144", "r520", "r667", "r728", "us-gaap Other Assets Noncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap Assets", "weight": "1.0", "order": "10.0", "presentation": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other.", "auth ref": "r144", "us-gaap Other Liabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "Total liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other.", "auth ref": "r109", "r522", "r575", "r576", "r728", "r49", "r88", "us-gaap Other Noncash Income Expense Abstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpenseAbstract", "presentation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "Other income (expense), net", "auth ref": "11", "us-gaap Other Nonoperating Income Expense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "parentTag": "us-gaap OtherOperatingIncomeExpenseNet", "weight": "1.

"The amount of cash paid for royalties during the current period." } } } , "auth ref": { "r4" } } , "vtak PaymentsOfConvertiblePromissoryNotesAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "PaymentsOfConvertiblePromissoryNotesAndAccruedInterest", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 23.0 } } , "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Payments of convertible promissory notes and accrued interest", "label": "[Payments of convertible promissory notes and accrued interest]" } } } , "auth ref": { } } , "vtak PaymentsOfCostsRelatedToTheWarrantRepricing": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "PaymentsOfCostsRelatedToTheWarrantRepricing", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 22.0 } } , "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Payments of costs related to the warrant repricing", "label": "[Payments of costs related to the warrant repricing]" } } } , "auth ref": { } } , "vtak PaymentsOfOfferingCostsRelatedToThePrivatePlacementOfSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "PaymentsOfOfferingCostsRelatedToThePrivatePlacementOfSecurities", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 25.0 } } , "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Payments of offering costs related to the private placement of securities", "label": "[Payments of offering costs related to the private placement of securities]" } } } , "auth ref": { } } , "us-gaap PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Payments Of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } } , "auth ref": { "r19" } } , "vtak PaymentsOwedOnRoyaltiesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "PaymentsOwedOnRoyaltiesPayable", "crdr": "credit", "presentation": { "http://vtak.com/role/RoyaltiesPayableDetails1": { "lang": { "en-us": { "role": { "label": "Payments owed on royalties payable" } } } , "auth ref": { } } , "us-gaap PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Non-cash consideration for Catheter acquisition", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } } , "auth ref": { "r16", "r393" } } , "us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 16.0 } } , "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Cash acquired as part of business combination", "label": "[Payments to Acquire Businesses, Net of Cash Acquired]", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } } , "auth ref": { "r16" } } , "us-gaap PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 15.0 } } , "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "[Payments to Acquire Property, Plant, and Equipment]", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } } , "auth ref": { "r79" } } , "vtak PerShareOfNonAssessibleShareOfCommonStock": { "xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "PerShareOfNonAssessibleShareOfCommonStock", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Non assessable share of common stock, per share" } } } , "auth ref": { } } , "vtak PercentageOfSharesExercised": { "xbrltype": "percentItemType", "nsuri": "http://vtak.com/20240930", "localname": "PercentageOfSharesExercised", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Percentage of shares exercised" } } } , "auth ref": { } } , "vtak PercentageOfSharesExercisedBeneficially": { "xbrltype": "percentItemType", "nsuri": "http://vtak.com/20240930", "localname": "PercentageOfSharesExercisedBeneficially", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Percentage of shares exercised beneficially" } } } , "auth ref": { } } , "vtak PlacementAgentWarrantsDescription": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "PlacementAgentWarrantsDescription", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Placement agent warrants description" } } } , "auth ref": { } } , "us-gaap PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://vtak.com/role/BusinessCombinationDetailsNarrative": "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "http://vtak.com/role/SubsequentEventsDetailsNarrative", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } } , "auth ref": { "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825" } } , "us-gaap PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://vtak.com/role/BusinessCombinationDetailsNarrative", "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "http://vtak.com/role/SubsequentEventsDetailsNarrative", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } } , "auth ref": { "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825" } } , "us-gaap PlanOfReorganizationDescriptionOfEquitySecuritiesIssuedOrToBeIssued": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanOfReorganizationDescriptionOfEquitySecuritiesIssuedOrToBeIssued", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Equity Incentive Plan description", "documentation": "Description of the terms of equity securities to be issued or to be issued to prepetition creditors in accordance with the plan of reorganization, including the amount and impact, if any, on diluted earnings per share." } } } , "auth ref": { "r53" } } , "us-gaap PledgingPurposeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeAxis", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Pledging Purpose Axis", "documentation": "Information by pledging purpose of pledged asset owned." } } } , "auth ref": { "r461", "r685", "r700", "r737" } } , "us-gaap PledgingPurposeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeDomain", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Pledging purpose of pledged asset owned." } } } , "auth ref": { "r461", "r685", "r700", "r737" } } , "vtak PreFundedUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedUnitsOutstanding", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Pre-Funded Units" } } } , "auth ref": { } } , "vtak PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedWarrantMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrant [Member]" } } } , "auth ref": { } } , "vtak PreFundedWarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedWarrantOneMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrant One [Member]" } } } , "auth ref": { } } , "vtak PreFundedWarrantThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedWarrantThreeMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrant Three [Member]" } } } , "auth ref": { } } , "vtak PreFundedWarrantTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedWarrantTwoMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrant Two [Member]" } } } , "auth ref": { } } , "vtak PreFundedWarrantUnits": { "xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedWarrantUnits", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrant Units" } } } , "auth ref": { } } , "vtak PreFundedWarrantsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreFundedWarrantsWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetails": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } } , "auth ref": { "r64", "r580" } } , "vtak PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreferredStockSharesDesignated", "presentation": { "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares designated" } } } , "auth ref": { } } , "us-gaap PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } } , "auth ref": { "r64", "r580" } } , "vtak PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreferredStockSharesDesignated", "presentation": { "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } } , "auth ref": { "r64", "r580", "r599", "r886", "r897" } } , "vtak PreferredStockSharesSeriesAConvertibleMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "PreferredStockSharesSeriesAConvertibleMember", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock" } } } , "auth ref": { } } , "us-gaap PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockTextBlock", "presentation": { "http://vtak.com/role/EquityOfferings": { "lang": { "en-us": { "role": { "label": "Preferred Stock [Text Block]", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } } , "auth ref": { "r91" } } , "us-gaap PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 21.0 } } , "presentation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Preferred Stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } , "auth ref": { "r64", "r523", "r699" } } , "us-gaap PreferredUnitsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredUnitsIssued", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrant Units Issued", "documentation": "The number of preferred units issued." } } } , "auth ref": { "r96" } } , "us-gaap PreferredUnitsOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredUnitsOfferingCosts", "crdr": "debit", "presentation": {

"http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Equity Offerings Costs", "documentation": "The cumulative amount of offering costs allocated to the preferred partners." } } }, "auth_ref": { "r96" } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://vtak.com/role/BusinessCombinationDetails1": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r749" } }, "vtak-PrincipalAmountOfRelatedPartyDebt": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "PrincipalAmountOfRelatedPartyDebt", "crdr": "debit", "presentation": { "http://vtak.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Principal Amount", "label": "[Principal Amount]" } } }, "auth_ref": { } }, "vtak-PrincipalAmountPerShares": { "xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "PrincipalAmountPerShares", "presentation": { "http://vtak.com/role/PreferredStockDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Principal amount per share" } } }, "auth_ref": { } }, "vtak-PrincipalAmountOfRelatedPartyDebt": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "PrincipalAmountOfRelatedPartyDebt", "crdr": "debit", "presentation": { "http://vtak.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "label": "Principal Amount" } } }, "auth_ref": { } }, "vtak-PrivateInvestmentInPublicEquityDescription": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "PrivateInvestmentInPublicEquityDescription", "presentation": { "http://vtak.com/role/PreferredStockDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Description of private investment in public equity" } } }, "auth_ref": { } }, "us-gaap-PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetails1": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "verboseLabel": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": { } }, "vtak-ProFormaFinancialInformationoMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ProFormaFinancialInformationoMember", "presentation": { "http://vtak.com/role/BusinessCombinationDetails3": { "lang": { "en-us": { "role": { "label": "Pro Forma Financial Information [Member]" } } }, "auth_ref": { } }, "us-gaap-ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "http://vtak.com/role/RelatedPartiesDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds", "label": "[Proceeds from Issuance Initial Public Offering]", "terseLabel": "Public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": { "r3" } }, "vtak-ProceedsFromIssuanceInitialPublicOfferingsNet": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "ProceedsFromIssuanceInitialPublicOfferingsNet", "crdr": "debit", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Net proceeds from public offering" } } }, "auth_ref": { } }, "us-gaap-ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Proceeds From Issuance Of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r3" } }, "vtak-ProceedsFromIssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCosts": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndOtherEquityClassifiedContractsPublicOfferingNetOfIssuanceCosts", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 26.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs" } } }, "auth_ref": { } }, "vtak-ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and warrants, net of fees withheld." } } }, "auth_ref": { } }, "us-gaap-ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Gross proceeds from warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": { "r3" } }, "us-gaap-ProceedsFromNotesPayable": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from note payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": { "r17" } }, "vtak-ProceedsFromNotesPayableDueToRelatedParties": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "ProceedsFromNotesPayableDueToRelatedParties", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from notes payable due to related parties" } } }, "auth_ref": { } }, "vtak-ProceedsFromPublicOffering": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "ProceedsFromPublicOffering", "crdr": "debit", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Gross proceeds" } } }, "auth_ref": { } }, "vtak-ProceedsFromThePrivatePlacementOfSecurities": { "xbrltype": "monetaryItem", "nsuri": "http://vtak.com/20240930", "localname": "ProceedsFromThePrivatePlacementOfSecurities", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from the private placement of securities" } } }, "auth_ref": { } }, "us-gaap-ProceedsFromWarrantExercises": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "http://vtak.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "verboseLabel": "Proceeds", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": { "r752" } }, "srt-ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://vtak.com/role/RoyaltiesPayableDetails": { "lang": { "en-us": { "role": { "label": "Product Or Service Axis" } } }, "auth_ref": { "r222", "r480", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r652", "r675", "r710", "r711", "r712", "r714", "r716", "r793", "r794", "r798", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881" } }, "us-gaap-ProfitLoss": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r135", "r153", "r154", "r162", "r168", "r173", "r179", "r181", "r182", "r258", "r298", "r299", "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } }, "us-gaap-PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlock", "nsuri": "http://vtak.com/20240930", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://vtak.com/role/PropertyPlantAndEquipmentDisclosureTextBlock": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r87", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r

[illegible]

[http://vtak.com/role/RoyaltiesPayableDetails"/>http://vtak.com/role/RoyaltiesPayableDetails](#)"}], "lang": {"en-us": {"role": {"label": "Royalty Percentage" } } }}, "auth ref": [] }, "vtak RoyaltyThreeMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "RoyaltyThreeMember", "presentation": [{"http://vtak.com/role/RoyaltiesPayableDetails"}], "lang": {"en-us": {"role": {"label": "Royalty Three [Member]" } } }}, "auth ref": [] }, "us-gaap RoyaltyTrustDistributableIncomePolicy": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyTrustDistributableIncomePolicy", "presentation": [{"http://vtak.com/role/SummaryOfSignificantAccountingPolicies"}], "lang": {"en-us": {"role": {"label": "Royalties Payable", "label": "Oil and Gas Royalty Trust Distributable Income [Policy Text Block]", "documentation": "Disclosure of accounting policy for a royalty trust in determining distributable income and how distributable income differs from income determined on the basis of US GAAP." } } }}, "auth ref": [{"r483"}], "vtak RoyaltyTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "RoyaltyTwoMember", "presentation": [{"http://vtak.com/role/RoyaltiesPayableDetails"}], "lang": {"en-us": {"role": {"label": "Royalty Two [Member]" } } }}, "auth ref": [] }, "us-gaap SaleOfStockNameOfTransactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [{"http://vtak.com/role/EquityOfferingsDetails", "http://vtak.com/role/EquityOfferingsDetails1", "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/SubsequentEventsDetails"}], "lang": {"en-us": {"role": {"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }}, "auth ref": [{"r484}], "us-gaap SaleOfStockPricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [{"http://vtak.com/role/BusinessCombinationDetailsNarrative"}], "lang": {"en-us": {"role": {"label": "Closing stock price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }}, "auth ref": [{"r485}], "us-gaap ScheduleOfAccruedLiabilitiesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [{"http://vtak.com/role/AccruedExpensesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }}, "auth ref": [{"r486}], "us-gaap ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [{"http://vtak.com/role/BusinessCombinationTables"}], "lang": {"en-us": {"role": {"label": "Schedule of acquisition date fair values and estimated useful lives", "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }}, "auth ref": [{"r487}], "us-gaap ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [{"http://vtak.com/role/BusinessCombinationTables"}], "lang": {"en-us": {"role": {"label": "summary the preliminary estimated fair value", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }}, "auth ref": [{"r488}], "vtak ScheduleOfCommonStockOutstandingWarrantsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfCommonStockOutstandingWarrantsTableTextBlock", "presentation": [{"http://vtak.com/role/EquityOfferingsTables"}], "lang": {"en-us": {"role": {"label": "Schedule of common stock warrants outstanding" } } }}, "auth ref": [{"r489}], "us-gaap ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTableTextBlock", "presentation": [{"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of the fair value measurements within the fair value hierarchy of the Company's financial instruments", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }}, "auth ref": [{"r490}], "vtak ScheduleOfDisaggregatedProductSalesByGeographicAreaTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfDisaggregatedProductSalesByGeographicAreaTableTextBlock", "presentation": [{"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of disaggregated product sales by geographic area" } } }}, "auth ref": [{"r491}], "us-gaap ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "presentation": [{"http://vtak.com/role/LeasesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of future lease payments for all lease", "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date." } } }}, "auth ref": [{"r492}], "us-gaap ScheduleOfImpairedIntangibleAssetsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfImpairedIntangibleAssetsTableTextBlock", "presentation": [{"http://vtak.com/role/IntangibleAssetsTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Intangible Assets", "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported." } } }}, "auth ref": [{"r493}], "us-gaap ScheduleOfInventoryCurrentTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [{"http://vtak.com/role/InventoriesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }}, "auth ref": [{"r494}], "vtak ScheduleOfIssuanceOfSecuritiesFromWarrantExercisesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfIssuanceOfSecuritiesFromWarrantExercisesTableTextBlock", "presentation": [{"http://vtak.com/role/SubsequentEventsTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Issuance of Securities from Warrant Exercises" } } }}, "auth ref": [{"r495}], "vtak ScheduleOfIssuanceOfWarrantstextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfIssuanceOfWarrantstextBlock", "presentation": [{"http://vtak.com/role/EquityOfferingsTables"}], "lang": {"en-us": {"role": {"label": "Schedule of issuance of warrants" } } }}, "auth ref": [{"r496}], "vtak ScheduleOfOperatingLeaseExpenseAndCashPaidForLeasesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfOperatingLeaseExpenseAndCashPaidForLeasesTableTextBlock", "presentation": [{"http://vtak.com/role/LeasesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of operating lease expense and cash paid for leases" } } }}, "auth ref": [{"r497}], "vtak ScheduleOfRelatedPartiesAndTheAmountsOwedToEachRelatedPartyTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfRelatedPartiesAndTheAmountsOwedToEachRelatedPartyTableTextBlock", "presentation": [{"http://vtak.com/role/RelatedPartiesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Related parties and the amounts owed to each related party" } } }}, "auth ref": [{"r498}], "vtak ScheduleOfRightOfUseLeaseAssetsAndLeaseLiabilitiesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfRightOfUseLeaseAssetsAndLeaseLiabilitiesTableTextBlock", "presentation": [{"http://vtak.com/role/LeasesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Right of use lease assets and lease liabilities" } } }}, "auth ref": [{"r499}], "vtak ScheduleOfSeriesAConvertiblePreferredStockOccurredSubsequentToTheIssuanceTablTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfSeriesAConvertiblePreferredStockOccurredSubsequentToTheIssuanceTablTextBlock", "presentation": [{"http://vtak.com/role/PreferredStockTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Series A Convertible Preferred Stock occurred subsequent to the issuance" } } }}, "auth ref": [{"r500}], "us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [{"http://vtak.com/role/StockbasedCompensationTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Options Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }}, "auth ref": [{"r501}], "vtak ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsPlacementFeesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsPlacementFeesTableTextBlock", "presentation": [{"http://vtak.com/role/EquityOfferingsTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Black-Scholes Model Based on Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }}, "auth ref": [{"r502}], "vtak ScheduleOfSignificantUnobservableInputsUsedInTheFairValueMeasurementTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "ScheduleOfSignificantUnobservableInputsUsedInTheFairValueMeasurementTableTextBlock", "presentation": [{"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Significant unobservable inputs used in the fair value measurement" } } }}, "auth ref": [{"r503}], "us-gaap ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "presentation": [{"http://vtak.com/role/StockbasedCompensationTables"}], "lang": {"en-us": {"role": {"label": "Schedule of Unrecognized Estimated Stock Based Compensation Expense by Award Type", "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement." } } }}, "auth ref": [{"r504}], "us-gaap ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [{"http://vtak.com/role/LeasesTables"}], "lang": {"en-us": {"role": {"label": "Schedule of weighted average discount rate", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }}, "auth ref": [{"r505}], "us-gaap ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [{"http://vtak.com/role/IntangibleAssetsTables"}], "lang": {"en-us": {"role": {"label": "Schedule of estimated future amortization expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }}, "auth ref": [{"r506}], "vtak SecuritiesPurchaseAgreementClaaBMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SecuritiesPurchaseAgreementClaaBMember", "presentation": [{"http://vtak.com/role/EquityOfferingsDetailsNarrative"}], "lang": {"en-us": {"role": {"label": "Securities Purchase AgreeMent Class B [Member]" } } }}, "auth ref": [{"r507}], "vtak SecuritiesPurchaseAgreementMember": {"xbr

"parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" } }, "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth ref": { "r77" } }, "us-gaap-SeniorLongTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLongTermNotes", "crd": "credit", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Short-term promissory notes", "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth ref": { "r13", "r699" } }, "vtak-SeptemberTwoThousandTwentyFourPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeptemberTwoThousandTwentyFourPublicOfferingMember", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "September 2024 Public Offering [Member]" } } }, "auth ref": { "vtak-SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": { "http://vtak.com/role/ConsolidatedBalanceSheetsParentetical" }, "lang": { "en-us": { "role": { "label": "Series A convertible preferred stocks [Member]" } } }, "auth ref": { "vtak-SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesAWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } }, "auth ref": { "vtak-SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesBWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]" } } }, "auth ref": { "vtak-SeriesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesCWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series C Warrants [Member]" } } }, "auth ref": { "vtak-SeriesEWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesEWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series E Warrants [Member]" } } }, "auth ref": { "vtak-SeriesFWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesFWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series F and Series G Warrants [Member]" } } }, "auth ref": { "vtak-SeriesFWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesFWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series F Warrants [Member]" } } }, "auth ref": { "vtak-SeriesGWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesGWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series G Warrants [Member]" } } }, "auth ref": { "vtak-SeriesHWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesHWarrantMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series H Warrant [Member]" } } }, "auth ref": { "vtak-SeriesHWarrantSeriesWarrantSeriesWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesHWarrantSeriesWarrantSeriesWarrantMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series H Warrant, Series I Warrant, Series J Warrant" } } }, "auth ref": { "vtak-SeriesHWarrantsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesHWarrantsWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series I Warrant [Member]" } } }, "auth ref": { "vtak-SeriesI WarrantsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesI WarrantsWarrantsMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series I Warrants [Member]" } } }, "auth ref": { "vtak-SeriesKWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesKWarrantsMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series K Warrants [Member]" } } }, "auth ref": { "vtak-SeriesXConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesXConvertiblePreferredStockMember", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" } }, "lang": { "en-us": { "role": { "label": "Series X convertible preferred stock [Member]" } } }, "auth ref": { "vtak-SeriesXPreferredStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesXPreferredStockShares", "presentation": { "http://vtak.com/role/BusinessCombinationDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series X preferred stock shares" } } }, "auth ref": { "vtak-SeriesXConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesXConvertiblePreferredSharesMember", "presentation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets" } }, "lang": { "en-us": { "role": { "label": "Series X convertible preferred stocks [Member]" } } }, "auth ref": { "vtak-SeriesXConvertiblePreferredStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "SeriesXConvertiblePreferredStocksMember", "presentation": { "http://vtak.com/role/NetLossPerShareDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Series x convertible preferred stocks [Member]" } } }, "auth ref": { "us-gaap-ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crd": "debit", "calculation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" } }, "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" } }, "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "[Share-Based Payment Arrangement, Noncash Expense]", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth ref": { "r5" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": { "http://vtak.com/role/EquityOfferingsDetails2" }, "lang": { "en-us": { "role": { "label": "Exercise Price", "verboseLabel": "Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth ref": { "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://vtak.com/role/EquityOfferingsDetails", "http://vtak.com/role/EquityOfferingsDetails1" }, "lang": { "en-us": { "role": { "label": "Expected dividend yield", "verboseLabel": "Expected dividend yield", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth ref": { "r355" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails", "http://vtak.com/role/StockbasedCompensationDetails1" }, "lang": { "en-us": { "role": { "label": "Volatility", "verboseLabel": "Volatility", "terseLabel": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth ref": { "r354" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://vtak.com/role/EquityOfferingsDetails", "http://vtak.com/role/EquityOfferingsDetails1", "http://vtak.com/role/EquityOfferingsDetails2" }, "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "verboseLabel": "Risk-free interest rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth ref": { "r356" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Eligible employees withhold percentage of earnings to purchase shares of common stock", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth ref": { "r39" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": { "http://vtak.com/role/EquityOfferingsDetails3" }, "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised]", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth ref": { "r10" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": { "http://vtak.com/role/EquityOfferingsDetails3" }, "lang": { "en-us": { "role": { "negatedLabel": "Expired", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth ref": { "r101" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": { "http://vtak.com/role/EquityOfferingsDetails3" }, "lang": { "en-us": { "role": { "label": "Issued", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth ref": { "r9" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": { "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/EquityOfferingsDetails3", "http://vtak.com/role/EquityOfferingsDetails4" }, "lang": { "en-us": { "role": { "label": "Warrants outstanding", "periodStartLabel": "Warrants outstanding, Beginning balance", "periodEndLabel": "Warrants outstanding, Ending balance", "verboseLabel": "Warrants outstanding", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth ref": { "r99", "r100" } }, "vtak-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisable", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2" }, "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable at September 30, 2024", "label": "Exercisable at

September 30, 2024"} } } },"auth ref": { "vtak_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedVested": { "xbrltype": "sharesItemtype", "nsuri": "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "periodEndLabel": "Vested and expected to vest at September 30, 2024", "label": "[Vested and expected to vest at September 30, 2024]" } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "negatedLabel": "Stock option canceled/forfeited", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period]", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } } },"auth ref": { "r339"} } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "label": "Stock option options granted", "documentation": "Net number of share options (or share units) granted during the period." } } } },"auth ref": { "r807"} } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "periodStartLabel": "Stock option outstanding beginning of the period", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Stock option outstanding end of the period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } },"auth ref": { "r333", "r334"} } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Maximum annual increase of outstanding stock reserved for future issuance, Percentage", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } } },"auth ref": { "vtak_ShareBasedCompensationArrangementWeightedAverageExercisePrice": { "xbrltype": "perShareItemtype", "nsuri": "http://vtak.com/20240930", "localname": "ShareBasedCompensationArrangementWeightedAverageExercisePrice", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercised price outstanding end of period", "label": "[Weighted average exercised price outstanding end of period]" } } } },"auth ref": { "vtak_ShareBasedCompensationArrangementWeightedAverageExercisePriceOptionsExercised": { "xbrltype": "perShareItemtype", "nsuri": "http://vtak.com/20240930", "localname": "ShareBasedCompensationArrangementWeightedAverageExercisePriceOptionsExercised", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "label": "Weighted average exercised price options exercised", "documentation": "Weighted average exercised price of shares exercised." } } } },"auth ref": { "vtak_ShareBasedCompensationArrangementWeightedAveragePrice": { "xbrltype": "perShareItemtype", "nsuri": "http://vtak.com/20240930", "localname": "ShareBasedCompensationArrangementWeightedAveragePrice", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercised price outstanding beg of period", "label": "[Weighted average exercised price outstanding beg of period]" } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://vtak.com/role/EquityOfferingsDetails4", "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/RelatedPartiesDetailsNarrative", "http://vtak.com/role/RoyaltiesPayableDetails", "http://vtak.com/role/StockbasedCompensationDetails3", "http://vtak.com/role/SubsequentEventsDetailsNarrative", "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } } },"auth ref": { "r329", "r330", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r354", "r355", "r356", "r357"} } },"us-gaap_ShareBasedCompensationAwardFranchiseOneMember": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardFranchiseOneMember", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "lang": { "en-us": { "role": { "label": "First Contribution [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } } },"auth ref": { "us-gaap_ShareBasedCompensationAwardFranchiseThreeMember": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardFranchiseThreeMember", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "lang": { "en-us": { "role": { "label": "Third Contribution [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } } },"auth ref": { "us-gaap_ShareBasedCompensationAwardFranchiseTwoMember": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardFranchiseTwoMember", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "lang": { "en-us": { "role": { "label": "Second Contribution [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } } },"auth ref": { "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to: methodology and assumption used in measuring cost." } } } },"auth ref": { "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r354", "r355", "r356", "r357"} } },"us-gaap_ShareBasedCompensationAwardFranchiseOneMember": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardFranchiseOneMember", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "lang": { "en-us": { "role": { "label": "Public offering price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value outstanding ending balance", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding]", "periodStartLabel": "Aggregate Intrinsic Value outstanding beginning balance", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2024", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "presentation": { "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Vested period", "documentation": "Period from grant date that an equity-based award expires, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://vtak.com/role/EquityOfferingsDetails", "http://vtak.com/role/EquityOfferingsDetails1", "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/StockbasedCompensationDetails", "http://vtak.com/role/StockbasedCompensationDetails1", "lang": { "en-us": { "role": { "label": "Expected life (in years)", "verboseLabel": "Expected life (in years)", "terseLabel": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } },"auth ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails2", "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value, Exercisable at September 30, 2024", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value]", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } } },"auth ref": { "r339"} } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Percentage of fair market value of share of common stock to purchase", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } } },"auth ref": { "us-gaap_SharesIssued": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "label": "[Shares Issued]", "periodEndLabel": "Balance, shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } } },"auth ref": { "r8"} } },"us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": { "http://vtak.com/role/SubsequentEventsDetailsNarrative", "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "label": "[Shares Issued, Price Per Share]", "documentation": "Per share or per unit amount of equity securities issued." } } } },"auth ref": { "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares", "presentation": { "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Number of options", "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date." } } } },"auth ref": { "r35"} } },"vtak_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfSharesE886": { "xbrltype": "perShareItemtype", "nsuri": "http://vtak.com/20240930", "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfSharesE886", "presentation": { "http://vtak.com/role/RelatedPartiesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Remaining number of options exercise price", "documentation": "Remaining number of options exercise price." } } } },"auth ref": { "vtak_ShippingAndHandlingCostsPolicyTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://vtak.com/20240930", "localname": "ShippingAndHandlingCostsPolicyTextBlock", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Shipping and Handling Costs", "documentation": "Shipping and handling costs." } } } },"auth ref": { "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": { "en-us": { "role": { "label": "Short term loan", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } } },"auth ref": { "r55", "r107", "r699", "r847"} } },"us-gaap_ShortTermDebtMember": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtMember", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": { "en-us": { "role": { "label": "Short Term Promissory Notes [Member]", "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer." } } } },"auth ref": { "us-gaap_ShortTermDebtRefinancedAmount": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtRefinancedAmount", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative", "lang": { "en-us": { "role": { "label": "Short-term financing", "documentation": "Amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } } },"auth ref": { "r34"} } },"us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "verboseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } } },"auth ref": { "r84", "r167"} } },"vtak_SouthCarolinaOfficeLeaseAgreementMember": { "xbrltype": "domainItemtype", "nsuri": "http://vtak.com/20240930", "localname": "SouthCarolinaOfficeLeaseAgreementMember", "presentation": {

<http://vtak.com/role/LeasesDetailsNarrative>": { "lang": { "en-us": { "role": { "label": "South Carolina Office Lease Agreement [Member]" } } }, "auth ref": { "us-gaap-StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Product Warranty", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth ref": { "r795" } } }, "us-gaap-StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": "http://vtak.com/role/CondensedConsolidatedBalanceSheets", "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": "http://vtak.com/role/EquityOfferingsDetails": "http://vtak.com/role/EquityOfferingsDetails1", "http://vtak.com/role/EquityOfferingsDetailsNarrative": "http://vtak.com/role/NetLossPerShareDetailsNarrative", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": "http://vtak.com/role/PreferredStockDetails", "http://vtak.com/role/PreferredStockDetailsNarrative": "http://vtak.com/role/StockbasedCompensationDetails": "http://vtak.com/role/StockbasedCompensationDetails1", "http://vtak.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth ref": { "r133", "r147", "r148", "r149", "r168", "r187", "r188", "r197", "r198", "r204", "r205", "r258", "r298", "r300", "r301", "r302", "r305", "r306", "r310", "r311", "r313", "r314", "r317", "r421", "r548", "r549", "r550", "r551", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r580", "r602", "r622", "r631", "r632", "r633", "r634", "r635", "r735", "r755", "r761" } } }, "us-gaap-StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Statement Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth ref": { "r8", "r65", "r68", "r69", "r134", "r156", "r157", "r158", "r170", "r171", "r172", "r174", "r179", "r180", "r182", "r203", "r259", "r260", "r295", "r319", "r380", "r381", "r386", "r387", "r388", "r390", "r394", "r395", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r422", "r423", "r424", "r425", "r426", "r427", "r430", "r432", "r437", "r532", "r541", "r542", "r543", "r558", "r622" } } }, "srt-StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails3": { "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth ref": { "r223", "r224", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r520", "r571", "r572", "r627", "r628", "r629", "r630", "r636", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r653", "r676", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r713", "r720", "r798", "r853", "r854", "r855", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881" } } }, "us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": "http://vtak.com/role/BusinessCombinationDetails1", "http://vtak.com/role/BusinessCombinationDetails2", "http://vtak.com/role/BusinessCombinationDetails3": "http://vtak.com/role/BusinessCombinationDetailsNarrative", "http://vtak.com/role/CondensedConsolidatedBalanceSheets": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "http://vtak.com/role/EquityOfferingsDetails": "http://vtak.com/role/EquityOfferingsDetails1", "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/EquityOfferingsDetails3", "http://vtak.com/role/EquityOfferingsDetails4": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/IntangibleAssetsDetails": "http://vtak.com/role/LeasesDetailsNarrative": "http://vtak.com/role/NetLossPerShareDetailsNarrative", "http://vtak.com/role/NotesPayableDetailsNarrative", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": "http://vtak.com/role/PreferredStockDetails", "http://vtak.com/role/PreferredStockDetailsNarrative": "http://vtak.com/role/PropertyAndEquipmentDetails": "http://vtak.com/role/RelatedPartiesDetails", "http://vtak.com/role/RelatedPartiesDetailsNarrative": "http://vtak.com/role/RoyaltiesPayableDetails": "http://vtak.com/role/RoyaltiesPayableDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetails": "http://vtak.com/role/StockbasedCompensationDetails1", "http://vtak.com/role/StockbasedCompensationDetails2", "http://vtak.com/role/StockbasedCompensationDetails3": "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetailsNarrative": "http://vtak.com/role/SubsequentEventsDetails": "http://vtak.com/role/SubsequentEventsDetailsNarrative", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails3": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "r170", "r171", "r172", "r203", "r432", "r480", "r546", "r569", "r573", "r574", "r575", "r576", "r577", "r578", "r580", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r600", "r603", "r604", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r622", "r721" } } }, "us-gaap-StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows (Unaudited)" } } }, "auth ref": { "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth ref": { "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)" } } }, "auth ref": { "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": "http://vtak.com/role/BusinessCombinationDetails1", "http://vtak.com/role/BusinessCombinationDetails2", "http://vtak.com/role/BusinessCombinationDetails3": "http://vtak.com/role/BusinessCombinationDetailsNarrative", "http://vtak.com/role/CondensedConsolidatedBalanceSheets": "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://vtak.com/role/ConsolidatedBalanceSheetsParenthetical": "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative", "http://vtak.com/role/EquityOfferingsDetails": "http://vtak.com/role/EquityOfferingsDetails1", "http://vtak.com/role/EquityOfferingsDetails2", "http://vtak.com/role/EquityOfferingsDetails3", "http://vtak.com/role/EquityOfferingsDetails4": "http://vtak.com/role/EquityOfferingsDetailsNarrative", "http://vtak.com/role/IntangibleAssetsDetails": "http://vtak.com/role/LeasesDetailsNarrative": "http://vtak.com/role/NetLossPerShareDetailsNarrative", "http://vtak.com/role/NotesPayableDetailsNarrative", "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": "http://vtak.com/role/PreferredStockDetails", "http://vtak.com/role/PreferredStockDetailsNarrative": "http://vtak.com/role/PropertyAndEquipmentDetails", "http://vtak.com/role/RelatedPartiesDetails", "http://vtak.com/role/RelatedPartiesDetailsNarrative": "http://vtak.com/role/RoyaltiesPayableDetails", "http://vtak.com/role/RoyaltiesPayableDetailsNarrative", "http://vtak.com/role/StockbasedCompensationDetails": "http://vtak.com/role/StockbasedCompensationDetails1", "http://vtak.com/role/StockbasedCompensationDetails2", "http://vtak.com/role/StockbasedCompensationDetails3": "http://vtak.com/role/StockbasedCompensationDetailsNarrative", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails3": "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth ref": { "r170", "r171", "r172", "r203", "r226", "r432", "r480", "r546", "r569", "r573", "r574", "r575", "r576", "r577", "r578", "r580", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r594", "

1, "auth ref": 11, "us-gaap StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 26.0 } }, "presentation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": { "http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": 1, "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "periodStartLabel": "Balance, amount", "periodEndLabel": "Balance, amount", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth ref": { "r65", "r68", "r69", "r85", "r82", "r599", "r623", "r624", "r699", "r728", "r756", "r776", "r836", "r886" } }, "us-gaap StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://vtak.com/role/CondensedConsolidatedBalanceSheets": 1, "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth ref": 11 }, "us-gaap SubordinatedBorrowingInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubordinatedBorrowingInterestRate", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Interest rate of loan", "documentation": "Stated interest rate of the subordinated debt." } } }, "auth ref": 11 }, "us-gaap SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "verboseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth ref": { "r428", "r445" } }, "us-gaap SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth ref": { "r428", "r445" } }, "us-gaap SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": { "http://vtak.com/role/SubsequentEventsDetails": { "http://vtak.com/role/SubsequentEventsDetailsNarrative": 1, "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth ref": { "r428", "r445" } }, "us-gaap SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth ref": 11 }, "us-gaap SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://vtak.com/role/SubsequentEvents": 1, "lang": { "en-us": { "role": { "verboseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth ref": { "r444", "r446" } }, "us-gaap SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://vtak.com/role/EquityOfferingsDetails": { "http://vtak.com/role/EquityOfferingsDetails1": 1, "lang": { "en-us": { "role": { "label": "Subsidiary Sale Of Stock Axis", "documentation": "Information by type of sale of the entity's stock." } } }, "auth ref": 11 }, "vtak SummaryOfPreliminaryPurchasePriceAllocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "SummaryOfPreliminaryPurchasePriceAllocationTableTextBlock", "presentation": { "http://vtak.com/role/BusinessCombinationTables": 1, "lang": { "en-us": { "role": { "label": "Summary Of preliminary purchase price allocations" } } }, "auth ref": 11 }, "vtak SummaryOfSalesBasedRoyaltyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vtak.com/20240930", "localname": "SummaryOfSalesBasedRoyaltyTableTextBlock", "presentation": { "http://vtak.com/role/RoyaltiesPayableTables": 1, "lang": { "en-us": { "role": { "label": "summary of sales-based royalties" } } }, "auth ref": 11 }, "us-gaap SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://vtak.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": 1, "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "auth ref": 11 }, "us-gaap SupplementalIncomeStatementElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalIncomeStatementElementsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations (Unaudited)" } } }, "auth ref": 11 }, "vtak TerminatePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "TerminatePayment", "crdr": "credit", "presentation": { "http://vtak.com/role/RoyaltiesPayableDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Termination payments for Royalties" } } }, "auth ref": 11 }, "vtak ThreeAndFiveCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ThreeAndFiveCustomersMember", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Three and Five Customers Member" } } }, "auth ref": 11 }, "vtak ThreeAndFourCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "ThreeAndFourCustomersMember", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Three and Four Customers [Member]" } } }, "auth ref": 11 }, "vtak TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Title Of Individual Axis" } } }, "auth ref": { "r767", "r840" } }, "vtak TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": { "http://vtak.com/role/StockbasedCompensationDetails": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "auth ref": 11 }, "vtak TopMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TopMember", "presentation": { "http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "auth ref": 11 }, "vtak TotalPurchasePriceOffFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "TotalPurchasePriceOffFairValue", "crdr": "credit", "presentation": { "http://vtak.com/role/BusinessCombinationDetails": 1, "lang": { "en-us": { "role": { "label": "Total Purchase Price" } } }, "auth ref": 11 }, "us-gaap TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPolicies": 1, "lang": { "en-us": { "role": { "label": "Accounts Receivable and Allowances for Credit Losses", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth ref": { "r117", "r118", "r119", "r769", "r770", "r771" } }, "vtak TrademarkLockeTMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TrademarkLockeTMember", "presentation": { "http://vtak.com/role/BusinessCombinationDetails2": 1, "lang": { "en-us": { "role": { "label": "Trademark - Locke T [Member]" } } }, "auth ref": 11 }, "vtak TrademarkVivoMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TrademarkVivoMember", "presentation": { "http://vtak.com/role/BusinessCombinationDetails2": 1, "lang": { "en-us": { "role": { "label": "Trademark - VIVO [Member]" } } }, "auth ref": 11 }, "vtak TrademarksTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TrademarksTradeNamesMember", "presentation": { "http://vtak.com/role/IntangibleAssetsDetails": 1, "lang": { "en-us": { "role": { "label": "Trademarks/trade Names - Locke T [Member]" } } }, "auth ref": 11 }, "vtak TrademarksTradeNamesVivoMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TrademarksTradeNamesVivoMember", "presentation": { "http://vtak.com/role/IntangibleAssetsDetails": 1, "lang": { "en-us": { "role": { "label": "Trademarks/trade Names - VIVO [Member]" } } }, "auth ref": 11 }, "del TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://vtak.com/role/Cover": 1, "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth ref": 11 }, "us-gaap TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": { "http://vtak.com/role/NotesPayableDetailsNarrative": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth ref": { "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r309", "r316", "r409", "r420", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r533", "r680", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r701", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r772", "r773", "r774", "r775", "r830", "r831", "r832", "r833", "r834", "r835" } }, "vtak TwoThousandTwentyThreeWarrantRepricingMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandTwentyThreeWarrantRepricingMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetails": 1, "lang": { "en-us": { "role": { "label": "2023 Warrant Repricing [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandEighteenEquityStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandEighteenEquityStockPurchasePlanMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "2018 Equity Stock Purchase Plan [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandEighteenStockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandEighteenStockCompensationPlanMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "2018 Stock Compensation Plan [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandTwentyFourInducementOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandTwentyFourInducementOfferMember", "presentation": { "http://vtak.com/role/OrganizationAndNatureOfOperationsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "2024 Inducement Offer [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandTwentyStockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandTwentyStockCompensationPlanMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "2020 Stock Option Plan [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandTwentyThreeStockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandTwentyThreeStockCompensationPlanMember", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "2023 Stock Option Plan [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandTwentyThreeWarrantRepricingMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandTwentyThreeWarrantRepricingMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetails": 1, "lang": { "en-us": { "role": { "label": "2023 Warrant Repricing [Member]" } } }, "auth ref": 11 }, "vtak TwoThousandTwentyTwoOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "TwoThousandTwentyTwoOfferingMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetails2": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "2022 Offering [Member]", "verboseLabel": "2022 Offering [Member]" } } }, "auth ref": 11 }, "vtak USMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "USMember", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails3": 1, "lang": { "en-us": { "role": { "label": "US [Member]" } } }, "auth ref": 11 }, "vtak UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "UnderwritingAgreementMember", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Underwriting Agreement [Member]" } } }, "auth ref": 11 }, "us-gaap UnderwritingCommitments": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnderwritingCommitments", "presentation": { "http://vtak.com/role/EquityOfferingsDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Underwriting discounts and commissions", "documentation": "Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled." } } }, "auth ref": { "r514" } }, "vtak UnobservableInput": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "UnobservableInput", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails1": 1, "lang": { "en-us": { "role": { "label": "Unobservable Input" } } }, "auth ref": 11 }, "us-gaap UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPolicies": 1, "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth ref": { "r28", "r29", "r30", "r124", "r125", "r128", "r129" } }, "vtak ValuationTechnique": { "xbrltype": "stringItemType", "nsuri": "http://vtak.com/20240930", "localname": "ValuationTechnique", "presentation": { "http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails1": 1, "lang": { "en-us": { "role": { "label": "Valuation Technique" } } }, "auth ref": 11 }, "vtak ValueOfOptionsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "ValueOfOptionsIssued", "crdr": "credit", "presentation": { "http://vtak.com/role/StockbasedCompensationDetailsNarrative": 1, "lang": { "en-us": { "role": { "label": "Value of options issued" } } }, "auth ref": 11 }, "vtak VestedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://vtak.com/20240930", "localname": "VestedPercentage", "presentation": {

[http://vtak.com/role/RelatedPartiesDetailsNarrative-1](#), "lang": "en-us", "role": "label", "label": "Vested percentage"}}, {"auth ref": [], "us-gaap-VestingAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": {"http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative-1", "lang": "en-us", "role": "label", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement."}}, {"auth ref": "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825"}, {"us-gaap-VestingDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": {"http://vtak.com/role/EmployeeBenefitPlanDetailsNarrative-1", "lang": "en-us", "role": "documentation", "label": "Vesting schedule of award under share-based payment arrangement."}}, {"auth ref": "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825"}, {"vivo-VivoDemoClinicalSystemsMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "VivoDemoClinicalSystemsMember", "presentation": {"http://vtak.com/20240930", "localname": "VivoDemoClinicalSystemsMember", "presentation": {"http://vtak.com/role/SummaryOfSignificantAccountingPoliciesDetails2", "lang": "en-us", "role": "label", "label": "VIVO DEMO/Clinical Systems/Member", "verboseLabel": "VIVO DEMO/Clinical Systems/Member"}}, {"auth ref": [], "us-gaap-WarrantExercisePriceIncrease": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceIncrease", "presentation": {"http://vtak.com/role/RelatedPartiesDetailsNarrative-1", "lang": "en-us", "role": "label", "label": "Exercise price", "documentation": "[Warrant, Exercise Price, Increase] documentation: Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."}}, {"auth ref": "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325"}, {"vtak-WarrantOneMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantOneMember", "presentation": {"http://vtak.com/20240930", "localname": "WarrantOneMember", "presentation": {"http://vtak.com/role/EquityOfferingsDetails2", "lang": "en-us", "role": "label", "label": "Warrant One [Member]"}}, {"auth ref": [], "vtak-WarrantRepricingMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantRepricingMember", "presentation": {"http://vtak.com/role/EquityOfferingsDetailsNarrative-1", "lang": "en-us", "role": "label", "label": "Warrant Repricing [Member]"}}, {"auth ref": [], "vtak-WarrantTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantTwoMember", "presentation": {"http://vtak.com/role/EquityOfferingsDetails2", "lang": "en-us", "role": "label", "label": "Warrant Two [Member]"}}, {"auth ref": [], "us-gaap-WarrantsAndRightsOutstanding": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": {"http://vtak.com/role/EquityOfferingsDetails2", "lang": "en-us", "role": "label", "label": "Warrants outstanding value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."}}, {"auth ref": "r831", "r832", "r833"}, {"vtak-WarrantsExercised": {"xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantsExercised", "presentation": {"http://vtak.com/role/SubsequentEventsDetailsNarrative-1", "lang": "en-us", "role": "label", "label": "Warrants exercised"}}, {"auth ref": [], "vtak-WarrantsExercisedAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantsExercisedAmount", "crdr": "credit", "presentation": {"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Warrants exercised (see Note 13), amount"}}, {"auth ref": [], "vtak-WarrantsExercisedShares": {"xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantsExercisedShares", "presentation": {"http://vtak.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": "en-us", "role": "label", "label": "Warrants exercised (see Note 13), shares"}}, {"auth ref": [], "vtak-WarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://vtak.com/20240930", "localname": "WarrantsMember", "presentation": {"http://vtak.com/role/EquityOfferingsDetails2", "lang": "en-us", "role": "label", "label": "Warrants [Member]"}}, {"auth ref": [], "vtak-WeightedAverageExercisePrice": {"xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageExercisePrice", "presentation": {"http://vtak.com/role/EquityOfferingsDetailsNarrative-1", "lang": "en-us", "role": "label", "label": "Weighted average exercise price"}}, {"auth ref": [], "vtak-WeightedAverageExercisedPriceCanceledForfeited": {"xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageExercisedPriceCanceledForfeited", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average exercised price canceled/forfeited"}}, {"auth ref": [], "vtak-WeightedAverageExercisedPriceExercisableEndOfPeriod": {"xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageExercisedPriceExercisableEndOfPeriod", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average exercised price exercisable at September 30, 2024", "documentation": "[Weighted average exercised price exercisable at September 30, 2024]"}}, {"auth ref": [], "vtak-WeightedAverageExercisedPriceOptionsGranted": {"xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageExercisedPriceOptionsGranted", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average exercised price options granted"}}, {"auth ref": [], "vtak-WeightedAverageExercisedPriceVestedAndExpectedToVestEndOfThePeriod": {"xbrltype": "perShareItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageExercisedPriceVestedAndExpectedToVestEndOfThePeriod", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average exercised price vested and expected to vest end of the period"}}, {"auth ref": [], "vtak-WeightedAverageNumberofSharesOutstandingBasicAndDiluted": {"xbrltype": "sharesItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageNumberofSharesOutstandingBasicAndDiluted", "presentation": {"http://vtak.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "label": "Weighted average common shares used in computing net loss per share, basic and diluted"}}, {"auth ref": [], "vtak-WeightedAverageRemainingLifeEndOfPeriod": {"xbrltype": "durationItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageRemainingLifeEndOfPeriod", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average remaining life end of period"}}, {"auth ref": [], "vtak-WeightedAverageRemainingLifeEndOfPeriodExercisableBegin": {"xbrltype": "durationItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageRemainingLifeEndOfPeriodExercisableBegin", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average remaining life end of period exercisable begin"}}, {"auth ref": [], "vtak-WeightedAverageRemainingLifeEndOfPeriodExercisableEnd": {"xbrltype": "durationItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageRemainingLifeEndOfPeriodExercisableEnd", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average remaining life end of period exercisable end"}}, {"auth ref": [], "vtak-WeightedAverageRemainingLifeVestedAndExpectedToVestEndOfPeriod": {"xbrltype": "durationItemType", "nsuri": "http://vtak.com/20240930", "localname": "WeightedAverageRemainingLifeVestedAndExpectedToVestEndOfPeriod", "presentation": {"http://vtak.com/role/StockbasedCompensationDetails2", "lang": "en-us", "role": "label", "label": "Weighted average remaining life vested and expected to vest end of period"}}, {"auth ref": [], "std ref": "r0", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"}, {"auth ref": [], "std ref": "r1", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "05", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-05-13"}, {"auth ref": [], "std ref": "r2", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"}, {"auth ref": [], "std ref": "r3", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "28", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, {"auth ref": [], "std ref": "r4", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "25", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"}, {"auth ref": [], "std ref": "r5", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "28", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, {"auth ref": [], "std ref": "r6", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "28", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, {"auth ref": [], "std ref": "r7", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "28", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, {"auth ref": [], "std ref": "r8", "role": "role", "label": "Name", "accountingStandardsCodification": {"Section": "45", "Paragraph": "28", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, {"auth ref": [], "std ref": "r9

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r867": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6"}, "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r868": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6"}, "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r869": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6"}, "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r870": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6"}, "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r871": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A"}, "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r872": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A"}, "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r873": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A"}, "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r874": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A"}, "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r875": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A"}, "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r876": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A"}, "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r877": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B"}, "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r878": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B"}, "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r879": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B"}, "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r880": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2"}, "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r881": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2"}, "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r882": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4"}, "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4", "r883": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1"}, "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1", "r884": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1"}, "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1", "r885": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3"}, "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3", "r886": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3"}, "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "r887": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3"}, "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "r888": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1"}, "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1", "r889": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2"}, "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2", "r890": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3"}, "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3", "r891": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6"}, "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6", "r892": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2"}, "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2", "r893": {"role": "0001654954-24-014300-xbrl.zip;#10 ()E:5D05H0I9X (60 0 = T-G1A:RTR;M=J,T=DS,S,YX MV9T,E6CVTD)+FG=U(F(I)5A33+ MK 9 236 ?P=P)()2IW L=Z&MG(C)=SQPP=8 OSY1W/41448;H\$V M#G8BB,L07CQ2B=GNX&=&UE&<@#3#1W.V.M'=O JE/ CY -W7WY.9C.M'=> @IBWf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

[illegible]

[illegible]

[illegible]

[illegible]

BR0\##)LW MW900 "F\I@: ?D, C6X%5/RV05B BT7P2-@Z, * "C!CN

[illegible]

[illegible]

[illegible]

[illegible]

[The content of this block is extremely garbled and appears to be a corrupted or heavily redacted document. It contains no legible text.]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Company's common shares and participating securities. The Company's Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and outstanding warrants contain participating rights in distributions made to common stockholders and, therefore, are participating securities. The Company did not declare nor pay any dividends nor distributions in the current period. Furthermore, the participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per common share.

Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic net loss per share for the periods presented herein because common stock equivalent shares from warrants, stock options, non-vested restricted stock awards, restricted stock units, Series A Convertible Preferred Stock, and Series X Convertible Preferred Stock were antidilutive (see Note 12, Net Loss per Share).

Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed dividends declared. The Company recorded a deemed dividend for the modification of existing warrants and issuance of new warrants during the three and nine months ended September 30, 2023 of \$0 and \$0.8 million, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders for the three and nine months ended September 30, 2023. There was no deemed dividend for the three and nine months ended September 30, 2024.

Recently Announced Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 require disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. These amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently reviewing the impact that the adoption of ASU 2023-07 may have on our consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740). Improvements to Income Tax Disclosures. This standard requires public entities to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is required to adopt this standard prospectively in fiscal year 2025 for the annual reporting period ending December 31, 2025. The Company does not believe the impact of the new guidance and related codification improvements will have material impact to its financial position, results of operations and cash flows.

The unaudited condensed consolidated financial statements of the Company include the accounts of the Company and Old Gatherer. All intercompany transactions have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Financial Accounting Standards Board ("FASB") establishes these principles to ensure financial condition, results of operations, and cash flows are consistently reported. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the FASB Accounting Standards Codification ("ASC"). Certain footnotes and other financial information normally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, such statements include all adjustments which are considered necessary for fair presentation of the unaudited condensed consolidated financial statements of the Company. The operating results presented herein are not necessarily an indication of the results that may be expected for the year. The unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission ("SEC") on April 3, 2024.

The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ materially from those estimates. The Company's unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the accounting for the Old Gatherer business combination (see Note 3, Business Combination), allowance for credit losses, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, fair value of royalties payable, evaluation of probable loss contingencies, fair value of preferred stock and warrants issued, and the fair value of equity awards granted.

The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent short-term, highly liquid investments with maturities of 90 days or less at the date of purchase. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.

The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.

Certain prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.

The Company's Board of Directors and executive management team represents the entity's chief operating decision makers. To date, the Company's executive management team has viewed the Company's operations as one segment that includes the marketing, sales, and development of medical technologies in the field of cardiac electrophysiology. As a result, the financial information disclosed materially represents all of the financial information related to the Company's sole operating segment.

Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to identify inputs used in measuring fair value as follows:

Level 1 - Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

Level 3 - Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Cash equivalents, prepaid expenses, trade accounts receivable, accounts payable, and accrued expenses are reported on the condensed consolidated balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments.

Fair value measurements within the fair value hierarchy of the Company's financial instruments:

	Level 1	Level 2	Level 3
Cash Equivalents	\$987 thousand	\$250,000	\$250,000
Prepaid Expenses	\$250,000	\$250,000	\$250,000
Trade Accounts Receivable	\$250,000	\$250,000	\$250,000
Accounts Payable	\$250,000	\$250,000	\$250,000
Accrued Expenses	\$250,000	\$250,000	\$250,000

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

ASU 2023-07, **Segment Reporting (Topic 280)**: Improvements to Reportable Segment Disclosures/**em>**. The amendments in ASU 2023-07 require disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("**CODM**") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's **CODM**. The amendments in this update also expand the interim segment disclosure requirements. These amendments do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently reviewing the impact that the adoption of ASU 2023-07 may have on our consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, **"Income Taxes (Topic 740): Improvements to Income Tax Disclosures"**, which requires public entities to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is required to adopt this standard prospectively in fiscal year 2025 for the annual reporting period ending December 31, 2025. The Company does not believe the impact of the new guidance and related codification improvements will have material impact to its financial position; results of operations and cash flows.

The following table summarizes the final purchase price allocations relating to the Merger (in thousands):

	Fair Value as of January 9, 2023
Cash and cash equivalents	\$6.4 million
Accounts receivable	\$1.2 million
Prepaid expenses and other current assets	\$0.1 million
Property and equipment	\$0.1 million
Lease right-of-use assets	\$0.1 million
Goodwill	\$1.2 million
Intangible assets	\$1.2 million
Liabilities assumed	\$1.2 million
Total	\$10.3 million

The Company allocated the purchase price to the assets acquired and liabilities assumed at fair value. The purchase price allocation reflects various fair value estimates and analyses, including certain tangible assets acquired and liabilities assumed, the valuation of intangible assets acquired, liabilities assumed, and goodwill, which were subject to change within the measurement period as valuations were being finalized (generally one year from the acquisition date). Measurement period adjustments were recorded in the reporting period in which the estimates are finalized, and adjustment amounts were determined. During the three months ended June 30, 2023, the Company recorded measurement period adjustments based on changes to certain estimates and assumptions and their related impact to the purchase price allocation. Developed technology was revised from \$35.1 million to \$27.0 million; trademarks were revised from \$1.7 million to \$1.3 million; customer relationships were revised from \$20 thousand to \$62 thousand; goodwill was revised from \$56.0 million to \$68.0 million; and royalties payable were revised from \$7.6 million to \$14.2 million.

The following table summarizes the final purchase price allocations relating to the Merger (in thousands):

	Fair Value as of January 9, 2023
Cash and cash equivalents	\$6.4 million
Accounts receivable	\$1.2 million
Prepaid expenses and other current assets	\$0.1 million
Property and equipment	\$0.1 million
Lease right-of-use assets	\$0.1 million
Goodwill	\$1.2 million
Intangible assets	\$1.2 million
Liabilities assumed	\$1.2 million
Total	\$10.3 million

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<table border=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<p style="font-size:10pt;font-family:times new roman;margin:0px"></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"></p></td></tr></tbody></table>2024-10-032024-10-0425000025000002024-10-162024-10-1619600019600002024-10-182024-10-2143400043400002024-10-182024-10-211010000101000010100002024-10-182024-10-211750001750001750002024-10-292024-10-292350002350000